





































































Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic 
Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human 
Services. 
 
This information is distributed solely for the purpose of pre dissemination public comment under 
applicable information quality guidelines.  It has not been formally disseminated by the Agency for Toxic 
Substances and Disease Registry.  It does not represent and should not be construed to represent any 

















A Toxicological Profile for Antimony and Compounds was released in 1992.  This present edition 
supersedes any previously released draft or final profile.   
 
Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at: 
 
Agency for Toxic Substances and Disease Registry 
 
Division of Toxicology and Human Health Sciences 
 
Environmental Toxicology Branch 
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This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary. 
 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is 
also presented, but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced. 
 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a public health statement that describes, in nontechnical language, a substance's relevant 
toxicological properties.  Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance's health effects is described in a health effects summary.  Data needs that are of 
significance to the protection of public health are identified by ATSDR and EPA. 
 
Each profile includes the following: 
 
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects; 
 
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and 
 
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans. 
 
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.  We plan to 
revise these documents in response to public comments and as additional data become available.  
Therefore, we encourage comments that will make the toxicological profile series of the greatest use. 
 
Electronic comments may be submitted via: www.regulations.gov. 
Follow the on-line instructions for submitting comments. 
 
Written comments may also be sent to:  
 Agency for Toxic Substances and Disease Registry 
 Division of Toxicology and Human Health Sciences 
 Environmental Toxicology Branch 
 
Regular Mailing Address: Physical Mailing Address: 
1600 Clifton Road, N.E. 4770 Buford Highway 
Mail Stop F-57 Building 102, 1st  floor, MS F-57 






















     
    
  
  
   
   
   




    
 
   









The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise
necessary to support the site-specific response actions conducted by ATSDR. 
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been
peer-reviewed.  Staffs of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel
and is being made available for public review.  Final responsibility for the contents and views expressed
in this toxicological profile resides with ATSDR.
Patrick N. Breysse, Ph.D., CIH
 
Director, National Center for Environmental Health and
 
Agency for Toxic Substances and Disease Registry
 
Centers for Disease Control and Prevention
 













   
   
  






     
   
    
  
 
    
   
 
   
    
 
    
     




    
      
   
   
 
 
    









    
  
   
 
viiANTIMONY AND COMPOUNDS
QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances may find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets,
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (e.g.,death, systemic, immunologic, reproductive), by route of exposure, and by
length of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies
are reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Chapter 1 How Can (Chemical X) Affect Children?
 
Chapter 1 How Can Families Reduce the Risk of Exposure to (Chemical X)?
 
Section 3.8 Children’s Susceptibility
 
Section 6.6 Exposures of Children
 
Other Sections of Interest:
Section 3.9 Biomarkers of Exposure and Effect
Section 3.12 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)
Internet:  http://www.atsdr.cdc.gov
The following additional materials are available online:
Case Studies in Environmental Medicine are self-instructional publications designed to increase primary
health care providers’ knowledge of a hazardous substance in the environment and to aid in the
evaluation of potentially exposed patients (see https://www.atsdr.cdc.gov/csem/csem.html).


























   
 
   
 
 
   
   
  

















    
    
 
    
 
 
    
   
viiiANTIMONY AND COMPOUNDS
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident (see https://www.atsdr.cdc.gov/MHMI/index.asp).  Volumes I and II are planning guides
to assist first responders and hospital emergency department personnel in planning for incidents
that involve hazardous materials.  Volume III—Medical Management Guidelines for Acute
Chemical Exposures—is a guide for health care professionals treating patients exposed to 
hazardous materials.
Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances (see 
https://www.atsdr.cdc.gov/toxfaqs/Index.asp).
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA
30341-3724 • Phone:  770-488-7000 • FAX:  770-488-7015 • Web Page:
https://www.cdc.gov/nceh/.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 395 E Street, S.W., Suite 9200, 
Patriots Plaza Building, Washington, DC 20201 • Phone:  202-245-0625 or 1-800-CDC-INFO 
(800-232-4636) • Web Page: https://www.cdc.gov/niosh/.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone:  919-541-3212 • Web Page:
https://www.niehs.nih.gov/.
Clinical Resources (Publicly Available Information)
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266 • Web Page:
http://www.acoem.org/.
The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with
recognized expertise in medical toxicology.  Contact: ACMT, 10645 North Tatum Boulevard, 











    
 
 
   
 
     
   
 
   
  
     
 
ixANTIMONY AND COMPOUNDS
Suite 200-111, Phoenix AZ 85028 • Phone: 844-226-8333 • FAX:  844-226-8333 • Web Page:
http://www.acmt.net.
The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists 
who respond to questions from public health professionals, clinicians, policy makers, and the 
public about the impact of environmental factors on the health of children and reproductive-aged
adults.  Contact information for regional centers can be found at http://pehsu.net/findhelp.html.
The American Association of Poison Control Centers (AAPCC) provide support on the prevention and 
treatment of poison exposures.  Contact:  AAPCC, 515 King Street, Suite 510, Alexandria VA
22314 • Phone: 701-894-1858 • Poison Help Line: 1-800-222-1222 • Web Page:
http://www.aapcc.org/.














This page is intentionally blank.












Melanie Buser, M.P.H. 
 
Susan Zells Ingber, A.B., M.S.P.P. 
 
Jessilynn Taylor, M.S., CDR USPHS 
 
ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA 
 
 
Lisa Ingerman, Ph.D., D.A.B.T. 
 
H. Danielle Johnson, B.S. 
 
Mary Kawa, M.A. 
 
Mario Citra, Ph.D. 
 







THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
 
 
1. 	 Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
 
2. 	 Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
 
3.	  Data Needs Review.  The Environmental Toxicology Branch reviews data needs sections to 
assure consistency across profiles and adherence to instructions in the Guidance. 
 























This page is intentionally blank.










A peer review panel was assembled for antimony and compounds.  The panel consisted of the following 
members:  
 
1.	  David Dorman, DVM, Ph.D., DABVT, DABT, Professor, Toxicology, School of Veterinary 
Medicine, North Carolina State University, Raleigh, North Carolina; 
 
2.	  Nelson Belzile, Ph.D., Full Professor, Chair, Department of Chemistry and Biochemistry, 
Laurentian University, Sudbury, Canada; and 
 
3.	  Jeffrey L Burgess, MD, MPH, MS, Professor, Associate Dean for Research, Mel and Enid 
Zuckerman College of Public Health, University of Arizona, Tucson, Arizona. 
 
These experts collectively have knowledge of antimony’s and antimony compounds’ physical and 
chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal 
exposure, and quantification of risk to humans.  All reviewers were selected in conformity with the 
conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental 
Response, Compensation, and Liability Act, as amended. 
 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.   
 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
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1ANTIMONY AND COMPOUNDS




This Public Health Statement summarizes the Agency for Toxic Substances and Disease Registry’s 
(ATSDR) findings on antimony, including chemical characteristics, exposure risks, possible health effects 
from exposure, and ways to limit exposure.
The U.S. Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites make up the National Priorities List (NPL) and are sites targeted for long-term federal
clean-up activities.  The EPA has found antimony and compounds in at least 565 of the 1,832 current or 
former NPL sites.  The total number of NPL sites evaluated for antimony and compounds is not known.  
But the possibility remains that as more sites are evaluated, the sites where antimony and compounds are 
found may increase. This information is important because these future sites may be sources of exposure,
and exposure to antimony and compounds may be harmful.
If you are exposed to antimony, many factors determine whether you’ll be harmed.  These include how
much you are exposed to (dose), how long you are exposed (duration), how often you are exposed 
(frequency), and how you are exposed (route of exposure).  You must also consider the other chemicals
you are exposed to and your age, sex, diet, family traits, lifestyle, and state of health.
WHAT IS ANTIMONY?
Antimony is a silvery white metal of medium hardness that breaks easily.  Antimony is usually mixed 
with other metals such as lead and zinc to form mixtures of metals called alloys.  These alloys are used in
lead storage batteries, solder, sheet and pipe metal, bearings, castings, type metal, ammunition, and 
pewter. Antimony trioxide is used in the production of polyethylene terephthalate (PET) water bottles.
WHAT HAPPENS TO ANTIMONY WHEN IT ENTERS THE ENVIRONMENT?
Antimony is found in the earth's crust at about 0.2–0.3 grams per metric ton).  Antimony is often found 
with other metals.  Ores containing antimony are mined and then either changed into antimony metal or
combined with oxygen to form antimony oxide.  Antimony enters the environment during the mining and 
processing of antimony-containing ores and in the production of antimony metal, alloys, and antimony
oxide, and combinations of antimony with other substances.  Antimony was mined in the United States;
however, the last mine closed in 2001.  Impure antimony ore and metal are brought into the United States
***DRAFT FOR PUBLIC COMMENT***
   
 














   
  
 
     





    
 










    
 
   
  
  
    
      
2ANTIMONY AND COMPOUNDS
1.  PUBLIC HEALTH STATEMENT
from other countries for processing.  Small amounts of antimony are released into the environment by
incinerators and coal-burning power plants.
HOW MIGHT I BE EXPOSED TO ANTIMONY?
You may be exposed to antimony by breathing air, drinking water, and eating foods that contain it.  You 
may be exposed by skin contact with soil, water, and other substances that contain antimony.  You may
breathe and have skin contact with high levels of antimony in dust if you live or work near antimony
mines or processing companies.  Children may also be exposed to antimony by eating dirt.
The amount of antimony in rivers and lakes is very low.  The levels are usually less than 1 microgram per
liter (µg/L).  Antimony does not appear to accumulate in fish or other aquatic animals.  Soil usually
contains very low concentrations of antimony.  Soils near mines and other work sites may contain high 
levels of antimony.
Food may contain small amounts of antimony.  Antimony levels as high as 9.7 µg/L have been reported 
in drinking water.  Water in PET bottles may contain higher levels of antimony.  
You may also be exposed to antimony in the workplace.  If you work in industries that process antimony
ore and metal or make chemicals that contain antimony, such as antimony oxide, you may be exposed to 
antimony by breathing dust or through skin contact.
For more information on how you may be exposed to antimony, see Chapter 6.
HOW CAN ANTIMONY ENTER AND LEAVE MY BODY?
Antimony can enter your body when you drink water or eat food, soil, or other substances that contain 
antimony.  Antimony can also enter your body if you breathe air or dust containing it.  We do not know if 
antimony can enter your body through your skin.
When you breathe air containing antimony, antimony particles can be deposited in your lungs.  Some of
these particles can be coughed up and swallowed.  Small particles deposited deeper in the lungs are likely
to pass through the lining of the lungs and enter the bloodstream.  Antimony in your lungs will enter your
blood after several days or weeks, depending on the antimony compound.  Less soluble compounds like
antimony trioxide will stay in the lungs longer.  A small amount of the antimony that you eat or drink
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enters the blood after a few hours. The amount and the form of antimony in the food or water will affect
how much antimony enters your blood.  The amount of antimony that will enter your blood from your
lungs is not known.  Antimony in the blood will be distributed throughout the body, with the highest
amounts in the blood, spleen, liver, and kidneys.  Antimony will leave your body in feces and urine over
several weeks.
Further information on how antimony enters and leaves your body is presented in Chapter 3.
HOW ANTIMONY CAN AFFECT MY HEALTH?
Antimony in the air can cause lung effects in workers and laboratory animals.  Antimony can also cause
heart problems.  It can damage the heart muscle and cause changes in electrocardiogram (EKG) readings.
High levels of antimony in drinking water can cause vomiting and abdominal pain.  These effects have 
also been reported by antimony workers.  Stomach ulcers have been seen in animals exposed to antimony
in drinking water for several months.  Antimony can also cause eye irritation if it gets in the eye.
Antimony can have beneficial effects when used for medical reasons.  It has been used as a medicine to
treat people infected with certain types of parasites. The patients typically receive a number of injections 
with antimony-containing compounds.  Some side effects have been reported, including heart problems, 
nausea and vomiting, and muscle and joint pain.
Lung cancer has been observed in some studies of workers, and mice breathing high concentrations of
antimony.  The International Agency for Research on Cancer has determined that antimony trioxide is
possibly carcinogenic to humans (group 2B) and antimony trisulfide is not classifiable as to its
carcinogenicity (group 3). Antimony has not been classified for cancer effects by the Department of
Health and Human Services or the EPA.
More information on how antimony can affect your health is presented in Chapters 2 and 3.
HOW CAN ANTIMONY AFFECT CHILDREN?
This section discusses potential health effects of antimony and antimony compounds exposure in humans
from when they’re first conceived to 18 years of age.
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We do not know if children would be more susceptible to antimony toxicity than adults.  Studies in 
workers and in rats have shown that antimony can decreases infant growth. There is also limited
information suggesting that antimony can damage the developing cardiovascular system in rats.
HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO ANTIMONY?
If your doctor finds that you have been exposed to significant amounts of antimony and compounds, ask
whether your children might also be exposed.  Your doctor might need to ask your state health department
to investigate.  You may also contact the state or local health department with health concerns.
Use bottled water if you have concerns about the presence of antimony in your tap water.  Prevent
children from eating or playing in the dirt if you live near a waste site that has been contaminated with
antimony.
ARE THERE MEDICAL TESTS TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
ANTIMONY? 
Antimony levels can be measured in urine, feces, blood, and hair.  In the United States, small amounts of
antimony are found in the urine of most people.  High levels of antimony in the blood or urine can show
that you have been recently exposed to higher than normal levels of antimony.  Although these tests can 
show that you have been exposed to higher than normal antimony levels, they cannot be used to predict
how much antimony you have been exposed to or whether the exposure will result in an adverse health
effect. For more information, see Chapters 3 and 7.
WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT
HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  Regulations
can be enforced by law.  Federal agencies that develop regulations for toxic substances include the
Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA),
and the Food and Drug Administration (FDA).  Recommendations provide valuable guidelines to protect
public health but are not enforceable by law.  Federal organizations that develop recommendations for
toxic substances include the Agency for Toxic Substances and Disease Registry (ATSDR) and the 
National Institute for Occupational Safety and Health (NIOSH).
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1.  PUBLIC HEALTH STATEMENT
Regulations and recommendations can be expressed as “not-to-exceed” levels; that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value usually based on levels that affect
animals; levels are then adjusted to help protect humans.  Sometimes these not-to-exceed levels differ
among federal organizations.  Different organizations use different exposure times (e.g., an 8-hour
workday or a 24-hour day), different animal studies, or emphasize some factors over others, depending on 
their mission.
Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that issued the regulation
or recommendation.
EPA has determined that exposure to drinking water containing 0.01 milligrams of antimony per liter
(mg/L) is not expected to cause effects that are harmful to children exposed for 1 or 10 days.  Lifetime
exposure to drinking water containing 0.006 mg/L is not likely to cause adverse health effects.
OSHA has set a limit of 0.5 mg/m3 of antimony in workroom air to protect workers during an 8-hour
work shift (40-hour workweek).  NIOSH also recommends that the concentration in workroom air be
limited to 0.5 mg/m3 for antimony and for stibine (antimony hydride) averaged over an 8-hour work shift.  
Further information on regulations and guidelines pertaining to antimony is provided in Chapter 8.
WHERE CAN I GET MORE INFORMATION?
If you have any questions or concerns, please contact your community or state health or environmental
quality department, or contact ATSDR at the address and phone number below.  You may also contact
your doctor if experiencing adverse health effects or for medical concerns or questions.  ATSDR can also
provide publicly available information regarding medical specialists with expertise and experience 
recognizing, evaluating, treating, and managing patients exposed to hazardous substances.






Agency for Toxic Substances and Disease Registry

Division of Toxicology and Human Health Sciences
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1.  PUBLIC HEALTH STATEMENT
Toxicological profiles and other information are available on ATSDR’s web site:
http://www.atsdr.cdc.gov.
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7ANTIMONY AND COMPOUNDS
2. RELEVANCE TO PUBLIC HEALTH
2.1  	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO ANTIMONY AND
COMPOUNDS IN THE UNITED STATES
Antimony is naturally present in the earth’s crust at levels of about 0.2–0.3 mg/kg (ppm), but these levels
vary by location.  It can be transported into streams and waterways from natural weathering of soil, as 
well as from anthropogenic sources.  Antimony enters the environment during the mining and processing
of antimony-containing ores and in the production of antimony metal, alloys, antimony oxide, and 
combinations of antimony with other substances.  Antimony was mined in the United States; however, the
last mine closed in 2001.  Impure antimony ore and metal are imported into the United States from other
countries for processing.  Small amounts of antimony are released into the environment by incinerators
and coal-burning power plants.  Studies indicate that antimony is retained in the soil through adsorption 
and can sorb onto clay minerals, oxides, and hydroxides in the soil and aquatic sediment.
Antimony is predominantly in the +5 oxidation state in both aerobic freshwater and seawater.  These
waters also contain antimony in the +3 oxidation state to a lesser extent. Trivalent antimony is the 
dominant oxidation state of antimony in anaerobic environments.  The predominant trivalent species in 
the environment is antimony trihydroxide (Sb(OH)3) and the predominant pentavalent species is 
hexahydroxoantimonate (Sb(OH)6-), as predicted by thermodynamic calculations.
Antimony can be reduced and methylated by microorganisms in anaerobic sediment, releasing volatile 
methylated antimony compounds into the water.  Multiple microorganisms have been found to methylate
antimony in the soil and water and other anaerobic environments.
The general population is exposed to low levels of antimony from ingestion of food and drinking water
and possibly by inhalation of particulate matter containing antimony in ambient air.  Occupational
exposures of antimony may occur at smelters, coal-fired plants, and refuse incinerators that process or
release antimony.
2.2  	 SUMMARY OF HEALTH EFFECTS 
Antimony and its compounds are among the oldest known remedies in the practice of medicine and they
have been used to treat a variety of illnesses over the last 600 years.  Currently, antimony compounds are
used to treat the parasitic disease leishmaniasis. Toxic side effects in humans following intraperitoneal,
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2. RELEVANCE TO PUBLIC HEALTH
intravenous, or intramuscular injection of an antimony-containing drug have been reported, including
altered electrocardiograms (EKGs), vomiting, diarrhea, and joint and/or muscle pain.  These side effects
are more frequently observed following administration of trivalent antimony compounds, especially
antimony potassium tartrate or antimony sodium tartrate; side effects have also been found in humans
administered pentavalent organic compounds such as sodium antimony gluconate or meglumine
antimoniate.
Adverse health effects have also been observed in humans and animals following inhalation, oral, or
dermal exposure to antimony and antimony compounds.  These studies predominantly assessed the
toxicity of trivalent antimony compounds, particularly antimony trioxide and antimony potassium tartrate.  
In both humans and animals, the respiratory tract is the predominant target of antimony toxicity following
inhalation exposure, and a systematic review of the data (see Appendix B for additional information)
supports the conclusion that antimony is presumed to cause respiratory health effects in humans.  The
lung is the primary target of toxicity within the respiratory tract, and effects are observed following
acute-, intermediate-, and chronic-duration exposure.  In antimony workers, pneumoconiosis and clinical
signs such as coughing and laryngitis have been reported.  A relationship between exposure level and
effect cannot be established from these data because the workers were also exposed to other compounds,
including arsenic oxide, iron oxide, hydrogen chloride, and hydrogen sulfide.  In laboratory animals, the
lung effects include the accumulation of antimony particles in the lungs, increases in alveolar/intra-
alveolar macrophages, decreases in antimony lung clearance times, chronic interstitial inflammation, and
interstitial fibrosis. Lung effects have been found in rats, mice, and rabbits following exposure to 
antimony trioxide, antimony trisulfide, and antimony ore; lung effects have also been observed in
laboratory animals following exposure to stibine gas.  Intermediate- and chronic-duration studies 
demonstrated that pulmonary damage can occur postexposure due to the persistence of the antimony
trioxide in the lung.  At the end of a 13-week or 1-year exposure to antimony trioxide, histological
alterations in the lungs were limited to increases in alveolar/intra-alveolar macrophages; however, after
27-week or 1-year recovery periods, respectively, interstitial inflammation and fibrosis were observed.
Other respiratory effects that have been observed in some studies include squamous metaplasia of the 
epiglottis and hyperplasia of the nasal respiratory epithelium.  The lowest lowest-observed-adverse-effect
levels (LOAELs) for respiratory tract effects following acute-, intermediate-, and chronic-duration 
exposures are 12 mg Sb/m3 as antimony trioxide, 4.11 mg Sb/m3 as antimony trioxide, and 1.6 mg Sb/m3 
as antimony trioxide, respectively.
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2. RELEVANCE TO PUBLIC HEALTH
Cardiovascular effects, especially myocardial damage and alterations in EKGs, have been observed in
humans and animals exposed to antimony.  Based on the systematic review of the available data 
(Appendix B), ATSDR concluded that antimony is suspected to cause cardiovascular health effects,
specifically myocardial and EKG alterations, in humans.  In workers exposed to antimony trisulfide dust, 
EKG alterations were found in about 50% of the workers.  A small number of animal studies included 
EKG readings; these studies reported alterations in rats, rabbits, and dogs exposed to airborne antimony
trisulfide.  No alterations were observed in guinea pigs or pigs exposed to airborne antimony trioxide for
intermediate or chronic durations.  These findings are supported by reports of altered EKG readings
(particularly prolongation of the QT interval) in individuals exposed to repeated injections of antimony
and in experimental studies in laboratory animals injected with trivalent or pentavalent antimony
compounds.
Historically, antimony has been known for its emetic properties.  Gastrointestinal tract irritation is a 
presumed health effect of antimony in humans based on the systematic review of occupational exposure
studies and inhalation and oral exposure studies in laboratory animals.  Abdominal pain, vomiting, 
nausea, and ulcers have been observed in antimony workers.  Gastrointestinal effects have also been 
observed in humans receiving intramuscular injections of antimony.  Vomiting has also been observed in 
dogs following acute oral exposure and chronic inflammation and/or ulceration was observed in the
forestomach of mice following acute oral exposure to antimony potassium tartrate or chronic inhalation 
exposure to antimony trioxide.  Overt signs of gastrointestinal irritation or histological alterations of the
gastrointestinal tract have not been observed in numerous inhalation or oral exposure studies in rats.
There are some data to indicate that antimony decreases blood glucose levels following intermediate or
chronic oral exposure in rats, with supporting data from an intermediate-duration study finding decreased 
blood glucose levels in rats administered intramuscular injections of organic pentavalent compounds.  
Based on the systematic review, it was categorized as a suspected health effect in humans.
The developmental toxicity of antimony has not been extensively evaluated in humans or animals.  
Decreases in growth have been reported in the infants of female antimony workers; interpretation of the
results of this study is limited by the lack of study details, particularly regarding the control group,
antimony concentrations in the facility, type of work the women performed, and potential exposure to 
other compounds.  Studies in animals support the findings of this occupational exposure study.  Decreases
in pup growth were observed in the offspring of rats orally exposed to antimony trichloride during
gestation and lactation, and decreases in birth weight or fetal weight were observed in rats administered
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2. RELEVANCE TO PUBLIC HEALTH
organic pentavalent antimony compounds via subcutaneous or intramuscular injection or administered 
antimony trichloride via intramuscular injection.  Antimony does not appear to result in external or
skeletal abnormalities in rats following oral or parenteral administration.  Based on these data, 
developmental toxicity is a suspected human health effect (see Appendix B for additional information).  
Exposure to antimony during gestation and/or lactation and post-weaning exposure has resulted in 
impaired vasomotor response to 1-noradrenaline, 1-isoprenaline, and acetylcholine in 30- and 60-day-old 
rat pups.
Other health effects that have been observed in animals orally exposed to higher doses of antimony
include hepatocellular vacuolization, hematological alterations including decreases in red blood cell
counts and hemoglobin levels, and histological alterations in the thyroid.
Dermatosis and ocular irritation have been reported in workers exposed to airborne antimony. The
dermatitis was seen more often during the summer months and in workers exposed to high temperatures.  
It is probably the result of antimony being dissolved in sweat and penetrating the sweat glands.  In 
general, dermal effects have not been observed in animal studies.  Animal studies do provide support for
antimony being considered an ocular irritant.  Eye irritation has been reported in animals exposed to 
stibine gas and following instillation of antimony thioantimonate into rabbit eyes.  Additionally, increases 
in corneal opacities and cataracts have been observed in animals repeatedly exposed to airborne antimony
trioxide.
Two occupational exposure studies examining carcinogenicity of antimony have found increases in lung
cancer deaths.  Mixed results have been found in chronic inhalation studies in rats.  Increases in lung
neoplasms were observed in rats exposed to 4.2 or 36 mg Sb/m3 as antimony trioxide for approximately
1 year.  A third 1-year exposure study (followed by a 1-year recovery) did not find lung neoplasms in rats
exposed to 3.8 mg Sb/m3. A 2-year inhalation study conducted by the National Toxicology Program
found increases in the incidence of alveolar/bronchiolar adenomas in rats and alveolar/bronchiolar
adenomas and carcinomas in mice.  No increases in tumors were found in rats or mice following lifetime
oral exposure to antimony potassium tartrate.  The International Agency for Research on Cancer
categorized antimony trioxide in group 2B (possibly carcinogenic to humans) and antimony trisulfide in
group 3 (not classifiable as to its carcinogenicity to humans).  The NTP and EPA have not classified the 
carcinogenicity of antimony.
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2.3  MINIMAL RISK LEVELS (MRLs)
As summarized in Table 2-1, inhalation MRLs have been derived for acute-, intermediate-, and chronic-
duration exposure to antimony and oral MRLs have been derived for acute- and intermediate-duration 
exposure to antimony.  Refer to Section 3.6.2 and Appendix A for detailed information regarding MRL
derivation.
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Table 2-1. Minimal Risk Levels (MRLs) for Antimonya 
Exposure Point of Uncertainty
duration MRL Critical effect departure factor Reference
Inhalation exposure
Acute 0.001 mg Sb/m3 Squamous metaplasia of BMCLHEC of 30b NTP 2016
the epiglottis of mice 0.035 mg 
exposed to ≥12 mg Sb/m3 
Sb/m3 
Intermediate Adopted the acute-duration inhalation MRL of 0.001 mg Sb/m3 
Chronic 0.0003 mg Chronic lung BMCLHEC of 30b Newton et al.
Sb/m3 inflammation in female 0.008 mg 1994
rats Sb/m3 
Oral exposure
Acute 1 mg Sb/kg/day Focal ulceration of the NOAEL of 100c NTP 1992
forestomach in mice 99 mg 
Sb/kg/day
Intermediate 0.0006 mg Decreased serum NOAEL of 100c Poon et al.
Sb/kg/day glucose levels in female 0.064 mg 1998
rats Sb/kg/day
Chronic Insufficient data for derivation of an MRL








cUncertainty factors:  10 for extrapolation from animals to humans and 10 for human variability.
 
BMCL = benchmark concentration lower confidence limit; HEC = human equivalent concentration; NOAEL = no-

observed-adverse-effect level; LOAEL = lowest observed adverse effect level
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3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of antimony and 
compounds.  It contains descriptions and evaluations of toxicological studies and epidemiological
investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic
data to public health.
Studies in which humans or animals are exposed to various antimony compounds are discussed in this
chapter.  The antimony compounds include organic forms (antimony potassium tartrate, antimony sodium
tartrate, antimony acetate), inorganic trivalent antimony (antimony trioxide, antimony trichloride,
antimony trisulfide, stibine), inorganic pentavalent antimony (antimony pentoxide, antimony
pentasulfide), antimony-containing drugs (stibocaptate, stibophen, meglumine), and metallic antimony.  
No limitations were placed on the selection of compounds for inclusion in this toxicological profile. Most
of the available data evaluated the toxicity of trivalent antimony, in particular antimony trioxide.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (e.g., death, systemic, immunological, neurological, 
reproductive, developmental, and carcinogenic effects).  These data are discussed in terms of three 
exposure periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
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considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of antimony are 
indicated in Table 3-1 and Figure 3-1.  
A User's Guide has been provided at the end of this profile (see Appendix C).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure 
Health effects have been observed in humans and animals following inhalation exposure to several
antimony compounds.  Health effects following exposure to airborne stibine (antimony hydride), 
antimony trisulfide, antimony ore, antimony trioxide, antimony pentoxide, antimony trichloride, antimony
pentasulfide, and metallic antimony are discussed below.  Of these, stibine is a naturally occurring gas;
for ease of comparison, its concentrations will be expressed in units of mg/m3 (1 ppm stibine =
5.1 mg/m3).
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In the previous version of the toxicological profile for antimony (ATSDR 1992) and in other documents, 
intermediate- and chronic-duration studies conducted in rats exposed to antimony trioxide were cited as 
unpublished reports (Bio/Dynamics 1985, 1990); these studies have subsequently been published as
Newton et al. (1994).  Unless data are unique to the unpublished version of the studies, data from these
studies will be cited to Newton et al. (1994).  Additionally, data from the Groth et al. (1986) chronic rat
study of antimony trioxide and antimony ore were also cited as an unpublished report (Wong et al. 1979);
to avoid confusion that these are separate studies, the data will be cited only to Groth et al. (1986).
3.2.1.1  Death 
No studies were located regarding death in humans after inhalation exposure to antimony.
Deaths occurred in guinea pigs exposed to approximately 37.9 mg antimony/m3 as antimony trioxide dust
for approximately 60–178 days (Dernehl et al. 1945) and in guinea pigs and rats exposed to 1,395 mg
antimony/m3 as stibine gas for 30 minutes (Price et al. 1979).  Pulmonary edema was a contributing factor
to the death of rats and guinea pigs exposed to stibine (Price et al. 1979).  None of the rats or guinea pigs
exposed to ≤799 mg antimony/m3 for 30 minutes died (Price et al. 1979).  Lower concentrations of
antimony trisulfide (84–105 mg antimony/m3), antimony trioxide (≥36 mg antimony/m3), or antimony ore
(17.5 mg antimony/m3) did not affect the survival of rats exposed for approximately 1 year (Gross et al.
1952; Groth et al. 1986; Newton et al. 1994; Watt 1983). However, a 2-year exposure to ≥8.3 mg Sb/m3 
as antimony trioxide resulted in decreased survival in female rats and male and female mice (NTP 2016).
The decreased survival was attributed to lung inflammation and/or lung carcinomas (mice only).
The LOAEL values for death in animals exposed to stibine or antimony trioxide are presented in 
Table 3-1 and plotted in Figure 3-1.
3.2.1.2  Systemic Effects
The highest NOAEL values and all reliable LOAEL values for each systemic effect in each species and
duration are presented in Table 3-1 and plotted in Figure 3-1. Summaries of systemic effects in humans 
are presented in Table 3-2.
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30 minutes; 0, 122, 
799, 1,395 
CS, BW, HP 1395 Increased mortality (8/10) at an unspecified 
time post-exposure.
Price et al. 1979 
(stibine) 
2 Rat (Sprague 
Dawley)
5M, 5F
30 minutes; 0, 122, 
799, 1,395 
CS, BW, GN, 
HP 
1395 Increased mortality (7/10) at an unspecified 
time post-exposure.
Price et al. 1979 
(stibine) 
Systemic Effects
3 Rat (Sprague 
Dawley)
5M, 5F
30 minutes; 0, 122, 
799, 1,395 










1395 Pulmonary edema and congestion were 
observed at 1395 mg Sb/m3 . 
Price et al. 1979 
(stibine) 
Endocr 122 






16 days; 0, 3.1, 
6.3, 12, 25, 50 mg  






25 Chronic inflammation in the lungs at ≥25 mg 
Sb/m3; increase in squamous metaplasia in 








17 days; 0, 3.1, 
6.3, 12, 25, 50 






12 Squamous metaplasia in epiglottis 
epithelium at 12 mg Sb/m3; increases in 






5 days; 0 or 19.9








Degenerative changes in the heart, liver, 
and kidneys, and inflammation of the lungs 
were observed. Morphological changes in 
heart tissue were accompanied by
alterations in the EKG. Only qualitative data 
were presented.
Brieger et al. 1954  
(antimony trisulfide)
7 Guinea Pig 
(Hartley)
5M, 5F
30 minutes; 0, 122, 
799, 1,395 








Pulmonary edema and congestion at 1395 
mg Sb/m3; investigators did not report 
whether pulmonary effects were observed in 
controls. Renal tubular dilation in 3/10 
animals at 799 mg Sb/m3; investigators did 
not report whether renal lesions occurred at 
1395 mg Sb/m3 . 
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13 weeks; 0, 0.21, 
0.902, 4.11, 19.60  












≥4.11 mg Sb/m3, increases in 
alveolar/intraalveolar macrophages, 
increases in relative lung weight, and 
increases in lung clearance half-times were 
observed. Increased incidences of chronic 
interstitial inflammation and fibrosis were 
observed at 19.60 mg Sb/m3 in the lungs at 
the end of a 27-week recovery period.






1.5-2 months; 0, 
209 











Unspecified pathological changes in the 
lungs, liver, kidneys, and pancreas; only
qualitative data were provided.
Belyaeva 1967 
(antimony trioxide)




6 weeks; 0, 2.20 




Bd Wt 2.20 
2.20 
2.20 
Altered EKG and microscopic changes in 
heart muscle consistent with degeneration of 
the myocardium and mild congestion and 
focal hemorrhages in the lungs. 






7 weeks; 0, 3.81 








Occasional swelling of myocardial fibers, but 
no consistent changes in the EKG.






10 weeks; 0, 3.98







3.98 EKG changes indicative of myocardial injury; 
occasional swelling of myocardial fibers. 






6 weeks; 0, 4.02 









4.02 Altered EKG, heart enlargement, swelling of 
myocardial fibers; only qualitative data were
presented.




















Pneumonitis, decreases in total and 
differential leukocyte counts, fatty 
degeneration in the liver, and hypertrophy of 
lymphoid follicles in the spleen were 
observed.
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1.5-2 months; 0, 
209 
Developmental Effects
MX, DX, BW, 
GN, HP, OF
209 Reduced fertility (16/24 conceived compared 
to 10/10 in controls) and histological 
alterations in reproductive organs; only











MX, DX, BW, 
GN, HP, OF
209 Reduced litter size; it is unknown if this was 









2 years; 0, 2.5, 8.3, 
25 
CS, LE, BW, 
GN, HP
8.3 Decreased survival in females at ≥8.3 mg 









2 years; 0, 2.5, 8.3, 
25 
CS, LE, BW, 
GN, HP
8.3 Decreases in survival at ≥8.3 mg Sb/m3 . NTP 2016
(antimony trioxide)
Systemic Effects
19 Rat (Fisher 6 hours/day CS, BW, OP, Resp 0.05c 0.43 Moderate or severe lenticular degeneration Newton et al. 1994  
344) 5 days/week HE, BI, HP Cardio 3.8 was observed at 3.8 mg Sb/m3 . An increase (antimony trioxide)
65M, 65F 12 months; 0, 0.05, Hemato 3.8 in alveolar/intraalveolar macrophages were 
0.43, 3.8 Ocular 0.05 0.43 observed in all antimony groups.  An 
Bd Wt 3.8 increase in chronic interstitial inflammation 
was observed in rats exposed to 0.43 
(females only) and 3.8 mg Sb/m3 and 
terminated during the recovery period.  An 
80% decrease in lung clearance was 
observed at 3.8 mg Sb/m3 . 
20 Rat (Sprague- 25 hours/week GN, HP Resp 84 Gross and microscopic alterations in the Gross et al. 1952
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52 weeks; 0, 36 



















36 Interstitial fibrosis and alveolar-wall cell 
hypertrophy and hyperplasia which persisted 
after exposure termination.   
Groth et al. 1986
(antimony trioxide)




52 weeks; 0, 17.5  



















17.5 Interstitial fibrosis and alveolar-wall cell 
hypertrophy and hyperplasia which persisted 
after exposure termination.   
Groth et al. 1986
(antimony ore)





55 weeks; 0, 1.6,
4.2 
CS, LE, BW, 






















1.6 Focal fibrosis, adenomatous hyperplasia, 
multinucleated giant cells, cholesterol clefts, 
pneumocyte hyperplasia, and pigmented 
macrophages in lungs. Incidence of lesions 
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2 years; 0, 2.5, 8.3, 
25 
























Respiratory: inflammation, proteinosis, 
hyperplasia, and fibrosis at ≥2.5 mg Sb/m3; 
hyperplasia of nasal respiratory epithelium at 
2.5 mg Sb/m3 (males only) and 25 mg Sb/m3 
(males and females) and squamous 
metaplasia of nasal epithelium in males at 
25 mg Sb/m3; Musculoskeletal: bone 
marrow hyperplasia at 25 mg Sb/m3; 
Cardiovascular: chronic inflammation of 
NTP 2016
(antimony trioxide)
muscular arteries at 8.3 (females only) and
25 mg Sb/m3; Renal: hyaline droplet 
accumulation at 8.3 (females only) and 25 
mg Sb/m3 and nephropathy in females at 25 
mg Sb.m3; Body weight:  decreases in body
weight gain in females at 2.5 (10%), 8.3 
(20%), and 25 (28%) mg Sb/m3 and in males 
at 25 mg Sb/m3 (20%); Ocular: ciliary body
inflammation at 25 mg Sb/m3 and retinal 





CS, LE, BW, 
GN, HP






Respiratory:  chronic, inflammation, fibrosis 












bronchiolar epithelial hyperplasia at ≥2.5 mg 
Sb/m3; laryngeal respiratory epithelial 
hyperplasia were observed at ≥8.3 mg 





respiratory epithelium in females at 25 mg 
Sb/m3; and epithelial hyperplasia in the 
trachea of males exposed to 25 mg Sb/m3 . 
Hematological:  hematopoietic cell 
proliferation in the spleen in females at 25 
mg Sb/m3 . Cardiovascular: chronic 
inflammation of epicardium at ≥8.3 mg 
Sb/m3 . Gastrointestinal: chronic active 
inflammation in the forestomach of males at 
25 mg Sb/m3 . Musculoskeletal: bone 
marrow hyperplasia at ≥2.5 mg Sb/m3 . 
Body weight:  decreases in body weight 
gain in males at 8.3 and 25 mg Sb/m3 (11 
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55 weeks; 0, 1.6,
4.2 
CS, LE, BW, 





















No histological alterations were observed. Watt 1983 (antimony trioxide) 
Immuno/Lymphoret
27 Rat (Fisher 
344)
65 M, 65 F
6 hours/day 
5 days/week
12 months; 0, 0.05, 
0.43, 3.8 
LE, CS, BW, 
HP, OP, GN, 
OW, HP
0.43 3.8 Increased incidence of reticuloendothelial 
cell hyperplasia in peribronchiolar lymph 
nodes; no tests of immunocompetence were 
conducted in the study.
Newton et al. 1994 
(antimony trioxide)




52 weeks; 0, 36 
LE, CS, BW, 
GN, HP
36 No histological alterations in spleen or lymph 
nodes. 
Groth et al. 1986
(antimony trioxide)




52 weeks; 0 ,17.5  
LE, CS, BW, 
GN, HP
17.5 Mononuclear cell granulomas in 
tracheobronchial lymph nodes.
Groth et al. 1986
(antimony ore)





55 weeks; 0, 1.6,
4.2 
CS, LE, BW, 
OW, HE, BI, 
GN, HP









2 years; 0, 2.5, 8.3, 
25 
CS, LE, BW, 
GN, HP
2.5 Lymphoid hyperplasia in bronchial and 








2 years; 0, 2.5, 8.3, 
25 
CS, LE, BW, 
GN, HP
2.5 Lymphoid hyperplasia in the bronchial and 
mediastinal (males only) lymph nodes and 









55 weeks; 0, 1.6,
4.2 
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52 weeks; 0, 36 
LE, CS, BW, 
GN, HP
36 No histological alterations in the brain. Groth et al. 1986
(antimony trioxide)





55 weeks; 0, 1.6,
4.2 mg 
CS, LE, BW, 
OW, HE, BI, 
GN, HP







2 years; 0, 2.5, 8.3, 
25 
CS, LE, BW, 
GN, HP









2 years; 0, 2.5, 8.3, 
25 
CS, LE, BW, 
GN, HP




38 Pig (Sinclair 6 hours/day CS, LE, BW, 4.2 No histological alterations in the brain. Watt 1983 
S-1 miniature 5 days/week OW, HE, BI, (antimony trioxide)
pig) 55 weeks; 0, 1.6, GN, HP
2-3 F 4.2 
Reproductive Effects




52 weeks; 0, 36 
LE, CS, BW, 
GN, HP
36 No histological alterations were observed in 
reproductive tissues. 
Groth et al. 1986
(antimony trioxide)




52 weeks; 0, 17.5  
LE, CS, BW, 
GN, HP
17.5 No histological alterations in reproductive 
tissues.
Groth et al. 1986 (antimony
ore)





55 weeks; 0, 1.6,
4.2 
CS, LE, BW, 
OW, HE, BI, 
GN, HP
 4.2 Exposure to antimony trioxide dusts did not 
significantly affect the gross or microscopic 
appearance of the ovaries and uterus. 






2 years; 0, 2.5, 8.3, 
25 
CS, LE, BW, 
GN, HP
2.5 An increase in epithelial hyperplasia of the 
prostate gland was observed in 2.5 and 8.3 
mg Sb/m3; increases in severity were
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2 years; 0, 2.5, 8.3, 
GN, HP reproductive tissues. (antimony trioxide)
25 
44 Pig (Sinclair 6 hours/day CS, LE, BW, 4.2 Exposure to antimony trioxide dusts did not Watt 1983 (antimony trioxide) 
S-1 miniature 5 days/week OW, HE, BI, significantly affect the gross or microscopic 
pig) 55 weeks; 0, 1.6, GN, HP appearance of the ovaries and uterus. 
2-3F 4.2 
Cancer




52 weeks; 0, 36 
LE, CS, BW, 
GN, HP
36 Increased incidence of lung neoplasms in 
females. 
Groth et al. 1986 (antimony
trioxide)




52 weeks; 0, 17.5  
LE, CS, BW, 
GN, HP
17.5 Increased incidence of lung neoplasms in 
females. 
Groth et al. 1986 (antimony
ore)





55 weeks; 0, 1.6,
4.2 






2 years; 0, 2.5, 8.3, 
25 
CS, LE, BW, 
GN, HP
8.3 Alveolar/bronchiolar adenomas in females at 
≥8.3 mg Sb/m3, benign pheochromocytoma 
in adrenal medulla at 25 mg Sb/m3, and 
combined incidence of benign and malignant 
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2 years; 0, 2.5, 8.3, 
GN, HP adenomas, carcinomas, or combined were
observed at ≥2.5 mg Sb/m3 . Other 
(antimony trioxide)
25 neoplastic lesions included malignant 
lymphoma in females at ≥2.5 mg Sb/m3 and 
fibrous histiocytoma in the skin in males at 
25 mg Sb/m3 . 
aThe number corresponds to entries in Figure 3-1.

bUsed to derive an acute-duration inhalation MRL of 0.001 mg Sb/m3 calculated using benchmark dose analysis.  The BMCL10 of 0.94 mg Sb/m3 was adjusted for intermittent exposure (6 

hours/day, 5 days/week), multiplied by the RDDR of 0.206, and divided by an uncertainty factor of 30 (3 for extrapolation from animals to humans with dosimetric adjustments and 10 for human 

variability).   

cUsed to derive a chronic-duration inhalation MRL of 0.0003 mg Sb/m3. The BMCL10 of 0.10 mg Sb/m3 was adjusted for intermittent exposure (6 hours/day, 5 days/week), multiplied by the 

RDDR of 0.436, and divided by an uncertainty factor of 30 (3 for extrapolation from animals to humans with dosimetric adjustments and 10 for human variability).   

Parameters monitored:  BI = biochemical changes; BW = body weight; CS= clinical signs; DX = developmental toxicity; GN = gross necropsy; HE = hematology; HP = histopathology; LE = 

lethality; MX = maternal toxicity; OF = organ function; OP = ophthalmology; OW = organ weight
 
Bd wt = body weight; BMCL = lower 95% confidence limit on the benchmark concentrations; Cardio = cardiovascular; EKG = electrocardiogram; Endocr = endocrine; F = female(s); 
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Figure 3-1. Levels of Significant Exposure to Antimony - Inhalation

































Human - NOAEL Animal - NOAEL 
Human - LOAEL, Less Serious Animal - LOAEL, Less Serious 
Human - LOAEL, More Serious Animal - LOAEL, More Serious 
Human - Cancer Effect Level Animal - Cancer Effect Level 
Animal - LD50/LC50 Minimal Risk Level for effects other than cancer 
C-Cat K-Monkey J-Pigeon O-Other D-Dog M-Mouse E-Gerbil 
R-Rat H-Rabbit S-Hamster 
P-Pig   A-Sheep G-Guinea Pig 
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Human - NOAEL Animal - NOAEL 
Human - LOAEL, Less Serious Animal - LOAEL, Less Serious 
Human - LOAEL, More Serious Animal - LOAEL, More Serious 
Human - Cancer Effect Level Animal - Cancer Effect Level 
Animal - LD50/LC50 Minimal Risk Level for effect other than cancer 
C-Cat K-Monkey J-Pigeon O-Other D-Dog M-Mouse E-Gerbil 
R-Rat H-Rabbit S-Hamster 
P-Pig   A-Sheep G-Guinea Pig 
Q-Cow F-Ferret  N-Mink 
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Figure 3-1. Levels of Significant Exposure to Antimony - Inhalation (Continued) 
Intermediate (15-364 days) 
1000 
Respiratory Cardio Hematological 
Systemic 
Hepatic Renal Endocrine Body Weight Reproductive Developmental 
9R 9R 9R 9R 9R 15R 16R 
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Figure 3-1. Levels of Significant Exposure to Antimony - Inhalation (Continued) 
Chronic (≥365 days) 
Systemic 
Musc/ Immuno/ 





























































































*Doses represent the lowest dose tested per study that produced a tumorigenic
response and do not imply the existence of a threshold for the cancer endpoint. 
Human - NOAEL Animal - NOAEL 
Human - LOAEL, Less Serious Animal - LOAEL, Less Serious 
Human - LOAEL, More Serious Animal - LOAEL, More Serious 
Human - Cancer Effect Level Animal - Cancer Effect Level 
Animal - LD50/LC50 Minimal Risk Level for effects other than cancer 
C-Cat K-Monkey J-Pigeon O-Other D-Dog M-Mouse E-Gerbil 
R-Rat H-Rabbit S-Hamster 
P-Pig   A-Sheep G-Guinea Pig 










    
   
 







   






















   
   















    
  
 
   












3.  HEALTH EFFECTS
Table 3-2. Health Effects in Humans Exposed to Antimony Dusts
Reference Study population Exposure 	 Outcomes
Belyaeva 1967	 Female workers at an antimony
metallurgical facility; some of the 
women worked in a more dusty
section of the facility.  A control
group was also examined;
however, no information was
provided whether the controls
were matched to the exposed 
group or whether they had similar
jobs without antimony exposure.
The number of subjects was not
reported; antimony levels were 
measured in 308 and 115 blood 
samples from workers and 
controls, respectively.
Brieger et al.	 112 workers involved in the
1954	 production of grinding wheels.
Workers were employed for
8 months to 2 years. No control
group was used.
Exposure:  Workers were exposed to 
metallic antimony, antimony trioxide, and 
antimony pentasulfide.  The antimony levels
in the blood and urine were 0.5–20.2 and 
0.5–18.2 mg/dL, respectively, in the workers
in the dusty section of the facility and 0.5– 
18.2 mg/L and 0.5–16.2 mg/dL, respectively,
in the less dusty section.  The blood 
antimony level in the control group ranged
from 0 to 3.3 mg/dL.
Exposure:  Antimony trisulfide levels ranged 
from 0.42 to 3.9 mg Sb/m3, with the majority
of the findings >2.2 mg Sb/m3.
Confounding exposure: Workers were 
also exposed to phenol formaldehyde resin.
Reproductive effects: Reproductive 
disturbances were reported in 77.5% of the 
workers and 56% of controls.  Increases in the
occurrence of disturbances in the menstrual
cycle were found (61.2% in workers and 35.7%
in controls.  Increases in spontaneous abortion 
(12.5%) were found in the workers, as compared 
to controls (4.1%).
Developmental effects: Decreases in infant
body weight gain were observed beginning at
6 months of age. By 12 months of age, infants
of workers weighed 8.96 kg compared to 
10.05 kg in the controls.
Respiratory effects: No signs of respiratory
irritation were reported.
Cardiovascular effects: Altered EKG readings
(mostly T waves) were found in 37/75 workers.
Increased blood pressure was observed in 
14/112 workers and low blood pressure was
observed in 24/112 workers; significance of
these findings are not known since there was no
control group.
Gastrointestinal effects: A higher incidence of
ulcers were found in the antimony exposed 
workers (63 per 1,000) compared to the total
plant population (15 in 1,000).
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Table 3-2. Health Effects in Humans Exposed to Antimony Dusts
Reference Study population Exposure 	 Outcomes
Cooper et al.	 28 antimony process workers
involved in extraction of antimony
ore to antimony trioxide.
Workers employed for 1– 
15 years.  No control group was
used.
Jones 1994	 Retrospective cohort mortality
study of 192 workers involved in 
the production of antimony metal,
antimony alloys, and antimony
trioxide. Employed for at least
3 months.  Cause of death of
maintenance workers and zircon 
plant worker, and office workers
at the same facility was
examined.
Kim et al. 1999	 Study of 12 workers (mean age 
of 35 years) exposed to antimony
trioxide at a manufacturing facility
for an average of 30 months.
Another group of 22 workers
(mean age of 33 years) at the 
facility not near the antimony
sources was also examined.  A
second control group of
33 volunteers (mean age of
50 years) without occupational
exposure to antimony was also 
examined.
Exposure: Antimony trioxide levels ranged 
from 0.081 to 138 mg Sb/m3 at 47 locations
within the facility.
Exposure: No monitoring data were 
provided.
Confounding exposure:  Investigators
noted that the workers were likely exposed 
to arsenic in the antimony ore. Smoking 
status was not included as a potential
confounding variable.
Exposure:  The mean antimony
concentration in the exposed workers was
0.766 mg/m3.  Geometric mean urine 
antimony concentrations were 410.8, 112.5,
and 27.8 μg/g creatinine in the exposed 
workers, control workers, and volunteer
controls, respectively.
Respiratory effects: No consistent alterations
in lung function (only 14 subjects were 
examined).  Pneumoconiosis was confirmed in 
three workers and suspected in five other
workers.
Respiratory effects: No significant increases in 
deaths from respiratory effects.
Cancer: Increase in lung cancer deaths in 
antimony workers and maintenance workers.
Only significant in workers hired prior to 1940
and between 1946 and 1950. Workers with
latency period of >20 years had the highest
increase in lung cancer deaths.
Immunological effects:  Significant decreases
in serum IgG1 and IgE levels were observed in 
exposed workers compared to control groups.  A
significant association between IgG4 levels and 
urine antimony levels were found in the exposed 
workers; no associations were found for other
IgG subgroups or for IgE. No alterations in Il-2 
or interferon-gamma levels were in the exposed 
workers, as compared to control workers.
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Table 3-2. Health Effects in Humans Exposed to Antimony Dusts







Linked data from the Nurses’
Health Study with EPA’s Air
Toxic data (n=97,430 females).
51 males employed at a smelting 
facility.  Mean duration of
employment was 17.9 years
(range of 9–31 years).  All
workers experienced 
pneumoconiotic changes. No 
control group was used.
Exposure: Median antimony concentrations
for each exposure quartile were 0.000034,
0.000138, 0.000287, and 0.000682 μg/m3.
Exposure: Workers were exposed to 
antimony oxides; 39–89% of dust was
antimony trioxide and 2.1–7.8% was
antimony pentoxide.  No monitoring data 
were provided.
Confounding exposure:  Investigators
noted that the airborne dust contained silica 
(0.82–4.72%), ferric trioxide (0.90–3.81%),
and arsenic oxide (0.21–6.48%). No 
information on smoking was provided.
Neurological effects: No significant
association between antimony levels and risk of
Parkinson’s disease was found. Risk estimates
were adjusted for age, smoking, and population 
density.
Respiratory effects: Clinical signs included 
chronic coughing (61%) and upper airway
inflammation (35%). Respiratory effects
included Type 1p pneumoconiosis (67%),
chronic bronchitis (37%), chronic emphysema 
with pulmonary function changes (34%), inactive
tuberculosis (18%), and pleural adhesions
(28%).  No consistent pattern of lung function 
alterations was found.
Dermal effects: Dermatosis (63%) found
predominantly in workers exposed to
excessively high temperatures.
Ocular effects: Conjunctivitis (28%).
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Table 3-2. Health Effects in Humans Exposed to Antimony Dusts
Reference Study population Exposure 	 Outcomes
Renes 1953	 78 males involved in smelting or
employed as maintenance 
workers. Workers were 
employed for at least 2 weeks.
No control group was used.
Schnorr et al.	 1,014 workers at an antimony
1995	 smelter in Texas.  Employed for
at least 3 months; average length 
of employment was 6.8 years.
Exposure: Average concentrations in the 
breathing zone were 10.07 mg/m3 in the 
furnace area and 11.81 mg/m3 in the cupel
area.
Confounding exposure:  Arsenic was
present in smelting material; average levels
of arsenic in the furnace and cupel areas
were 1.10 and 0.36 mg/m3, respectively.
Workers were also exposed to hydrogen 
sulfide and iron oxide.
Exposure: Monitoring surveys conducted in 
1975 and 1976 found geometric mean 
antimony levels of 0.5551 mg/m3 using area 
samples and 0.747 mg/m3 using personal
samples.
Confounding exposure:  Investigators
noted that the workers were also exposed to 
arsenic. Smoking status was not included 
as a potential confounding variable.
Respiratory effects: Soreness and bleeding of
the nose (>70%), laryngitis (11%), and rhinitis
(20%) of workers.
Gastrointestinal effects: 11% reported
gastrointestinal symptoms (abdominal cramps,
diarrhea, vomiting).
Dermal effects:	 Dermatitis (20%).
Neurological effects: Nine workers reported 
nerve tenderness and tingling, severe 
headaches, and prostration.  Antimony was
detected in urine samples from 7/9 of these 
workers.
Respiratory effects: Increase in deaths from
influenza (SMR=1.23) and pneumoconiosis/
other respiratory disease among workers with 
Spanish surnames.
Cardiovascular effects: Increased deaths.
from ischemic heart disease among Spanish 
surname workers as compared to a survey of
Mexican-American population or to Spanish 
surnamed workers at a cadmium facility; the 
statistical significance of this finding was not
reported.
Cancer: Nonsignificant increase in deaths from
lung cancer especially among workers with the 
longest period since first employed (>20 years)
and the longest duration of employment
(>10 years) (SMR=1.55; 90% CI 0.86–2.60).
Significant positive trend in lung cancer deaths
with increasing duration of employment when 
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Table 3-2. Health Effects in Humans Exposed to Antimony Dusts
Reference Study population Exposure 	 Outcomes
Stevenson 1965 Case series of 23 workers at an
antimony smelter exposed to 
antimony trioxide dust and 
reporting dermatitis.
Taylor 1966	 Case series of seven workers
acutely exposed to high levels of
antimony trichloride.
Exposure: Antimony concentrations were 
not reported; investigators noted that most of
the antimony trioxide dust was <1 μm in 
diameter.
Confounding exposure: The antimony
sulfide ore contained minute traces of lead,
arsenic, and iron; the investigators also 
noted that sulfur dioxide was released during 
the smelting process.
Exposure: It is likely that the workers were
exposed to up to 73 mg Sb/m3.
Confounding exposure: The workers were 
exposed to ≤146 mg/m3 hydrogen chloride.
compared to an ethnic-specific rate.
Dermal: Erythematous papules were most
commonly reported in the antecubital area and 
shins.  The investigators noted that these areas
were most exposed to heat, which resulted in 
sweating.  The rash typically subsided 3– 
14 days after the workers were transferred to 
cooler working environments.
Respiratory: 7/7 workers reported upper
respiratory tract soreness; this is likely due to 
the hydrogen chloride exposure.
Gastrointestinal: Abdominal pain (4/7),
vomiting (3/7), and anorexia (5/7) were reported 
by workers.
CI = confidence interval; EKG = electrocardiogram; EPA = Environmental Protection Agency; SMR = standardized mortality ratio
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Respiratory Effects. Studies of workers exposed to antimony compounds (primarily antimony
trioxide) have reported upper and lower respiratory effects.  Upper respiratory effects included soreness 
and bleeding of the nose, rhinitis, and laryngitis in workers at an antimony smelter (Renes 1953). One of
the more commonly reported lower respiratory effects is pneumoconiosis in workers involved in 
extraction of antimony trioxide from antimony ores and workers at antimony smelters (Cooper et al. 
1968; Potkonjak and Pavlovich 1983; Schnorr et al. 1995).  Other lower respiratory effects include
chronic coughing, upper airway inflammation, and chronic bronchitis (Potkonjak and Pavlovich 1983). In
the two studies that conducted lung function tests, no consistent pattern of alterations was found (Cooper
et al. 1968; Potkonjak and Pavlovich 1983).  Three studies provided some monitoring data.  In the study
reporting upper respiratory effects, the average antimony concentrations were 10.07–11.81 mg/m3 (Renes 
1953).  In the two studies reporting pneumoconiosis, antimony levels were 0.081–138 mg/m3 in one study
(Cooper et al. 1968) and 0.747 mg/m3 (geometric mean concentration) in the second study (Schnorr et al. 
1995).  Several studies reported that the workers were also exposed to arsenic, which was present in the 
antimony ores (Jones 1994; Potkonjak and Pavlovich 1983; Renes 1953; Schnorr et al. 1995); the workers 
were also exposed to other compounds including iron oxide and hydrogen sulfide (Potkonjak and 
Pavlovich 1983; Renes 1953).  In contrast to these studies of workers exposed to antimony ores and/or
antimony oxides, respiratory irritation was not noted in workers exposed to ≤3.9 mg Sb/m3 as antimony
trisulfide for 8 months to 2 years (Brieger et al. 1954).
Studies in laboratory animals, particularly rats, support the findings of the epidemiology studies and 
suggest that the respiratory tract is one of the most sensitive targets of inhaled antimony toxicity.  The
lungs appear to be the most sensitive portion of the respiratory tract, and the severity of the respiratory
effects appear to be concentration- and duration-related.  Although most of the studies were conducted 
using antimony trioxide, studies with stibine (Price et al. 1979), antimony trisulfide (Brieger et al. 1954), 
and antimony ore (Groth et al. 1986) have also reported lung effects.
Exposure to antimony aerosols results in deposition of the particles in the lungs, which leads to increases 
in the number of alveolar macrophages, inflammation, and fibrosis.  The earliest and most sensitive effect
of inhaled antimony is increased alveolar and/or intra-alveolar macrophages. Intermediate- and chronic-
duration studies found increases in alveolar and/or intra-alveolar macrophages in rats exposed to
concentrations as low as 4.11 mg Sb/m3 as antimony trioxide following a 13-week exposure (Newton et
al. 1994) and 0.05 mg Sb/m3 as antimony trioxide following a 1-year exposure (Newton et al. 1994).  The
increases in macrophages persisted for at least 27 weeks or 1 year, respectively, after exposure 
termination. The proliferation of macrophages is a normal physiological response to the deposition of
***DRAFT FOR PUBLIC COMMENT***
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insoluble particulates in the lung and increases in the number of alveolar macrophages in the absence of
evidence of lung damage were not considered adverse. The increases in antimony lung deposition also 
resulted in increases in lung clearance half-times.  Following a 13-week exposure (Newton et al. 1994), 
the lung clearance half-times were 5.5 and 5.25 months in male and female rats, respectively, exposed to 
4.11 mg Sb/m3 and 10 and 8.25 months in male and female rats, respectively, exposed to 19.60 mg Sb/m3; 
by comparison, the half-times were 3.75 months in both male and female rats exposed to 0.902 mg Sb/m3. 
Similarly, in the 1-year exposure study (Newton et al. 1994; data reported in Bio/Dynamics 1990), the
antimony lung clearance half-times in male and female rats were 3.0 and 4.2 months, respectively, at
0.43 mg Sb/m3 and 8.7 and 10.2 months, respectively, at 3.8 mg Sb/m3, as compared to 2.5 and
2.2 months, respectively, in the 0.05 mg Sb/m3 group.  The investigators noted that the decrease in lung
clearance was higher than anticipated if it was solely due to volumetric overloading, suggesting that
clearance was also affected by the intrinsic toxicity of antimony trioxide. In a 2-year study using smaller
particles (mass median aerodynamic diameter [MMAD] of 1.0–1.4 μm compared to 3.05 μm in the
Newton et al. [1994] study), estimated clearance half-times were 136, 206, and 262 days (approximately
4.5, 6.8, and 8.6 months) for exposures to 2.5, 8.3, and 25 mg Sb/m3, respectively, as antimony trioxide
(NTP 2016).
The lowest antimony trioxide concentrations resulting in histological alterations (lung inflammation) in 
rats are 19.60 and 0.43 mg Sb/m3 in intermediate- and chronic-duration studies (Newton et al. 1994), 
respectively. In both studies, the increases in the incidence of lung inflammation were observed at the 
end of a 27-week or 1-year recovery period; these effects were not observed at the end of the exposure 
period (highest concentrations tested were 19.60 and 3.8 mg Sb/m3 in the intermediate and chronic 
studies, respectively). In contrast, NTP (2016) found significant increases in the incidence in chronic
inflammation and other lung lesions in rats exposed to ≥2.5 mg Sb/m3 for 1 year; the smaller particle size 
in the NTP (2016) study may explain the difference between the studies.  The lowest concentrations in
mice resulting in lung inflammation are 25 mg Sb/m3 following a 16-day exposure and 0.25 mg Sb/m3 
following a 2-year exposure (NTP 2016). Inflammation was also observed in rabbits exposed to 19.9 mg
Sb/m3 as antimony trisulfide for 5 days (Brieger et al. 1954) and in guinea pigs after intermediate-
duration exposure to 37.9 mg Sb/m3 as antimony trioxide (Dernehl et al. 1945).  Chronic exposure to 
higher concentrations (≥1.6 mg Sb/m3 as antimony trioxide or 17.5 mg Sb/m3 as antimony ore) resulted in
lung fibrosis (Groth et al. 1986; Newton et al. 1994; NTP 2016; Watt 1983). Other lesions observed in 
the lungs include proteinosis and alveolar/bronchiolar epithelial hyperplasia in rats and mice exposed to 
2.5 mg Sb/m3 as antimony trioxide for 1 or 2 years (NTP 2016), pulmonary edema and congestion in rats
and guinea pigs exposed to a lethal stibine concentration of 1,395 mg Sb/m3 for 30 minutes (Price et al. 
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1979), alveolar hypertrophy and hyperplasia and cholesterol clefts in rats exposed to 36 mg Sb/m3 as 
antimony trioxide or 17.5 mg Sb/m3 as antimony ore for 52 weeks (Groth et al. 1986) or rats exposed to 
4.2 mg Sb/m3 for 55 weeks (Watt 1983), lipoid pneumonia in rats exposed to 84–105 mg Sb/m3 as 
antimony trioxide for 14.5 months (Gross et al. 1952), and focal hemorrhages in the lungs of rats exposed 
to 2.20 mg Sb/m3 as antimony trisulfide for 6 weeks (Brieger et al. 1954).
The NTP (2016) 2-year antimony trioxide study also reported hyperplasia of the nasal respiratory
epithelium in rats exposed to ≥2.5 mg Sb/m3, squamous metaplasia of the respiratory epithelium in rats
and mice exposed to 25 mg Sb/m3, laryngeal epithelial hyperplasia in mice exposed to ≥8.3 mg Sb/m3, 
and hyperplasia of tracheal epithelium in mice exposed to 25 mg Sb/m3.
Cardiovascular Effects. Altered EKG readings were observed in workers exposed to 0.42–3.9 mg
Sb/m3 as antimony trisulfide for 8 months to 2 years (Brieger et al. 1954).  Of the 75 workers examined, 
37 showed changes in the EKG, mostly of the T-waves; these workers had also been exposed to phenol
formaldehyde resin (Brieger et al. 1954).  In a cohort mortality study, an increase in death from ischemic
heart disease was observed among antimony smelter workers with Spanish surnames (Schnorr et al.
1995); the statistical significance of this finding was not reported.  These limited data on cardiovascular
effects in humans are supported by the finding of cardiac effects following parenteral administration of
antimony to humans (see discussion of other routes of exposure in Section 3.2.4).
Inhalation exposure to antimony trisulfide dust (dust sample taken from an antimony production facility)
resulted in degenerative changes in the myocardium and related EKG abnormalities (elevation of the
RS-T segments and flattening of T-waves) in a variety of animal species (Brieger et al. 1954).  Five days 
of exposure to 19.9 mg Sb/m3 as antimony trisulfide resulted in EKG alterations in rabbits.  In
intermediate-duration studies, EKG alterations were observed in rats, rabbits, and dogs exposed to 2– 
4 mg Sb/m3 as antimony trisulfide for 6–10 weeks (Brieger et al. 1954).  It should be noted that elevated 
levels of arsenic were also present in the facilities’ dust samples.  This study also reported degenerative 
changes of the myocardium in rats, rabbits, and dogs exposed to antimony trisulfide, which consisted of
hyperemia and swelling of myocardial fibers (Brieger et al. 1954).  Most studies with antimony trioxide
exposure did not find cardiovascular effects.  No EKG alterations were observed in pigs exposed to 
4.2 mg Sb/m3 as antimony trioxide for 1 year (Watt 1983) or guinea pigs exposed to 37.9 mg Sb/m3 for an 
intermediate-duration (Dernehl et al. 1945), and myocardial damage was not observed in rats exposed to
concentrations as high as 19.60 mg Sb/m3 for 13 weeks (Newton et al. 1994) or 36 mg Sb/m3 for 
approximately 1 year (Groth et al. 1986; Newton et al. 1994; Watt 1980) or guinea pigs exposed to 
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37.9 mg Sb/m3 for 2–30 weeks (Dernehl et al. 1945). NTP (2016) found chronic inflammation of the
epicardium of mice exposed to ≥8.3 mg Sb/m3 for 2 years and chronic inflammation of muscular arteries
in rats exposed to ≥8.3 mg Sb/m3.
Gastrointestinal Effects. A variety of gastrointestinal symptoms have been reported in workers
engaged in activities including acute exposure to antimony trichloride (Taylor 1966) and chronic
exposure to antimony trisulfide (Brieger et al. 1954) or antimony oxide (Renes 1953).  The symptoms
include abdominal pain, diarrhea, vomiting, and ulcers; no additional information was provided.  A causal
relationship to antimony exposure has not been definitely established because workers were exposed to a 
variety of other agents, in addition to antimony, that might cause or contribute to gastrointestinal effects 
(e.g., hydrogen chloride, sodium hydroxide) and the studies did not examine unexposed workers.  
Furthermore, in all likelihood, both inhalation and oral exposure to antimony occur at the workplace.  
Assuming that gastrointestinal effects are related to antimony exposure, site monitoring data indicate that
effective exposure levels may range from approximately 2 to 70 mg Sb/m3.
Symptoms of gastrointestinal disturbances were not reported in animals, and no histopathological
alterations were observed in rats exposed to ≤36 mg Sb/m3as antimony trioxide or 17.5 mg Sb/m3 as 
antimony ore for 1 year (Groth et al. 1986; Watt 1980) or pigs exposed to 4.2 mg Sb/m3 as antimony
trioxide for 55 weeks (Watt 1983). However, chronic active inflammation was observed in the 
forestomach of mice exposed to 25 mg Sb/m3 as antimony trioxide for 2 years (NTP 2016).
Hematological Effects. Information on the hematological toxicity of antimony is limited to a case
report of three workers exposed to stibine, arsine, and hydrogen sulfide (Dernehl et al. 1944).  Two of the
three workers reported hematuria with weakness, headache, and abdominal and lumbar pain.  It is not
known if stibine was the causative agent of these effects. No studies were located regarding
hematological effects in humans after inhalation exposure to other antimony compounds.
Toxicologically significant hematological effects have not been observed in rats and pigs following
intermediate- or chronic-duration exposure to antimony aerosols ranging from approximately 4 to 20 mg 
Sb/m3 as antimony trioxide (Newton et al. 1994; Watt 1983).  One study reported decreases in total
leukocyte counts and in polymorphonuclear leukocyte and eosinophil counts in guinea pigs exposed to 
36.9 mg Sb/m3 as antimony trioxide for 2–30 weeks (Dernehl et al. 1945) and another study reported 
hematopoietic cell proliferation in the spleen of female mice exposed to 25 mg Sb/m3 for 2 years (NTP
2016).
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Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans after
inhalation exposure to antimony.
No histopathological alterations were noted in the musculoskeletal system in rats exposed to 4.2 mg
antimony/m3 as antimony trioxide for 1 year (Watt 1980). Bone marrow hyperplasia was observed in rats
exposed to 25 mg Sb/m3 and mice exposed to ≥2.5 mg Sb/m3 for 2 years (NTP 2016); the investigators 
noted that the hyperplasia in the mice was predominantly of myeloid cell type, which may have been
secondary to the lung inflammation.
Hepatic Effects. No studies were located regarding hepatic effects in humans after inhalation 
exposure to antimony.
Parenchymatous or fatty degeneration was observed in rabbits exposed to 19.9 mg Sb/m3 as antimony
trisulfide for 5 days (Brieger et al. 1954) and in guinea pigs exposed to 37.9 mg Sb/m3 as antimony
trioxide for 2–30 weeks (Dernehl et al. 1945).  No hepatic effects were observed in rats exposed to 
≤36 mg Sb/m3 as antimony trioxide for 1 year (Groth et al. 1986; Watt 1983) or 17.5 mg Sb/m3 as 
antimony ore (Groth et al. 1986), or in rats or mice exposed to 25 mg Sb/m3 as antimony trioxide for
2 years (NTP 2016).
Renal Effects. No studies were located regarding renal effects in humans after inhalation exposure to 
antimony.
Two acute exposure studies have reported renal damage.  Tubular dilation was observed in guinea pigs
exposed to 799 mg Sb/m3 as stibine gas for 30 minutes (Price et al. 1979) and parenchymatous
degeneration was observed in rabbits exposed to 19.9 mg Sb/m3 as antimony trisulfide for 5 days (Brieger
et al. 1954).  No renal effects were noted in rats exposed to 17.5 mg Sb/m3 as antimony ore or up to 
36 mg Sb/m3 as antimony trioxide for 1 year (Groth et al. 1986; Watt 1983) or mice exposed to 25 mg
Sb/m3 as antimony trioxide for 2 years (NTP 2016). A 2-year exposure of rats resulted in an increase in
hyaline droplet accumulation at ≥8.3 mg Sb/m3 as antimony trioxide and nephropathy in female rats at
25 mg Sb/m3 (NTP 2016).
***DRAFT FOR PUBLIC COMMENT***
  
 








        
   
 
 
      




    




    




      
   
   
    
      
    







   
    
       
38ANTIMONY AND COMPOUNDS
3. HEALTH EFFECTS
Dermal Effects. Dermal effects have been reported in workers exposed to antimony oxides.  These
effects are likely due to direct skin contact with the antimony and are discussed in Dermal Effects portion
of Section 3.2.3.2.
Ocular Effects. Ocular effects likely due to direct contact with stibine or antimony trioxide have been
reported in animal studies. These findings are discussed in the Ocular Effects portion of Section 3.2.3.2.
NTP (2016) reported an increased incidence of ciliary body inflammation in rats exposed to 25 mg Sb/m3 
for 2 years.  A non-concentration-related increase in retinal atrophy was also observed in female rats 
exposed to ≥2.5 mg Sb/m3 (NTP 2016); the severity of the atrophy was similar to that observed in the
concurrent controls.  It is not known if these effects are due to direct contact or are systemic effects.
3.2.1.3  Immunological and Lymphoreticular Effects 
One study examined the possible immunotoxicity of antimony in workers. In this study (Kim et al.
1999), decreases in IgG2 and IgE levels were found.
No animal studies evaluated immune function following inhalation exposure to antimony.  In chronic-
exposure studies, hyperplasia of the reticuloendothelial cells in the peribronchiolar lymph nodes was
observed in female rats exposed to 3.8 mg Sb/m3 as antimony trioxide for 1 year with a 1-year recovery
period (Newton et al. 1994, incidence data reported in Bio/Dynamic 1990) and lymphoid hyperplasia was
observed in the bronchial and mediastinal lymph nodes of rats and mice exposed to ≥2.5 mg Sb/m3 as 
antimony trioxide for 2 years (NTP 2016). Another study reported the presence of mononuclear cell
granulomas in rats exposed to17.5 mg Sb/m3 as antimony ore for 1 year (Groth et al. 1986); this effect
was not found in rats similarly exposed to 36 mg Sb/m3 as antimony trioxide (Groth et al. 1986). The
investigators noted that the granulomas were similar to those found in the early stages of silicosis and
sarcoidosis.
3.2.1.4  Neurological Effects 
A causal relationship between exposure to airborne antimony and neurological effects in humans has not
been established.  Nerve tenderness and a tingling sensation, headaches, and prostration were reported in 
workers exposed to antimony oxide at a concentration of 10.07 mg antimony/m3 (Renes 1953).  However,
the factory workers were also exposed to arsenic, lead, copper, and possibly hydrogen sulfide and sodium
hydroxide.  Thus, it is difficult to determine if this effect was the result of antimony exposure. Another
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study attempted to link air monitoring levels of antimony with the risk of Parkinson’s disease in nurses 
and did not find a significant association (Palacios et al. 2014); it should be noted that the air
concentrations were very low (the median level in the highest quartile was 0.000682 μg/m3).
Information on the neurotoxicity of antimony in laboratory animals is limited to the chronic-duration
studies that found no histological alterations in the brain of rats (Groth et al. 1986; NTP 2016; Watt
1983), mice (NTP 2016), or pigs (Watt 1983) exposed to antimony trioxide.
3.2.1.5  Reproductive Effects
Disturbances in the menstrual cycle were reported in 61.2% of women exposed to airborne metallic 
antimony, antimony pentasulfide, and antimony trioxide in a metallurgical plant compared to the 35.7%
occurrence in controls (Belyaeva 1967); no other details were provided.  No information (such as age and 
whether they had similar jobs as the workers) was provided that could be used to evaluate the
appropriateness of the control group.  The investigators noted that 77.5% of the workers and 56% of the
controls had reproductive disturbances. The study also found an increase in the rate of spontaneous
abortions (particularly late term abortions) in the workers (12.5%) as compared to the rate in controls
(4.1%).
Data on the reproductive toxicity of antimony are limited to an intermediate-duration study conducted by
Belyaeva (1967), which found a reduction in fertility (67% conceived compared to 100% in controls) in 
rats exposed to 209 mg Sb/m3 as antimony trioxide.  No histological alterations were observed in the
reproductive tissues of rats exposed to antimony trioxide or antimony ore for 1 year (Groth et al. 1986;
Watt 1983) or mice exposed to antimony trioxide for 2 years (NTP 2016). Increases in the incidence of
epithelial hyperplasia were observed in the prostate of rats exposed to 2.5 or 8.3 mg Sb/m3 for 2 years 
(NTP 2016).
The NOAEL and LOAEL values for reproductive effects in rats and mice are presented in Table 3-1 and 
Figure 3-1.
3.2.1.6 Developmental Effects 
The study of women working at a metallurgical facility (Belyaeva 1967) also reported decreases in infant
body weight gain beginning at 6 months of age; at 12 months of age, they weighed 11% less than infants
from the control group. Interpretation of the results of this study is limited by the lack of information on 
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the control group, type of work the women performed, when the workers returned to work after giving
birth, and information on confounding exposure to other compounds.
A decreased number of offspring was observed in rats exposed to 209 mg antimony/m3 as antimony
trioxide prior to conception and throughout gestation.  No difference in fetal body weights was observed 
(Belyaeva 1967).  This LOAEL for developmental effects in rats is presented in Table 3-1 and Figure 3-1.
3.2.1.7  Cancer
Several studies of antimony oxide workers have examined the carcinogenic potential of antimony.  A
significant positive trend in lung cancer deaths with increasing duration of employment was observed in 
workers at an antimony smelter facility (Schnorr et al. 1995). Similarly, another study of workers
exposed to metallic antimony, antimony alloys, and antimony trioxide found increases in lung cancer
deaths in workers hired prior to 1940 or between 1946 and 1950 (Jones 1994). In both studies, the
workers were also exposed to arsenic and neither study included smoking status as a confounding
variable.
Four studies have evaluated the carcinogenicity of antimony trioxide in rats.  Increases in lung neoplasms 
(squamous cell carcinomas, bronchioalveolar adenomas and carcinomas, and scirrhous carcinoma) were
observed in female rats exposed to 4.2 mg Sb/m3 for 55 weeks with a 1-year recovery period (Watt 1983)
or 36 mg Sb/m3 for 52 weeks with a 20-week recovery period (Groth et al. 1986).  However, a third study
(Newton et al. 1994) did not find any neoplasms in male or female rats exposed to 3.8 mg Sb/m3 for 
1 year with a 1-year recovery period. Newton et al. (1994) stated that a pathologist who examined the
slides from the Groth et al. (1986), Watt (1983), and Newton et al. (1994) studies noted more extensive
lung damage and a considerable higher amount of antimony trioxide in the lungs of rats tested in the Watt
(1983) study as compared to those tested in the Newton et al. (1994) study even though the concentrations
were similar, suggesting that the actual concentrations tested by Watt (1983) may have been higher than
reported.  A fourth study found significant increases in the incidence of alveolar/bronchiolar adenomas at
8.3 mg Sb/m3 and benign pheochromocytomas in the adrenal gland of rats exposed to 25 mg Sb/m3 for 
2 years (NTP 2016).  Increases in lung neoplasms were also observed in rats exposed to 17.5 mg Sb/m3 as 
antimony ore for 52 weeks followed by a 1-year recovery period (Groth et al. 1986). In mice, a 2-year
exposure to antimony trioxide resulted in significant increases in alveolar/bronchiolar adenomas, 
carcinomas, or combined incidences at ≥2.5 mg Sb/m3, malignant lymphomas in females exposed to
≥2.5 mg Sb/m3, and fibrous histiocytomas in the skin of males exposed to 25 mg Sb/m3 (NTP 2016). No
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increases in lung tumors were observed in pigs exposed to 4.2 mg Sb/m3 as antimony trioxide (Watt
1983).
The CELs are recorded in Table 3-1 and Figure 3-1.
3.2.2 Oral Exposure
Health effects have been observed in humans and animals following oral exposure to a variety of
antimony compounds.  Adverse effects following exposure to antimony potassium tartrate (an organic 
form of trivalent antimony), antimony trichloride, antimony trioxide, and metallic antimony are discussed 
below. It should be noted that the results of the NTP (1992) study were published by Dieter et al. (1991);
these data will only be cited to NTP (1992) to avoid confusion that these are separate studies.
3.2.2.1  Death 
No studies were located regarding death in humans after oral exposure to antimony.
Mortality was not observed in rats following a single exposure to ≤188–17,000 mg Sb/kg as antimony
trioxide (Fleming 1982; Myers et al. 1978; Smyth and Carpenter 1948; Smyth and Thompson 1945) or to 
a 7,000 mg Sb/kg dose of metallic antimony (Bradley and Frederick 1941).  However, a lower single dose 
of organic antimony (300 mg Sb/kg dose as antimony potassium tartrate) resulted in death in rats
(Bradley and Frederick 1941).  Death was attributed to myocardial failure.  Significant increases in deaths 
were not observed in rats or mice exposed to 61 or 150 mg Sb/kg/day as antimony potassium tartrate in 
drinking water for 14 days (NTP 1992).  These data for death in animals suggest that organic antimony is 
more lethal than the inorganic compounds, probably due to increased absorption of the antimony
potassium tartrate, likely due to its increased solubility.
Intermediate-duration exposure to inorganic antimony compounds or metallic antimony did not result in 
increases in deaths in rats exposed to ≤1,570 mg Sb/kg/day as antimony trioxide in the diet (Hext et al.
1999; Hiraoka 1986) or ≤850 mg Sb/kg/day as metallic antimony (Hiraoka 1986). Chronic administration 
of a low dose of antimony potassium tartrate (0.63 mg Sb/kg/day) resulted in decreased lifespan in rats 
(Schroeder et al. 1970).  A decrease in survival was also noted in female mice exposed to 0.35 mg
Sb/kg/day as antimony potassium tartrate (Kanisawa and Schroeder 1969); however, there was no 
statistical analysis of the data.
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The reliable LOAEL values are presented in Table 3-3 and plotted in Figure 3-2.
3.2.2.2  Systemic Effects
The highest NOAEL values and all reliable LOAELs for each systemic effect in each laboratory species
and duration are presented in Table 3-3 and plotted in Figure 3-2; summaries of epidemiology studies are
presented in Table 3-4.
Respiratory Effects. In the only human study examining respiratory end points, no significant
association between urinary antimony levels and the prevalence of asthma was found among participants
in the 2007–2008 National Health and Nutrition Examination Survey (NHANES) (Mendy et al. 2012).
No histological alterations were observed in the respiratory tract in several studies at the highest doses 
tested; the highest NOAEL values were 61 or 150 mg Sb/kg/day in rats or mice, respectively, exposed to 
antimony potassium tartrate in drinking water for 14 days (NTP 1992), 1,408 mg Sb/kg/day in rats 
exposed to antimony trioxide in the diet for 90 days (Hext et al. 1999), and 42.17 mg Sb/kg/day in rats 
exposed to antimony potassium tartrate in drinking water for 13 weeks (Poon et al. 1998).
Cardiovascular Effects. Several investigators have utilized the NHANES dataset to examine the 
possible association between antimony and cardiovascular toxicity.  No significant associations were 
found between urinary antimony levels and the prevalence of congestive heart failure, coronary heart
disease, angina pectoris, heart attack, or stroke (Mendy et al. 2012). In two studies, significant
associations between urinary antimony levels and the prevalence of high blood pressure were found in 
adults (Shiue and Hristova 2014; Shiue 2014); antimony accounted for 6.2% of the population risk (Shiue
and Hristova 2014).
No histopathological alterations were observed in the heart following acute-duration exposure of rats and
mice to 61 or 150 mg Sb/kg/day as antimony potassium tartrate (NTP 1992) or following intermediate-
duration exposure to 1,408 mg Sb/kg/day as antimony trioxide (Hext et al. 1999) or 42.17 mg Sb/kg/day
as antimony potassium tartrate (Poon et al. 1998). In studies evaluating cardiovascular function, no 
significant alterations in blood pressure were observed in rats exposed to 0.7 mg Sb/kg/day as antimony
trichloride during pregnancy and/or lactation (Angrisani et al. 1988; Marmo et al. 1987; Rossi et al. 1987)
or rats chronically exposed to 0.63 mg Sb/kg/day as antimony potassium tartrate (Schroeder et al. 1970).  
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Table 3-3. Levels of Significant Exposure to Antimony – Oral 
43
Less 

















1 Rat 14 days BW, WI, CS, Resp 61 No histological or body weight alterations NTP 1992; Dieter et al. 1991 
(F344/N) (W); 0, 5.8, 10, OW, HP Cardio 61 were observed. (antimony potassium tartrate)
10M, 10F 21, 34, and 61 mg Gastro 61 




Bd wt 61 
Mouse 14 days BW, WI, CS, 
(B6C3F1) (W); 0, 21, 36, 63, OW, HP
10M, 10F 99, and 150 mg 
Sb/kg/day 
Resp 150 Focal ulceration in the forestomach in NTP 1992; Dieter et al. 1991 
Cardio 150 4/10 mice and minimal-to-moderate (antimony potassium tartrate)
Gastro 99b 150 hepatocellular cytoplasmic vacuolization 
Musc/Skel 150 in 10/10 mice. Decreased body weight 
Hepatic 99 150 gain was observed at 63 and 99 mg 
Renal 150 Sb/kg/day in males and females, 
Endocr 150 respectively; midway through the study.
Bd wt 63 99 Final body weights were within 93% of the 
controls. Dramatic decreases in water 
consumption were observed at all doses. 
3 Dog (Beagle) Once (W); 4.8 mg CS Gastro 4.8 The mean latency to vomit was 30 Houpt et al. 1984 (antimony







(W); 0, 0.07, and





No significant alterations in body weight or 
blood pressure were found in the dams. 
Angrisani et al. 1988; Marmo et al. 
1987 (antimony trichloride) 
5 Rat 10NS 14-20 days
(GW); 0, 390-500 
mg Sb/kg 




No evidence of digestive upset or 
alterations in body weight.









Bd Wt 1500 Terminal body weight reduced 16% 
relative to pair-fed controls.   
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7 Rat (Wistar) Daily CS, OP, BW, Resp 1408 No alterations in hematological or serum Hext et al. 1999 (antimony trioxide) 
12M, 12F 90 days
(F); M: 0, 70, 353, 






chemistry indices or histopathology were 
observed.
and 1408 mg Hemato 1408
Sb/kg/day; F:  0, 













(F); 0 or 700 mg 
Sb/kg/day 






No alterations in hematological 
parameters or body weight gain. 





(F); 0, 85, or 850
mg Sb/kg/day 






Body weight was decreased 10% at 85 
mg Sb/kg/day and 18% at 850 mg
Sb/kg/day.  Food consumption data were 
not provided.
Hiraoka 1986 (antimony metal)





(W); M: 0, 0.06, 
0.56, 5.58, and 
42.17 mg 
Sb/kg/day; F: 0, 
0.06, 0.64, 6.13, 
and 45.69 mg 
Sb/kg/day 
BW, FI, WI, 




























Hematological:  A 5% decrease in red 
blood cell levels and 12% decrease in 
platelet counts were observed in male rats 
exposed to 42.17 mg Sb/kg/day.  
Hepatic:  Liver effects included minimal 
nuclear anisokaryosis in males at ≤5.58 
mg Sb/kg/day and females at 0.06 mg 
Sb/kg/day and mild nuclear anisokaryosis 
at higher doses. These alterations were 
considered adaptive and not biologically
significant. Endocrine: Minimal to mild 
epithelial changes (increased cell height, 
decreased follicle size, and nuclear 
Poon et al. 1998 (antimony
potassium tartrate)
vesiculations) were observed in the 
thyroid at ≥0.06 mg Sb/kg/day. 
Metabolic: Decreases in serum glucose 
levels (15-17%) were observed in females 
exposed to ≥0.64 mg Sb/kg/day.  Other:
In the spleen, mild sinus congestion was 
observed at ≥0.56 mg Sb/kg/day in males 
and hyperplasia was observed at ≥0.64 
mg Sb/kg/day in females and at 42.17 mg 
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11 Rat (NS) 44 days; 0, 0.07, BW, OF Cardio 0.7 No alterations in blood pressure; 11% Rossi et al. 1987; Marmo et al. 









894 Significantly increased (21%) red blood 
cell count. Decreased body weight gain 
Smyth and Thompson 1945 
(antimony trioxide)
(F); 0, 50, 230, Bd Wt 230 890 accompanied with a decrease in food 
890 mg Sb/kg/day consumption. 




CS, BW, FI, 







Reduced terminal body weight, 
hematocrit, hemoglobin, and serum 
Sunagawa 1981 (antimony metal)
(F); 0, 370, 740, BI, HP Bd Wt 740 1500 albumin/globulin ratio; increased total 
1,500 mg 
Sb/kg/day 
serum protein. Increased incidence of 
disorder of the hepatic cords at 740 and 
1500 mg Sb/kg/day and cloudy swelling in 
the hepatic cords at 1500 mg Sb/kg/day.
14 Rat (Wistar) Daily CS, BW, FI, Hemato 620 Reduced red blood cell count (22%) at Sunagawa 1981 (antimony trioxide)
5M 24 weeks WI, OW, HE, Hepatic 620 620 and 1200 mg Sb/kg/day; increased 
(F); 0, 620, 1,200 BI, HP Bd Wt 1200 incidence of cloudy swelling in hepatic 
mg Sb/kg/day cords at 620 (3/5) and 1200 (2/5) mg 
Sb/kg/day, as compared to controls (0/5).
Immunological and Lymphoreticular Effects
15 Rat (Sprague Daily BW, FI, WI, 
0.06 
0.56 An increase in medullary volume in Poon et al. 1998 (antimony
Dawley) 13 weeks HE, BI, OW, thymus gland in males at ≥0.56 mg potassium tartrate)
15M, 15F (W); M: 0, 0.06, HP Sb/kg/day and females at ≥6.13 mg 
0.56, 5.58, and Sb/kg/day; the study did not evaluate 
42.17 mg immune function. 
Sb/kg/day; F: 0, 
0.06, 0.64, 6.13, 







OW, HP 1000   No significant alterations in sperm count, 
motility, or morphology or histological 
Omura et al. 2002 (antimony 
trioxide)






OW, HP 10   No significant alterations in sperm count, 
motility, or morphology or histological 
Omura et al. 2002 (antimony 
potassium tartrate)
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(G); 0, 10, or
or morphology or histological alterations in 
testes were observed. 
trioxide)
1000 mg Sb/kg
19 Mouse 5 days/week OW, HP 10   No significant alterations in sperm count Omura et al. 2002 (antimony 
(Crj:CD) 4 weeks or morphology or histological alterations in potassium tartrate)





44 days; 0, 0.07, 
0.7 mg Sb/kg/day 
BW, OF 0.07 0.7 Decreased pup growth on PND10-60; 
pups weighed 26% and 47% less than 
controls on PND 10 and 22, respectively. 




38 days; 0, 0.1, 1
mg Sb/kg/day 
BW, OF 0.1 Significant alterations in vasomotor 
response to 1-noradrenaline and 1-
isoprenaline at ≥0.1 mg Sb/kg/day at 60 
days of age and to acetylcholine at 1 mg 
Rossi et al. 1987; Marmo et al. 
1987 (antimony trichloride) 
Sb/kg/day at 60 days of age.
22 Rat 38 days BW; OF 0.1 Altered vasomotor response to 1- Angrisani et al. 1988; Marmo et al. 
(NS) (W); 0, 0.1, 1 mg noreadrenaline and 1-isoprenaline in pups 1987 (antimony trichloride) 
10M,F Sb/kg/day at 0.1 mg Sb/kg/day and to acetylcholine 
at 1 mg Sb/kg/day, no alterations in 






(W); 0 or 0.35 mg 
Sb/kg/day 






Lifetime (W); 0 or 
0.63 mg 
Sb/kg/day 
LE, BW, OW, 
UR, GN
0.63 Exposure to antimony significantly 
reduced survival rate in male and female 
rats. At the median life spans, males 
survived 106 days and females 107 days
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Table 3-3. Levels of Significant Exposure to Antimony – Oral 
47
Less 




















Lifetime (W); 0 or 
0.63 mg 
Sb/kg/day 








Decreased (28-30%) non-fasting serum 
glucose in males and females. 




Lifetime; 0 or 0.35 
mg Sb/kg/day 




No histological alterations in the liver or 
alterations in body weight gain.
Kanisawa and Schroeder 1969 
(antimony potassium tartrate)
aThe number corresponds to entries in Figure 3-2.

bUsed to derive an acute-duration oral MRL of 1 mg Sb/kg/day based on a NOAEL of 99 mg Sb/kg/day and divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 

10 for human variability). 

cUsed to derive an intermediate-duration oral MRL of 0.0006 mg Sb/kg/day based on a NOAEL of 0.06 mg Sb/kg/day and divided by an uncertainty factor of 100 (10 for extrapolation from animals 

to humans and 10 for human variability).
 
Parameters monitored:  BC = biochemistry; BI = biochemical changes; BW = body weight; CS = clinical signs; FI = food intake; GN = gross necropsy; HE = hematology; HP = histopathology; LE = 

lethality; OP = ophthalmology; OF = organ function; OW = organ weight; UR = urinalysis; WI = water intake;  

Cardio = cardiovascular; CI = confidence interval; d = day(s); Endocr = endocrine; F = female(s); Gastro = gastrointestinal; GC = gas chromatography; Hemato = hematological; hr = hour(s); 
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2M 
1R1R1R 1R 1R1R 1R 1R 
3D 
Human - NOAEL Animal - NOAEL 
Human - LOAEL, Less Serious Animal - LOAEL, Less Serious 
Human - LOAEL, More Serious Animal - LOAEL, More Serious 
Human - Cancer Effect Level Animal - Cancer Effect Level 
Animal - LD50/LC50 Minimal Risk Level for effects other than cancer 
C-Cat K-Monkey J-Pigeon O-Other D-Dog M-Mouse E-Gerbil 
R-Rat H-Rabbit S-Hamster 
P-Pig   A-Sheep G-Guinea Pig 
Q-Cow F-Ferret  N-Mink 
1 
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Figure 3-2. Levels of Significant Exposure to Antimony - Oral
Acute (≤ 14 days) 
Systemic 
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Figure 3-2. Levels of Significant Exposure to Antimony - Oral (Continued) 
Intermediate (15-364 days) 
Systemic 
Musc/ Immuno/ 
































































Human - NOAEL Animal - NOAEL 
Human - LOAEL, Less Serious Animal - LOAEL, Less Serious 
Human - LOAEL, More Serious Animal - LOAEL, More Serious 
Human - Cancer Effect Level Animal - Cancer Effect Level 
Animal - LD50/LC50 Minimal Risk Level for effect other than cancer 
C-Cat K-Monkey J-Pigeon O-Other D-Dog M-Mouse E-Gerbil 
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Human - NOAEL Animal - NOAEL 
Human - LOAEL, Less Serious Animal - LOAEL, Less Serious 
Human - LOAEL, More Serious Animal - LOAEL, More Serious 
Human - Cancer Effect Level Animal - Cancer Effect Level 
Animal - LD50/LC50 Minimal Risk Level for effects other than cancer 
C-Cat K-Monkey J-Pigeon O-Other D-Dog M-Mouse E-Gerbil 
R-Rat H-Rabbit S-Hamster 
P-Pig   A-Sheep G-Guinea Pig 
Q-Cow F-Ferret  N-Mink 
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Figure 3-2. Levels of Significant Exposure to Antimony - Oral (Continued) 
Chronic (≥365 days) 
Systemic 













    
   
 








     
    
 
 

























   
 
 





   
 
 
   
 
 
   
 
 




Table 3-4.  Health Effects in Humans Orally Exposed to Antimony







Populations living in two cities in Turkey
near the Black Sea; 13,012 cancer cases
were registered in 2000–2007.
Case-control study of 28 women in 
Newfoundland, Canada with an infant
diagnosed with neural tube defect;
mothers of age-matched infants living in 
the same geographical region served as
controls.
1,857 adults (49.6% males, 50.4%
females; mean age of 50.3 years)
participating in the 2007–2008 NHANES.
541 water samples were collected 
from the area; antimony levels were 
<20 μg/L in all samples.
Mean antimony levels in drinking 
water were 0.02 and 0.11 ppb in the 
control and case groups,
respectively.
Geometric mean urinary antimony
level was 0.06 μg/g creatinine (95%
CI 0.06–0.06).
Cancer effects: A positive relationship
between antimony levels and cancer incidence 
was found.  The study examined 17 metals and 
found that, in total, they accounted for only 8.2%
of the cancer incidence of the population.
Developmental effects: No significant
difference in antimony drinking water levels
between the cases and controls.
Medical conditions were self-reported.
Respiratory effects: No significant association 
with asthma.
Cardiovascular effects: No significant
associations for congestive heart failure,
coronary heart disease, angina pectoris, heart
attack, or stroke.
Hepatic effects: No significant associations
with liver conditions.
Endocrine effects: No significant association 
with thyroid conditions.
Other systemic effects: No significant
association with gout.
Cancer effects: No associations with cancer.
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Table 3-4.  Health Effects in Humans Orally Exposed to Antimony
Reference Study population Exposure 	 Outcomes
Shiue 2014	 5,864 adults aged ≥20 years participating 
in 2011–2012 NHANES.  High blood 
pressure (systolic blood pressure 
≥140 mmHg and diastolic blood pressure 
≥90 mmHg) was found in 31.1% of the 
total population (this rate includes
children, which were not included in the 
statistical analyses); blood pressure 
classification was based on a single blood
pressure measurement.
Shiue 2015	 5,031 adults (48.4% males, 51.6%
females) aged 20-–9 years participating in
2009–2010 NHANES; the mean age was
44 years. Ankylosing spondylitis
assessed via clinical measures of occiput-
to-wall distance and chest expansion;
values of >2 and >2.5 cm were considered 
abnormal; active lumbar flexion was also 
used to assess ankylosing spondylitis but
the criterion was not reported.
Shiue and	 Adults aged ≥20 years participating in 
Hristova 2014	 2009–2012 NHANES; based on data 
presented in the paper, 2,391 participants
were ≥18 years for age. See Shiue (2014)
for blood pressure criteria.
Urinary antimony level (mean levels
were not reported in the study) was
the biometric used for the analyses;
urine samples were collected by 20– 
30% of the whole NHANES cohort.
Urinary antimony level (mean levels
were not reported in the study) was
the biometric used for the analyses;
urine samples were collected by 20– 
30% of the whole NHANES cohort.
Urinary antimony level (mean levels
were not reported in the study) was
the biometric used for the analyses;
urine samples were collected by 20– 
30% of the whole NHANES cohort.
Cardiovascular effects: Significant association 
between urinary antimony levels and high blood 
pressure; OR of 1.56 (95% CI 1.29–1.89) with
adjusting for urine creatinine levels, age, sex,
body mass index, and ratio of family income to 
poverty level.  In weighted model (also includes
adjustment for subsample weighting), the OR
was 1.39 (95% CI 1.10–1.77).  The study also 
found significant associations for several other
metals (cobalt, cesium, manganese, lead, tin,
platinum, molybdenum, thallium, and tungsten).
Musculoskeletal effects: Significant
association between urinary antimony levels and
occiput-to-wall distance; OR of 1.74 (95% CI
1.15–2.62).  No association with chest
expansion (OR 0.90; 95% CI 1.65–1.29) or
active lumbar flexion (OR -0.05; 95% CI -0.17– 
0.03).
Cardiovascular effects: Significant association 
between urinary antimony levels and high blood 
pressure; OR of 1.99 (95% CI 1.30–1.95) with
adjusting for urine creatinine levels, age, sex,
body mass index, and ratio of family income to 
poverty level.  In weighted model (also includes
adjustment for subsample weighting), the OR
was 1.44 (95% CI 1.12–1.86).  The investigators
estimated that antimony accounted for 6.2% of
the population risk.
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Table 3-4.  Health Effects in Humans Orally Exposed to Antimony
Reference Study population Exposure Outcomes
Zheng et al.
2014
1,106 women in China. Umbilical cord antimony was
measured.
Developmental effects: Median umbilical cord 
antimony was significantly higher in women with 
adverse pregnancy outcomes (18.6 μg/L)
compared to controls (0.16 μg/L); however, the 
risk of adverse pregnancy outcome in 
association with antimony was not statistically
significant.
CI = confidence interval; NHANES = National Health and Nutrition Examination Survey; OR = odds ratio
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Alterations in vasomotor responses were observed in pups exposed to antimony chloride; these effects are
discussed under Developmental Effects.
Gastrointestinal Effects. Shortly after drinking lemonade contaminated with antimony potassium, 
workers began to vomit (Dunn 1928).  Gastrointestinal effects have also been reported in factory workers 
after exposure to airborne antimony dust.  As discussed in Section 3.2.1.2, the gastrointestinal effects 
probably resulted from swallowing the antimony dust.
Vomiting was observed in dogs following a single exposure to antimony potassium tartrate (Houpt et al.
1984).  Other studies have not reported overt signs of gastrointestinal effects in rats or mice following
acute- or intermediate-duration exposures to antimony trioxide or antimony potassium tartrate (Fleming
1982; Hext et al. 1999; NTP 1992; Poon et al. 1998).  Focal ulceration was observed in the forestomach 
of mice exposed to 150 mg Sb/kg/day as antimony potassium tartrate for 2 weeks (NTP 1992).  
Histological alterations were not observed in rats (Hext et al. 1999; NTP 1992; Poon et al. 1998).
Hematological Effects. No studies were located regarding hematological effects in humans after oral
exposure to antimony.
Animal studies have examined potential hematological effects of three antimony compounds (metallic 
antimony, antimony trioxide, and antimony potassium tartrate) following intermediate-duration exposure.  
No alterations in hemoglobin levels or hematocrit were observed in rats exposed to 850 mg Sb/kg/day as
metallic antimony; however, a decrease in hematocrit level was observed 4 weeks postexposure (Hiraoka 
1986).  In a second study, no consistent dose-related alterations in red blood cell counts were observed in 
rats exposed to 370–1,500 mg Sb/kg/day; however, significant decreases in hemoglobin and hematocrit
were observed at 1,500 mg Sb/kg/day (Sunagawa 1981).  Mixed results were found for antimony trioxide.  
Smyth and Thompson (1945) reported an increase in red blood cell count in rats at 894 mg Sb/kg/day and 
Sunagawa (1981) reported a decrease in red blood cell counts at 620 mg Sb/kg/day; neither study found 
alterations in hemoglobin levels.  In contrast, no alterations in hematological parameters (including red
blood cell counts) were found in rats exposed to 700 mg Sb/kg/day (Hiraoka 1986) or 1,408 mg
Sb/kg/day (Hext et al. 1999). Decreases in red blood cell and platelet counts were observed in male rats 
exposed to 42.17 mg Sb/kg/day as antimony potassium tartrate; no effects were found in female rats
(Poon et al. 1998).  The inconsistent findings across studies and compounds preclude determining
whether antimony adversely affects the hematological system.
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Musculoskeletal Effects. Shiue (2015) found a significant association between urinary antimony
levels and one of the three clinical measures of ankylosing spondylitis among adults participating in the 
NHANES; however, no associations were found for the other two measures of ankylosing spondylitis.
No histological alterations in musculoskeletal tissue were observed in rats or mice acutely exposed to
61 or 150 mg Sb/kg/day as antimony potassium tartrate (NTP 1992) or in rats exposed to 1,408 mg
Sb/kg/day as antimony trioxide for 90 days (Hext et al. 1999).
Hepatic Effects. Mendy et al. (2012) did not find a significant association between urinary antimony
levels and liver conditions among NHANES participants.
Minimal to mild hepatocellular cytoplasmic vacuolization, primarily in the centrilobular region, was
observed in mice exposed to 150 mg Sb/kg/day as antimony potassium tartrate for 2 weeks (NTP 1992).  
Minimal cloudy swelling of the hepatic cords has been observed in rats exposed to 620 mg Sb/kg/day as
antimony trioxide or 740 mg Sb/kg/day as metallic antimony for 24 weeks (Sunagawa 1981).  Increases 
in the incidence of nuclear anisokaryosis and hepatocellular portal density were observed in all groups of
rats exposed to antimony potassium tartrate in the drinking water for 13 weeks (Poon et al. 1998); the
severity of either alteration was considered mild in males at ≥5.58 mg Sb/kg/day and in females at
≥0.64 mg Sb/kg/day.  However, these alterations are adaptative changes and were not considered to be
biologically adverse.  Other studies have not found hepatic effects at doses as high as 61 mg Sb/kg/day as
antimony potassium tartrate in rats for 14 days (NTP 1992), 1,408 mg Sb/kg/day as antimony trioxide in 
rats for 90 days (Hext et al. 1999), or 0.35 mg Sb/kg/day as antimony potassium tartrate in mice for
lifetime exposure (Kanisawa and Schroeder 1969).
Renal Effects. No studies were located regarding renal effects in humans after oral exposure to
antimony.
Animal studies have not reported histological alterations in the kidneys of rats and mice acutely exposed
to 61 or 150 mg Sb/kg/day as antimony potassium tartrate (NTP 1992), rats exposed to ≤1,408 mg 
Sb/kg/day as antimony trioxide for an intermediate duration (Hext et al. 1999; Smyth and Thompson 
1945), or rats exposed to 42.17 mg Sb/kg/day as antimony potassium tartrate for an intermediate duration 
(Poon et al. 1998).
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Endocrine Effects. No significant association between urinary antimony levels and self-reported 
thyroid conditions were found in NHANES participants (Mendy et al. 2012).
In general, studies examining endocrine organs have not reported adverse effects at 61 or 150 mg
Sb/kg/day as antimony potassium tartrate in rats and mice exposed for 14 days (NTP 1992) or in rats
exposed to 1,408 mg Sb/kg/day as antimony trioxide for 90 days (Hext et al. 1999). Poon et al. (1998)
reported minimal to mild epithelial changes in the thyroid of rats exposed to ≥0.06 mg Sb/kg/day; 
however, the alterations were not dose-related and did not appear to affect thyroid function, and the
investigators did not consider them adverse.
Dermal Effects. No studies were located regarding dermal effects in humans after oral exposure to
antimony. No dermal effects were observed in rats exposed to antimony trioxide in drinking water for 
13 weeks at doses as high as 42.17 mg Sb/kg/day (Poon et al. 1998).
Ocular Effects. No studies were located regarding ocular effects in humans after oral exposure to
antimony. No histological alterations were observed in the eyes of rats exposed to 1,408 mg Sb/kg/day as
antimony trioxide for 90 days (Hext et al. 1999).
Body Weight Effects. No studies were located regarding body weight effects in humans after oral
exposure to antimony.
Most studies have not reported decreases in body weight gain in laboratory animals exposed to metallic 
antimony, antimony trioxide, or antimony potassium tartrate (Angrisani et al. 1988; Fleming 1982; Hext
et al. 1999; Hiraoka 1986; Kanisawa and Schroeder 1969; NTP 1992; Poon et al. 1998; Schroeder et al.
1970; Sunagawa 1981); the highest NOAEL values identified in these studies are listed in Table 3-3.  
Four studies did report decreases in body weight and/or weight loss.  NTP (1992) reported significant 
decreases in body weight gain in mice exposed to 99 mg Sb/kg/day (males) or 150 mg Sb/kg/day (males 
and females). Although these decreases in body weight gain were observed midway through the 2-week
study, the body weights of all groups of mice were within 93% of the controls at termination.  Decreases 
in body weight gain (body weights were 11–18% lower than controls) were observed in rats exposed to 
≥85 mg Sb/kg/day as metallic antimony for 12 weeks; the lower body weights in the 850 mg Sb/kg/day
group were still lower than controls after a 12-week recovery period (Hiraoka 1986). Smyth and 
Thompson (1945) reported a decrease in body weight gain in rats exposed to 890 mg Sb/kg/day as
antimony trioxide in the diet for 30 days; however, a decrease in food intake was also observed at that
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dose level.  A fourth study reported an 11% decrease in maternal weight gain in rats exposed to 0.7 mg
Sb/kg/day as antimony trichloride in drinking water during gestation and lactation (Rossi et al. 1987).
Metabolic Effects. No studies were located regarding metabolic effects in humans after oral exposure
to antimony.
Two studies have reported significant decreases in serum glucose levels following exposure to antimony
potassium tartrate.  In an intermediate-duration study, dose-related decreases in serum glucose levels were 
observed in female rats at ≥0.64 mg Sb/kg/day (Poon et al. 1998); the investigators did not report whether
blood samples were from fasting or nonfasting rats.  ATSDR notes that the serum glucose levels in all
groups (including controls) were higher than the normal range reported by the animal supplier (Charles
River Laboratories 2006). Decreases in nonfasting glucose were observed in male and female rats
exposed for a lifetime to 0.63 mg Sb/kg/day as antimony potassium tartrate (Schroeder et al. 1970); no 
significant alterations in fasting glucose levels were found.
Other Systemic Effects. Mendy et al. (2012) did not find a significant association between urinary
antimony levels and the incidence of self-reported gout among NHANES participants.
Splenic sinus congestion in males at ≥0.56 mg Sb/kg/day, sinus hyperplasia in females at ≥0.64 Sb/kg/day 
and males at 42.17 Sb/kg/day, and arterial cuff atrophy in males at 42.17 mg Sb/kg/day were observed in 
rats exposed to antimony potassium tartrate (Poon et al. 1998).
Two studies reported alterations in serum cholesterol levels in rats exposed to antimony potassium
tartrate; however, one study reported a decrease in female rats exposed to 45.69 mg Sb/kg/day (Poon et al.
1998) and the other reported an increase in rats exposed to 0.63 mg Sg/kg/day (Schroeder et al. 1970).
3.2.2.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans after oral exposure to antimony.
Limited information on the immunotoxicity of antimony is available in animals. In the thymus of rats
exposed to antimony potassium tartrate for 13 weeks, increases in medullary volume were observed in 
males exposed to ≥0.56 mg Sb/kg/day and in females exposed to ≥6.13 mg Sb/kg/day; a decrease in 
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cortical volume was also observed in females exposed to ≥6.13 mg Sb/kg/day (Poon et al. 1998). The
biological significance of these findings is not known.
3.2.2.4  Neurological Effects 
No studies were located regarding neurological effects in humans after oral exposure to antimony.
None of the available studies adequately examined the potential neurotoxicity of antimony following oral
exposure.  Acute- and intermediate-duration studies that included histological examination of major
tissues and organs did not report treatment-related alterations in the brain (Hext et al. 1999; NTP 1992;
Poon et al. 1998).
3.2.2.5  Reproductive Effects
No studies were located regarding reproductive effects in humans after oral exposure to antimony.
Information on the reproductive toxicity of antimony in laboratory animals is limited to a series of
experiments conducted by Omura et al. (2002).  No significant alterations in sperm count, motility, or
morphology or histological alterations of the testes were observed in rats and mice exposed to 1,000 mg
Sb/kg/day as antimony trioxide or 10 mg Sb/kg/day as antimony potassium tartrate.
3.2.2.6  Developmental Effects 
A case-control study examined the possible relationship between levels of metals in drinking water and 
neural tube defects and did not find a significant association for antimony (Longerich et al. 1991).  Zheng
et al. (2014) found significantly higher median umbilical cord antimony levels in women with adverse
pregnancy outcomes, but did not find a statistically significant association between antimony and adverse
pregnancy outcomes.  See Table 3-4 for more information on these studies.
Decreases in growth on postnatal days (PNDs) 10–22 were observed in the pups of rats exposed to 0.7 mg
Sb/kg/day during gestation and lactation (Rossi et al. 1987); a decrease in maternal body weight gain was 
also observed at these doses.  No differences in the number of newborn pups per litter or macroscopic 
teratogenic effects were observed in the offspring of rats treated during gestation with 0.7 mg Sb/kg/day 
as antimony trichloride (Rossi et al. 1987).
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3. HEALTH EFFECTS
Studies by Angrisani et al. (1988) and Rossi et al. (1987) (data from both studies were also reported in 
Marmo et al. 1987) suggest that antimony may interfere with the normal development of the 
cardiovascular system.  Alterations in vasomotor reactivity were observed in 30- and 60-day-old pups
exposed during gestation and/or lactation and from weaning to PND 60; the estimated dose during the
postnatal period was 0.1 mg Sb/kg/day.  However, no alterations in arterial blood pressure were observed.  
Although the investigators describe this as altered development, comparisons were not made between the 
vasomotor responses in mature rats and in pups.
3.2.2.7  Cancer
Two epidemiology studies evaluated the possible association between antimony and cancer incidence (see 
Table 3-4).  Colak et al. (2015) found a positive association between antimony levels in drinking water
samples and cancer incidence among populations of three Turkish cities; the antimony levels in the water
were <20 μg/L.  Mendy et al. (2012) did not find a significant association between urinary antimony
levels and self-reported cancer among adult NHANES participants.
No alterations in neoplastic lesion incidence were observed in rats (Schroeder et al. 1970) or mice 
(Kanisawa and Schroeder 1969) exposed 0.63 or 0.35 mg Sb/kg/day, respectively, as antimony potassium
tartrate in drinking water for a lifetime.  The use of these studies to assess carcinogenicity is limited
because only one exposure level was used, which was below the maximum tolerated dose.
3.2.3 Dermal Exposure 
The dermal toxicity of antimony compounds is discussed below.  Data were located on the health effects 
following application of antimony trioxide, antimony thioantimonate (a mixture of antimony trisulfide 
and antimony pentasulfide), and antimony oxide to the skin or eye or following dermal or ocular contact
with airborne antimony dust.
3.2.3.1  Death 
No studies were located regarding death in humans after dermal exposure to antimony.
In a repeated exposure study, three of eight rabbits died due to exposure to antimony trioxide in an 
artificial sweat paste for 5–8 treatments; the remaining animals received 21 treatments and survived
(Fleming 1982).  Since the application area was not occluded, it is likely that the animals ingested the
***DRAFT FOR PUBLIC COMMENT***
   
 








      
      
 
 
   
 
   
  
   
   
    
   
 
 
      
      
    
   
      
 
       
   
     
 
 
    
  
      
     
 
      
   




paste. Damage to the cardiac portion of the stomach was noted in two of the three rabbits that died.  No
antimony-related deaths were reported in rabbits exposed to 3.3% antimony as antimony thioantimonate
in calcium cup grease for 13 weeks (Horton et al. 1986).
3.2.3.2  Systemic Effects
Respiratory, cardiovascular, gastrointestinal, hematological, hepatic, renal, dermal, and ocular effects
following dermal or ocular exposure are presented below.  No studies were located regarding
musculoskeletal or body weight effects in humans and animals following dermal exposure to antimony.  
The highest NOAEL for each antimony compound and all reliable LOAEL values for each systemic
effect for each species are recorded in Table 3-5; the results of the Fleming (1982) study was not included 
in the LSE table since it is very likely that the animals ingested large amounts of the antimony trioxide
paste.
Respiratory Effects. No studies were located regarding respiratory effects in humans following
dermal exposure to antimony.  Hyperemia in the lungs was observed in a rabbit that died after six or
eight applications of an antimony trioxide paste to shaven and abraded skin.  The antimony trioxide
(concentration not reported) was combined with a mixture resembling acidic sweat (Fleming 1982).  The
application area was not occluded; thus, the ingestion of the paste likely occurred.
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans 
following dermal exposure to antimony.  Application of 3.3% antimony as antimony thioantimonate in 
calcium cup grease did not result in alterations in EKG readings or heart pathology in rabbits (Horton et
al. 1986).
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans 
following dermal exposure to antimony.  Hemorrhages in the cardiac portion of the stomach were 
observed in a rabbit that died after six or eight applications of an antimony trioxide-acidic sweat paste 
(Fleming 1982).  Because the application area was not occluded, ingestion of the paste is possible.
Hematological Effects. No studies were located regarding hematological effects in humans 
following dermal exposure to antimony.  No alterations in hematological indices were observed in rabbits 
exposed to 3.3% antimony as antimony thioantimonate for 13 weeks (Horton et al. 1986).
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Once; 0 or 20,900 
mg Sb 
CS Dermal 20,900 mg Sb No evidence of skin irritation. Gross et al. 1955
(antimony trioxide)
Rabbit Once;  BW, OF, BI Ocular 84 mg Sb No evidence of eye irritation. Gross et al. 1955
10M 0 or 84 mg Sb (antimony trioxide)
Rabbits Once CS Ocular 0.066 g Sb Eye irritation consisting of conjunctival Horton et al. 1986 
(NS)
12 NS
0 or 0.066 g Sb, erythema, chemosis, and discharge 24 
hours post-exposure.  Superficial 
(antimony thioantimonate)
corneal injury in 4/12 rabbits 7-days 





0, 122, 799, 1,395 
mg Sb/m3 













0, 122, 799, 1,395 
mg Sb/m3 




No signs of eye irritation were reported. Price et al. 1979 
(Stibine) 
Immunological and Lymphoreticular Effects
Guinea pigs 4 times CS 6.6% Sb Negative in skin sensitization test.   Horton et al. 1986 
(Hartley)
10F
0 or 6.6% Sb, (antimony thioantimonate)
INTERMEDIATE EXPOSURE
Systemic Effects
Rabbits 6 hours/day LE, CS, BW, Cardio 3.3 No treatment related alterations in Horton et al. 1986 









hematology, clinical chemistry, or body
weight.








0, 0.21, 0.902, 




Non-concentration-related increases in 
corneal irregularities were observed 
(approximately 30% in each group).
Newton et al. 1994  
(antimony trioxide)












































































***DRAFT FOR PUBLIC COMMENT***
3.  HEALTH EFFECTS
Table 3-5. Levels of Significant Exposure to Antimony – Dermal 
62












Rabbits 6 hours/day LE, CS, BW, 
3.3 
No histopathological alterations in the Horton et al. 1986 
(New Zealand 5 days/week OF, HE, HP %Sb testes were reported.  (antimony thioantimonate)
white) 13 weeks 










0 or 36 mg Sb/m3 







No dermal or ocular effects were 
observed.








0 or 17.5 mg 
Sb/m3 







No dermal or ocular effects were 
observed.








0, 0.05, 0.43, and 
3.8 mg Sb/m3 






Increased incidence of cataracts at the 
end of the 12-month recovery period at 
≥0.43 mg Sb/m3 . 








0, 2.5, 8.3, and 25 
mg Sb/m3 






Chronic inflammation and ulcers 










0, 2.5, 8.3, and 25 
mg Sb/m3 







No dermal or ocular effects were noted. NTP 2016 
(antimony trioxide)
Parameters monitored:  BI = biochemical changes; BW = body weight; CS= clinical signs; DX = developmental toxicity; FI = food intake; GN = gross necropsy; HE = hematology;
HP = histopathology; LE = lethality; OF = organ function; OP = ophthalmology; OW = organ weight
Bd wt = body weight; Cardio = cardiovascular; F = female(s); M = male(s); NS = not specified; Sb = antimony
   
 








      
  
   
 
 
          
 
    
  
 
       












    
  
  
     
 
 
         





Hepatic Effects. No studies were located regarding hepatic effects in humans following dermal
exposure to antimony.  No alterations in serum clinical chemistry parameters or histopathology of the
liver were observed in rabbits exposed to 3.3% antimony as antimony thioantimonate for 13 weeks
(Horton et al. 1986).
Renal Effects. No studies were located regarding renal effects in humans following dermal exposure
to antimony.  Increases in blood urea nitrogen and creatinine levels were observed in male rabbits 
exposed to 3.3% antimony as antimony thioantimonate; however, the levels were within the normal
species variation and no histological alterations were observed in the kidneys (Horton et al. 1986).
Dermal Effects. Several studies have reported dermatitis in workers exposed to airborne antimony
dust (Potkonjak and Pavlovich 1983).  The dermatitis associated with exposure to airborne antimony is
characterized as epidermal cellular necrosis with associated acute inflammatory cellular reactions 
(Stevenson 1965).  The dermatitis is seen more often during the summer months and in workers exposed 
to high temperatures (Potkonjak and Pavlovich 1983; Stevenson 1965).  Stevenson (1965) concluded that
the dermatitis resulted from the action of antimony trioxide on the dermis after dissolving in sweat and 
penetrating the sweat glands. Transferring the worker to a cooler environment often resulted in the rash 
clearing up within 3–14 days.  Antimony trioxide is not a skin sensitizer in humans following topical
application (see Section 3.2.3.3).
In general, animal studies involving exposure to airborne antimony have not reported dermal effects 
(Groth et al. 1986; Newton et al. 1994).  In a 13-week rat study (Newton et al. 1994 as reported in 
Bio/Dynamics 1985), alopecia was observed in females exposed to 0.902 or 4.11 mg Sb/m3, but not
females exposed to 19.60 mg Sb/m3 or in males.  Additionally, alopecia was not observed in a 1-year
study conducted by this group (Newton et al. 1994). An intermediate-duration dermal exposure study did 
not report antimony-related skin irritation in rabbits exposed to 3.3% antimony as antimony antimonite
(Horton et al. 1986); hyperkeratosis was observed in the vehicle control and antimony groups at similar
incidences.
Ocular Effects. Eye irritation was reported in 27.5% of workers at an antimony smelter; it is unclear
if this was due to antimony oxides or other constituents in the smelter dust (Potkonjak and Pavlovich 
1983).
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Several animal studies provide evidence that antimony is an ocular irritant. Eye irritation and closure 
were observed in rats exposed to ≥799 mg Sb/m3 as stibine gas (Price et al. 1979); eye irritation was not
noted in similarly exposed guinea pigs (Price et al. 1979).  Exposure to airborne antimony trioxide
resulted in corneal opacities in rats exposed to ≥0.21 mg Sb/m3 for 13 weeks (Newton et al. 1994) and
cataracts (focal posterior cataracts, posterior subcapsular cataracts, and complete cataracts) were observed
in rats exposed to ≥0.43 mg Sb/m3 for 1 year followed by a 1-year recovery period (Newton et al. 1994).  
An increase in the incidence of chromodacryorrhea was also observed in the chronic study; the
investigators suggested that this may have been secondary to dental abnormality, infectious disease, or
xerosis. Instillation of 0.066 g antimony as antimony thioantimonate into the eyes of rabbits resulted in 
eye irritation (Horton et al. 1986).
3.2.3.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans following dermal exposure to
antimony.
In a skin sensitization assay, 6.6% antimony as antimony thioantimonate in liquid petrolatum did not
result in sensitization in guinea pigs (Horton et al. 1986).  When the antimony thioantimonate was
administered in calcium cup grease, a positive result for sensitization was found; however, this was likely
due to the vehicle, since no reaction was found when antimony thioantimonate in petrolatum was used as
the challenge agent (Horton et al. 1986).
No studies were located regarding the following effects in humans or animals after dermal exposure to 
antimony:
3.2.3.4  Neurological Effects 
3.2.3.5  Reproductive Effects
3.2.3.6  Developmental Effects 
3.2.3.7  Cancer
3.2.4 Other Routes of Exposure 
Trivalent and pentavalent antimony compounds have been used for the treatment of parasitic diseases,
particularly leishmaniasis and schistosomiasis, for over 100 years.  Although trivalent antimony in the
form of potassium or sodium antimony tartrate was first used, it was later discontinued due to the side 
effects.  Pentavalent organic antimony compounds have been used for the last 60 years.  The two 
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predominant forms are sodium antimony gluconate (sodium stibogluconate) and meglumine antimoniate 
(N-methyl-D-glucamine or Glucantime) (Haldar et al. 2011).  In the treatment of parasitic diseases, the 
patient receives multiple injections of the antimony compounds.  Numerous investigators have reported
adverse effects associated with these treatments. These studies provide useful information for identifying 
potential targets of antimony toxicity, although the relevance to environmental exposure is not known 
given the poor absorption of antimony compounds following inhalation, oral, or dermal exposure (see 
Section 3.4.1).  The primary targets of toxicity appear to the heart (alterations in EKG readings), 
gastrointestinal tract (nausea, abdominal pain, vomiting, diarrhea, anorexia), musculoskeletal system
(myalgia, arthralgia), liver (increases in alanine and aspartate aminotransferases), pancreas (increases in
serum amylase levels), and nervous system (headache, dizziness) (Andersen et al. 2005; Dancaster et al.
1966; Lawn et al. 2006; Neves et al. 2009; Palacios et al. 2001; Sundar et al. 1998; Thakur 1998; Zaki et
al. 1964).  Alterations in electrocardiograms, particularly prolongation of QT interval, have been reported 
following injection of sodium antimony tartrate (Honey 1960), sodium antimony gluconate (Dancaster et
al. 1966; Lawn et al. 2006; Sundar et al. 1998; Thakur 1998), and meglumine antimoniate (Neves et al.
2009).  Whereas a very high incidence was reported in patients treated with sodium antimony tartrate
(98%, with 30% categorized as severe EKG changes) (Honey 1960), a much lower incidence (8–25%)
was found in patients treated with pentavalent antimony (Dancaster et al. 1966; Neves et al. 2009). The
cardiotoxicity of antimony (Alvarez et al. 2005; Bromberger-Barnea and Stephens 1965; Cotten and 
Logan 1966) and the differences in the cardiotoxicity of trivalent and pentavalent antimony (Alvarez et al.
2005) are supported by animal studies.  Whereas intramuscular injections of 16 mg Sb/kg/day as 
meglumine antimoniate for 26 days resulted in a slight prolongation of the QT duration in guinea pigs, 
intramuscular administration of 10 mg Sb/kg/day as antimony potassium tartrate for 8–12 days resulted in 
bradycardia and a more marked elongation of the QT interval (Alvarez et al. 2005).
Significant decreases in blood glucose levels were observed in rats exposed to 900 mg Sb/kg/day as 
stibogluconate or 300 or 900 mg Sb/kg/day meglumine antimoniate administered via intramuscular
injections for 30 days (Alkhawajah et al. 1992); the investigator did not note whether the animals were
fasted prior to measurement of blood glucose levels.
Three studies have evaluated the developmental toxicity of pentavalent antimony.  Subcutaneous
administration of 300 mg Sb/kg as meglumine antimoniate or intramuscular administration of 100 or
300 mg Sb/kg/day as sodium stibogluconate or meglumine antimoniate to rats during gestation or during 
gestation and lactation resulted in decreases in birth weight and number of viable offspring (Alkhawajah
et al. 1996; Coelho et al. 2014a; Miranda et al. 2006).  Intramuscular administration of 100 mg Sb/kg/day 
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as antimony trichloride also resulted in decreases in viable fetuses and fetal body weight (Alkhawajah et
al. 1996).  Increases in resorptions were also observed in rats administered ≥100 mg Sb/kg/day as sodium
stibogluconate, meglumine antimoniate, or antimony trichloride (Alkhawajah et al. 1996).  Miranda et al.
(2006) also found a significant increase in dilated ureters following gestation exposure; no other external
or visceral abnormalities were found. No alterations in neurological development or sperm counts were
observed in offspring exposed during gestation and lactation (Coelho et al. 2014a).
3.3  GENOTOXICITY
The genotoxicity of trivalent and pentavalent antimony has been evaluated in in vivo studies in humans, 
rats, and mice and in in vitro studies in bacterial and mammalian systems. As summarized in Table 3-6, 
most studies of antimony trioxide did not find clastogenic alterations in orally exposed (gavage
administration) rats or mice (Elliott et al. 1998; Gurnani et al. 1992a, 1992b; Kirkland et al. 2007).  One
study (Gurnani et al. 1992a, 1993) found significant increases in chromosomal aberrations in mice bone
marrow cells following repeated exposure to antimony trioxide; no significant alterations were found 
following a single exposure.  However, other studies testing similar doses did not find increases in
chromosomal aberrations (Kirkland et al. 2007) or micronuclei formation (Elliott et al. 1998; Kirkland et 
al. 2007) following repeated exposure. One occupational exposure study of workers exposed to a flame
retardant containing antimony trioxide did not find increases in the occurrence of micronuclei or sister
chromatid exchange (Cavallo et al. 2002). Two studies of pentavalent organic antimony found positive
results for micronuclei formation (Hantson et al. 1996; Lima et al. 2010) or DNA damage (Lima et al. 
2010).
The results of in vitro genotoxicity studies are presented in Table 3-7.  In general, no alterations in the
occurrence of gene mutations were found in bacterial assays testing metallic antimony (Asakura et al.
2009), antimony trioxide (Elliott et al. 1998; Kuroda et al. 1991), antimony trichloride (Kubo et al. 2002; 
Kuroda et al. 1991), antimony pentachloride (Kuroda et al. 1991), or antimony pentoxide (Kuroda et al. 
1991) or in mammalian assays with antimony thioantimonate (Tu and Sivak 1984) or antimony trioxide
(Elliott et al. 1998).  Evidence of DNA damage was observed for antimony trioxide, antimony trichloride, 
and antimony pentachloride in rec assays with Bacillus subtilis (Kanematsu et al. 1980; Kuroda et al. 
1991).  Unlike the in vivo data, most studies found increases in the occurrence of chromosomal
aberrations (Asakura et al. 2009; Elliott et al. 1998; Paton and Allison 1972; Tu and Sivak 1984), 
micronuclei formation (Gebel et al. 1998a; Huang et al. 1998; Migliore et al. 1999; Schaumlöffel and
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Table 3-6.  Genotoxicity of Antimony In Vivo
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Kirkland et al. 2007
Kirkland et al. 2007
Cavallo et al. 2002
Hantson et al. 1996
Lima et al. 2010
Elliott et al. 1998
Elliott et al. 1998
Kirkland et al. 2007
Kirkland et al. 2007
Cavallo et al. 2002
Hantson et al. 1996
Lima et al. 2010



























– = negative result; + = positive result; DNA = deoxyribonucleic acid
***DRAFT FOR PUBLIC COMMENT***
   
 








    
 
      




   
     
 
 
     
   
 














   
 




   
 




   
 




   
 




    
 





       
   
 














    
 






























Table 3-7.  Genotoxicity of Antimony In Vitro
Results
With Without
End point Species (test system) activation activation Reference Compound
Prokaryotic organisms
Gene Salmonella typhimurium






TA100, TA98 (Ames test)
TA100, TA98 (plate 
incorporation)
TA100, TA98 (plate 
incorporation)
TA100, TA98 (plate 
incorporation)
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Table 3-7.  Genotoxicity of Antimony In Vitro
Results
With Without
End point Species (test system) activation activation Reference Compound
Mammalian cells
Gene Chinese hamster ovary – – Tu and Sivak Antimony
mutation cells (HGPRT locus) 1984 thioantimonate
L5178Y mouse lymphoma – – Elliott et al. Antimony
1998 trioxide
Chromosomal Human leukocytes No data + Paton and Antimony
aberrations Allison 1972 sodium tartrate
+ + Elliott et al. Antimony
1998 trioxide
Chinese hamster ovary + + Tu and Sivak Antimony
cells 1984 thioantimonate
+ + Asakura et al. Metallic
2009 antimony
Micronuclei Human bronchial epithelial No data + Huang et al. Antimony
 
formation cells (BES-6) 1998 trichloride
 
Human fibroblasts No data + Huang et al. Antimony
 
1998 trichloride
Human lymphocytes No data + Migliore et al. Potassium
1999 antimonate
Human lymphocytes No data + Schaumlöffel Antimony
and Gebel 1998 trichloride
V79 Chinese hamster No data + Gebel et al. Antimony
cells 1998a trichloride
Chinese hamster ovary No data + Huang et al. Antimony
cells 1998 trichloride
Sister V79 Chinese hamster No data + Kuroda et al. Antimony
chromatid ovary cells 1991 trichloride
exchange
No data + Kuroda et al. Antimony
1991 trioxide
No data – Kuroda et al. Antimony
1991 pentachloride
No data – Kuroda et al. Antimony
1991 pentoxide
***DRAFT FOR PUBLIC COMMENT***
   
 








    
 
      




   
   
 
   
 
 
   
 




   
 











Table 3-7.  Genotoxicity of Antimony In Vitro
Results
With Without
End point Species (test system) activation activation Reference Compound
DNA damage Human lymphocytes No data – Lima et al. 2010 N-Methyl-
(comet assay) glucamine
antimonate
Human lymphocytes No data + Schaumlöffel Antimony
(comet assay) and Gebel 1998 trichloride
V79 Chinese hamster No data + Gebel et al. Antimony
cells (comet assay) 1998a trichloride
aOnly positive for TA1537 strain.
– = negative result; + = positive result 
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Gebel 1998), and sister chromatid exchange (Kuroda et al. 1991) in mammalian cells exposed to trivalent
antimony compounds or metallic antimony.  Pentavalent antimony compounds were negative in sister
chromatid exchange assays (Kuroda et al. 1991).  Similarly, DNA damage was observed in mammalian
cells exposed to antimony trichloride (Gebel et al. 1998a; Schaumlöffel and Gebel 1998), but negative for
pentavalent organic antimony (Lima et al. 2010).
3.4  TOXICOKINETICS
3.4.1 Absorption 
3.4.1.1  Inhalation Exposure 
Inhaled antimony particles that deposit in the respiratory tract are subject to three general distribution
processes:  (1) bronchial and tracheal mucociliary transport to the gastrointestinal tract; (2) transport to 
thoracic lymph nodes (e.g., lung, tracheobronchial, mediastinal); or (3) absorption into blood and/or
lymph and transfer to other tissues (e.g., peripheral lymph tissues, liver, kidney).  The above processes
apply to all forms of deposited antimony, although the relative contributions of each pathway and rates
associated with each pathway vary with the physical characteristics (e.g., particle size, solubility).
Particles having diameters >5 µm deposit in the upper airways (extrathoracic, tracheobronchial regions)
and are cleared from the respiratory tract primarily by mucociliary transport to the gastrointestinal tract.
Smaller particles (≤5 µm, respirable particles) are deposited primarily in the pulmonary region (terminal
bronchioles and alveoli).  Particles are cleared from the pulmonary region primarily by absorption, lymph 
drainage, macrophage phagocytosis and migration, and upward mucociliary flow.  Total alveolar
clearance is mediated largely by alveolar macrophages, primarily via migration of particle-laden 
macrophages to the ciliated airways and to a lesser extent via penetration through the interstitium to the 
pulmonary lymphatic system (Yu and Rappaport 1996).  Exposure to 1.6 μm particles of antimony
tartrate resulted in a greater deposition of antimony in the upper respiratory tract than exposure to 0.7 or
0.3 μm particles (Felicetti et al. 1974a; Thomas et al. 1973).  Furthermore, the antimony deposited in the
upper respiratory tract was cleared after several hours via mucociliary clearance.  Particles of the two
smaller sizes were relatively insoluble in the lung and were slowly absorbed over several weeks (Thomas 
et al. 1973).  No valence-specific difference in the body burden was observed 1 day after exposure to 
trivalent or pentavalent antimony tartrate (Felicetti et al. 1974b).
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Dissolved antimony is absorbed into blood; the rate of absorption will depend on solubility.  The
International Commission on Radiological Protection (ICRP 1981) considers oxides, hydroxides, halides, 
sulfides, sulfates, and nitrates of antimony to be class W chemicals.  All other common compounds of
antimony are assigned to class D.  Class W and D chemicals are considered to have respiratory tract
clearance rates of weeks and days, respectively.  The ICRP classifications are based on animal data 
(Felicetti et al. 1974a, 1974b; Thomas et al. 1973).  Data from deceased antimony smelter workers 
suggest that the elimination half-times of some forms of antimony in the lungs may be longer than weeks
(Gerhardsson et al. 1982).
Using data from the Newton et al. (1994) 1-year study of rats exposed to several concentrations of
antimony trioxide, Yu and Rappaport (1996) and Newton et al. (1994) found that the pulmonary clearance 
half-time increased with increasing antimony lung burdens. Clearance was significantly decreased at lung
burdens of >0.11 mg (Yu and Rappaport 1996).  In rats exposed to antimony trioxide for 1 year, Newton 
et al. (1994) estimated a pulmonary clearance time of 2 months in rats with a lung burden of 200 μg and 
10 months in rats with a lung burden of 2,000 μg.  In rats exposed to 0.06, 0.51, or 4.50 mg antimony
trioxide/m3 (ratio of 1:10:90), the lung burden ratios were 1:11:138.  The decrease in clearance rates is 
likely due to antimony-specific impairment of alveolar macrophages (Yu and Rappaport 1996).  As would
be expected, lung burdens increased with exposure duration.  In rats exposed for 90 days, there was an 
initial rapid accumulation phase, which lasted 2–4 weeks, followed by a second slower accumulation 
phase; there was no indication that lung accumulation reached steady state. However, a 1-year study 
showed that steady-state lung burden was reached after approximately 6 months of exposure to antimony
trioxide (Newton et al. 1994).
3.4.1.2  Oral Exposure
No quantitative data on the absorption of antimony from the gastrointestinal tract in humans were located.  
However, results of studies in animals suggest that antimony is poorly absorbed from the gastrointestinal
tract.  Estimates of the absorption of antimony tartrate and antimony trichloride in animals range from
2 to 7% (Felicetti et al. 1974b; Gerber et al. 1982).  A study of pentavalent antimony estimated a 
bioavailability of 10% in dogs administered via gavage a single dose of 100 mg antimony/kg as
meglumine antimoniate (Ribeiro et al. 2010); the mean absorption time was 3.1 hours. Gastrointestinal 
absorption of antimony is likely to be affected by numerous factors, including chemical form of the
ingested antimony, solubility, age, and diet.  Although quantitative information on the absorption of
antimony is not available for all forms, ICRP (1981) has recommended 10% for antimony tartrate and 1%
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for all other forms of antimony as reference values for gastrointestinal absorption in humans. A dog study
(Ribeiro et al. 2010) showed that maximum blood concentration was reached 0.89 hours after gavage
administration of 100 mg Sb/kg as meglumine antimoniate.
The gastrointestinal absorption of antimony may be saturable.  A comparison of blood concentrations
24 hours after administration of 100 or 1,000 mg/kg antimony trioxide found only a 2-fold difference,
even though there was a 10-fold difference in doses (Kirkland et al. 2007).
3.4.1.3  Dermal Exposure 
No studies were located regarding absorption of antimony in humans following dermal exposure.
Exposure to high levels of antimony trioxide or a mixture of antimony trioxide and pentoxide resulted in 
death in rabbits (Myers et al. 1978).  Since the application area was occluded, the study suggests that at
least some forms of antimony can be absorbed through the skin.
3.4.2 Distribution 
Very low levels of antimony are found in unexposed humans.  Autopsy data on Japanese adults (Sumino 
et al. 1975) and other data on selected body fluids are presented in Table 3-8.  The mean body burden of
antimony was 0.7 mg (Sumino et al. 1975).  The skin and hair had the highest levels of antimony.  A 
somewhat higher estimate of 7.9 mg for total body burden is reported by ICRP (1981).  ICRP (1981) has
recommended reference values of 5.9 mg of antimony in soft tissue and 2.0 mg in skeletal tissue.
Studies of antimony concentrations in the liver and kidneys of dogs, cats, and horses exposed to 
background antimony found no differences in liver or kidney antimony concentrations in dogs and cats 
(Paßlack et al. 2014b, 2014c), but found that the liver antimony levels were significantly higher than 
kidney levels in horses (Paßlack et al. 2014a).  No sex- or age-related differences in antimony 
concentrations were found (Paßlack et al. 2014a, 2014b, 2014c).  In dogs and cats, chronic kidney disease
did not appear to influence the antimony levels in the liver or kidneys (Paßlack et al. 2014b, 2014c).
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Table 3-8. Background Levels of Antimony Found in Various Tissues of Humans
Tissue Mean concentration (µg/g) ± standard deviation Reference
Hair 0.12±0.18 Muramatsu and Parr 1988
0.096 Takagi et al. 1986
Adrenal gland 0.073±0.14 Sumino et al. 1975
Skin 0.096±0.10 Sumino et al. 1975
Lung 0.062±0.056 Sumino et al. 1975
Large intestine 0.047±0.062 Sumino et al. 1975
Trachea 0.045±0.031 Sumino et al. 1975
Cerebellum 0.030±0.032 Sumino et al. 1975
Kidney 0.043±0.041 Sumino et al. 1975
Not detected Muramatsu and Parr 1988
Small intestine 0.039±0.044 Sumino et al. 1975
Heart 0.032±0.038 Sumino et al. 1975
Pancreas 0.030±0.029 Sumino et al. 1975
Spleen 0.029±0.025 Sumino et al. 1975
Liver 0.023±0.026 Sumino et al. 1975
Not detected Muramatsu and Parr 1988
Cerebrum 0.017±0.024 Sumino et al. 1975
Blood 0.016±0.022 Sumino et al. 1975
0.34±2.0 Mansour et al. 1967
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3.4.2.1  Inhalation Exposure 
Information on the distribution of antimony in humans following inhalation exposure was not located.  
Studies in hamsters demonstrate that the highest concentrations of antimony are found in the lungs, 
gastrointestinal tract, liver, kidney, and skeleton (Felicetti et al. 1974b).  In hamsters, the levels of
trivalent antimony increase more rapidly in the liver than pentavalent antimony.  Skeletal uptake is greater
following exposure to pentavalent antimony than trivalent antimony (Felicetti et al. 1974b).  One day
postexposure, the highest percentage of body burden is found in the gastrointestinal tract.  Following
exposure to trivalent antimony tartrate, antimony is also retained in the skin, liver, skeleton, and lung (in 
descending order).  For pentavalent antimony, the highest percentage of body burden (outside of
gastrointestinal tract) is skin, skeleton, and liver. Studies involving exposure to antimony trioxide, a
relatively insoluble compound, demonstrate that most antimony is retained in the lungs (Newton et al. 
1994).
The relative partitioning between erythrocytes and plasma is a function of valency.  Following exposure
to trivalent antimony, erythrocyte levels are elevated, compared to the elevated plasma antimony levels 
after inhalation exposure to pentavalent antimony (Felicetti et al. 1974b; Newton et al. 1994).  In
hamsters, the ratios of erythrocyte to plasma antimony levels were 1.14 for trivalent antimony and 
0.29 for pentavalent antimony at exposure termination and 8.1 and 2.9, respectively, 1-day postexposure
(Felicetti et al. 1974b). The clearance of antimony from the blood appears to differ among animal
species.  Elevated blood antimony levels persist longer in rats than in mice and dogs (Felicetti et al.
1974a; Thomas et al. 1973).
3.4.2.2  Oral Exposure
Data on the distribution of antimony in humans following oral exposure to antimony were not located.
Following oral exposure in animals, the major sites of accumulation, outside of the gastrointestinal tract, 
are the liver, kidney, bone, lung, spleen, and thyroid (Ainsworth et al. 1991; Kirkland et al. 2007; NTP
1992; Sunagawa 1981).  In rats exposed to antimony potassium tartrate for 13 weeks, the highest
concentration of antimony was found in the red blood cells, followed by the spleen, liver, kidney, brain 
and fat, and serum (Poon et al. 1998).  Neither NTP (1992) nor Sunagawa (1981) reported dose-related
increases in tissue antimony levels; however, Poon et al. (1998) reported apparent dose-related increases 
in kidney, liver, spleen, and red blood cell antimony levels. This lack of dose-responsiveness may be a 
reflection of decreased absorption at higher antimony concentrations or may represent saturation in some 
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tissues.  Antimony levels tend to reach a plateau in the livers and lungs of voles fed a diet containing
antimony trioxide (Ainsworth et al. 1991). In rats exposed to antimony potassium tartrate in drinking
water for 16 days (NTP 1992) or 13 weeks (Poon et al. 1998) or antimony trioxide once or 3 times in an 
8-day period (Kobayashi and Ogra 2009), the blood had the highest concentration of antimony.  The
antimony levels in blood were 3 times higher than the levels in the kidney, heart, spleen, and liver (NTP
1992).  In the blood, pentavalent antimony is primarily found in the serum of dogs administered 100 mg
antimony/kg as meglumine antimoniate (Ribeiro et al. 2010); trivalent antimony was found primarily in 
the red blood cells of rats exposed to antimony potassium tartrate for 90 days (Poon et al. 1998) or
antimony trioxide once or 3 times (Kobayashi and Ogra 2009).
Evidence is insufficient to determine if there are valency differences in the distribution of orally
administered antimony.  A study of rats exposed to similar concentrations of metallic antimony and
antimony trioxide found some differences (Sunagawa 1981).  Similar antimony concentrations were
found in the liver and blood of rats exposed to metallic antimony compared to a 10-fold higher
concentration in the blood compared to the liver in rats exposed to antimony trioxide.
There are limited data on the maternal transfer of antimony following oral exposure.  Elevated antimony 
levels were found in the pups of rat dams fed radiolabeled antimony chloride (exact compound not
reported) during pregnancy and lactation (Gerber et al. 1982).  The highest activities (in descending
order) were detected in the bone, muscle, spleen, heart, kidney, and lung.  After exposure termination,
antimony levels rapidly declined, with a half-life of approximately 10 days.  When in utero exposed pups
were cross-fostered to controls, antimony levels were maintained.  In control newborns cross-fostered to 
antimony dams, there was a rapid increase in antimony level, reaching 80% of the levels of pups exposed 
during gestation and lactation.
3.4.2.3  Dermal Exposure 
No information on the distribution of antimony in humans or animals following dermal exposure to 
antimony was located.
3.4.2.4  Other Routes of Exposure
No information on the distribution of antimony in humans following parenteral exposure was located.  In
animals, antimony is recovered primarily in the liver, with smaller amounts in the spleen, heart, lungs, 
and muscle (Gellhorn et al. 1946; Gerber et al. 1982).
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As discussed in the inhalation and oral exposure sections, trivalent antimony is incorporated into the
erythrocytes, mainly in the hemoglobin fraction (Edel et al. 1983; Lippincott et al. 1947) and pentavalent
antimony is primarily distributed into the plasma fraction of blood (Edel et al. 1983).
Following intraperitoneal administration of trivalent antimony compounds, the concentration of antimony
in the liver exceeded the antimony concentration in the spleen (Gellhorn and van Dyke 1946). In
contrast, administration of pentavalent antimony compounds resulted in spleen concentrations that
exceeded the liver concentration. Similarly, a 21-day subcutaneous administration of 300 mg
antimony/kg as meglumine antimoniate (pentavalent antimony) to rats resulted in the highest antimony
concentrations in the spleen; high levels were also found in the kidneys, femur, thyroid, and liver (Coelho 
et al. 2014b).  The antimony concentration in the spleen was at least 4–5 times higher than in other
tissues; the concentrations in the kidneys, femur, and thyroid were similar and about 2 times higher than 
in the liver. Twenty-one days after the last exposure, the highest concentration was found in the spleen 
followed by the femur and thyroid (similar concentrations), lungs, adrenals, kidneys, and liver (Coelho et
al. 2014b). In contrast, intraperitoneal administration of antimony potassium tartrate (1.5–11 mg/kg/day)
to rats for 16 days resulted in the highest antimony concentration in the blood, followed by the liver, 
spleen, heart, and kidney (NTP 1992).  At the lower doses, the liver and spleen had similar
concentrations, which were 2 times higher than the heart and kidney levels.  Following a 13-week
exposure to 24 mg/kg/day, the blood antimony concentration was >2 times higher than the spleen levels;
the spleen had 20% more antimony than the liver, and the heart and kidney had similar concentrations that
were approximately 10-fold lower than blood.
A series of experiments in which rat dams were administered subcutaneous injections of 300 mg
pentavalent antimony/kg/day as meglumine antimoniate during gestation and/or lactation demonstrates 
maternal-fetal and maternal-infant transfer of antimony (Coelho et al. 2014a).  The levels of antimony in 
the blood of the offspring were approximately 44, 60, 77, and 135% of maternal blood levels when 
antimony was administered on gestation days (GDs) 0–20, GD 0 through PND 13, PNDs 1–13, and
PNDs 5–19, respectively.
3.4.3 Metabolism
Antimony is a metal and, therefore, does not undergo metabolism.  Antimony can covalently interact with
sulfhydryl groups and phosphate, as well as numerous reversible binding interactions with endogenous
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ligands (e.g., proteins).  It is not known if these interactions are toxicologically significant. There are 
limited data on the in vivo conversion of pentavalent antimony to trivalent antimony.  In humans
administered Ulamina (an experimental drug containing antimony pentachloride and N-methyl-
glucamine) via intramuscular injection, 23% of the pentavalent antimony was converted to trivalent
antimony (Vasquez et al. 2006).
3.4.4 Elimination and Excretion 
3.4.4.1  Inhalation Exposure 
Increased levels of urinary antimony have been noted in workers exposed to antimony trioxide (Cooper et
al. 1968; Ludersdorf et al. 1987).  In animals, antimony is excreted via the urine and feces.  Some of the
fecal antimony may represent unabsorbed antimony that is cleared from the lung via mucociliary action 
into the esophagus to the gastrointestinal tract.  Antimony is excreted predominantly in the urine
following pentavalent antimony injection and in the feces after trivalent antimony administration (Edel et 
al. 1983; Felicetti et al. 1974b).
The whole-body clearance of trivalent or pentavalent antimony tartrate in hamsters is biphasic.  One day 
postexposure, 65 and 60% of the initial body burden of trivalent and pentavalent antimony, respectively,
was excreted (Felicetti et al. 1974b). The half-life of the slow phase was approximately 16 days.
3.4.4.2  Oral Exposure
Information on the excretion of antimony in humans following oral exposure was not located.  However,
information obtained from human and animal studies in which antimony was administered parenterally
provides some insight regarding the routes and rates of excretion that can be anticipated after oral
exposure in humans.  Animal studies have shown that ingested antimony is only partially absorbed from
the gastrointestinal tract (Felicetti et al. 1974b; Gerber et al. 1982).  Assuming that this is also true for
humans, fecal excretion is probably an important route of excretion of ingested antimony in humans.  
Antimony absorbed from the gastrointestinal tract appears to be excreted in the urine and feces to a 
variable degree, depending on the chemical form.
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3.4.4.3  Dermal Exposure 
No information on the excretion of antimony following dermal exposure in humans or animals was
located.
3.4.4.4  Other Routes of Exposure 
Pentavalent antimony is rapidly excreted in humans following intravenous or intramuscular
administration, with >50% excreted in the urine 6 hours after injection (Goodwin and Page 1943; Rees et
al. 1980).  Trivalent antimony is predominantly excreted in the feces and not as rapidly excreted in the 
urine as pentavalent antimony.  Twenty-four hours after injection, approximately 25% was excreted in the
urine (Goodwin and Page 1943).
Following repeated intramuscular administration of trivalent antimony in humans, approximately 15%
was excreted per day at the beginning of treatment and 25% at the end of treatment.  Fecal antimony
excretion ranged from 4% in the beginning of treatment to 15.4% of the daily administered dose toward 
the end of treatment (Lippincott et al. 1947).
Twenty-four hours following intraperitoneal administration of trivalent antimony in rats, 33% of the
compound was excreted via the feces and 6% in the urine.  In contrast, 88% of the pentavalent antimony
was excreted in the urine and 1% in the feces (Edel et al. 1983). Another study found that 45–55% of the
antimony administered via intravenous or intraperitoneal administration of antimony trichloride was
excreted in the urine or feces within 4 days (Bailly et al. 1991). Route-specific differences in the 
excretion routes were found.  Following intraperitoneal injection, the amount of antimony in the feces
was 4 times higher than the amount in the urine; in contrast, the amount in urine and feces was similar
when administered via intravenous administration. Antimony was partially excreted in the bile likely 
bound to glutathione; some of the biliary antimony was reabsorbed in the intestine via enterohepatic
circulation (Bailly et al. 1991).
The elimination of pentavalent antimony following intramuscular injection fits into a two-compartment
pharmacokinetic model.  The half-life of the rapid phase of elimination was 2 hours (Chulay et al. 1988;
Vasquez et al. 2006); the slower phase was 76 hours (Chulay et al. 1988). A more recent study that had a
lower detection limit suggested that antimony elimination fits a three-compartment model; the terminal 
half-life was >30 days (Friedrich et al. 2012).
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3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true
complexities of biological systems.  However, if the uptake and disposition of the chemical substance(s)
are adequately described, this simplification is desirable because data are often unavailable for many
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biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-3 shows a conceptualized representation of a PBPK model.
If PBPK models for antimony exist, the overall results and individual models are discussed in this section
in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.
No PBPK models for antimony were identified.
3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
There are very limited data on pharmacokinetic mechanisms. Maciaszczyk-Dubinska et al. (2012)
suggested that trivalent antimony can enter the cell via aquaglyceroporins, which are membrane proteins,
because trivalent antimony in the trihydroxylated uncharged form resembles glycerol. There is also some 
evidence that trivalent antimony can enter the cell via hexose transporters.  Sun et al. (2000) suggested
that trivalent antimony forms a stable complex with glutathione, which provides a possible transport
mechanism.
3.5.2 Mechanisms of Toxicity
Several in vitro studies have investigated the cardiotoxicity of antimony, particularly damage to the 
myocytes, which results in cell death and alterations and could lead to abnormalities in EKGs and 
arrhythmias.  Tirmenstein (1995, 1997) found that exposure to antimony potassium tartrate resulted in 
several biochemical alterations in cardiac myocytes including the disruption of cellular thiol homeostasis,
particularly the depletion of glutathione, induction of lipid peroxidation, and binding to vicinal thiols such 
as pyruvate dehydrogenase.  The inhibition of pyruvate dehydrogenase subsequently leads to a decrease 
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Figure 3-3.  Conceptual Representation of a Physiologically Based
 

















































Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  Krishnan and Andersen 1994
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in cellular ATP levels. These biochemical alterations all contribute to cell death.  Additionally, exposure
to antimony potassium tartrate disrupts calcium homeostasis in myocytes.  Wey et al. (1997) found a
progressive elevation of resting (or diastolic) transient calcium levels in myocytes and an eventual
cessation of beating activity that preceded cell death. Further investigations by this group found that
antimony potassium tartrate reduced calcium availability during excitation-contraction and that there was
a decreased flux of calcium through voltage-dependent L-type calcium channels in the myocyte 
(Toraason et al. 1997).  The decreased influx of calcium was likely due to enhanced removal of calcium
(Toraason et al. 1997).  The investigators noted that the reduced influx and enhanced efflux of calcium 
could account for the reduced cardiac output observed in in vivo studies.  Another study found that
trivalent antimony increased cardiac calcium currents, resulting in a prolonged action potential (Kuryshev
et al. 2006). The prolonged action potential results in a delay in cardiac repolarization, which could 
explain the QT prolongation observed in EKGs and arrhythmias in humans administered antimony for the
treatment of leishmaniasis (Kuryshev et al. 2006).  Similar findings were observed in myocytes exposed 
to pentavalent antimony, although the investigators concluded that this was likely due to the conversion 
of pentavalent antimony to trivalent antimony.  Pentavalent antimony also increased sodium current
amplitude, which was not observed in trivalent antimony exposed myocytes.  However, the change in
sodium current amplitude was not likely to contribute to arrhythmia since it was not accompanied by any
obvious changes in channel gating (Kuryshev et al. 2006).
3.5.3 Animal-to-Human Extrapolations 
Overall, the available human and laboratory animal data suggest that the end points of antimony toxicity
are similar across species. The primary effects observed in antimony workers are respiratory effects such
as pneumoconiosis and evidence of heart damage.  Lung damage is the primary effect reported in rats,
mice, and rabbits exposed to airborne antimony trioxide.  Additionally, parenteral administration studies
in laboratory animals have found EKG alterations, which is a commonly reported side effect in humans
receiving repeated injections of antimony compounds, particularly trivalent compounds, for the treatment
of leischmaniasis. Although similar end points have been identified, there are limited data comparing the 
potency across species of antimony administered via environmentally relevant routes of exposure. NTP
(2016) found species differences in the toxicity and carcinogenicity of antimony trioxide.  Although rats
and mice were exposed to the same concentrations, alveolar/bronchiolar carcinomas were observed in 
mice exposed to ≥2.5 mg Sb/m3, but carcinomas were not observed in rats exposed to 2.5 or 25 mg Sb/m3. 
This study also found differences in lung burdens between rats and mice.  In rats, lung burdens appeared 
to reach steady state at lower concentrations (2.5 and 8.3 mg Sb/m3); lung burden steady state was not
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reached at any of the exposure concentrations in mice. In an NTP (1992) 13-week intraperitoneal
injection study, antimony potassium tartrate was more toxic in rats than mice.  Increases in mortality and 
hepatocellular degeneration and necrosis were observed in rats; no deaths or histopathological alterations
were observed in mice administered the same dosages.
3.6  HAZARD IDENTIFICATION AND MINIMAL RISK LEVELS
3.6.1 Hazard Identification 
Systematic review of the available human and animal studies that assessed the potential health effects 
associated with inhalation or oral exposure to antimony identified a number of potential targets of
toxicity. Hazard identification conclusions were determined for the most sensitive end points (i.e., end
points occurring at the low concentrations/doses); these included respiratory, cardiovascular (myocardial
and EKG alterations), gastrointestinal, metabolic (serum glucose levels), and developmental effects.  
Based on the level of evidence in human studies and animal studies, each health effect was categorized
into one of four possible hazard identification conclusion categories:  known to be a hazard to humans, 
presumed to be a hazard to humans, suspected to be a hazard to humans, or not classifiable as to the
hazard in humans. The levels of evidence needed for each category are discussed in Appendix B. The
hazard identification conclusions for antimony, resulting from the systematic review, are also presented in 
Appendix B and are summarized as follows:
•	 Antimony is presumed to cause respiratory effects following inhalation exposure based on low 
evidence in workers exposed to antimony oxides and a high level of evidence in several animal
species exposed to antimony trioxide, antimony trisulfide, and antimony ore.
•	 Antimony is suspected to cause myocardial and EKG alterations based on inadequate evidence in
an inhalation occupational exposure study and low evidence in inhalation and oral exposure
studies in animals.  This hazard identification conclusion is supported by numerous reports of
cardiovascular effects in patients administered antimony compounds for the treatment of
leishmaniasis and injection studies in animals.
•	 Antimony is presumed to cause gastrointestinal tract irritation based on inadequate evidence in
human studies and high evidence in animal studies.
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•	 Antimony is suspected to cause decreases in serum glucose levels based on high evidence from
two animal oral exposure studies, supported by an animal intramuscular exposure study; human 
data are lacking.
•	 Antimony is suspected to cause developmental effects, particularly decreases in postnatal growth,
based on inadequate evidence in humans and high evidence in a small number of animal studies.
3.6.2 Minimal Risk Levels (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for antimony and 
compounds.  An MRL is defined as an estimate of daily human exposure to a substance that is likely to be
without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.
MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the
most sensitive health effect(s) for a specific duration within a given route of exposure.  MRLs are based 
on noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
3.6.2.1  Inhalation MRLs
Acute-Duration. No human studies have evaluated the acute inhalation toxicity of antimony.  In 
laboratory animals, the acute toxicity has been evaluated for stibine, antimony trisulfide, and antimony
trioxide. These studies clearly identify the respiratory tract as one of the most sensitive targets of
antimony toxicity (Brieger et al. 1954; NTP 2016; Price et al. 1979).  A 30-minute exposure to 1,395 mg 
Sb/m3 as stibine resulted in pulmonary edema and congestion and death in rats and guinea pigs (Price et
al. 1979).  Chronic lung inflammation was observed in rabbits exposed to 19.9 mg Sb/m3 as antimony
trisulfide for 5 days (7 hours/day) and in rats exposed to 25 mg Sb/m3 as antimony trioxide for
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12 exposures over a 16-day period (6 hours/day) (NTP 2016).  NTP (2016) also found squamous
metaplasia in the epiglottis of rats and mice exposed to 25 or 12 mg Sb/m3, respectively.  The primary
extrarespiratory effects also observed following acute exposure were degenerative changes in the heart
and altered EKGs in rabbits exposed to 19.9 mg Sb/m3 as antimony trisulfide.
The Brieger et al. (1954) and NTP (2016) studies were considered for derivation of an acute-duration 
inhalation MRL.  Although the rats and mice in the NTP (2016) study were exposed to antimony trioxide
over a 16- or 17-day period, the animals were only exposed for 12 or 13 times and the study was
considered to be more reflective of effects associated with acute-duration exposure than intermediate-
duration exposure.  Since the Brieger et al. (1954) study only tested one concentration of antimony
trisulfide, the LOAEL of 19.9 mg Sb/m3 for lung and cardiovascular effects was considered the point of
departure (POD) for this study.  For the NTP (2016) study, the incidence data for squamous metaplasia in 
rats and mice were fit to all available dichotomous models in EPA’s Benchmark Dose Software (BMDS) 
using the extra risk option.  Since the response level for chronic inflammation was 0% in the controls, 3.1, 
6.3, and 12 mg Sb/m3 groups and 100% at 25 or 50 mg Sb/m3, benchmark dose (BMD) modeling was not
conducted for this end point and the NOAEL was used as the POD. A summary of the potential PODs
(BMCLs for the selected models, LOAELs, or NOAELs for models without adequate fit) is presented in
Table 3-9.  Human equivalent concentrations (HECs) were calculated for each potential POD by adjusting
for intermittent exposure (6 hours/24 hours, 5 days/7 days for NTP [2016] and 7 hours/day for Brieger et
al. [1954]) and multiplying the PODADJ by the regional deposited dose ratio (RDDR) for the appropriate
region of the respiratory tract. The RDDRs were calculated using EPA’s RDDR calculator with the 
calculated average male and female terminal body weights of 0.189 and 0.281 kg for rats and mice,
respectively, for the NTP (2016) study and a reference body weight of 4.0 kg for the rabbits.  The PODHEC 
values are presented in Table 3-9.  The lowest PODHEC was 0.035 mg Sb/m3 for squamous metaplasia of
the epiglottis in mice. This value was divided by an uncertainty factor of 30 (3 for extrapolation from
animals to humans with dosimetric adjustments and 10 for human variability) resulting in an MRL of
0.001 mg Sb/m3.
Intermediate-Duration. Information on the toxicity of inhaled antimony following intermediate-
duration exposure primarily comes from a 13-week study in rats exposed to antimony trioxide (Newton et
al. 1994) that identified the respiratory tract as the most sensitive effect and 6–10-week studies in rats,
rabbits, and dogs (Brieger et al. 1954) that examined a limited number of end points and identified the
respiratory tract and myocardium as the most sensitive end points.  The systematic review identified the
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Table 3-9.  Summary of Potential Points of Departures (PODs) and Human 





PODs RDDR HECsb 
End point (reference) (mg Sb/m3) valuesa (mg Sb/m3)
Squamous metaplasia of the epiglottis in male and female rats 2.95 (BMCL10) 0.162c 0.085
(NTP 2016)
Chronic lung inflammation (NTP 2016) 12 (NOAEL) 0.545c 1.1
Squamous metaplasia of the epiglottis in male and female mice 0.94 (BMCL10) 0.206c 0.035
(NTP 2016)
Lung inflammation in rabbits (Brieger et al. 1954) 19.9 (LOAEL) 0.203d 1.2
Degenerative changes in the heart and altered EKG readings in 19.9 (LOAEL) 1.060d 6.2 
rabbits (Brieger et al. 1954)
aRDDR values specific for each region of the respiratory tract (extrathoracic and pulmonary) were calculated using 
EPA’s RDDR calculator, with the average of the male and female terminal body weights of 0.189 and 0.0281 kg for
rats and mice, respectively, and 4.0 kg for rabbits.
bHEC calculated by multiplying the duration-adjusted POD (POD x 6 hours/24 hours x 5 days/7 days for the NTP
[2016] studies and POD x 7 hours/24 hours x 5 days/7 days for the Brieger et al. [1954] study) by the RDDR value.
cCalculated using a particle size of 1.4 μm (sigma g of 1.9).

dCalculated using a particle size of 2 μm (sigma g of 1.9); these are assumed values; the investigators noted that 

most of the particles were <2 μm, but did not provide any additional information.
	
BMCL = 95% lower confidence limit on the benchmark concentration; EKG = electrocardiogram;
 
EPA = Environmental Protection Agency; LOAEL = lowest-observed-adverse-effect level; MRL = Minimal Risk Level;
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respiratory effects as presumed health effects in humans and myocardial damage and alterations in EKGs 
as suspected health effect in humans.  In the Newton et al. (1994) study, exposure to ≥4.11 mg Sb/m3 
resulted in increases in alveolar/intra-alveolar macrophages, increases in relative lung weights, and
increases in lung clearance half-times in rats killed at the end of the exposure period.  In rats allowed to 
recover for 27 weeks, significant increases in the incidences of chronic interstitial inflammation and
fibrosis were observed in rats exposed to 19.60 mg Sb/m3.  Mild congestion and focal hemorrhages were 
also observed in the lungs of rats exposed to 2.20 mg Sb/m3 as antimony trisulfide for 6 weeks (Brieger et
al. 1954); however, the investigators did not report the incidence of this effect, which precludes assessing
the significance of the finding.  Brieger et al. (1954) also found antimony trisulfide-induced alterations in 
EKGs and histological alterations in the myocardium of rats exposed to 2.20 mg Sb/m3 for 6 weeks, dogs
exposed to 3.98 mg Sb/m3 for 10 weeks (no alterations were observed in dogs exposed to 3.81 mg Sb/m3 
for 7 weeks), and rabbits exposed to 4.02 mg Sb/m3 for 6 weeks. A third intermediate-duration study, 
reported unspecified lesions in the lungs, liver, kidneys, and pancreas (only qualitative data were
provided), decreases in fertility, and decreases in litter size in rats exposed to 209 mg Sb/m3 as antimony
trioxide for 1.5–2 months (Belyaeva 1967).
The lung effects (increases in lung clearance time, chronic interstitial inflammation, and interstitial 
fibrosis) and the myocardial effects (histological alterations and altered EKGs) observed in the rats and
rabbits were considered as the basis for an intermediate-duration MRL for antimony; the effects observed 
in dogs were not considered because reference values are not available for estimating the RDDR. BMD 
modeling was utilized to estimate the potential PODs for the histological alterations in the lungs observed 
in the Newton et al. (1994) study, but could not be utilized for the cardiac effects from the Brieger et al. 
(1954) studies due to the lack of incidence data. These incidence data were fit to all available 
dichotomous models in EPA’s BMDS (version 2.6.0) using the extra risk option; see Appendix A for
details on the BMD modeling results.
A summary of the PODs and HECs are presented in Table 3-10.  The PODHEC values, which were based
on BMCL10 or NOAEL values, ranged from 0.19 to 0.078 mg Sb/m3 and the PODHEC values, based on 
LOAEL values, were 0.89 and 1.5 mg Sb/m3. To compare the two types of PODs, the PODHEC values 
based on LOAELs were divided by an uncertainty factor of 10 resulting in values of 0.15 and 0.089 mg
Sb/m3. The PODHEC values for the increased lung clearance half-time, chronic lung interstitial 
inflammation, and degenerative heart effects and altered EKG readings in rabbits were similar, and the
lowest value of 0.057 mg Sb/m3 for chronic lung inflammation was selected as the basis of the MRL.
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Table 3-10. Summary of Potential Points of Departures (PODs) and Human 





PODs RDDR HECsb 
End point (reference) (mg Sb/m3) valuesa (mg Sb/m3)
Increased lung clearance half-times in rats (Newton et al. 1994) 0.902 (NOAEL) 0.487c 0.078
Chronic lung interstitial inflammation in rats (Newton et al. 1994) 0.66 (BMCL10) 0.487c 0.057
Chronic lung fibrosis in rats (Newton et al. 1994) 2.14 (BMCL10) 0.487c 0.19
Degenerative changes in heart and altered EKG readings in rats 2.20 (LOAEL) 3.185d 1.5
(Brieger et al. 1954)
Degenerative changes in heart and altered EKG readings in 3.98 (LOAEL) NAe NA
dogs (Brieger et al. 1954)
Degenerative changes in heart and altered EKG readings in 4.02 (LOAEL) 1.060d 0.89
rabbits (Brieger et al. 1954)
aRDDR values specific for each region of the respiratory tract (extrathoracic and pulmonary) were calculated using 
EPA’s RDDR calculator, with estimated body weight of 0.230 kg for the Newton et al. (1994) study and reference 
body weights of 0.267 and 4.0 kg for rats and rabbits in the Brieger et al. (1954) study.
bHEC calculated by multiplying the duration-adjusted POD (POD x 6 hours/24 hours x 5 days/7 days for the Newton 
et al. [1994] study and 7 hours/day, 5 days/week for the Brieger et al. [1954] study) by the RDDR value.
cCalculated using a particle size of 3.05 μm (sigma g of 1.57).

dCalculated using a particle size of 2 μm (sigma g of 1.9), which is an assumed value; the investigators noted that
	
most of the particles were <2 μm, but did not provide any additional information.
 
eRDDR calculator does not have default values for dogs and HECs could not be calculated.
 
BMCL = 95% lower confidence limit on the benchmark concentration; EKG = electrocardiogram;
 
EPA = Environmental Protection Agency; LOAEL = lowest-observed-adverse-effect level; MRL = Minimal Risk Level;
 
NOAEL = no-observed-adverse-effect level; RDDR = regional deposited dose ratio 
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This human equivalent value of 0.057 mg Sb/m3 was divided by an uncertainty factor of 30 (3 for
extrapolation from animals to humans with dosimetric adjustments and 10 for human variability) resulting
in an MRL of 0.002 mg Sb/m3. However, this MRL is slightly higher than the acute-duration inhalation 
MRL, and ATSDR adopted the acute-duration MRL of 0.001 mg Sb/m3 for intermediate-duration 
exposure.
Chronic-Duration. The toxicity of airborne antimony has not been extensively studied in humans.  
Several occupational exposure studies have reported lung effects (pneumoconiosis and chronic bronchitis)
in workers at antimony smelters (Cooper et al. 1968; Potkonjak and Pavlovich 1983; Schnorr et al. 1995).  
Signs of upper respiratory tract irritation including bleeding of the nose, rhinitis, upper airway
inflammation, and laryngitis (Potkonjak and Pavlovich 1983; Renes 1953) have also been reported in 
workers.  Other effects that have been observed in workers include altered EKGs (Brieger et al. 1954) and 
dermatitis, which is likely due to direct contact with skin (Potkonjak and Pavlovich 1983; Renes 1953).
One study also reported reproductive disturbances and developmental effects (decreases in infant growth)
in female workers exposed to metallic antimony, antimony trioxide, and antimony pentasulfide (Belyaeva
1967).  Although some studies provided exposure levels, these studies were not considered suitable for
derivation of chronic MRLs because many studies did not include control groups, wide ranges of
antimony levels were reported, and many involved co-exposure to other compounds including arsenic.
A number of studies have evaluated the chronic toxicity of antimony compounds in rats and mice.  These
studies provide strong evidence that the respiratory tract is the primary target of antimony toxicity, which 
is supported by the systematic review of the toxicity data that concluded that respiratory tract toxicity is a
presumed health effect in humans.  Four studies identified LOAEL values <5 mg Sb/m3 for lung effects in 
rats (Newton et al. 1994; NTP 2016; Watt 1983) and mice (NTP 2016).  Watt (1983) found increases in 
the incidence of focal fibrosis, adenomatous hyperplasia, cholesterol clefts, and pneumocyte hyperplasia 
in rats exposed to 1.6 mg Sb/m3 for 55 weeks.  In rats and mice exposed to 2.5 mg Sb/m3 as antimony
trioxide for 2 years, inflammation, proteinosis, alveolar/bronchiolar hyperplasia, and fibrosis were 
observed in the lungs (NTP 2016).  An increase in chronic lung inflammation and increased lung
clearance times were observed in female rats exposed to 0.43 mg Sb/m3 and in male and female rats 
exposed to 3.8 mg Sb/m3 as antimony trioxide for 12 months; the inflammation was only observed after a
1-year recovery period (Newton et al. 1994).  Higher LOAELs for lung effects were identified for other
antimony compounds: 17.5 mg Sb/m3 as antimony ore for interstitial fibrosis (Groth et al. 1986) and 
84 mg Sb/m3 as antimony trisulfide for lipoid pneumonia (Gross et al. 1952).  Although these LOAELs
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are higher than those identified for antimony trioxide, the available data do not allow a comparison 
between compounds since adverse effects were often observed at the lowest concentration tested.  A
summary of the NOAEL and LOAEL values identified in animal studies is presented in Table 3-11.  In 
addition to the pulmonary effects, effects have also been observed in the lymph nodes (lymphoid 
hyperplasia in bronchial and mediastinal lymph nodes), eyes (lenticular degeneration), and bone marrow
(hyperplasia); the LOAELs for these effects (see Table 3-11) are similar to those identified for respiratory
effects.
As summarized in Table 3-11, Newton et al. (1994) identified the lowest LOAEL value for chronic
interstitial lung inflammation and lenticular degeneration in rats exposed to 0.43 mg Sb/m3 for 1 year with 
a 1-year recovery period; these effects were not observed at 0.05 mg Sb/m3. The other chronic-duration 
studies identified higher LOAEL values.
BMD modeling was utilized to estimate the potential PODs for lung inflammation and lenticular
degeneration in rats (Newton et al. 1994). The incidence data were fit to all available dichotomous
models in EPA’s BMDS (version 2.6.0) using the extra risk option. The results of the BMD modeling are 
presented in Appendix A.  A summary of the potential PODs for each end point based on NOAEL, 
LOAEL, or BMCL values is presented in Table 3-12.  HECs were calculated by multiplying the duration-
adjusted POD by the RDDR; the RDDR was calculated for each region of the respiratory tract using
EPA’s RDDR calculator and the reported particle sizes.  The lowest PODHEC was 0.008 mg Sb/m3 for 
lung inflammation in female rats. Thus, the BMCLHEC of 0.008 mg Sb/m3 was divided by an uncertainty
factor of 30 (3 for extrapolation from animals to humans with dosimetric adjustments and 10 for human 
variability) resulting in an MRL of 0.0003 mg Sb/m3.
3.6.2.2  Oral MRLs 
Acute-Duration. Studies conducted in the 1920s and 1940s demonstrate that antimony potassium
tartrate is a gastrointestinal irritant in humans (Dunn 1928) and animals (as reviewed by Elinder and 
Friberg 1986), resulting in vomiting and diarrhea shortly after exposure.  Houpt et al. (1984)
demonstrated that the mean latency to vomit was 30 minutes after dogs drank 4.8 mg Sb/kg as antimony
potassium tartrate. These gastrointestinal effects are likely due to the antimony concentration rather than
the dose.  NTP (1992) evaluated the acute toxicity of antimony potassium tartrate in 14-day drinking
water studies in rats and mice.  In rats, the highest concentration (61 mg Sb/kg/day) did not result in 
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Table 3-11. Summary of NOAEL and LOAEL Values for Effects Observed in 

Target Tissues Following Chronic Duration Inhalation Exposurea
 
Effect NOAEL LOAEL Reference
Chronic interstitial inflammation in male rats exposed to 0.43 3.8 Newton et al.
antimony trioxide for 1 year 1994
Chronic interstitial inflammation in female rats exposed to 0.05 0.43 Newton et al.
antimony trioxide for 1 year 1994
Lenticular degeneration in rats exposed to antimony trioxide for 0.05 0.43 Newton et al.
1 year 1994
Lipoid pneumonia in rats exposed to antimony trisulfide for 84b Gross et al. 1952
14.5 months
Interstitial fibrosis and alveolar wall hypertrophy and hyperplasia 36c Groth et al. 1986
in rats exposed to antimony trioxide for 1 year
Interstitial fibrosis and alveolar wall hypertrophy and hyperplasia 17.5c Groth et al. 1986
in rats exposed to antimony ore for 1 year
Focal fibrosis, pneumocyte hyperplasia in rats exposed to 1.6 Watt 1983
antimony trioxide for 55 weeks
Lung inflammation, proteinosis, alveolar epithelial hyperplasia, 2.5 NTP 2016
bronchiole epithelial hyperplasia, lung fibrosis in rats exposed to
antimony trioxide for 2 years
Nasal respiratory epithelial hyperplasia in rats exposed to 2.5 NTP 2016
antimony trioxide for 2 years
Lymphoid hyperplasia in bronchial and mediastinal lymph nodes 2.5 NTP 2016
in rats exposed to antimony trioxide for 2 years
Lung inflammation, alveolar fibrosis, pleural fibrosis and 2.5 NTP 2016
inflammation, and alveolar and bronchiolar epithelial hyperplasia 
in mice exposed to antimony trioxide for 2 years
Nasal respiratory epithelial inflammation in mice exposed to 2.5 NTP 2016
antimony trioxide for 2 years
Bone marrow hyperplasia in mice exposed to antimony trioxide 2.5 NTP 2016
for 2 years
Lymphoid hyperplasia of bronchial lymph nodes in mice 2.5 NTP 2016
exposed to antimony trioxide for 2 years
aUnless otherwise noted, exposures were for 6 hours/day, 5 days/week
bExposures were for 25 hours/week
cExposures were for 7 hours/day, 5 days/week
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level
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Table 3-12. Summary of Potential Points of Departure (PODs) for Derivation of
 
Chronic-Duration Inhalation MRL for Antimony
 
POD HECb 
End point (reference) (mg Sb/m3) RDDRa (mg Sb/m3)
Chronic interstitial inflammation in male rats (Newton et 0.43 (NOAEL) 0.330 0.025
al. 1994)
Chronic interstitial inflammation in female rats (Newton 0.10 (BMCL10) 0.436 0.0008
et al. 1994)
Lenticular degeneration in rats (Newton et al. 1994) 0.05 (NOAEL) 2.797 0.025
aRDDR values specific for each region of the respiratory tract (pulmonary and extrarespiratory) were calculated using
EPA’s RDDR calculator, with reference body weights of 0.380 and 0.229 kg for male and female rats and particle 
size of 3.76 μm (sigma g of 1.79).
bHEC calculated by multiplying the duration-adjusted POD (POD x 6 hours/24 hours x 5 days/7 days) by the RDDR
value.
BMCL = 95% lower confidence limit on the benchmark concentration; EPA = Environmental Protection Agency;
HEC = human equivalent concentration; MRL = Minimal Risk Level; NOAEL = no-observed-adverse-effect level; 
RDDR = regional deposited dose ratio
***DRAFT FOR PUBLIC COMMENT***
   
 








   
     
 






   
     
  
   
  
 
   
  
 




     
     
    
      
 
   
      
  
 
    
    
94ANTIMONY AND COMPOUNDS
3. HEALTH EFFECTS
significant alterations in body weight or histopathological alterations in major tissues and organs.  In 
mice, exposure to 150 mg Sb/kg/day resulted in focal ulceration in the forestomach and minimal to
moderate hepatocellular cytoplasmic vacuolization.  Exposure to 99 and 150 mg Sb/kg/day resulted in a
transient decrease in body weight gain; at termination, body weights were within 93% of controls. The
decreases in body weight may have been secondary to the dramatic decrease in water intake, which was 
also observed in the exposed mice.
Although the Houpt et al. (1984) study identified the lowest LOAEL for acute exposure, this study was 
not selected as the basis of the MRL because the study only evaluated overt signs of gastrointestinal
irritation and was a single exposure study.  The mouse study (NTP 1992) was selected as the key study
for derivation of the acute-duration oral MRL.  The NOAEL of 99 mg Sb/kg/day for forestomach and 
liver lesions was selected as the POD for the MRL.  BMD modeling was not conducted since lesions were 
only observed in the high-dose group.  The transient decrease in body weight observed at 99 and 150 mg
Sb/kg/day was not selected as the POD because this decrease may have been the result of decreased water
consumption likely due to taste aversion.  This NOAEL of 99 mg Sb/kg/day was divided by a total
uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability),
resulting in an acute duration MRL of 1 mg Sb/kg/day.
Intermediate-Duration. Several studies have evaluated the intermediate-duration toxicity of
antimony compounds.  Observed effects include reductions in body weight gain, hematological effects 
(alterations in red blood cell and platelet levels), decreases in serum glucose levels, thyroid (epithelial
alterations), and developmental effects (decreased pup body weight and altered vasomotor response in 
pups).  The results of several 12–24-week studies provide evidence for compound-specific differences in
toxicity, which are likely reflective of differences in the relative absorption of the compounds.  More
soluble compounds such as antimony potassium tartrate and antimony trichloride appear to be more toxic
than antimony trioxide; see Table 3-13 for a list of LOAELs for different antimony compounds.
The lowest LOAEL values were identified for altered vasomotor response in pups, decreased pup growth, 
and decreases in serum glucose levels and these three end points were considered for the basis of the 
intermediate-duration MRL.  Developmental toxicity and decreases in serum glucose levels were both
considered suspected health effects in humans based on the systematic review of the available data on
antimony; of the two developmental effects, only the decrease in growth was considered for MRL
derivation due to the uncertainty associated with estimating the dose for the vasopressor studies.  In these 
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Table 3-13.  List of NOAEL and LOAEL Values in Rats Exposed to Antimony or
 
Antimony Compounds for Intermediate Durations
 
NOAEL LOAEL
Effect, duration (reference) Compound (mg Sb/kg/day) (mg Sb/kg/day)
Altered vasomotor response in pups Antimony trichloride 0.1
exposed during lactation (maternal dose was in drinking water (post-weaning
0.8 mg Sb/kg/day) and post-lactation on dose)
PNDs 22–60 (Angrisani et al. 1988)
Altered vasomotor response in pups Antimony trichloride 0.1
exposed during gestation and lactation in drinking water (post-weaning
(maternal dose was 0.7 mg Sb/kg/day) and dose)
post-lactation on PNDs 22–60 (Rossi et al.
1987)
Decreased pup growth on PNDs 10–60 in Antimony trichloride 0.07 0.7
pups exposed during gestation, lactation, in drinking water
and postnatally (Rossi et al. 1987)
Decreases in serum glucose in female rats Antimony potassium 0.06 0.64
exposed for 13 weeks (Poon et al. 1998) tartrate in drinking 
water
Decreased red blood cell count in male rats Antimony metal in 620
exposed for 24 weeks (Sunagawa 1981) diet
Cloudy swelling in hepatic cords in male rats Antimony metal in 620
exposed for 24 weeks (Sunagawa 1981) diet
Increased disorder of hepatic cords in male Antimony trioxide in 370 740
rats exposed for 24 weeks (Sunagawa 1981) diet
No alterations in hematological, serum Antimony trioxide in 1,408
clinical chemistry, or histopathology of major diet
tissues and organs in rats exposed for
13 weeks (Hext et al. 1999)
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; PND = postnatal day
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studies, rats were exposed during gestation and/or lactation and then exposed on PNDs 22–60; the 0.1 mg
Sb/kg/day dose is an estimate of the postnatal exposure, but does not include an estimate of prenatal
exposure or exposure via breast milk.  BMD modeling was considered for the decreases in serum glucose 
levels and decreases in pup body weight on PNDs 10 and 22.  The serum glucose levels and pup body
weights were fit to all available continuous models in EPA’s BMDS (version 2.6.0).  None of the models
provided adequate fit to the serum glucose data or the PND 10 body weight data.  Thus, a NOAEL/ 
LOAEL approach was utilized to identify the POD for the intermediate-duration oral MRL.  The NOAEL
and LOAEL values for the decreased serum glucose level and the decreased pup body weight were
similar and the end point with the lowest LOAEL (decreased serum glucose level) was selected as the 
basis of the MRL.  The NOAEL of 0.064 mg Sb/kg/day was divided by an uncertainty factor of
100 (10 for extrapolation from animals to humans and 10 for human variability), resulting in an MRL of
0.0006 mg Sb/kg/day.
Chronic-Duration. Two studies have evaluated the chronic toxicity of antimony (Kanisawa and
Schroeder 1969; Schroeder et al. 1970) in rats and mice exposed to antimony potassium tartrate in 
drinking water for a lifetime.  Decreases in survival were observed in rats exposed to 0.63 mg Sb/kg/day
(Schroeder et al. 1970) and in mice exposed to 0.35 mg Sb/kg/day (Kanisawa and Schroeder 1969).  Both 
studies examined a limited number of end points.  In rats, no cardiovascular or body weight alterations
were observed; however, a decrease in nonfasting glucose levels was found at 0.63 mg Sb/kg/day.  No 
hepatic or body weight alterations were observed in mice. Given the limited number of end points
examined and decreases in survival at the only dose tested, neither study was considered suitable for
derivation of a chronic-duration oral MRL.
3.7  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
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disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering,
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans and/or animals after exposure to 
antimony.
No in vitro studies were located regarding endocrine disruption of antimony.
3.8  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when most biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
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Children sometimes differ from adults in their susceptibility to adverse health effects from exposure to
hazardous chemicals, but whether there is a difference depends on the chemical(s) (Guzelian et al. 1992;
NRC 1993).  Children may be more or less susceptible than adults to exposure-related health effects, and
the relationship may change with developmental age (Guzelian et al. 1992; NRC 1993).  Vulnerability
often depends on developmental stage.  There are critical periods of structural and functional
development during both prenatal and postnatal life that are most sensitive to disruption from exposure to 
hazardous substances.  Damage from exposure in one stage may not be evident until a later stage of
development. There are often differences in pharmacokinetics and metabolism between children and
adults.  For example, absorption may be different in neonates because of the immaturity of their
gastrointestinal tract and their larger skin surface area in proportion to body weight (Morselli et al. 1980;
NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young children (Ziegler et al. 
1978).  Distribution of xenobiotics may be different; for example, infants have a larger proportion of their
bodies as extracellular water, and their brains and livers are proportionately larger (Altman and Dittmer
1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and Dickerson 1964).  Past
literature has often described the fetus/infant as having an immature (developing) blood-brain barrier that 
is leaky and poorly intact (Costa et al. 2004).  However, current evidence suggests that the blood-brain 
barrier is anatomically and physically intact at this stage of development, and the restrictive intracellular
junctions that exist at the blood-CNS interface are fully formed, intact, and functionally effective 
(Saunders et al. 2008, 2012).
However, during development of the brain, there are differences between fetuses/infants and adults that
are toxicologically important. These differences mainly involve variations in physiological transport
systems that form during development (Ek et al. 2012).  These transport mechanisms (influx and efflux)
play an important role in the movement of amino acids and other vital substances across the blood-brain 
barrier in the developing brain; these transport mechanisms are far more active in the developing brain
than in the adult.  Because many drugs or potential toxins may be transported into the brain using these
same transport mechanisms—the developing brain may be rendered more vulnerable than the adult.  
Thus, concern regarding possible involvement of the blood-brain barrier with enhanced susceptibility of
the developing brain to toxins is valid.  It is important to note however, that this potential selective
vulnerability of the developing brain is associated with essential normal physiological mechanisms; and
not because of an absence or deficiency of anatomical/physical barrier mechanisms.
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The presence of these unique transport systems in the developing brain of the fetus/infant is intriguing;
whether these mechanisms provide protection for the developing brain or render it more vulnerable to 
toxic injury is an important toxicological question.  Chemical exposure should be assessed on a case-by-
case basis.  Research continues into the function and structure of the blood-brain barrier in early life
(Kearns et al. 2003; Saunders et al. 2012; Scheuplein et al. 2002).
Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of
growth and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion,
particularly in newborns given their low glomerular filtration rate and not having developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
No studies are available comparing the toxicity of antimony in adults and children.  The health effects 
observed in adults are presumed to also occur in children.  The developmental toxicity of antimony has
been assessed in an inhalation study (Belyaeva 1967), an oral study (Rossi et al. 1987), and parenteral
studies (Alkhawajah et al. 1996; Coelho et al. 2014a; Miranda et al. 2006). A decrease in litter size was 
observed in rats exposed to 209 mg Sb/m3 as antimony trisulfide 4 hours/day for 1.5–2 months; no 
alterations in birth weight or pup body weights on PND 21 were found.  In contrast, an oral exposure
study (Rossi et al. 1987) reported no alterations in litter size in the offspring of rats exposed to 0.7 mg
Sb/kg/day as antimony trichloride during gestation and lactation; however, significant decreases in pup 
body weight on PNDs 10–60 were found.  Decreases in litter size, fetal body weight, and birth weight
were observed in rats injected with meglumine antimoniate, sodium stibogluconate, or antimony trioxide
***DRAFT FOR PUBLIC COMMENT***
   
 








   
      
     
      
   
 
  
        




   
 
    
    
 
 
     
     
 
 
   
   
    
  
 
   
     
  





during gestation (Alkhawajah et al. 1996; Coelho et al. 2014a; Miranda et al. 2006).  This study also 
provided evidence of transplacental transfer of antimony.  Elevated antimony levels were found in fetal 
blood; the levels were 70% of those found in the dams (Miranda et al. 2006).  However, gestation and
lactational exposure to meglumine antimoniate resulted in blood antimony levels in pups that exceeded
maternal blood levels (Coelho et al. 2014a).
A study by Cruz et al. (2007) compared plasma antimony levels in children (aged 2–7 years) to those of
adults following intramuscular injections of 20 mg Sb/kg as meglumine antimoniate for 20 days for the
treatment of leishmaniasis.  The plasma antimony concentrations were significantly lower in children
compared to adults and a significantly shorter elimination half-life was estimated in the children
(1.48 hours) compared to the adults (1.99 hours).
3.9  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment
of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  However, several
factors can confound the use and interpretation of biomarkers of exposure.  The body burden of a
substance may be the result of exposures from more than one source. The substance being measured may
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from
exposure to several different aromatic compounds).  Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken.  It may be difficult to
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids
(e.g., essential mineral nutrients such as copper, zinc, and selenium).  Biomarkers of exposure to 
antimony are discussed in Section 3.9.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health 
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impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by antimony are discussed in Section 3.9.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.11, Populations That Are Unusually Susceptible.
3.9.1  Biomarkers Used to Identify or Quantify Exposure to Antimony
Elevated blood, hair, urine, and fecal levels of antimony indicate high exposure to antimony.  A 
significant correlation exists between the level of pentavalent antimony (N-methylglucamine antimonate)
administered intraperitoneally to humans and antimony levels in hair (Dorea et al. 1989).  However, 
Dorea et al. (1989) only tested two levels of antimony (10 and 20 mg antimony/kg/day).  It should be
noted that hair antimony levels have not been established as a reliable biomarker of antimony exposure.
Factory workers exposed to antimony trioxide (0.042–0.70 mg antimony/m3) had elevated urine and 
blood antimony levels (Ludersdorf et al. 1987).  Antimony levels in the urine and blood were 1.1 and 0.9– 
5.0 μg/L, respectively, compared to 0.6 μg/L urine levels and 0.4 μg/L blood levels in unexposed workers. 
Another study of workers producing antimony pentoxide and sodium antimoniate found significant
correlations between airborne antimony levels and urinary antimony levels, particularly if the air levels 
were compared to postshift increases in urinary levels (Bailly et al. 1991).  Animal data suggest that urine 
and blood levels remain elevated several days after exposure (Felicetti et al. 1974b).
3.9.2  Biomarkers Used to Characterize Effects Caused by Antimony
No toxic symptoms specific to antimony exposure have been identified.  Toxic effects that reportedly
occur in humans include pneumoconiosis, altered EKG readings, and gastrointestinal effects.  No
quantitative biomarkers associated with these effects are known.
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3.10  INTERACTIONS WITH OTHER CHEMICALS
No information on the influence of other compounds on the toxicity of inhaled or ingested antimony was
located.
3.11  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to antimony than will most persons
exposed to the same level of antimony in the environment.  Factors involved with increased susceptibility
may include genetic makeup, age, health and nutritional status, and exposure to other toxic substances
(e.g., cigarette smoke).  These parameters result in reduced detoxification or excretion of antimony, or
compromised function of organs affected by antimony.  Populations who are at greater risk due to their
unusually high exposure to antimony are discussed in Section 6.7, Populations with Potentially High 
Exposures.
Individuals with existing chronic respiratory or cardiovascular disease or problems may have an increased
risk of antimony toxicity since the respiratory and cardiovascular systems are targets of antimony toxicity.
Because antimony is excreted in the urine, individuals with kidney dysfunction may be unusually
susceptible.
3.12  METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to antimony.  Because some of the treatments discussed may be experimental and unproven, this
section should not be used as a guide for treatment of exposures to antimony.  When specific exposures 
have occurred, poison control centers, board certified medical toxicologists, board-certified occupational
medicine physicians and/or other medical specialists with expertise and experience treating patients 
overexposed to antimony can be consulted for medical advice.  The following texts provide specific
information about treatment following exposures to antimony:
Tarabar AF.  2015.  Antimony.  In:  Goldfrank’s toxiologic emergencies, 10th Edition.  New York, NY.  
McGraw Hill, 1161-1167.
Schonwald S.  2004.  Antimony.  In:  Dart, RC, ed. Medical toxicology, 3rd Edition. Philadelphia, PA:
Lippincott Williams & Wilkins, 1391-1392.
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Shannon MW, Borron SW, Burns MJ.  2007.  Antimony. In:  Haddad and Winchester's clinical
management of poisoning and drug overdose.  Philadelphia, PA:  Saunders Elsevier, 917, 1158.  
These texts are provided solely for informational purposes and are not intended as a substitute for
consultation with a medical professional.
Additional relevant information can be found in the front section of this profile under QUICK
REFERENCE FOR HEALTH CARE PROVIDERS.
3.12.1  Reducing Peak Absorption Following Exposure 
Human exposure to antimony may occur by inhalation, ingestion, or dermal contact.  Mitigation 
approaches to reduce absorption of antimony have included general recommendations of removal from
the exposure and removal of contaminated clothing from the exposed individual.  For ingestion, gastric
lavage may be beneficial (Tarabar 2014).  Exposed eyes and skin should be flushed with a clean neutral
solution such as water or normal saline.
3.12.2  Reducing Body Burden
Antimony may be found in the blood and urine several days after exposure.  Pentavalent antimony is
rapidly excreted in humans following intravenous or intramuscular administration, with >50% excreted in 
the urine 6 hours after injection (Goodwin and Page 1943; Rees et al. 1980).  Trivalent antimony is not as
rapidly excreted in the urine and is primarily excreted in the feces over a 24-hour period of time as noted 
after intraperitoneal administration in laboratory animals (Edel et al. 1983).
Little data are available on reducing the antimony body burden.  The effectiveness of chelation therapy 
has been tested in laboratory animals (Eagle et al. 1947).  Administration of dimercaprol (also referred to 
as British anti-Lewisite or BAL) decreased the mortality associated with intravenous administration of
fuadin or tartar emetic in rabbits.  Dimercaprol was also used as a treatment in four individuals ingesting
food contaminated with tartar emetic (Lauwers et al. 1990).  Administration of dimercaprol resulted in 
increases in urinary excretion of antimony.  In a study in mice administered lethal doses of potassium
antimony tartrate, administration of dimercaptosuccinic acid was the most effective in decreasing the
mortality incidence, as compared to Tiron, sodium 2,3-dimercaptopropane, and D-penicillamine
(Basinger et al. 1981).  Other chelating agents tested, including dimercaprol, tartaric acid, 
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ethylenediaminetetraacetic acid (EDTA), and sodium diethledithiocarbamate, were not effective in 
increasing survival; it is noted that dimercaprol was administered at a low dose due to toxicity.
3.12.3  Interfering with the Mechanism of Action for Toxic Effects
No information on interfering with the mechanism of action was identified.
3.13  ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of antimony is available. Where adequate information is not
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the adverse health effects (and techniques for
developing methods to determine such health effects) of antimony.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health risk assessment. This definition should not be interpreted to 
mean that all data needs discussed in this section must be filled.  In the future, the identified data needs
will be evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.13.1  Existing Information on Health Effects of Antimony
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
antimony are summarized in Figure 3-4.  The purpose of this figure is to illustrate the existing
information concerning the health effects of antimony.  Each dot in the figure indicates that one or more 
studies provide information associated with that particular effect. The dot does not necessarily imply
anything about the quality of the study or studies, nor should missing information in this figure be
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature.
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As seen in Figure 3-4, there are data available on the health effects of antimony in humans following
inhalation, oral, or dermal exposure.  The inhalation data consist of several reports of workers exposed to 
inorganic forms of antimony.  However, most of these studies are incomplete because the workers were 
exposed to a variety of compounds or the exposure level was not reported.  One oral study involving
accidental drinking of lemonade contaminated with potassium antimony tartrate was located.  Other
studies are population-based studies examining the relationship between urinary antimony levels and 
health effects.  The dermal data on humans are limited to a study in which antimony was applied to the
skin of volunteers and occupational exposure studies involving dermal exposure to airborne antimony.
As compared to the human data, more complete information on the systemic health effects of antimony in
animals was located.  Inhalation studies predominantly evaluated the systemic toxicity of antimony
trioxide, although some studies were available for antimony trisulfide and antimony ore.  One inhalation 
study evaluated the reproductive and developmental toxicity of antimony.  Several studies that examined 
the toxicity of metallic antimony, antimony trioxide, antimony trichloride, and potassium antimony
tartrate via oral exposure were located.  Sensitive measurements of cardiovascular toxicity were not
examined in most of these studies.  One developmental toxicity study in rats was located; internal
examination of pups was not performed.  The acute and intermediate toxicity of dermally applied
antimony trioxide, antimony oxide, and antimony thioantimonate has been examined.  However, the
available studies did not examine the systemic toxicity of antimony; they were designed to assess the 
dermal and/or ocular toxicity of antimony.
3.13.2  Identification of Data Needs 
Acute-Duration Exposure. Information on the target organs of acute exposure in humans to 
antimony is limited.  Based on one human study, the gastrointestinal tract appears to be a target following
inhalation exposure to antimony (Taylor 1966).  Animal studies have shown that the respiratory tract and
heart are the primary targets following inhalation exposure to antimony (Brieger et al. 1954; NTP 2016;
Price et al. 1979); there are also limited data suggesting that the liver and kidney are also targets of
antimony toxicity (Brieger et al. 1954).  An acute inhalation MRL based on respiratory effects in mice 
(NTP 2016) was derived.  The gastrointestinal tract appears to be a target in humans and animals 
following oral exposure to antimony.  This is based on a report of workers who accidentally drank
lemonade contaminated with antimony potassium tartrate (Dunn 1928), a dog study reporting vomiting
after ingestion of antimony potassium tartrate (Houpt et al. 1984), and a mouse study reporting
forestomach ulceration (NTP 1992).  Results of the mouse study also suggest that the liver may be a 
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107ANTIMONY AND COMPOUNDS
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target of antimony toxicity.  An acute oral MRL based on the forestomach and liver effects observed in
mice was derived.  There is no information on the target organs in humans following dermal exposure to 
antimony.  Application of antimony to the skin or eyes of animals results in mild irritation (Gross et al.
1955; Horton et al. 1986; Myers et al. 1978); eye irritation was also observed when animals were exposed 
to airborne antimony compounds (Price et al. 1979).  Information about the toxicity of different antimony
compounds, as well as differences in valence states, was not located.  Additional acute-duration studies by
the inhalation, oral, and dermal routes would provide information on differences in the potency of various
antimony compounds.
Intermediate-Duration Exposure. No reports of health effects in humans following intermediate-
duration inhalation, oral, or dermal exposure were located.  Animal data suggest that the heart and
respiratory tract are the likely targets of antimony toxicity following inhalation exposure (Brieger et al.
1954; Newton et al. 1994).  Developmental and reproductive effects have also been reported in animals
(Belyaeva 1967).  There is no information on human health effects following intermediate-duration oral
exposure to antimony.  The database was adequate for derivation of an intermediate-duration inhalation 
MRL; however, the resulting value was slightly higher than the acute-duration MRL and the acute MRL
was adopted for an intermediate-duration MRL.  Several studies in rats have evaluated the toxicity of
antimony following oral exposure (Angrisani et al. 1988; Hext et al. 1999; Poon et al. 1998; Rossi et al.
1987; Sunagawa 1981). These studies have investigated the toxicity of several trivalent antimony
compounds (antimony trichloride, antimony potassium tartrate, and antimony trioxide) and metallic
antimony and found differences in effect levels that may be related to solubility and absorption efficiency.  
The most sensitive effects were decreases in blood glucose levels, alterations in red blood cell counts, 
hepatic alterations, and developmental toxicity.  Although the database was considered adequate for
derivation of an intermediate-duration oral MRL, additional studies examining EKGs would increase the
confidence in this MRL, since myocardial damage is a suspected human health effect but has not been
adequately assessed in oral exposure studies.  An intermediate-duration dermal exposure study did not
report significant alterations in the liver, kidney, skin, or EKGs (Horton et a. 1986).  An intermediate-
duration study reported corneal opacities in rats exposed to airborne antimony trioxide (Newton et al. 
1994).  Additional dermal exposure studies could provide useful information on the dermal toxicity of
different antimony compounds.
Chronic-Duration Exposure and Cancer. There are several human studies that indicate that the 
targets appear to be the respiratory tract, heart, and skin following chronic-duration exposure (Brieger et
al. 1954; Cooper et al. 1968; Potkonjak and Pavlovich 1983).  Animal studies provide strong evidence
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that the respiratory tract is the primary target of antimony toxicity (Gross et al. 1952; Groth et al. 1986; 
Newton et al. 1994; NTP 2016; Watt 1983).  Most of the studies tested antimony toxicity, and studies
evaluating antimony ore (Groth et al. 1986) or antimony trisulfide (Gross et al. 1952) reported lung
effects at the lowest concentration tested; therefore, they are not useful for comparing the relative toxicity
of various antimony compounds.  Chronic animal studies were considered adequate for deriving a 
chronic-duration inhalation MRL.  Several epidemiology studies have evaluated the potential toxicity of
environmental exposure to antimony using urinary antimony levels as a biometric (Mendy et al. 2012; 
Shiue 2014, 2015; Shiue and Hristova 2014); these studies are not adequate for establishing causality.  
Data on chronic oral toxicity are limited to two studies involving lifetime exposure to antimony potassium
tartrate (Kanisawa and Schroeder 1969; Schroeder et al. 1970).  Both studies only tested one
concentration and examined a limited number of end points; since decreases in survival were observed in
both studies, they were not considered suitable for derivation of a chronic-duration oral MRL.  Well-
designed oral experiments, using several exposure levels and measuring all sensitive toxicological end
points, would provide information on the health effects associated with long-term exposure to antimony.
Two occupational exposure studies have found increases in the risk of lung cancer in workers (Jones
1994; Schnorr et al. 1995); the carcinogenicity of antimony in humans following oral or dermal exposure
has not been investigated.  Evidence for the carcinogenicity of inhaled antimony in animals is mixed.  
Two 1-year studies reported lung tumors in rats exposed to relatively low levels of antimony trioxide
(Groth et al. 1986; Watt 1983).  A study using similar exposure levels and exposure durations did not find 
evidence of carcinogenicity (Newton et al. 1994). On the other hand, a 2-year study concluded that there
was some evidence of carcinogenic activity in male and female rats and clear evidence of carcinogenic 
activity in male and female mice (NTP 2016). The oral cancer data in animals are limited to studies that
used very low levels of antimony (Kanisawa and Schroeder 1969; Schroeder et al. 1970).  No dermal
cancer studies in animals were located; however, an inhalation study found an increase in squamous cell
carcinoma of the skin, which may have been related to exposure to antimony trioxide (NTP 2016).  Oral
and dermal studies in rodents using several exposure levels including the maximum tolerated level would 
provide useful information because prolonged exposure to antimony in humans may occur.
Genotoxicity. In vivo studies have evaluated the potential of trivalent and pentavalent antimony
compounds to induce clastogenic effects and damage DNA in humans (Cavallo et al. 2002; Hantson et al.
1996), rats (Kirkland et al. 2007), and mice (Elliott et al. 1998; Gurnani et al. 1992a, 1992b; Lima et al. 
2010).  In vitro studies have examined the potential of metallic antimony, antimony trioxide, antimony
trichloride, antimony pentachloride, antimony pentoxide, and antimony potassium tartrate to induce gene
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mutations (Asakura et al. 2009; Elliott et al. 1998; Kubo et al. 2002; Kuroda et al. 1991; Lantzsch and 
Gebel 1997; Zeiger et al. 1992) or DNA damage (Kanematsu et al. 1980; Kuroda et al. 1991) in bacteria.  
In vitro studies have also evaluated the potential of a variety of trivalent and pentavalent antimony
compounds to induce clastogenic damage, gene mutations, or DNA damage in mammalian cells (Asakura 
et al. 2009; Elliott et al. 1998; Gebel et al. 1998a; Huang et al. 1998; Kuroda et al. 1991; Lima et al. 2010;
Migliore et al. 1999; Paton and Allison 1972; Schaumlöffel and Gebel 1998; Tu and Sivak 1984).  No 
additional studies of genotoxicity are suggested at this time.
Reproductive Toxicity. Women exposed to antimony in the workplace have reported menstrual
disturbances and a higher incidence of spontaneous abortions compared with nonexposed workers
(Belyaeva 1967).  From this report, it is unclear what the exposure level was, whether the women were 
exposed also to other compounds, and whether the controls had comparable jobs. Reproductive effects 
(failure to conceive, uterine metaplasia) have been observed in rats exposed to airborne antimony
(Belyaeva 1967).  Data on the reproductive toxicity of antimony following oral exposure are limited to a
series of studies evaluating sperm parameters in rats and mice exposed to antimony trioxide or antimony
potassium tartrate (Omura et al. 2002). Well-designed studies to assess the effects of inhalation or orally
administered antimony on reproductive performance would provide information on possible reproductive
effects that might be relevant to humans.
Developmental Toxicity. An increased number of spontaneous abortions was observed in women 
exposed to antimony in the workplace (Belyaeva 1967).  However, there are several limitations to this 
study, as discussed above in the reproductive toxicity section.  No overt developmental effects were 
observed in the offspring of these women.  Two other epidemiology studies did not find associations
between antimony levels in drinking water and the prevalence of neural tube defects (Longerich et al.
1991) and or between umbilical cord antimony levels and adverse pregnancy outcomes (Zheng et al. 
2014).  A developmental toxicity study in rats found decreases in pup growth and no alterations in the 
occurrence of structural abnormalities resulting from gestational exposure to antimony potassium tartrate 
in drinking water (Rossi et al. 1987).  Additionally, two studies examining the effect of antimony on the
development of the cardiovascular system found alterations in vasomotor reactivity in the offspring
(Angrisani et al. 1988; Rossi et al. 1987); however, since this end point was not examined in adults, it is
difficult to determine whether the effects are developmental in nature.  Additional studies examining the
potential of antimony to affect the development of the cardiovascular system would be useful.
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Immunotoxicity. There is limited information on the immunotoxicity of antimony.  A human study
found alterations in immunoglobin levels (Kim et al. 1999).  Inhalation studies have reported hyperplasia
in the bronchial and mediastinal lymph nodes following chronic exposure in rats and mice (Newton et al.
1994; NTP 2016).  An oral study found histological alterations in rats exposed to antimony potassium
tartrate (Poon et al. 1998). A skin sensitization study concluded that dermal exposure to antimony
thioantimonate did not result in sensitization (Horton et al. 1986).  Additional studies are needed to
evaluate whether antimony alters immune function.
Neurotoxicity. The potential neurotoxicity of antimony has not been investigated in humans or
animals following inhalation, oral, or dermal exposure.  An occupational exposure study (Renes 1953)
reported some neurological effects; however, the lack of a control group and co-exposure to other
compounds including arsenic limits establishing causality with antimony.  Animal studies have not found 
histological alterations in the brain following inhalation or oral exposure (Groth et al. 1986; Hext et al. 
1999; NTP 1992, 2016; Poon et al. 1998; Watt 1983).  A study in which mice were repeatedly
administered antimony potassium tartrate via intraperitoneal injections reported degenerative changes in
the anterior horn cells of the lumbar spine and sciatic nerve edema (Mansour and Reese 1965).  Although
this effect has not been observed by other routes of exposure, this end point has not been well studied.  
Sensitive tests of neurophysiological function may detect early signs of neurotoxicity following
inhalation, oral, or dermal exposure to antimony.
Epidemiological and Human Dosimetry Studies. There are several epidemiological
occupational exposure studies (Belyaeva 1967; Brieger et al. 1954; Cooper et al. 1968; Jones 1994; Kim
et al. 1999; Potkonjak and Pavlovich 1983; Renes 1953; Schnorr et al. 1995; Stevenson 1965).  However, 
most of these studies are incomplete because the exposure level and/or particle size of the airborne 
antimony was not reported, many studies did not include control groups, and/or the workers were often
exposed to a variety of other compounds.  Several studies have used NHANES data sets to examine 
associations between urinary antimony levels and health effects (Mendy et al. 2013; Shiue 2014, 2015;
Shiue and Hristova 2014); these studies are not suitable for establishing causality. Epidemiological
studies would be useful in order to determine the effects of long-term exposure in humans, with particular
attention paid to cardiovascular and respiratory effects. If a cause/effect relationship was established
between antimony exposure and health effects in humans, monitoring of individuals living near hazardous
waste sites could be performed in order to verify that exposure levels do not exceed recommended limits 
and that body tissue and fluid levels remain below potentially hazardous levels.
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Biomarkers of Exposure and Effect.
Exposure. Antimony levels can be measured in blood, urine, feces, and hair, and background urinary
levels of antimony have been established in the general U.S. population (CDC 2015).  Antimony levels in
blood, urine, and feces have been shown to increase in response to increased antimony exposure (Cooper
et al. 1968; Edel et al. 1983; Felicetti et al. 1974a, 1974b; Gerber et al. 1982; Goodwin and Page 1943;
Ludersdorf et al. 1987; Rees et al. 1980).  Studies that quantified the relationship between blood and/or
urinary levels and airborne antimony concentrations or antimony intake would provide valuable
information for screening.
Effect. No antimony-specific biomarkers of effects have been identified.  Future studies on the toxicity of
antimony should use several antimony exposure levels; this may lead to the identification of subtle
biochemical or physiological biomarkers of effects.
Absorption, Distribution, Metabolism, and Excretion. There is some information on the
toxicokinetic properties of antimony following oral or inhalation exposure in humans and animals
(Ainsworth et al. 1991; Cooper et al. 1968; Edel et al. 1983; Felicetti et al. 1974a, 1974b; Gerber et al. 
1982; Gerhardsson et al. 1982; Goodwin and Page 1943; Kirkland et al. 2007; Kobayashi and Ogra 2009;
Ludersdorf et al. 1987; Newton et al. 1994; Rees et al. 1980; Ribiero et al. 2010; Sumino et al. 1975;
Sunagawa 1981; Thomas et al. 1973; Yu and Rappaport 1996).  However, there is limited comparative
information on the absorption, distribution, and excretion of different antimony compounds.  
Furthermore, the site and mechanism of antimony absorption from the gastrointestinal tract have not been 
elucidated. The influence of nutritional factors as well as the presence of food in the gastrointestinal tract
on absorption are not known.  Information on the absorption, distribution, and excretion of antimony
following dermal application is not known.  In addition, a study on the effect of oxidation state on the
cellular uptake of antimony and the effect of water solubility of an antimony compound on lung retention/ 
absorption would provide useful information on the toxicity of different antimony compounds.  A study
that examined these aspects of antimony would be useful in assessing the potential target organs
following dermal exposure to antimony.
Comparative Toxicokinetics. Species differences in the toxicokinetics of antimony have been 
identified (Ainsworth et al. 1990; Felicetti et al. 1974a; Gross et al. 1955; Thomas et al. 1973).  However, 
the absorption, distribution, and excretion of antimony following oral or inhalation exposure in humans is
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not known.  Thus, it is not possible to determine which animal species is the best model for assessing the 
toxicity of antimony.  Information on the toxicokinetic properties of antimony in humans would be useful.
Methods for Reducing Toxic Effects. There is limited information on reducing the toxic effects of
antimony.  Laboratory animal studies have evaluated the effectiveness of several chelating agents in
decreasing the lethality of injected antimony compounds (Basinger et al. 1981; Eagle et al. 1947).  
However, there are limited data on the effectiveness of these treatments in humans.  Studies examining
the effectiveness of chelating agents and possible side effects would be helpful in determining the most
effective treatment for antimony toxicity.  Antimony is widely distributed throughout the body.  The hair
and skin contain the highest levels of antimony.  The adrenal glands, lung, large intestine, trachea, 
cerebellum, and kidneys also contain relatively high levels of antimony (Muramatsu and Parr 1988;
Sumino et al. 1975). No information on methods of mitigating the toxicity of antimony were located.  
Studies that examined such methods would be useful in the treatment of antimony toxicity.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
No studies have examined the potential differences in antimony toxicity between adults and children. A 
toxicokinetic study comparing the distribution and elimination of intramuscularly administered 
pentavalent antimony found differences in serum antimony levels and elimination half-times between
children and adults (Cruz et al. 2007).  Toxicity and toxicokinetic studies involving inhalation and oral
exposure to mature and young animals would provide valuable information for determining whether
children are more susceptible to antimony toxicity.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.13.3  Ongoing Studies 
No ongoing studies examining the toxicity or toxicokinetics of antimony were identified in the National 
Institute of Health (NIH) RePORTER (2015) database.
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
Antimony (Sb) is in the fourth row of group 5A (IUPAC group 15) in the periodic table, residing between 
arsenic and bismuth.  Antimony displays four oxidation states: -3, 0, +3, and +5.  The most common and 
stable oxidation states of antimony in aqueous solutions and biological fluids are Sb(III) and Sb(V).  
Antimony is sometimes referred to as a metalloid, indicating that it displays both metallic and nonmetallic 
characteristics (Li 2011).
Table 4-1 lists the common synonyms, trade names, and other pertinent identification information for
antimony and selected antimony compounds.
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
The physical and chemical properties of antimony and selected antimony compounds are given in
Table 4-2.  Antimony metal is stable under ordinary conditions.  Antimony is a poor conductor of heat
and electricity (Li 2011).  Antimony forms complex ions with organic and inorganic acids.  Stable
complexes, such as Sb2S42-, may form when antimony is in the presence of sulfur (Bodek et al. 1988).
Stibine (SbH3) is a gaseous antimony compound in which antimony is in the -3 valence state.  Stibine is 
formed by the action of acids on metal antimonides or antimony alloys by the reduction of antimony
compounds, or by the electrolysis of acidic or basic solutions where antimony is present in the cathode.  
There is a danger of stibine being liberated from overcharged lead storage batteries in which antimony is 
alloyed into the lead.  Stibine slowly decomposes into metallic antimony and hydrogen.  It is readily, and 
sometimes violently, oxidized by air to form antimony trioxide and water (Freedman et al. 1978).
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Antimony and Compoundsa 
Characteristic Information
Chemical name Antimony Antimony pentasulfide Antimony pentoxide
Synonym(s) Antimony black; Antimonial saffron; Antimonic oxide;
stibium, antimony antimonic sulfide; antimony pentaoxide;
regulus antimony red; antimony; diantimony pentoxide;
golden antimony sulfide, stibic anhydride;
antimony persulfidec antimonic anhydride;
antimonic acidc 
Registered trade name(s) No data No data No data
Chemical formula Sbb S5Sb2d O5Sb2d 
Chemical structure Sb No data No data
Identification numbers:
CAS registry 7440-36-0 1315-04-4 1314-60-9
NIOSH RTECS CC4025000 CC6125000c CC6300000c 
EPA hazardous waste No data No data No data
OHM/TADS 7216595 No data No data
DOT/UN/NA/IMDG shipping UN 2871 No data No data
HSDB 508 No data No data
NCI No data No data No data
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Antimony and Compoundsa 
Characteristic Information
Chemical name Ammonium potassium tartrate Antimony trichloride








Registered trade name(s) No data No data
Chemical formula C8H4K2O12Sb2∙3H2Od Cl3Sb
Chemical structure
Identification numbers:
CAS registry 28300-74-5 10025-91-9
NIOSH RTECS CC6825000 CC4900000
EPA hazardous waste No data No data
OHM/TADS 7217219 7217220
DOT/UN/NA/IMDG shipping UN 1551 UN 1733
HSDB 1428 439
NCI No data No data
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Antimony and Compoundsa 
Characteristic	 Information











Registered trade name(s)	 Hdf; LPf; KRf; White 
Starf; White Star Mf; 
KR-LTSf; Thermoguard 
Sf; Thermoguard Lf; 
H Gradef; L Gradef; Fire







EPA hazardous waste No data
OHM/TADS 7217222
DOT/UN/NA/IMDG shipping UN 1549 antimony
compounds, inorganic


















































eFreedman et al. 1978
fAvento and Touval 1980
gCotton and Wilkinson 1966
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System;
RTECS = Registry of Toxic Effects of Chemical Substances
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Antimony and Compoundsa 
Property Information
Chemical name Antimony Antimony pentasulfide Antimony pentoxide
Molecular weight 121.75 403.80 323.5 (anhydrous)
Color Silvery white Yellow Yellow
Physical state Solid Solid Solid
Valence state 0 +5 +5
Melting point (°C) 630.5 75 (decomposes) 380 (decomposes)f 
Boiling point (°C) 1,750; 1,325b; 1,635c No data No data
Density (g/cm3) at 20°C 6.684 (at 25°C); 6.688b 4.12 3.78
Odor No data Odorlessc No data
Odor threshold:
Water No data No data No data
Air No data No data No data
Taste No data No data No data
Taste threshold No data No data No data
Solubility:
Water at 20°C Insoluble Insoluble Very slightly soluble
Organic solvents No data Insoluble No data
Partition coefficients:
Log Kow No data No data No data
Log Koc No data No data No data
Vapor pressure (mmHg) at 1 (at 886°C)d No data No data
20°C
Henry's law constant at 25°C No data No data No data
Autoignition temperature No data No data No data
Flashpoint No data No data No data
Flammability limits No data No data No data
Conversion factors (ppm to
mg/m3)
Nonee Nonee Nonee 
Explosive limits No data No data No data
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Antimony and Compoundsa 
Property Information
Chemical name Antimony potassium tartrate Antimony trichloride
Molecular weight 333.93 228.11
Color Colorless Colorless
Physical state Solid Solid
Valence state +3 +3
Melting point (°C) 100 (-½ mole H2O) 73.4
Boiling point (°C) No data 283, 222.6g 
Density (g/cm3) at 20°C 2.6 3.140 (at 25°C)
Odor Odorlessg Sharp, unpleasant
Odor threshold:
Water No data No data
Air No data No data
Taste Sweetish, metallicc No data
Taste threshold No data No data
Solubility
Water at 20°C 83 g/L (cold) 6,016 g/L (at 0°C)
Organic solvents Insoluble in alcohol; soluble in glycerine Soluble in ABS alcohol,




Log Kow No data No data
Log Koc No data No data
Vapor pressure (mmHg) at No data 1 (at 49.2°C, sublimes)
20°C
Henry's law constant at 25°C No data No data
Autoignition temperature No data No data
Flashpoint No data No data
Flammability limits No data No data
Conversion factors (ppm to
mg/m3)
Nonee Nonee 
Explosive limits No data No data
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Antimony and Compoundsa 
Property Information
Chemical name Antimony trioxide Antimony trisulfide Stibine






Physical state Solid Solid Gas
Valence state +3 +3 -3
Melting point (°C) 656 550 -88
Boiling point (°C) 1,550 (sublimes);
1,425g 
1,150 -17g 
Density (g/cm3) at 20°C 5.2 (senarmontite);
5.67 (valentinite)
4.64 (stibinite); 4.12 
(amorphous solid)
2.204 (at -17°C)
Odor Odorless No data Disagreeable, like 
hydrogen sulfideg 
Odor threshold:
Water No data No data No data
Air No data No data No data
Taste No data No data No data
Taste threshold No data No data No data
Solubility
Water at 20°C Very slightly soluble 1.75 mg/L (at 18°C) 4.1 g/L (at 0°C)




insoluble in acetic acid
Soluble in carbon 
disulfide, ethanolg 
Partition coefficients
Log Kow No data No data No data
Log Koc No data No data No data
Vapor pressure (mmHg) at
20°C
1 (at 574°C)d No data No data
Henry's law constant at 25°C No data No data No data
Autoignition temperature No data No data No data
Flashpoint No data No data No data
Flammability limits No data No data No data
Conversion factors (ppm to
mg/m3)
Nonee Nonee 1 ppm stibine =
5.1 mg/m3 
Explosive limits No data No data No data
aAll information obtained from Weast (1988) except where noted.
bHerbst et al. 1985
cWindholz 1983
dHSDB 2013
eSince these substances exist in the atmosphere in the particulate state, the concentration is expressed as mg/m3.
fLewis 2012
gFreedman et al. 1978
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121ANTIMONY AND COMPOUNDS
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
Tables 5-1 and 5-2 list the number of facilities in each state that have produced, imported, processed, or
used antimony and its compounds, according to reports made to the EPA under requirements of
Section 313 of the Emergency Planning and Community Right-to-Know Act of 1986 and subsequently
published in the Toxic Chemical Release Inventory (TRI14 2016).  Only certain types of facilities were 
required to report; therefore, this is not an exhaustive list.  The number of individual facilities and the
amount produced on site varied in each state.
Fifteen countries mine antimony.  The world total mine production was 118,000 metric tons in 
2000 (USGS 2004).  The majority, 85% of the world total, of antimony is mined in China.  Between 1977 
and 1984, the amount of antimony mined in the United States ranged from 311 to 760 metric tons 
(Llewellyn 1989; Plunkert 1982).  The United States no longer mines antimony.  The last domestic mine
in the United States closed in 2001.  According to the U.S. Bureau of Mines, six companies produced 
primary antimony metal and metal oxide products in the United States in 1992.  These six companies
were ASARCO Incorporated, Omaha, Nebraska; Amspec Chemical Corp., Gloucester City, New Jersey;
Anzon America, Laredo, Texas; Laurel Industries Inc., La Porte, Texas; Sunshine Mining Co., Kellogg, 
Idaho; and U.S. Antimony Corp, Thompson Falls, Montana (HSDB 2005a).
In 1992, the total U.S. primary antimony consumption was 12,221 metric tons, of which 3,297 metric tons
were for metal products, 2,103 metric tons for nonmetal products, and 6,821 metric tons for flame
retardants (USGS 2004). Most of the primary antimony generated in the United States was generated as 
antimony trioxide.  Antimony trioxide is produced by oxidizing antimony sulfide ore or antimony metal 
in air at 600–800°C (Avento and Touval 1980).  In 1987 and 1988, 18,758, and 18,226 metric tons of the
oxide were produced, respectively (U.S. Bureau of Mines 1989).  Consumption trends have generally
paralleled those of production.
Antimony is also produced as a byproduct of smelting primary lead ores.  Primary smelter outputs were
19,675 metric tons in 1992.  Almost as much antimony is produced from scrap as from ore.  Antimony
produced from secondary sources is primarily derived from "old scrap," generally consisting of lead 
battery plates, type metal, and bearing metal.  "New scrap," which is derived from drosses and scrap 
generated during fabrication, constituted 6% of the secondary antimony in 1992 (HSDB 2005a; Llewellyn
1989).  Secondary antimony is chiefly consumed as antimonial lead; a small percentage goes into the 
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1.  Facilities that Produce, Process, or Use Antimony
Number of Minimum amount on Maximum amount on site 
Statea facilities site in poundsb in poundsb Activities and usesc 
AL 4 1,000 999,999 1, 5, 7, 8
AR 2 100 99,999 7, 8
AZ 1 0 99 11
CA 4 0 999,999 2, 3, 7, 9, 12, 14
CT 1 1,000 9,999 7
FL 1 0 99 1, 5
IA 2 1,000 99,999 8
ID 3 1,000 999,999 8, 9, 12
IL 1 10,000 99,999 8, 11
IN 3 1,000 99,999 1, 5, 8, 9, 12, 14
KS 2 10,000 99,999 1, 4, 7, 8
KY 2 10,000 99,999 2, 3, 4, 6, 7, 8, 9
MI 2 10,000 99,999 7
MN 3 1,000 999,999 7, 8, 12
MO 4 0 99,999 1, 6, 7, 8, 9, 12, 13
MS 3 10,000 99,999 8
MT 1 100,000 999,999 1, 2, 3, 4, 5, 7
NC 4 1,000 99,999 7, 8, 14
NE 3 1,000 99,999 7, 8
NH 1 0 0 0
NJ 2 10,000 999,999 2, 4, 9, 11
NV 2 10,000 99,999 8, 12
NY 2 1,000 9,999 8
OH 12 100 999,999 1, 2, 3, 7, 8, 9, 10, 11
OR 1 10,000 99,999 12
PA 6 1,000 999,999 7, 8, 10, 14
SC 1 100,000 999,999 7, 14
TN 3 1,000 99,999 1, 4, 7, 8
TX 5 0 99,999 1, 5, 8, 9, 12
VA 3 1,000 99,999 2, 3, 7, 8
WA 2 1,000 99,999 7, 8, 11
WI 2 1,000 9,999 8
aPost office state abbreviations used.
 




1. Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14. Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI14 2016 (Data are from 2014)
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-2.  Facilities that Produce, Process, or Use Antimony Compounds
Minimum
Number of amount on site Maximum amount on
Statea facilities in poundsb site in poundsb Activities and usesc 
AK 1 10,000 99,999 1, 5, 12, 13, 14
AL 8 1,000 99,999 2, 3, 7, 8, 10, 11, 12
AR 3 1,000 99,999 8, 9, 12
AZ 3 10,000 999,999 1, 2, 5, 8, 13, 14
CA 15 1,000 999,999 1, 2, 3, 4, 6, 7, 8, 9, 10, 12
CO 2 100,000 999,999 1, 2, 3, 4, 6, 13
CT 4 10,000 999,999 7, 8
DE 1 100,000 999,999 1, 2, 3, 7, 8, 14
FL 2 10,000 999,999 2, 3, 7, 8
GA 22 100 999,999 1, 2, 3, 5, 6, 7, 8, 14
IA 2 1,000 99,999 7, 8
ID 3 10,000 99,999 1, 5, 7, 13, 14
IL 21 0 999,999 1, 2, 3, 5, 6, 7, 8, 10, 12, 13, 14
IN 27 0 9,999,999 1, 2, 3, 4, 5, 7, 8, 9, 12, 13, 14
KS 8 1,000 999,999 1, 3, 6, 7, 8
KY 19 100 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
LA 9 0 999,999 1, 3, 5, 7, 10, 11, 12
MA 17 1,000 999,999 1, 2, 3, 4, 6, 7, 8, 9
MD 1 0 0 0
MI 9 1,000 99,999 1, 2, 3, 4, 5, 7, 8, 9, 14
MN 10 1,000 999,999 7, 8, 9, 11, 12
MO 10 1,000 9,999,999 1, 2, 3, 4, 7, 8, 12
MS 11 1,000 9,999,999 6, 7, 8, 12
MT 2 100,000 999,999 1, 5, 12, 14
NC 20 1,000 99,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 14
ND 1 100,000 999,999 1, 5, 12, 13, 14
NE 5 1,000 99,999 6, 7, 8, 12
NH 2 1,000 99,999 7, 8
NJ 10 1,000 999,999 2, 3, 7, 8, 10
NV 8 0 9,999,999 1, 2, 5, 7, 12, 13, 14
NY 6 1,000 99,999 1, 7, 8, 12, 13, 14
OH 45 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 12
OK 1 0 0 0
OR 2 10,000 99,999 2, 3, 4, 7, 8
PA 29 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12
PR 1 10,000 99,999 6, 10
RI 4 1,000 999,999 7, 8, 12
SC 22 0 999,999 1, 2, 3, 5, 6, 7, 8, 10, 12
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-2.  Facilities that Produce, Process, or Use Antimony Compounds
Minimum
Number of amount on site Maximum amount on
Statea facilities in poundsb site in poundsb Activities and usesc 
TN 18 1,000 999,999 1, 2, 3, 5, 6, 7, 8, 10, 12, 13, 14
TX 44 0 499,999,999 1, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT 5 10,000 49,999,999 1, 3, 4, 5, 8, 9, 12, 13
VA 7 1,000 999,999 6, 7, 8
VT 1 100,000 999,999 8
WA 2 0 0 0
WI 12 0 999,999 1, 3, 5, 7, 8, 13, 14
WV 4 10,000 99,999 1, 5, 6, 7, 8, 13
WY 1 100,000 999,999 1, 3, 4, 9, 13, 14
aPost office state abbreviations used.
bAmounts on site reported by facilities in each state.
cActivities/Uses:
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI14 2016 (Data are from 2014)
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125ANTIMONY AND COMPOUNDS
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
production of other lead- and tin-based alloys.  Secondary antimony production was 17,736 metric tons in 
1992, with 1,043 metric tons originating from new scrap and 16,693 metric tons from old scrap (HSDB
2005a; Llewellyn 1989; Plunkert 1982).
The method of treating antimony ore after mining depends on the type of ore and its antimony content.  
High-grade (45–60%) sulfide ore that is free from lead and arsenic can be extracted by melting using a 
technique known as liquation.  In this process, the ore is heated to 550–660°C in a crucible or
reverberatory furnace in a reducing atmosphere.  Also, high-grade sulfide ores can be reduced to the metal
by a technique in which the ore is heated with iron scrap, known as iron precipitation.  The iron replaces
the antimony, forming iron sulfide.  Another antimony ore treatment technique takes high-grade oxide
ores and reduces them with charcoal in a reverberatory furnace.  An alkaline flux is used to reduce 
volatilization losses; loss of antimony due to volatilization can be as high as 12–20%.  The method of
choice for low-grade (<20%) sulfide ores is volatilizing roasting.  In this process, the ore is heated to 
about 500°C in a controlled amount of oxygen, so that the antimony trioxide formed is volatilized and 
then recondensed.  Intermediate-grade sulfide or oxide ores are generally handled by smelting (Carapella
1978; Herbst et al. 1985).  The impure metal may be refined by pyrometallurgical techniques or
electrolysis.
5.2  IMPORT/EXPORT
China is the largest exporter of antimony to the United States, most of which is imported as antimony
metal.  In 2014, total U.S. imports were 365 metric tons for ore and concentrate, 6,210 metric tons for
metal, alloys, waste, and scraps, and 17,600 metric tons for antimony oxide.  Total U.S. imports were
24,200 metric tons in 2014 and 24,700 metric tons in 2013 (USGS 2015).
The last domestic antimony producing mine in the United States closed in 2001.  In 1988, the United 
States exported 624 metric tons of antimony metal, alloys, and scrap and 1,227 metric tons of antimony
oxide (U.S. Bureau of Mines 1989).  Canada was the largest recipient of these exports. The United States 
also exported 942 metric tons of antimony metal, alloy, waste, and scrap in 1992 (HSDB 2005a).
5.3  USE 
Pure antimony is a brittle metal and is restricted in its use due to its poor mechanical properties (Grund et
al. 2012; HSDB 2005a).  As an alloy, it is mixed with other metals to increase their hardness, mechanical
strength, corrosion resistance, and electrochemical stability or to decrease their coefficient of friction.
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Some antimony alloys expand slightly upon cooling, a valuable property for use in type metal and other
castings (Carapella 1978).  Antimonial lead is used in small arms ammunition, cable sheathing and lead 
pipe, and the storage-battery grids, grid plates, straps, and terminals of lead-acid batteries (Grund et al.
2012).
The application of antimony in lead-acid batteries has decreased, and most of the use of antimony in the 
batteries is in recycling.  Historically, antimony improves fluidity and electrical stability, and increases
the fatigue strength and creep resistance of the lead in the batteries (Carapella 1978). Alloys of tin and 
antimony are utilized in electrical equipment, such as the end and side seams of cans, car radiators, and 
plumbing.  Alloys of tin, copper, and antimony are utilized to produce Britannia metal and pewter.  Metal
products utilize 20% of primary antimony produced (Grund et al. 2012), and 50% of primary antimony is
used in plastics to impart flame retardancy.  Antimony trioxide is utilized as a flame retardant when
combined with a halogen (van Velzen et al. 1998).  Antimony is used in the manufacture of chromate 
pigments, as an opacifer for ceramic glaze, as a gas bubble and color remover in lead crystal glass and
glass for television tubes, and as a polymerization catalyst to manufacture polyester fibers (Grund et al. 
2012).
Antimony compounds have also been used for the treatment of parasitic diseases such as leishmaniasis.
Other antimony salts are used in certain pesticides, ammunition primers, flares, tracer shells, and
fireworks, and in the manufacture of disk-brake pads and cutting disks (Grund et al. 2012).
5.4  DISPOSAL
Much of the antimony used in antimonial lead is recycled. This is evident from the large amount of 
secondary antimony production.  Most antimonial lead comes from auto batteries.  Little information 
concerning the disposal of antimony and its compounds has been found in the literature.  Wastes from
mining and smelting are generally disposed of in landfills. This is evident from the amounts of releases to
land from companies that produce antimony and its compounds (Section 6.2.1).  In addition, many
companies transfer their antimony waste to publicly-owned treatment works or to off-site facilities for
disposal.  Plastics and articles of clothing that contain small amounts of antimony oxide flame retardants
will generally be placed in landfills or undergo incineration along with normal industrial or municipal 
trash.
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Antimony and its compounds have been designated as priority pollutants by EPA (1988).  As such, 
persons who generate, transport, treat, store, or dispose of antimony-containing material must comply
with regulations of the federal Resource Conservation and Recovery Act (RCRA).  No limitations on the
disposal of antimony ore from mines and mills have been promulgated in the Code of Federal Regulations
(EPA 1988).
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
Antimony and antimony-containing compounds have been identified in at least 565 of the
1,832 hazardous waste sites that have been proposed for inclusion on the EPA National Priorities List
(NPL) (ATSDR 2015).  However, the number of sites in which antimony and compounds have been
evaluated is not known.  The frequency of these sites can be seen in Figure 6-1. Of these sites, 558 are
located within the United States and 4 are located in the Commonwealth of Puerto Rico, 2 are located in 
the Virgin Islands, and 1 is located in Guam (not shown).
Antimony is a natural constituent of soil and is transported into streams and waterways from natural
weathering of soil, as well as from anthropogenic sources (Callahan et al. 1979; Mok and Wai 1990).  
Antimony is naturally present in the earth’s crust at levels of about 0.2–0.3 µg/g (ppm), but these levels
vary by location (Telford et al. 2008).  Studies indicate that antimony is retained in the soil through 
adsorption and can sorb onto clay minerals, oxides, and hydroxides in the soil and aquatic sediment
(Wilson et al. 2010).
Background levels of antimony in ambient area are typically <20 ng/m3.  However, levels of antimony in 
ambient air can be >1,000 ng/m3 near plants that convert antimony ores into metal or manufacture
substances such as antimony trioxide (Ragaini et al. 1977).
Background levels of antimony in groundwater in the United States from 1992 to 2003 was low, with 
median concentrations of <1 μg/L (USGS 2011).  Anthropogenic activity such as mining activities, and
coal and municipal waste combustion can result in increases in antimony levels in ambient water
(Jablonska-Czapla et al. 2014).  Most dissolved antimony in natural waters under aerobic conditions is
present in the pentavalent oxidation state as antimonate species (Sb(OH)6-).  Anthropogenic emissions
commonly contain antimony in the trivalent oxidation state (e.g., antimony trioxide); however, it is
unclear how quickly antimonite oxidizes to antimonate under natural conditions. Under anoxic reducing
conditions, trivalent species such as Sb(OH3), Sb(OH4)-, and Sb2S4- are the most thermodynamically stable
forms of antimony.
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6.  POTENTIAL FOR HUMAN EXPOSURE
Figure 6-1.  Frequency of NPL Sites with Antimony and Compounds
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6.  POTENTIAL FOR HUMAN EXPOSURE
Antimony can be reduced and methylated by microorganisms in anaerobic sediment, releasing volatile
methylated antimony compounds into the water.  Multiple microorganisms have been found to methylate
antimony in the soil and water and some anoxic or poorly oxygenated environments (Bentley and 
Chasteen 2002).
The general population is exposed to low levels of antimony in ambient air and food.  Individuals can be
exposed to antimony in polyethylene terephthalate (PET) water bottles (reviewed in Belzile et al. 2011) or 
from products containing antimony flame retardants. Occupationally exposed workers will have the 
highest levels of exposure to antimony (Quiroz et al. 2011; Smith et al. 1995).
6.2  RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing
facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces,
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
6.2.1 Air
Estimated releases of 7,397 pounds (~3 metric tons) of antimony to the atmosphere from 88 domestic 
manufacturing and processing facilities in 2014, accounted for <1%of the estimated total environmental
releases from facilities required to report to the TRI (TRI14 2016). These releases are summarized in
Table 6-1.  Estimated releases of 22,767 pounds (10 metric tons) of antimony compounds to the
atmosphere from 458 domestic manufacturing and processing facilities in 2014, accounted for <1% of the
estimated total environmental releases from facilities required to report to the TRI (TRI14 2016).  These
releases are summarized in Table 6-2.
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Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
AL 4 169 577 0 477,514 0 476,851 1,408 478,260
AR 2 49 103 0 0 13,675 152 13,675 13,827
AZ 1 0 0 0 0 0 0 0 0
CA 4 2 23 0 14,489 2 14,241 275 14,517
CT 1 0 0 0 0 239 0 239 239
FL 1 9 0 0 1,664 0 9 1,664 1,673
IA 2 0 0 0 14 0 14 0 14
ID 3 3 1 0 11,716 0 11,720 0 11,720
IL 1 3 0 0 0 No data 3 0 3
IN 3 19 3 0 23,015 9,294 1,033 31,298 32,331
KS 2 14 0 0 0 19 14 19 33
KY 2 1 0 0 0 0 1 0 1
MI 2 10 0 0 3,662 0 10 3,662 3,672
MN 3 7 452 0 43,315 0 7 43,767 43,773
MO 4 8 39 0 361 1,771 353 1,826 2,180
MS 3 1 0 0 3 159 1 162 163
MT 1 5,491 0 0 0 0 5,491 0 5,491
NC 4 18 0 0 5,988 0 3,419 2,587 6,006
NE 3 107 5 0 2,650 36 107 2,691 2,798
NH 1 No data No data No data No data No data No data No data No data
NJ 2 0 0 0 0 0 0 0 0
NV 2 6 0 0 82,660 4 82,666 4 82,670
NY 2 30 5 0 5 3,625 35 3,630 3,665
OH 12 419 0 0 1,456 1,880 419 3,336 3,755
OR 1 0 0 0 19,713 487 19,713 487 20,200
PA 6 241 253 0 3,508 1,845 358 5,489 5,847
SC 1 4 4 0 101,589 No data 4 101,594 101,598
TN 3 255 255 0 750 224 1,010 474 1,484
TX 5 7 3 0 13,585 0 13,578 17 13,595
VA 3 500 0 0 0 0 500 0 500
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Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
WA 2 25 5 0 139 0 25 144 169
WI 2 0 0 0 0 0 0 0 0
Total 88 7,397 1,729 0 807,797 33,260 631,735 218,449 850,184
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.
 
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 




gClass I wells, Class II-V wells, and underground injection.
 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 

impoundments, other land disposal, other landfills.
 




jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
 
kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI14 2016 (Data are from 2014)
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Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
AK 1 0 40 0 13,000 0 13,040 0 13,040
AL 8 100 5 0 3,381 694 105 4,075 4,180
AR 3 58 7 0 2 422 63 426 489
AZ 3 552 10 0 514,372 0 514,874 60 514,934
CA 15 24 407 0 316,758 7,164 62 324,291 324,353
CO 2 165 0 0 4,159 0 165 4,159 4,324
CT 4 15 250 0 6,402 32,499 15 39,151 39,166
DE 1 0 0 0 0 0 0 0 0
FL 2 0 0 0 1,290 0 0 1,290 1,290
GA 22 490 2,075 0 29,165 7,570 500 38,800 39,301
IA 2 6 0 0 250 0 6 250 256
ID 3 1,508 75 0 130,488 0 132,071 0 132,072
IL 21 850 278 24,371 64,978 2,398 55,059 38,071 93,130
IN 27 1,454 6,459 0 592,850 36,733 86,014 551,486 637,500
KS 8 329 5 0 20,975 492 329 21,472 21,801
KY 19 2,236 2,887 0 51,401 31,266 49,072 47,601 96,672
LA 9 733 3,159 0 1,967 5,694 3,906 7,647 11,553
MA 17 651 428 0 9,388 61,972 655 71,784 72,439
MD 1 No data No data No data No data No data No data No data No data
MI 9 276 98 0 12,691 699 276 13,488 13,764
MN 10 172 3,595 0 14,518 2,495 3,737 17,043 20,779
MO 10 18 4,111 0 232,926 0 214,688 22,367 237,056
MS 11 106 359 0 1,693 30,082 107 32,132 32,240
MT 2 140 0 0 9,240 40 9,380 40 9,420
NC 20 462 259 0 22,653 8,120 971 30,523 31,494
ND 1 56 0 0 125,000 No data 125,056 No data 125,056
NE 5 10 5 0 38,326 1,627 26,028 13,939 39,967
NH 2 1 0 0 2,390 50 1 2,440 2,441
NJ 10 114 13 0 2,827 4,588 119 7,423 7,541
NV 8 53 150 0 3,951,301 382 3,951,504 382 3,951,886
NY 6 28 439 0 66,155 2 1,095 65,529 66,624
OH 45 976 93 239 51,470 15,598 1,218 67,159 68,376
OK 1 No data No data No data No data No data No data No data No data
OR 2 0 0 0 0 3,361 0 3,361 3,361
PA 29 534 473 0 79,150 32,830 9,789 103,198 112,987
PR 1 10 0 0 62,510 0 10 62,510 62,520
RI 4 33 6 0 7,895 3,600 38 11,496 11,534
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Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
SC 22 540 3,035 0 16,596 3,111 854 22,427 23,282
TN 18 5,865 1,208 0 33,920 603 22,925 18,671 41,596
TX 44 1,640 1,741 15,418 432,674 40,495 390,539 101,429 491,968
UT 5 344 1,000 0 182,612 10,191 126,830 67,317 194,147
VA 7 70 671 0 11,172 51 91 11,872 11,964
VT 1 0 0 0 0 0 0 0 0
WA 2 No data No data No data No data No data No data No data No data
WI 10 1,834 9 0 99,136 8,127 1,838 107,269 109,107
WV 4 255 0 0 5,351 5,771 255 11,122 11,377
WY 1 57 0 0 2,358 0 2,415 0 2,415
Total 458 22,767 33,350 40,028 7,225,389 358,214 5,745,701 1,943,699 7,689,400
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.
 
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 




gClass I wells, Class II-V wells, and underground injection.
 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 

impoundments, other land disposal, other landfills.
 




jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
 
kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI14 2016 (Data are from 2014)
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Section 112 of the Clean Air Act (CAA) lists antimony as one of 188 hazardous air pollutants (HAPs)
known to cause or suspected of causing cancer or other serious human health effects or ecosystem
damage (EPA 2000).  EPA's National Emission Inventory (NEI) database contains data regarding sources 
that emit criteria air pollutants and their precursors, and HAPs for the 50 United States, Washington DC, 
Puerto Rico, and the U.S. Virgin Islands (prior to 1999, criteria pollutant emission estimates were
maintained in the National Emission Trends [NET] database and HAP emission estimates were 
maintained in the National Toxics Inventory [NTI] database).  The NEI database derives emission data 
from multiple sources, including state and local environmental agencies; the TRI database; computer
models for on-road and off-road emissions; and databases related to EPA's Maximum Achievable Control
Technology (MACT) programs to reduce emissions of HAPs.  Using composite data from the NTI
database from 1990 to 1993, it was estimated that the annual emissions of antimony in the United States
were approximately 103 tons per year during that time frame (EPA 2000).  Data downloaded from the
2011 NEI (see Table 6-3) indicated that the total emission of antimony was approximately
5,210,763 pounds, with the biggest contribution arising from electric generation by coal (EPA 2016).
Releases of antimony to the atmosphere result from natural and anthropogenic sources. Total emissions 
from both sources were reported to be 6,100 tons/year in the 1980s; anthropogenic sources such as coal
combustion, smelting, and refining were the major sources (Belzile et al. 2011).  It was also estimated that
41% of antimony emissions to the air were from natural sources in the 1980s.  The natural sources and
their median percentage contribution were:  wind-borne soil particles, 32.5%; volcanos, 29.6%; sea salt
spray, 23.3%; forest fires, 9.2%; and biogenic sources, 12.1% (Nriagu 1989).
Total mid-1990 atmospheric emissions of antimony were reported to be 1,561 tonnes/year total from
anthropogenic sources.  Emissions from the combustion of fuels, lead production, zinc production, copper
production, nonferrous production, pig iron and steel production, municipal waste, and sewage sludge
were found to be 319, 134, 95, 547, 7, 235, 34, and 730 tonnes, respectively (Pacyna and Pacyna 2001).
Atmospheric particulate matter was found to be enriched with antimony in Japan; brake abrasion dust
from automobiles and waste fly ash were found to be the predominant sources of antimony emissions.  
Emissions were estimated to be 21 tonnes/year from brake pads (Iijima et al. 2009).  Antimony levels in 
high-density traffic areas are likely due to abrasion of tires, brake lining, and other automotive
components that use of antimony alloys (Belzile et al. 2011).  In Gottingen, Germany, 176 kg/year of
antimony is emitted from brakes, tires, street surfaces, and vehicle exhaust (WHO 2003).
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Table 6-3.  2011 National Emission Inventory (NEI) Total National Emissions
Name Annual emissions (lb)
Bulk gasoline terminals 2.5134
Commercial cooking 264.183
Dust, construction dust 5.26327
Fires, agricultural field burning 330.6032
Fuel combustion, commercial/institutional, biomass 67.40831
Fuel combustion, commercial/institutional, coal 40.24683
Fuel combustion, commercial/institutional, natural gas 0.09
Fuel combustion, commercial/institutional, oil 143.801
Fuel combustion, commercial/institutional, other 1.411491
Fuel combustion, electric generation, biomass 188.6612
Fuel combustion, electric generation, biomass coal 13,020.77
Fuel combustion, electric generation, biomass natural gas 78.23796
Fuel combustion, electric generation, biomass oil 5,978.314
Fuel combustion, electric generation, biomass other 25.92661
Fuel combustion, industrial boilers, internal combustion engines, biomass 2,206.582
Fuel combustion, industrial boilers, internal combustion engines, coal 2,513.459
Fuel combustion, industrial boilers, internal combustion engines, natural gas 1,682.659
Fuel combustion, industrial boilers, internal combustion engines, oil 311.0068
Fuel combustion, industrial boilers, internal combustion engines, other 801.3158
Fuel combustion, residential, natural gas 0
Fuel combustion, residential, oil 0.00051
Fuel combustion, residential, other 0.647524
Industrial processes, cement manufacturing 78.64444
Industrial processes, chemical manufacturing 1,502.073
Industrial processes, ferrous metals 1,071.269
Industrial processes, mining 94.03349
Industrial processes, not elsewhere classified 25,172.5
Industrial processes, nonferrous metals 11,997.31
Industrial processes, oil and gas production 220.7644
Industrial processes, petroleum refineries 2,073.725
Industrial processes, pulp and paper 1,857.656
Industrial processes, storage and transfer 597.7857
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Table 6-3.  2011 National Emission Inventory (NEI) Total National Emissions
Name Annual emissions (lb)
Miscellaneous non-industrial, not elsewhere classified 20.64527
Mobile, commercial marine vessels 69.72685
Mobile, locomotives 314.1618
Solvent, degreasing 416.547
Solvent, graphic arts 19.95
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Increased emissions from fly ash were also reported in Japan.  Fly ash is produced in waste incineration 
(Iijima et al. 2009).  Antimony concentrations in fly ash were reported to be 4.7 µg/g total in Japan, 1– 
3.9 µg/g in various countries, and 1.99 µg/g total in Spain (Smichowski 2008).
6.2.2 Water
Estimated releases of 1,729 pounds (~0.8 metric tons) of antimony to surface water from 88 domestic 
manufacturing and processing facilities in 2014, accounted for <1% of the estimated total environmental
releases from facilities required to report to the TRI (TRI14 2016). These releases are summarized in
Table 6-1.  Estimated releases of 33,350 pounds (15 metric tons) of antimony compounds to surface water
from 458 domestic manufacturing and processing facilities in 2014, accounted for <1% of the estimated
total environmental releases from facilities required to report to the TRI (TRI14 2016). These releases are
summarized in Table 6-2.
Antimony is a natural constituent of soil and is transported into streams and waterways in runoff either
due to natural weathering or disturbed soil (Cole et al. 1984).
Antimony is also found in water due to contamination from mining and smelter, shooting ranges, and 
road sides that contain dust from brake pads and tires.
6.2.3 Soil 
Estimated releases of 807,797 pounds (~366 metric tons) of antimony to soils from 88 domestic
manufacturing and processing facilities in 2014, accounted for about 95% of the estimated total
environmental releases from facilities required to report to the TRI (TRI14 2016).  These releases are
summarized in Table 6-1.  Estimated releases of 7,225,389 pounds (3,278 metric tons) of antimony
compounds to the soil from 458 domestic manufacturing and processing facilities in 2014, accounted for
about 94% of the estimated total environmental releases from facilities required to report to the TRI
(TRI14 2016).  Another 40,028 pounds (18 metric tons) were injected underground.  These releases are
summarized in Table 6-2.
Antimony is a natural constituent of soil and is produced from the weathering of soil parent materials
(Wilson et al. 2010).  Contamination of the soil leads to increased concentrations of antimony.  Most of
the antimony released to the environment is released to land. The industries that release the largest
amount of antimony are smelters that produce antimony and antimony trioxide. Much of this release is 
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slag, which is the residue from smelting operations.  Other releases to land include sludge from publicly
owned treatment works (POTWs) and municipal refuse (Eckel and Langley 1988).
Antimony was reported to be in 166 of the 1,397 soil samples at the Lawrence Berkeley National
Laboratory.  The samples were obtained from soil boring sites from the construction of 71 groundwater
monitoring wells.  A 12% occurrence of antimony was reported, and levels found in the sample site (0.7– 
22 mg/kg) exceeded the background levels of antimony normally found in the soil (DOE 2009a).
6.3  ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
The oxidized form of antimony, Sb(V), is expected to be the more stable form in the environment;
however, Sb(III) is formed under certain environmental conditions (Mitsunobu et al. 2006).  Similarly, 
inorganic species are expected to be more present than organic species of antimony in most
environmental systems (Wilson et al. 2010).
Sb(V) corresponds to the octahedral antimonite ion, Sb(OH)6-, while Sb(III) corresponds to the uncharged 
antimonous acid, Sb(OH)3 in antimony water systems.  In the soil, antimony oxidation state and 
environmental reactions are largely dependent on the pH, redox conditions, and concentrations of co-
occurring reduction agents and oxidants in the system (Wilson et al. 2010).
Antimony can be retained in the soil primarily through adsorption.  Antimony can sorb to clay minerals,
or to oxides and hydroxides in the soil.  Sb(III) sorbs more strongly to manganese (III) oxyhydroxide
(MnOOH) than to aluminum hydroxide (Al(OH)3) or iron(III) oxide-hydroxide (FeOOH) (Wilson et al. 
2010).  Antimony Kd values ranged from 1 to 2,065 L/kg in a sorption study investigating plant uptake of
antimony (Nakamaru and Sekine 2008).
Antimony behavior in soil-water systems was found to be dependent on redox conditions in a study
evaluating soil collected at different depths at the Ichinokawa mine pit in Ehime, Japan.  Decreased 
antimony concentrations were observed in the soil as the water saturation increased.  Sb(V) was found to 
be stable under reducing conditions.  Antimony was found to have a positive correlation with iron and
manganese in the soil (Mitsunobu et al. 2006).
Sb(III) was found to bind more strongly to solids than Sb(V) in a study evaluating antimony solubility in 
soil from shooting ranges.  Sorption of antimony was highly dependent on pH.  At pH levels <7, Sb(V)
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was found to be almost completely sorbed.  At pH levels of at least 10, Sb(III) was found to be sorbed.  
The total release of antimony was found to be much higher than the releases from nickel, copper, bismuth,
thallium, and mercury in the soil at the seven Swiss shooting ranges (Johnson et al. 2005).
Miravet et al. (2006) examined the mobility of antimony from coal fly ash.  Fly ash, from coal fired 
power plants, contains a mixture of chemicals that may be distributed to soils, freshwater, seawater, or
groundwater.  Some portions of fly ash are not extractable or are unavailable under environmental
conditions; however, the leachable portion of fly ash has the potential to accumulate in organisms.  
Antimony was found to leach out of fly ash solution at pH 1–12.  Sb(V) was the major antimony species 
in the leachate.  Antimony was partially soluble at pH 5, and more soluble at acidic pH values.
Leaching experiments performed with river sediment samples from a mining district in Idaho also
indicated that Sb(V) was the major species released during leaching (Mok and Wai 1990).  The fraction of
antimony leached from sediment with deionized water after 10 days was highly correlated with the free 
iron and manganese oxide content of the sediment (correlation coefficients of 0.90 and 0.75, 
respectively).  Experiments on the pH dependence of leaching showed marked differences between
trivalent and pentavalent antimony (Mok and Wai 1990).  The release of trivalent antimony from the
sediment increased at low pH; in contrast, the release of pentavalent antimony from sediment increased
sharply at high pH (pH 11.4).  At pH 4.3, the concentrations of tri- and pentavalent antimony were 
comparable.  Antimony does not appear to bioconcentrate appreciably in fish and aquatic organisms.  No 
detectable bioconcentration occurred during a 28-day test in bluegills (EPA 1980).  Only low levels of
antimony have been reported in fish and aquatic organisms collected off the coast of Africa, Australia, 
and the Danube River in Austria (Callahan et al. 1979; Maher 1986).  Bioconcentration factors for
antimony ranged from 0.15 to 390 (Acquire 1989; Callahan et al. 1979).
Antimony sorption was studied in relation to its plant uptake.  Antimony Kd values ranged from 1 to 
2,065 L/kg.  The Kd values were significantly decreased with increasing phosphate concentrations, 
indicating that the addition of phosphate fertilizer may increase the potential for antimony uptake in 
plants.  No difference in antimony sorption to soil occurred when sulfates were added to the soil in this
study (Nakamaru and Sekine 2008).
Antimony can be taken up by plants through the roots and via surface deposition from aerosols.  Surface
deposition is the major pathway for soil-to-plant transfer of antimony in field conditions (Tschan et al.
2009).
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6.  POTENTIAL FOR HUMAN EXPOSURE
The Viola species were found to accumulate antimony in their roots, stems, leaves, flowers, and seeds.
Mean antimony concentrations in Viola allcharensis were 0.46 mg/kg in the root, 0.34 mg/kg in the stem, 
0.46 mg/kg in the leaf, 0.25 mg/kg in the flower, and 0.40 mg/kg in the seed.  Mean antimony
concentrations for the root, stem, leaves, flowers, and seeds of Viola arsenica were reported as 1.06, 0.25, 
0.72, 0.47, and 0.91 mg/kg, respectively.  Mean antimony concentrations for Viola macedonica were
0.25 mg/kg for each root, stem, leaves, and flowers (Baceva et al. 2014).
Certain plants may be used in phytoremediation because they are able to accumulate metals in their
tissues and have a high tolerance for those metals in contaminated soils.  In the Sao Domingos copper
mine, several plant species were found to accumulate antimony in their systems.  Concentrations of
antimony in the mine tailings ranged from 203 to 2,513 mg/kg.  Concentrations in plant species were
6.67 mg/kg for Erica andevalensis, 4.09 mg/kg for Erica australis, 3.59 mg/kg for Corrigiola 
telephypholia, 2.8 mg/kg for Echium plantagium, 2.02 mg/kg for Eritrae pulcheria, and 0.60 mg/kg for
Daphne gnidium and other plants (Anawar et al. 2011).
Root tissues of Maize (Zea mays) contained 0.35, 2.5, 3.98, 22.01, and 26.5–68.42 mg/kg of antimony, 
when exposed to 10, 50, 100, 500 and 1,000 mg/kg of antinomy, respectively.  Concentrations of
antimony at 10, 50, 100, 500, and 1,000 mg/kg corresponded to 0.82, 6.32, 13.76, 45.1, and 68.42 mg/kg 
in the shoot tissues.  Higher concentrations of antimony resulted in higher antimony accumulation in the
plants in this study (Pan et al. 2010).
In a similar study, antimony uptake was measured in maize (Z. mays) and sunflowers (Helianthus
annuus).  No significant differences in uptake between the two plant species were observed.  The 
bioaccumulation coefficient was reported as 0.93 for maize and 1.33 for sunflower (Tschan et al. 2008).
The mechanism of Baker yeast cell (Saccharomyces cerevisiae) antimony biosorption has also been
investigated. Sb(III) was removed from contaminated aqueous samples and accumulated in the Baker
yeast cells. Accumulation increased with increasing pH, incubation time, temperature, and amount of
yeast.  Sb(V) was undisturbed under the conditions of the test, indicating selective accumulation of
Sb(III) (Perez-Corona et al. 1997).
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6.3.2 Transformation and Degradation
6.3.2.1  Air
Little is known about the chemical forms and physical and chemical transformations of trace elements in
the atmosphere. This is primarily because analytical methods provide information concerning the metal
content rather than the specific compounds or species. In the absence of specific information, it is
generally assumed that elements of anthropogenic origin, especially those emanating from combustion 
sources, are present as the oxide.  Windblown dust particles may contain antimony in mineral species, 
such as sulfides and oxides, and are associated with silicates. When released into the atmosphere as an 
aerosol, antimony is believed to be oxidized to antimony trioxide by reaction with atmospheric oxidants.
6.3.2.2  Water
Most of the dissolved antimony in natural waters is present in the pentavalent oxidation state as the 
antimonate species (Sb(OH)6-) under aerobic conditions (Filella et al. 2002).  Anthropogenic emissions
commonly contain antimony in the trivalent oxidation state (antimonite; e.g., antimony trioxide); 
however, it is not certain how quickly antimonite oxidizes to antimonate under natural conditions.  Under
anoxic reducing conditions, trivalent species, such as Sb(OH3), Sb(OH4)- and Sb2S4-, are the most
thermodynamically stable forms.
The pentavalent form was reported to be the predominant species in a study examining the behavior of
antimony in oxic systems (Filella et al. 2002). The trivalent form was also found to be sometimes present
in oxic systems; however, >10% of the total dissolved amount of antimony was rarely found to be in the
trivalent form (Filella et al. 2009a).  Antimony speciation in various types of natural waters was analyzed 
in a study conducted in Warsaw Poland.  Of the 12 samples obtained from the different rivers, lakes, and 
ponds, the majority of the total antimony, or 96–99%, was in the pentavalent form (Garbos et al. 2000).
Han-Wen et al. (1982) estimated the rate of oxidation of the trivalent form to the pentavalent form by
adding known quantities of each into lake water and waste water samples and studying the change in 
concentration with respect to time. The trivalent form of antimony in lake water and waste water
appeared to be unstable since none could be detected after 6 hours; it is presumed that there were oxidants
in the water samples. The addition of tartaric acid (1% w/v) into the water samples had a stabilizing
effect (no changes in Sb(III) levels) after 5 days due to the fact that the rate of conversion of Sb(III) into
Sb(V) decreases with increasing acidity.
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6.  POTENTIAL FOR HUMAN EXPOSURE
Cutter (1992) estimated a much slower oxidation rate of trivalent antimony in seawater by measuring the 
depth profiles for antimony species in the upper 100 m of the Black sea.  No Sb(III) was detected in the
upper surface levels, but a gradual increase of Sb(III) concentration with a gradual decrease in Sb(V)
levels was observed with increasing depth beyond 60 m.  The maximum concentration of Sb(III) was
observed in the largely anaerobic region (90–100 m).  At this depth, no pentavalent antimony was
detectable.  An estimated pseudo first-order oxidation rate constant of 0.008 day-1 was calculated from
these data, corresponding to a residence time (1/rate constant) of about 125 days.  This rate included all
forms of removal since Sb(III) may also be scavenged by suspended particulate matter in the water
column.  It is presumed that the presence of the thermodynamically unstable trivalent species in aerobic
waters may, in part, be due to biotic processes involving the uptake of antimonate and the subsequent
biological conversion to the trivalent species.  These unstable species were reported to be able to persist
due to the low rates of conversion (Cutter 1992).  Likewise, as the trivalent species may be present in 
thermodynamically unfavorable (aerobic) environments, the pentavalent species has also been detected in
anoxic settings. As reported by Cutter (1992), the presence of pentavalent antimony in anoxic waters of
the Baltic Sea, the Black Sea, and the Saanich Inlet has been observed, and is due to the transport of
Sb(V) on sinking detritus from aerobic waters, formation of thioantimonate species, and advection of
surface waters containing high levels of pentavalent antimony.  All of these potential transport processes 
also assume a slow reduction rate of pentavalent conversion to the trivalent form.  The rate constant for
this reaction was estimated as 1.1x10-6 days-1 (Cutter 1992).
Antimony can be reduced and methylated by microorganisms in the aquatic environment, similar to 
arsenic, and become mobilized (Andreae et al. 1983; Austin and Millward 1988).  This reaction is most
likely to occur in reducing environments, such as in bed sediment.
Pseudomonas fluorescens K27, isolated from the Kesterson reservoir in California, was found to reduce
trimethyldibromoantimony to trimethylstibine (Bentley and Chasteeen 2002).  Sb(III) and methylated
antimony species were converted to stibine at approximately pH 7; however, Sb(V) was not converted.
Sb(III) was found to be oxidized in an Agrobacterium tumefaciens isolate.  The algal strain 5508, found at
the Yellowstone National Park in the geothermal environment of Dragon Spring, was also found to have
the capability to oxidize Sb(III) (Lehr et al. 2007).
The oxidation rate of As(III) and Sb(III) was studied using circumneutral pH (pH 5.5–6.5) and acidic
conditions similar to those in mine tailings under both abiotic and biotic conditions.  Under acidic
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conditions, both antimony and arsenic were slowly oxidized, but more rapid oxidation was observed in 
aerated abiotic solutions containing Fe(III) as opposed to solutions containing microbes; this process was 
accelerated by natural sunlight and increasing chloride ion concentration (Asta et al. 2012).  In unfiltered
(microbially active) circumneutral water, antimony was oxidized at a similar rate as in the acidic 
solutions; however, the rate of arsenic oxidation was enhanced and was several orders of magnitude 
greater than the rate of antimony oxidation.
6.3.2.3  Sediment and Soil
Transformation of antimony in the soil is dependent on the microbial population (Luo et al. 2014).  
Anaerobic microbial methylation occurs in the soil, producing trimethylstibine. Trimethylstibine was
produced by the pure cultures of Clostridium collagenovorans and Desulfovibrio vulgaris under
anaerobic conditions in sewage sludge.  Anaerobic digestion of sewage sludge by Methanobacterium
formicicum formed stibine, monomethylstibine, dimethylstibine, and trimethylstibine (Michalke et al.
2000). Under aerobic conditions, Scopulariopsis brevicaulis was found to methylate antimony through a
dimethylantimony species intermediate in the trimethylstibine pathway (Bentley and Chasteen 2002).
Five soil samples were collected in an antimony and arsenic mine field in the Hunan Province of China.
It was determined that Gemmatimonadetes and Actinobacteria aid in the bioremediation of antimony in 
the mine field soil (Luo et al. 2014).
6.3.2.4  Other Media
A 1998 study detected antimony in infant cot mattress covers that contained polyvinyl chloride (PVC).  
Antimony leached into extraction fluids from mattress samples (Jenkins et al. 1998). In the mid-1990s, it
was hypothesized that microbial growth on the cot mattress could generate stibines from the antimony
trioxide in the flame retardants.  It was also hypothesized that the stibine could result in sudden infant
death syndrome (SIDS) (Richardson 1994).  However, increases in liver and brain antimony levels have
not been found in infants dying from SIDS, as compared to infants dying from other causes (Boex et al. 
1998; Cullen et al. 2000).
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to antimony depends in part on the reliability of
supporting analytical data from environmental samples and biological specimens.  Concentrations of
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6.  POTENTIAL FOR HUMAN EXPOSURE
antimony in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits
of current analytical methods.  In reviewing data on antimony levels monitored or estimated in the
environment, it should also be noted that the amount of chemical identified analytically is not necessarily
equivalent to the amount that is bioavailable. The analytical methods available for monitoring antimony
in a variety of environmental media are detailed in Chapter 7.
6.4.1 Air
Background levels of antimony in ambient air are usually on the order of about 1 ng/m3, but can be higher
in urban environments.  In the vicinity of plants that convert antimony ores into metal (smelting
operations), or other point sources, levels can be >1,000 ng/m3.
The Air Quality System (AQS) database is EPA's repository of criteria air pollutant and HAPs monitoring
data.  Detailed air monitoring data for antimony in various cities in the United States for 2014 are shown 
in Table 6-4. Data for other years are available and may be accessed directly from the EPA website.
Daily mean concentrations ranged from 0.37 to 2 ng/m3 for antimony (total suspended particulate; TSP)
standard temperature and pressure (STP); 0.13–20.6 ng/m3 for antimony PM10 LC (local conditions);
0.56–2.18 ng/m3 for antimony PM10 STP; and 1.9–22 ng/m3 for antimony PM2.5 LC (EPA 2015a).
Antimony concentrations over the North Atlantic and North Pacific were 0.086 and 0.0037 ng/m3, 
respectively (Arimoto and Duce 1987; Austin and Millward 1988).  Two values reported for antimony in 
aerosols in clean continental and marine environments were 0.2 ng/m3 at the Jungfraujoch in the Swiss 
Alps and 0.00045 ng/m3 at American Samoa (Austin and Millward 1988).  The MMAD of antimony-
containing aerosols from a range of areas remote from anthropogenic sources was 0.86 μm (Milford and 
Davidson 1985).  The mass size distribution is bimodal, with the larger peak at about 0.6 μm and a
smaller one at about 3 μm.  An example of the size distribution of antimony-containing particles removed 
from anthropogenic sources was obtained in an 8-week study on an island in the German Bight.  The
concentration of antimony in a size fraction increased as the size decreased. The antimony concentration
ranged from 0.03 ng/m3 for particles >7.2 μm to 0.3 ng/m3 for particles <0.5 μm (Stoessel and Michaelis
1986).
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Table 6-4.  Median Antimony Levels in Ambient Air





Antimony (TSP) STP Rosemount, Minnesota 27 0
Antimony (TSP) STP Eagan, Minnesota 26 1.429
Antimony (TSP) STP Eagan, Minnesota 28 2
Antimony (TSP) STP Apple Valley, Minnesota 25 0.417
Antimony (TSP) STP Minneapolis, Minnesota 24 1.6
Antimony (TSP) STP Minneapolis, Minnesota 25 0.385
Antimony (TSP) STP Minneapolis, Minnesota 26 0.37
Antimony (TSP) STP Minneapolis, Minnesota 27 0
Antimony (TSP) STP St. Paul, Minnesota 27 0
Antimony (TSP) STP Virginia, Minnesota 27 0
Antimony (TSP) STP Duluth, Minnesota 22 0.4
Antimony (TSP) STP Duluth, Minnesota 25 0.4
Antimony (TSP) STP Newport, Minnesota 25 0
Antimony (TSP) STP Bayport, Minnesota 27 0
Antimony (TSP) STP Yukon, Oklahoma 28 0.425
Antimony (TSP) STP Oklahoma City, Oklahoma 40 0.5
Antimony (TSP) STP Tulsa, Oklahoma 40 0.667
Antimony (TSP) STP Tulsa, Oklahoma 39 0.59
Antimony (TSP) STP Tulsa, Oklahoma 39 0.789
Antimony (TSP) STP Tulsa, Oklahoma 38 0.784
Antimony PM10 LC Phoenix, Arizona 44 2.450909
Antimony PM10 LC Middletown, California 45 4.511111
Antimony PM10 LC Cobb, California 45 4.444444
Antimony PM10 LC Banning, California 10 1.05
Antimony PM10 LC San Jose, California 45 2.463111
Antimony PM10 LC Valrico, Florida 15 1.46
Antimony PM10 LC Valrico, Florida 15 1.58
Antimony PM10 LC Boston, Massachusetts 39 1.51
Antimony PM10 LC Boston, Massachusetts 23 1.49087
Antimony PM10 LC St. Louis, Missouri 3,705 20.64183
Antimony PM10 LC St. Louis, Missouri 40 1.74975
Antimony PM10 LC St. Louis, Missouri 40 1.7335
Antimony PM10 LC Underhill (Town of), Vermont 14 0.133571
Antimony PM10 LC Underhill (Town of), Vermont 3 0.25
Antimony PM10 LC Seattle, Washington 40 1.0185
Antimony PM10 STP Orlando, Florida 22 0.754545
Antimony PM10 STP Saint Petersburg, Florida 43 0.635349
Antimony PM10 STP Pinellas Park, Florida 45 0.697556
Antimony PM10 STP Northbrook, Illinois 27 0.681111
Antimony PM10 STP Ashland, Kentucky 34 2.182353
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Table 6-4.  Median Antimony Levels in Ambient Air





Antimony PM10 STP Ashland, Kentucky 2 1.3
Antimony PM10 STP Kentucky 33 0.562727
Antimony PM10 STP Kentucky 15 1.012667
Antimony PM10 STP Lexington-Fayette (corporate name for 33 1.047879
Lexington), Kentucky
Antimony PM10 STP Kentucky 34 0.754118
Antimony PM10 STP Calvert City (RR name Calvert), 32 0.59375
Kentucky
Antimony PM10 STP Providence, Rhode Island 50 0.6466
Antimony PM10 STP Providence, Rhode Island 24 0.631667
Antimony PM10 STP Houston, Texas 88 0.647727
Antimony PM2.5 LC Birmingham, Alabama 80 19.213
Antimony PM2.5 LC Birmingham, Alabama 76 18.539
Antimony PM2.5 LC Huntsville, Alabama 39 20.115
Antimony PM2.5 LC Montgomery, Alabama 41 17.768
Antimony PM2.5 LC Phenix City, Alabama 41 20.732
Antimony PM2.5 LC Fairbanks, Alaska 82 19.854
Antimony PM2.5 LC Fairbanks, Alaska 70 20.95
Antimony PM2.5 LC Alaska 30 24.15
Antimony PM2.5 LC Phoenix, Arizona 83 20.729
Antimony PM2.5 LC Tucson, Arizona 71 21.092
Antimony PM2.5 LC North Little Rock, Arkansas 81 20.259
Antimony PM2.5 LC Chico, California 47 10.383
Antimony PM2.5 LC Fresno, California 80 20.344
Antimony PM2.5 LC Calexico, California 39 15.897
Antimony PM2.5 LC Los Angeles, California 81 19.722
Antimony PM2.5 LC Portola, California 45 11.044
Antimony PM2.5 LC Rubidoux, California 79 19.241
Antimony PM2.5 LC Rubidoux, California 41 18.683
Antimony PM2.5 LC Arden-Arcade, California 84 19.929
Antimony PM2.5 LC Sacramento, California 46 12.109
Antimony PM2.5 LC El Cajon, California 17 19.529
Antimony PM2.5 LC Escondido, California 47 10.723
Antimony PM2.5 LC San Jose, California 72 19.326
Antimony PM2.5 LC Modesto, California 47 12.213
Antimony PM2.5 LC Visalia, California 47 11.106
Antimony PM2.5 LC Commerce City, Colorado 38 18.579
Antimony PM2.5 LC Colorado 69 20.457
Antimony PM2.5 LC Platteville, Colorado 35 17.529
Antimony PM2.5 LC New Haven, Connecticut 68 18.904
Antimony PM2.5 LC Dover, Delaware 13 19.615
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Table 6-4.  Median Antimony Levels in Ambient Air





Antimony PM2.5 LC Wilmington, Delaware 62 18.468
Antimony PM2.5 LC Washington, District Of Columbia 78 22.045
Antimony PM2.5 LC Davie, Florida 45 18.944
Antimony PM2.5 LC Valrico, Florida 79 20.101
Antimony PM2.5 LC Tallahassee, Florida 39 18.923
Antimony PM2.5 LC Pinellas Park, Florida 39 20.244
Antimony PM2.5 LC Macon, Georgia 42 18.429
Antimony PM2.5 LC Athens (corporation name Athens-Clarke 42 22.083
County), Georgia
Antimony PM2.5 LC Georgia 42 21.643
Antimony PM2.5 LC Georgia 68 19.478
Antimony PM2.5 LC Georgia 40 20.05
Antimony PM2.5 LC Columbus (Remainder), Georgia 41 22.695
Antimony PM2.5 LC Augusta-Richmond County (Remainder), 34 21.382
Georgia
Antimony PM2.5 LC Georgia 41 19.805
Antimony PM2.5 LC Hawaii 66 19.712
Antimony PM2.5 LC Idaho 80 20.438
Antimony PM2.5 LC Chicago, Illinois 42 22.405
Antimony PM2.5 LC Chicago, Illinois 75 20.907
Antimony PM2.5 LC Northbrook, Illinois 74 18.507
Antimony PM2.5 LC Naperville, Illinois 38 18.013
Antimony PM2.5 LC Granite City, Illinois 22 20.75
Antimony PM2.5 LC Roxana, Illinois 39 19.692
Antimony PM2.5 LC Belleville, Illinois 38 20.605
Antimony PM2.5 LC Jeffersonville, Indiana 41 19.22
Antimony PM2.5 LC Jasper, Indiana 41 20.232
Antimony PM2.5 LC Elkhart, Indiana 41 18.963
Antimony PM2.5 LC Middletown, Indiana 41 19.402
Antimony PM2.5 LC Gary, Indiana 39 19.372
Antimony PM2.5 LC Indianapolis (Remainder), Indiana 60 20.192
Antimony PM2.5 LC Evansville, Indiana 42 18.774
Antimony PM2.5 LC Cedar Rapids, Iowa 41 18.159
Antimony PM2.5 LC Des Moines, Iowa 41 18.11
Antimony PM2.5 LC Davenport, Iowa 81 20.302
Antimony PM2.5 LC Wichita, Kansas 42 19
Antimony PM2.5 LC Kansas City, Kansas 69 20.645
Antimony PM2.5 LC Ashland, Kentucky 42 20.571
Antimony PM2.5 LC Kentucky 41 17.5
Antimony PM2.5 LC Lexington-Fayette (corporate name for 42 19.726
Lexington), Kentucky
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Table 6-4.  Median Antimony Levels in Ambient Air





Antimony PM2.5 LC Louisville, Kentucky 81 20.951
Antimony PM2.5 LC Shreveport, Louisiana 39 18.205
Antimony PM2.5 LC Baton Rouge, Louisiana 76 18.941
Antimony PM2.5 LC Essex, Maryland 75 19.687
Antimony PM2.5 LC Beltsville, Maryland 82 21.451
Antimony PM2.5 LC Chicopee, Massachusetts 80 20.819
Antimony PM2.5 LC Boston, Massachusetts 84 20.077
Antimony PM2.5 LC Boston, Massachusetts 42 18.333
Antimony PM2.5 LC Grand Rapids, Michigan 82 20.951
Antimony PM2.5 LC Tecumseh, Michigan 42 19.583
Antimony PM2.5 LC Michigan 42 20.952
Antimony PM2.5 LC Michigan 42 19.512
Antimony PM2.5 LC Port Huron, Michigan 42 20.298
Antimony PM2.5 LC Allen Park, Michigan 81 20.062
Antimony PM2.5 LC Detroit, Michigan 41 18.402
Antimony PM2.5 LC Dearborn, Michigan 42 18.607
Antimony PM2.5 LC Blaine, Minnesota 82 20.043
Antimony PM2.5 LC Minneapolis, Minnesota 83 20.596
Antimony PM2.5 LC Rochester, Minnesota 42 19.738
Antimony PM2.5 LC Jackson, Mississippi 66 20.818
Antimony PM2.5 LC Missouri 82 22.079
Antimony PM2.5 LC Arnold, Missouri 82 20.152
Antimony PM2.5 LC Missouri 78 21.269
Antimony PM2.5 LC St. Louis, Missouri 81 20.16
Antimony PM2.5 LC Montana 68 19.096
Antimony PM2.5 LC Butte-Silver Bow (Remainder), Montana 53 19.519
Antimony PM2.5 LC Omaha, Nebraska 71 19.873
Antimony PM2.5 LC Sunrise Manor, Nevada 70 19.514
Antimony PM2.5 LC Reno, Nevada 66 19.955
Antimony PM2.5 LC Camden, New Jersey 68 19.831
Antimony PM2.5 LC Newark, New Jersey 68 20.368
Antimony PM2.5 LC North Brunswick Township, New Jersey 66 20.515
Antimony PM2.5 LC North Brunswick Township, New Jersey 38 18.842
Antimony PM2.5 LC Chester, New Jersey 68 19.625
Antimony PM2.5 LC Elizabeth, New Jersey 69 18.725
Antimony PM2.5 LC Albuquerque, New Mexico 84 19.5
Antimony PM2.5 LC Albany, New York 79 18.025
Antimony PM2.5 LC New York, New York 72 18.535
Antimony PM2.5 LC Buffalo, New York 38 18.526
Antimony PM2.5 LC New York 42 19.274
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Table 6-4.  Median Antimony Levels in Ambient Air





Antimony PM2.5 LC Rochester, New York 80 22.65
Antimony PM2.5 LC New York, New York 82 19.024
Antimony PM2.5 LC New York, New York 84 19.964
Antimony PM2.5 LC New York 80 20.556
Antimony PM2.5 LC Asheville, North Carolina 29 17.534
Antimony PM2.5 LC Hickory, North Carolina 12 24.917
Antimony PM2.5 LC Lexington, North Carolina 40 18.838
Antimony PM2.5 LC Winston-Salem, North Carolina 38 19.842
Antimony PM2.5 LC Charlotte, North Carolina 84 19.143
Antimony PM2.5 LC Rockwell, North Carolina 42 18.202
Antimony PM2.5 LC Raleigh, North Carolina 78 19.391
Antimony PM2.5 LC North Dakota 84 19.048
Antimony PM2.5 LC Cleveland, Ohio 38 22.013
Antimony PM2.5 LC Cleveland, Ohio 66 21.356
Antimony PM2.5 LC Cleveland, Ohio 36 20.75
Antimony PM2.5 LC Columbus, Ohio 42 18.75
Antimony PM2.5 LC Cincinnati, Ohio 83 19.88
Antimony PM2.5 LC Steubenville, Ohio 36 19.944
Antimony PM2.5 LC Ironton, Ohio 42 19.048
Antimony PM2.5 LC Sheffield, Ohio 41 22.61
Antimony PM2.5 LC Toledo, Ohio 37 18.432
Antimony PM2.5 LC Youngstown, Ohio 30 19.333
Antimony PM2.5 LC Dayton, Ohio 36 18.819
Antimony PM2.5 LC New Paris, Ohio 83 20.524
Antimony PM2.5 LC Canton, Ohio 41 19.341
Antimony PM2.5 LC Akron, Ohio 35 19.243
Antimony PM2.5 LC Oklahoma City, Oklahoma 40 18.538
Antimony PM2.5 LC Tulsa, Oklahoma 81 19.914
Antimony PM2.5 LC Altamont, Oregon 26 13.596
Antimony PM2.5 LC Altamont, Oregon 3 11.6
Antimony PM2.5 LC Lakeview, Oregon 30 13.482
Antimony PM2.5 LC Lakeview, Oregon 3 11.6
Antimony PM2.5 LC Eugene, Oregon 30 12.715
Antimony PM2.5 LC Eugene, Oregon 3 11.583
Antimony PM2.5 LC Portland, Oregon 71 19.993
Antimony PM2.5 LC Pennsylvania 41 20.378
Antimony PM2.5 LC Pittsburgh, Pennsylvania 70 19.164
Antimony PM2.5 LC Liberty, Pennsylvania 42 20.024
Antimony PM2.5 LC Pennsylvania 42 19.369
Antimony PM2.5 LC Johnstown, Pennsylvania 42 17.119
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Table 6-4.  Median Antimony Levels in Ambient Air





Antimony PM2.5 LC State College, Pennsylvania 37 20.378
Antimony PM2.5 LC Pennsylvania 28 17.732
Antimony PM2.5 LC Pennsylvania 40 18.8
Antimony PM2.5 LC Erie, Pennsylvania 40 20.2
Antimony PM2.5 LC Scranton, Pennsylvania 22 18.25
Antimony PM2.5 LC Lancaster, Pennsylvania 42 20.75
Antimony PM2.5 LC Freemansburg, Pennsylvania 37 18.541
Antimony PM2.5 LC Philadelphia, Pennsylvania 79 21.285
Antimony PM2.5 LC Philadelphia, Pennsylvania 42 19.607
Antimony PM2.5 LC Pennsylvania 39 18.128
Antimony PM2.5 LC Greensburg, Pennsylvania 38 18.684
Antimony PM2.5 LC York, Pennsylvania 41 21.561
Antimony PM2.5 LC East Providence, Rhode Island 80 19.894
Antimony PM2.5 LC South Carolina 36 17.597
Antimony PM2.5 LC Greenville, South Carolina 39 19.936
Antimony PM2.5 LC Dentsville (Dents), South Carolina 83 19.602
Antimony PM2.5 LC Sioux Falls, South Dakota 74 19.818
Antimony PM2.5 LC Nashville, Tennessee 41 21.988
Antimony PM2.5 LC Chattanooga, Tennessee 42 19.512
Antimony PM2.5 LC Knoxville, Tennessee 40 20.3
Antimony PM2.5 LC Loretto, Tennessee 41 20.988
Antimony PM2.5 LC Memphis, Tennessee 79 18.899
Antimony PM2.5 LC Dallas, Texas 86 2.033
Antimony PM2.5 LC Dallas, Texas 82 20.683
Antimony PM2.5 LC Midlothian, Texas 44 2.002
Antimony PM2.5 LC El Paso, Texas 75 21.407
Antimony PM2.5 LC Texas 46 1.972
Antimony PM2.5 LC Deer Park, Texas 83 19.813
Antimony PM2.5 LC Deer Park, Texas 42 18.595
Antimony PM2.5 LC Texas 41 18.817
Antimony PM2.5 LC Corpus Christi, Texas 42 1.993
Antimony PM2.5 LC Bountiful, Utah 41 18.512
Antimony PM2.5 LC Salt Lake City, Utah 74 21.378
Antimony PM2.5 LC Lindon, Utah 41 22.854
Antimony PM2.5 LC Burlington, Vermont 56 20.813
Antimony PM2.5 LC East Highland Park, Virginia 62 19.435
Antimony PM2.5 LC Vancouver, Washington 42 19.488
Antimony PM2.5 LC Seattle, Washington 77 20.052
Antimony PM2.5 LC Tacoma, Washington 39 17.731
Antimony PM2.5 LC Marysville, Washington 38 20.763
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Table 6-4.  Median Antimony Levels in Ambient Air





Antimony PM2.5 LC Yakima, Washington 42 19.952
Antimony PM2.5 LC West Virginia 70 19.636
Antimony PM2.5 LC South Charleston, West Virginia 13 18.846
Antimony PM2.5 LC Moundsville, West Virginia 27 18.185
Antimony PM2.5 LC Green Bay, Wisconsin 41 18.951
Antimony PM2.5 LC Horicon, Wisconsin 84 19.75
Antimony PM2.5 LC Milwaukee, Wisconsin 79 19.101
Antimony PM2.5 LC Wisconsin 42 18.881
Antimony PM2.5 LC Waukesha, Wisconsin 41 20.061
Antimony PM2.5 LC Wyoming 82 19.384
LC = local conditions; PM = particulate matter; STP = standard temperature and pressure; TSP = total suspended 
particulate
Source: EPA 2015a
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6.  POTENTIAL FOR HUMAN EXPOSURE
Antimony is enriched in coal and vaporized in fossil fuel combustion, resulting in the release of increased 
levels of antimony to the atmosphere.  After condensation, antimony is primarily found in fly ash 
(Miravet et al. 2006).  Antimony levels in coal fly ash leachates from two different samples obtained from
the Escucha coal-fired power station in Teruel, Spain were reported to be 0.01–0.07 µg/g for Sb(III) and 
0.17–0.41 µg/g for Sb(V) in the first sample.  Levels were slightly higher in the second sample:  Sb(III)
levels were 0.02–0.09 µg/g and Sb(V) levels were 0.16–0.56 µg/g.  The data indicate that Sb(V) was the
predominant species found in the leachate, and while the antimony was found to bind strongly to the
matrix, the study demonstrated that significant amounts of antimony can leach out of coal fly ash particles
(Miravet et al. 2006). Likewise, in Taipei, Taiwan, the total antimony content in fly ash was 4.7 µg/g, 
while in Barcelona, Spain, the Sb(III) content was 0.07–0.36 µg/g and the Sb(V) content was 1.63 µg/g.  
Antimony content (predominantly Sb(III)) in fly ash from various countries ranged from 1 to 3.9 µg/g
(Smichowski 2008).  Antimony emissions may have increased in Japan over the years due to the fact that
part of the process in the incineration of household wastes containing plastics occurs in Japan; thus, fly
ash originating from waste incineration may be an important source of antimony (Iijima et al. 2009).
Several older studies show that antimony can travel long distances, and that ambient levels may reflect
the origin of the air masses.  The geometric mean antimony concentrations in aerosols at three rural/ 
remote locations in New York State were 1.0, 0.72, and 0.33 ng/m3 (Dutkiewicz et al. 1987), and the
enrichment over crustal abundance ranged from 920 to 1,650.  The enrichment factor is smaller but
similar to the mean enrichment factor of 1,880 for antimony in 29 cities (Gladney et al. 1984).  The high 
enrichment indicates that the antimony is of anthropogenic origin.  An analysis of the New York State
data using backward-in-time air trajectories is consistent for the Midwest being the dominant source of
antimony.  An analysis of European sources and wind trajectories further illustrate that antimony may be
transmitted over long distances. The average concentrations at a city in southern Norway were
0.54 ng/m3 when the air masses came from the United Kingdom and 0.07 ng/m3 when they came from
over the Atlantic (Hillamo et al. 1988).
Twenty-four-hour samples collected at 10 locations in Washington, DC yielded average antimony
concentrations ranging from 1.1 to 3.0 ng/m3 (Kowalczyk et al. 1982).  As a result of a chemical element
balance analysis, the three major contributing sources in order of decreasing significance are believed to
be refuse incineration, motor vehicles, and coal combustion.  In a Houston study, the range of antimony
concentrations in fine (0.1–2.5 μm) aerosols was 0–12 ng/m3, whereas in particles >2.5 μm, the range was
0–4 ng/m3 (Johnson et al. 1984).  Median, mean, and maximum concentrations of antimony in aerosols at
three sites in Quebec, Ontario, and Nova Scotia were 0.05–0.10, 0.11–0.23, and 0.37–2.17 ng/m3, 
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respectively (Hopper and Barrie 1988).  According to the Texas Air Control Board, the first- and second-
highest annual average antimony concentrations in Texas between 1978 and 1982 were 452 and 50 ng/m3 
at Laredo and Dallas, respectively.  The statewide 1978–1982 average was below the minimum detectible 
mean of 90 ng/m3 (Wiersema et al. 1984).
Concentrations of antimony in 24-hour air samples at Kellogg, Idaho, an area with a large number of
operating mines, ranged from 5.21 to 1,210 ng/m3, with a mean of 146 ng/m3 (Ragaini et al. 1977).  The
6-month average concentration of antimony in air in an industrial area of England where a number of
ferrous and nonferrous metal smelting and manufacturing works were concentrated was 40 ng/m3.  This is
a factor of 50 higher than that found in rural areas (Pattenden et al. 1982).  The maximum concentration at
the industrial site was 69 ng/m3.
The mean monthly concentration of antimony in precipitation at Birkenes in southern Norway ranged 
from 0.2 to 2.3 µg/L, with a mean of 0.6 µg/L (Pacyna et al. 1984).  During the same period, the
respective air concentrations were 0.19–0.80 and 0.43 ng/m3. Rain samples were collected during two
storms upwind and downwind of a copper smelter in Tacoma, Washington.  Antimony in rainwater
originated primarily from the smelter.  The mean total antimony concentration in rainwater downwind
from the smelter was 1.3 µg/L; the concentration upwind was 0.03 µg/L (Vong et al. 1988).  Eighty
percent of the antimony in rainwater was dissolved (i.e., passed through a 0.45-μm filter).
Antimony is almost entirely found in the particulate, as opposed to the dissolved fraction of snow
(Landsberger et al. 1983).  The antimony content of snow particulate matter in samples from Montreal, 
Canada, ranged from 4 to 145 ppm.  Another sampling of snow around Montreal found total antimony
concentrations of 1–8.7 ppb and enrichment factors of 39–590 (Zikovsky and Badillo 1987).
Antimony is a component of ammunition, and studies have been performed to ascertain the elemental
concentrations of antimony in the air of indoor shooting ranges.  Antimony might be expected in such 
situations because it is alloyed with lead in bullets, and lead stibnite and antimony sulfides are used as 
primers (Dams et al. 1988).  After an intensive 3-hour shooting exercise, levels of antimony reached 
119 μg/m3 (190,000 ng/m3), or 4 orders of magnitude over ambient levels (Vandecasteele et al. 1988).  An
instructor at the shooting range had a time-weighted average (TWA) inhalable antimony concentration of
12.0 μg/m3 (1,200 ng/m3) compared with the threshold limit value (TLV) of 500 μg/m3 (500,000 ng/m3).  
An American study conducted at the National Guard Armory in Washington, DC, during routine daytime
and gun club use, found indoor antimony concentrations ranging from 57 to 216 μg/m3 (57,000– 
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6.  POTENTIAL FOR HUMAN EXPOSURE
216,000 ng/m3) versus background air ranging from 1.5 to 2.3 μg/m3 (1,500–2,300 ng/m3), an enrichment
of 9,900 over District of Columbia air (Olmez et al. 1985).  More than 60% of the antimony was
associated with respirable particles with an aerodynamic diameter <3.5 pm (<3,500 ppb).
6.4.2 Water
The National Water-Quality Assessment (NAWQA) program surveyed groundwater across the United
States from 1992 to 2003 and generally found low concentrations of antimony in the water.  Median 
concentrations were reported as <1 µg/L (ppb) (USGS 2011).  Other studies also reported low 
concentrations of antimony in water.  Eckel and Jacob (1989) gathered water monitoring data from the
Water Resources Division of the U.S. Geological Survey (USGS) covering the period from about 1960 to 
September, 1988, and found that all but 70 of 1,077 entries for dissolved antimony were below 5 µg/L.  
The geometric mean and standard deviation of the 70 values >5 µg/L were 12 and 1.93 µg/L, 
respectively.  The concentrations of dissolved antimony were 1.62 nM (0.197 µg/L) in the St. Lawrence 
River at Massena, New York and 2.73 nM (0.332 µg/L) in the Yukon River.  European rivers had 
dissolved antimony at concentrations ranging from <0.03 to 4.43 nM (0.004–0.539 µg/L) (Andreae and 
Froelich 1984).
Geothermal waters often have naturally elevated levels of trace metals such as arsenic, mercury, and
antimony.  The speciation of these compounds is complex and can change during sampling, storage, and 
analysis; therefore, results are usually reported as the total amount present in the geothermal water.
Analysis of 268 thermal springs in Yellowstone National Park showed total antimony levels ranging from
9 to 166 µg/L for sampling conducted from 1966 to 1975 (Stauffer and Thompson 1984).  USGS (2010)
analyzed water samples from streams, tributaries, drainage channels, and other water bodies at
104 locations in the Yellowstone National Park, Wyoming from 2006 to 2008.  The results of this study
are summarized in Table 6-5.
These data are consistent with antimony levels in geothermal waters in other parts of the world.  For
example, antimony levels ranged from 0.05 to 244 µg/L (n=75), with a mean value of 35 µg/L for
geothermal waters sampled in various locations of Japan.
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Sampling location Antimony (µg/L)
Norris-Mammoth Corridor and West Nymph Creek <1–6
Norris Geyser Basin <1–180
Gibbon Canyon and Geyser Springs Group 3–95
Crater Hills area 1–150
Ojo Caliente Spring and its discharge channel, Lower Geyser Basin 10–94
Porcupine Hills area 62–123
Midway Geyser Basin and the Rabbit Creek area 0–82
Mud Volcano area <0.5–6
Washburn Hot Springs <0.5
Source:  USGS 2010
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Anthropogenic activity can result in elevated levels of antimony in nearby water systems.  A study in 
Luxembourg found higher concentrations of antimony in samples close to an ore site as compared to 
concentrations further from the site (Filella et al. 2009b).  Similarly, a study in Corsica found higher
levels of antimony in the water after crossing the mining soils, with concentrations decreasing further
downstream (Migon and Mori 1999).
Sb(V) was the most prevalent species of antimony found in drinking water.  Sb(V) is expected to 
predominate due to the oxidative treatments used in water disinfection processes (Belzile et al. 2011). 
Sb(V) was also the predominant species in oceans at mean concentrations of 200 ng/L.  Sb(V) is
predominant in oxic and mildly reducing environments.  Sb(III) is predominant in anoxic waters and
porewaters, and in reducing conditions.  The presence of thermodynamically unfavorable Sb(III) in 
oxygenated surface waters has been attributed largely to phytoplankton activity (Chen et al. 2003).
The major antimony mining area in the United States was the Kellogg district in northern Idaho, and 
mining and smelting wastes have been dumped into the South Fork of the Coeur d'Alene River for over
80 years (Mok and Wai 1990).  The South Fork joins with the North Fork of the river to form the Main 
Stem of the Coeur d'Alene River somewhat below Kellogg.  Mean and maximum total dissolved 
antimony concentrations at two sites on the South Fork were 4.3 and 8.2 µg/L, respectively.  Mean and 
maximum concentrations at six stations on the Main Stem ranged from 0.6 to 1.0 and from 0.8 to 
1.9 µg/L, respectively.  Those at a station on the unpolluted North Fork were 0.09 and 0.2 µg/L, 
respectively.
Since antimony is used in solder, there has been interest as to whether antimony will leach from pipes
soldered with antimony-containing solder into drinking water.  Leaching of antimony from tin/antimony
(Sn/Sb) solder when it comes in contact with water with pH of 5.2–8.6 was evaluated using loops of pipe
containing 20 solder joints (Murrell 1987).  Antimony was undetectable (<4 ppb) in the water at first, but 
rose to 10 ppb after 4 days and 68 ppb (at pH 7.4) after 4 weeks.  A study was conducted at the University
of Washington to evaluate the potential for leaching of metals into drinking water from 95/5 Sn/Sb solder
(Herrera et al. 1982).  After a series of static and continuous-flow laboratory tests and evaluation of field 
samples from university buildings, it was concluded that increases in antimony concentration as a result
of corrosion and leaching were minimal and would not contribute significantly to dietary antimony intake.  
Only one of the field samples of standing water from university buildings containing Sn/Sb solder joints
was above the detection limit of 0.6 ppb.  The sample contained 2 ppb of antimony, one-half of which 
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was dissolved. Examination of the solder joints indicated that a double passivation film of tin monoxide
(SnO) and tin dioxide (SnO2) forms and inhibits leaching.
6.4.3 Sediment and Soil
Antimony is naturally present in the earth’s crust at levels of about 0.2–0.3 µg/g (ppm), but these levels
vary by location (Telford et al. 2008).  A survey of soils throughout the conterminous United States
conducted by the USGS showed that antimony concentrations ranged from <1 to 8.8 ppm (µg/g) with an 
average concentration of 0.48 ppm (µg/g).  This was the third lowest concentration of the 50 elements
surveyed (Shacklette and Boerngen 1984).  In this survey, samples were taken at a depth of 20 cm at
1,318 sampling sites.  Soils not derived from ore-bearing rock or close to industrial sources do not
generally contain more than 1 ppm (µg/g) of antimony.  Background concentrations for antimony in soil
ranged from 0.06 to 0.79 µg/g in seven Florida soil orders.  Concentrations were dependent on the
location, mineralization, parent material differences, varying degrees of anthropogenic influence, and
different sampling strategies (Wilson et al. 2010).  Elevated levels of antimony in soil samples are
commonly associated with anthropogenic activities such as mining, fossil fuel combustion, smelting, and 
other activities.  Samples of soil were collected from the decommissioned Hanford Site along the 
Columbia River in 2008. The Hanford site was utilized to produce plutonium.  Antimony was detected in 
27 out of 158 samples at a mean concentration of 0.113 µg/g.  Antimony and selenium were not able to be
detected in the majority of the samples (DOE 2009b).  The distribution of antimony at two sites in 
Austria, with close proximity to traffic routes, was evaluated by Amereih et al. (2005) at two sampling
depths (0–5 and 5–10 cm from the soil surface) and three distances (0.2, 2, and 10 m) from the edge of the
road.  In addition to roadside soil, samples were also obtained from Lungau, an alpine region with
negligible traffic.  Table 6-6 summarizes the results from this study during two sampling periods (2002 
and 2005).
Examining the monitoring data from this study shows clear trends in the antimony levels in the soils
reflective of anthropogenic contributions due to the presence of motor vehicles at the Knittelfeld and
Rankweil locations as compared to the site with negligible vehicular traffic.  Moreover, greater antimony
levels are observed at both sampling depths the nearer to the road the soil samples were obtained
(0.2 versus 2 versus 10 m). Levels of antimony decreased to near background levels within a few meters 
from the edge of the road.
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6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-6. Antimony Levels at Three Locations With Different Vehicular Traffic
Total Sb µg/g Total Sb µg/g
Locationa Distance from road (m) Sample depth (cm) (2002) (2005)
Lungau Not applicable 0–5 0.64 Not available
Lungau Not applicable 5–10 0.81 Not available
Knittelfeld 0.2 0–5 6.30 8.68
Knittelfeld 0.2 5–10 3.80 4.78
Knittelfeld 2 0–5 1.75 1.99
Knittelfeld 2 5–10 1.51 1.96
Knittelfeld 10 0–5 1.21 1.16
Knittelfeld 10 5–10 1.13 1.13
Rankweil 0.2 0–5 2.74 Not available
Rankweil 0.2 5–10 1.83 Not available
Rankweil 2 0–5 1.52 Not available
Rankweil 2 5–10 1.21 Not available
Rankweil 10 0–5 0.91 Not available
Rankweil 10 5–10 0.82 Not available
aVehicular traffic at the Knittelfeld and Rankweil sampling locations exceeds 20,000 vehicles per day, while there is
no vehicular traffic at the Lungau location.
Source: Amereih et al. 2005
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High concentrations of antimony were observed in soil at a shooting range.  Antimony concentrations
(only Sb(V)) were 4,000 µg/g in soil samples collected at a depth of 1 cm, 1,600–17,500 µg/g in soil
samples collected at 0–5 cm, 3,400 mg/kg at 5–15 cm, 1,300 µg/g at 16 cm, and 8,600 µg/g at 25–45 cm
at different sites at the shooting range (Scheinost et al. 2006).
Levels of mean antimony, Sb(III), and Sb(V) in contaminated soils from the Hillgrove mine located in 
New South Wales, Australia were measured in six samples. This facility mines for gold and antimony
and has been in operation for over 100 years.  There were higher levels of Sb(V) than Sb(III) in the soil
samples, ranging from 12 to 27 µg/g for Sb(III) and from 211 to 384 µg/g for Sb(V). Total mean 
antimony levels ranged from 470 to 849 µg/g (Telford et al. 2008).  Concentrations of antimony were also 
high in the sediment around mining sites in Corsica.  The levels of antimony decreased with increasing
distance downstream from the site.  Concentrations ranged from 8 to 1,108 µg/g in January 1993 and 
from 10 to 1,005 µg/g in March 1993 depending upon the sampling location (Migon and Mori 1999).  
The greatest concentrations occurred at a sampling location on the Presa River nearby the mine and
gradually decreased at sampling locations 10 km away where the Presa River runs into the Bravona River.
Levels of Sb(III), Sb(V), and total antimony were monitored at three locations in sediment from the
Plawniowice reservoir in Poland nearby metallurgy and coal mining operations (Jablonska-Czapla et al.
2014).  Levels of Sb(III) varied between approximately 20–45 µg/g in the upper (0–5 cm) sediment
profile and approximately 20–35 µg/g in sediment collected from a depth of 15–20 cm.  Sb(V) levels 
were similar in both the upper sediment samples and the lower sediment samples with levels ranging from
approximately 5 to 25 µg/g.
6.4.4 Other Environmental Media
Antimony trioxide (Sb2O3) is used in the production of PET.  The antimony content in PET has been
reported to be as high as 190–300 mg/kg.  Leaching of antimony into PET water bottles has been 
reported.  European PET bottled water contained 359 ng/L of antimony; however, the low-density PET 
from the same brand had 3.9 ng/L of antimony.  Increased temperature and length of time stored may
contribute to more antimony being released into the bottles.  Levels of antimony increased from 200 to 
7,800–9,700 ng/L in heated water bottles (at 80°C for 48 hours).  Heated PET packing materials had 
antimony concentrations ranging from 50 to 285 mg/kg and non-heated containers had levels <0.1– 
24 µg/kg.  Concentrations of antimony in food has been reported to be <1.0 µg/g (Belzile et al. 2011).
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Antimony has been detected in commercial juices. Juices of blackcurrant, mixed fruit, strawberry,
raspberry, sour cherry, mint, and synthetic caramel purchased from Greece, Denmark, and Scotland were 
analyzed for antimony content.  The highest concentration of antimony from the 42 samples was 
13.6 µg/L, reported in sour cherry juice packaged in glass (Hansen et al. 2010).
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
The general population may be exposed to antimony through ingestion of food and drinking water, 
inhalation of particulates from ambient air, or ingestion of contaminated soil or dust.  Occupational
exposures of antimony may occur at smelters, coal-fired plants, and refuse incinerators that process or
release antimony.  Dermal exposure may occur through skin contact with soil, water, or other substances 
containing antimony.  Absorption, distribution, and excretion of antimony are variable based on oxidation 
state.  Urinary excretion appears to be greater for Sb(V) than for Sb(III) compounds (Elinder and Friberg, 
1986).
In the Fourth National Report on Human Exposures to Environmental Chemicals reported by the Centers
for Disease Control and Prevention (CDC 2015) results from the NHANES updated tables 1999–2012 
were provided for antimony.  Antimony levels in urine (see Table 6-7), and urine (creatinine corrected)
(see Table 6-8) were evaluated for a variety of age groups and ethnicities.  Recent exposure to antimony
is reflected in urinary samples (CDC 2015). The geometric mean and median concentrations of urinary
antimony have decreased over time, which may be due to decreases in exposure or methodological
differences.
Gebel et al. (1998b) investigated urine, blood, and scalp hair for antimony biomonitoring.  No association
between elevated soil levels and urinary antimony levels were found in this study of >200 German
residents.  A high proportion of blood samples were below the limit of detection. Antimony was detected
in hair samples from individuals in Rio de Janeiro at concentrations that ranged from <0.03 to <1.8 µg/g.  
The samples were for both men and women and were collected from the scalp in the occipital area (back
of the head) (Miekeley et al. 1998).  In an analogous study, the mean concentration of antimony in hair
samples from 55 men and women from Scranton, Pennsylvania contained 0.096 ppm of antimony.  The
hair samples of populations from cities in four other countries contained mean antimony levels between
0.11 and 0.86 ppm (Takagi et al. 1986).  A Japanese national study analyzing antimony concentrations in
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Table 6-7.  Geometric Mean and Selected Percentiles of Urinary Antimony (in μg/L) for the U.S. Population from




(95% CI) 50th 75th 
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Table 6-7.  Geometric Mean and Selected Percentiles of Urinary Antimony (in μg/L) for the U.S. Population from
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6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-7.  Geometric Mean and Selected Percentiles of Urinary Antimony (in μg/L) for the U.S. Population from
the National Health and Nutrition Examination Survey (NHANES)
Selected percentiles (95% CI)Survey Geometric mean Sample 
years (95% CI) 50th 75th 90th 95th size
Non-Hispanic	 1999–2000 0.128 (0.115–0.144) 0.130 (0.110–0.140) 0.210 (0.190–0.230) 0.330 (0.280–0.350) 0.400 (0.360–0.500) 768
whites	 2001–2002 0.126 (0.117–0.135) 0.130 (0.120–0.130) 0.180 (0.170–0.190) 0.250 (0.230–0.300) 0.340 (0.310–0.390) 1,132
2003–2004 * 0.070 (<LOD–0.080) 0.130 (0.110–0.140) 0.190 (0.170–0.210) 0.280 (0.230–0.320) 1,074
2005–2006 0.069 (0.062–0.077) 0.070 (0.060–0.080) 0.110 (0.100–0.130) 0.210 (0.170–0.260) 0.300 (0.240–0.380) 1,041
2007–2008 0.057 (0.052–0.063) 0.060 (0.050–0.060) 0.090 (0.080–0.110) 0.150 (0.130–0.200) 0.230 (0.190–0.260) 1,095
2009–2010 0.053 (0.050–0.057) 0.050 (0.040–0.050) 0.090 (0.080–0.090) 0.160 (0.130–0.190) 0.230 (0.190–0.280) 1,225
2011–2012 * 0.044 (<LOD–0.049) 0.081 (0.069–0.095) 0.143 (0.118–0.159) 0.180 (0.159–0.231) 820
All Hispanics	 2011–2012 * 0.046 (<LOD–0.053) 0.079 (0.066–0.088) 0.128 (0.110–0.149) 0.174 (0.149–0.208) 573
Asians	 2011–2012 * <LOD 0.066 (0.054–0.075) 0.103 (0.075–0.145) 0.145 (0.100–0.194) 353
<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
 
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
 
CI = confidence interval
 
Source:  CDC 2015
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Table 6-8.  Geometric Mean and Selected Percentiles of Urinary Antimony (Creatinine Corrected) (in μg/g of






(95% CI) 50th 
Selected percentiles (95% CI)
75th 90th 95th 
Sample 
size
Total 1999–2000 0.124 (0.108–0.143) 0.119 (0.102–0.143) 0.185 (0.164–0.214) 0.276 (0.233–0.333) 0.385 (0.333–0.430) 2,276
2001–2002 0.126 (0.119–0.134) 0.120 (0.115–0.126) 0.173 (0.162–0.188) 0.267 (0.242–0.300) 0.364 (0.320–0.414) 2,689
2003–2004 * 0.080 (<LOD–0.086) 0.135 (0.119–0.143) 0.208 (0.192–0.230) 0.277 (0.250–0.294) 2,558
2005–2006 0.072 (0.068–0.077) 0.070 (0.060–0.070) 0.100 (0.100–0.110) 0.160 (0.150–0.190) 0.230 (0.190–0.290) 2,576
2007–2008 0.064 (0.060–0.068) 0.060 (0.060–0.060) 0.090 (0.080–0.100) 0.140 (0.140–0.160) 0.200 (0.170–0.230) 2,627
2009–2010 0.060 (0.056–0.064) 0.060 (0.050–0.060) 0.090 (0.080–0.090) 0.140 (0.120–0.160) 0.200 (0.180–0.230) 2,847
2011–2012 * 0.059 (0.055–0.063) 0.092 (0.085–0.100) 0.152 (0.135–0.171) 0.223 (0.181–0.261) 2,502
Age group
6–11 years 1999–2000 0.191 (0.147–0.248) 0.185 (0.156–0.220) 0.250 (0.200–0.417) 0.447 (0.271–0.741) 0.741 (0.333–10.30) 316
2001–2002 0.178 (0.159–0.200) 0.173 (0.150–0.193) 0.228 (0.200–0.272) 0.338 (0.265–0.480) 0.471 (0.313–0.727) 368
2003–2004 0.116 (0.103–0.130) 0.118 (0.098–0.136) 0.167 (0.146–0.187) 0.256 (0.194–0.317) 0.333 (0.250–0.500) 290
2005–2006 0.092 (0.081–0.104) 0.090 (0.080–0.110) 0.130 (0.110–0.150) 0.180 (0.150–0.210) 0.220 (0.180–0.270) 355
2007–2008 0.089 (0.079–0.100) 0.090 (0.070–0.100) 0.120 (0.110–0.140) 0.200 (0.150–0.240) 0.300 (0.200–0.370) 394
2009–2010 0.094 (0.084–0.106) 0.090 (0.080–0.100) 0.140 (0.120–0.160) 0.200 (0.170–0.250) 0.280 (0.220–0.320) 378
2011–2012 0.091 (0.081–0.102) 0.091 (0.078–0.100) 0.130 (0.116–0.147) 0.206 (0.153–0.283) 0.308 (0.218–0.340) 398
12–19 years 1999–2000 0.121 (0.104–0.140) 0.120 (0.095–0.146) 0.176 (0.146–0.207) 0.259 (0.206–0.310) 0.310 (0.228–0.421) 663
2001–2002 0.121 (0.112–0.131) 0.115 (0.106–0.127) 0.160 (0.138–0.186) 0.224 (0.199–0.245) 0.266 (0.244–0.310) 762
2003–2004 0.075 (0.068–0.082) 0.068 (0.061–0.077) 0.100 (0.092–0.113) 0.156 (0.126–0.173) 0.193 (0.172–0.255) 725
2005–2006 0.070 (0.065–0.076) 0.070 (0.060–0.080) 0.100 (0.090–0.110) 0.140 (0.120–0.150) 0.170 (0.150–0.250) 701
2007–2008 0.062 (0.054–0.070) 0.060 (0.050–0.070) 0.090 (0.070–0.100) 0.120 (0.100–0.160) 0.160 (0.110–0.240) 376
2009–2010 0.059 (0.053–0.066) 0.060 (0.050–0.060) 0.090 (0.070–0.100) 0.130 (0.110–0.170) 0.180 (0.150–0.220) 451
2011–2012 0.062 (0.055–0.069) 0.058 (0.051–0.067) 0.085 (0.070–0.106) 0.147 (0.115–0.181) 0.222 (0.122–0.373) 390
≥20 years 1999–2000 0.118 (0.104–0.135) 0.111 (0.097–0.135) 0.175 (0.149–0.209) 0.263 (0.227–0.320) 0.352 (0.320–0.391) 1,297
2001–2002 0.122 (0.115–0.129) 0.115 (0.108–0.121) 0.167 (0.153–0.181) 0.265 (0.241–0.300) 0.364 (0.318–0.405) 1,559
2003–2004 * 0.079 (<LOD–0.087) 0.135 (0.116–0.145) 0.209 (0.195–0.233) 0.278 (0.250–0.294) 1,543
2005–2006 0.070 (0.066–0.075) 0.060 (0.060–0.070) 0.100 (0.090–0.110) 0.170 (0.150–0.190) 0.250 (0.190–0.300) 1,520
2007–2008 0.062 (0.058–0.066) 0.060 (0.050–0.060) 0.090 (0.080–0.100) 0.140 (0.130–0.160) 0.200 (0.160–0.240) 1,857
2009–2010 0.057 (0.053–0.061) 0.050 (0.050–0.060) 0.080 (0.080–0.090) 0.130 (0.120–0.140) 0.190 (0.160–0.220) 2,018
2011–2012 * 0.056 (<LOD–0.060) 0.088 (0.078–0.097) 0.145 (0.127–0.171) 0.215 (0.179–0.240) 1,714










    
    







        
        










































































































































































































6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-8.  Geometric Mean and Selected Percentiles of Urinary Antimony (Creatinine Corrected) (in μg/g of






(95% CI) 50th 
Selected percentiles (95% CI)




Males 1999–2000 0.112 (0.099–0.127) 0.109 (0.095–0.127) 0.164 (0.146–0.181) 0.226 (0.204–0.268) 0.320 (0.235–0.391) 1,132
2001–2002 0.114 (0.107–0.123) 0.108 (0.103–0.115) 0.153 (0.138–0.171) 0.228 (0.205–0.250) 0.333 (0.281–0.438) 1,334
2003–2004 0.080 (0.076–0.084) 0.075 (0.069–0.081) 0.122 (0.111–0.132) 0.192 (0.173–0.209) 0.253 (0.230–0.278) 1,281
2005–2006 0.070 (0.064–0.077) 0.060 (0.060–0.070) 0.100 (0.090–0.120) 0.160 (0.130–0.220) 0.250 (0.170–0.310) 1,271
2007–2008 0.061 (0.057–0.066) 0.060 (0.050–0.060) 0.090 (0.080–0.100) 0.140 (0.130–0.160) 0.210 (0.160–0.260) 1,327
2009–2010 0.055 (0.050–0.060) 0.050 (0.050–0.060) 0.080 (0.070–0.100) 0.130 (0.120–0.150) 0.190 (0.160–0.210) 1,397
2011–2012 0.054 (0.050–0.058) 0.051 (0.048–0.057) 0.078 (0.071–0.089) 0.132 (0.120–0.151) 0.186 (0.161–0.224) 1,261
Females 1999–2000 0.137 (0.117–0.161) 0.131 (0.108–0.164) 0.213 (0.176–0.247) 0.320 (0.263–0.417) 0.429 (0.357–0.485) 1,144
2001–2002 0.139 (0.131–0.148) 0.132 (0.124–0.140) 0.196 (0.178–0.211) 0.295 (0.267–0.317) 0.371 (0.333–0.444) 1,355
2003–2004 * <LOD 0.143 (0.125–0.161) 0.225 (0.188–0.261) 0.288 (0.250–0.333) 1,277
2005–2006 0.074 (0.070–0.078) 0.070 (0.070–0.070) 0.110 (0.100–0.110) 0.170 (0.150–0.190) 0.220 (0.180–0.300) 1,305
2007–2008 0.067 (0.062–0.071) 0.060 (0.060–0.070) 0.100 (0.090–0.100) 0.140 (0.130–0.160) 0.200 (0.160–0.230) 1,300
2009–2010 0.064 (0.060–0.069) 0.060 (0.060–0.070) 0.090 (0.090–0.100) 0.150 (0.130–0.170) 0.220 (0.180–0.260) 1,450
2011–2012 * 0.066 (<LOD–0.071) 0.104 (0.094–0.112) 0.165 (0.145–0.193) 0.226 (0.183–0.303) 1,241
Race/ethnicity
Mexican 1999–2000 0.120 (0.107–0.135) 0.114 (0.105–0.129) 0.167 (0.148–0.203) 0.250 (0.209–0.315) 0.333 (0.280–0.357) 787
Americans 2001–2002 0.138 (0.128–0.149) 0.130 (0.117–0.143) 0.182 (0.159–0.203) 0.269 (0.229–0.308) 0.338 (0.308–0.429) 682
2003–2004 0.086 (0.076–0.098) 0.082 (<LOD–0.092) 0.129 (0.107–0.151) 0.189 (0.154–0.238) 0.238 (0.185–0.321) 618
2005–2006 0.087 (0.076–0.099) 0.080 (0.070–0.080) 0.120 (0.110–0.130) 0.190 (0.150–0.310) 0.370 (0.200–0.800) 652
2007–2008 0.069 (0.059–0.081) 0.060 (0.050–0.080) 0.100 (0.080–0.120) 0.160 (0.130–0.180) 0.200 (0.160–0.360) 515
2009–2010 0.066 (0.063–0.071) 0.060 (0.060–0.060) 0.100 (0.080–0.110) 0.160 (0.130–0.190) 0.240 (0.190–0.280) 613
2011–2012 0.063 (0.059–0.067) 0.061 (0.057–0.064) 0.089 (0.079–0.100) 0.133 (0.121–0.153) 0.183 (0.150–0.246) 317
Non-Hispanic 1999–2000 0.114 (0.099–0.133) 0.112 (0.098–0.130) 0.163 (0.144–0.183) 0.236 (0.195–0.338) 0.343 (0.255–0.425) 554
blacks 2001–2002 0.123 (0.113–0.134) 0.115 (0.106–0.127) 0.163 (0.150–0.181) 0.233 (0.208–0.267) 0.300 (0.248–0.373) 667
2003–2004 0.078 (0.071–0.085) 0.074 (0.069–0.082) 0.109 (0.096–0.124) 0.170 (0.148–0.192) 0.222 (0.179–0.257) 723
2005–2006 0.064 (0.058–0.071) 0.060 (0.050–0.070) 0.090 (0.080–0.090) 0.130 (0.120–0.150) 0.190 (0.150–0.220) 692
2007–2008 0.062 (0.059–0.066) 0.060 (0.050–0.070) 0.090 (0.080–0.090) 0.140 (0.120–0.160) 0.180 (0.160–0.220) 589
2009–2010 0.058 (0.053–0.063) 0.060 (0.050–0.060) 0.080 (0.070–0.090) 0.130 (0.110–0.160) 0.170 (0.150–0.190) 544
2011–2012 0.055 (0.049–0.060) 0.052 (0.047–0.058) 0.077 (0.069–0.088) 0.121 (0.104–0.147) 0.175 (0.140–0.232) 669










    
    



























































         
         
 
   






6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-8.  Geometric Mean and Selected Percentiles of Urinary Antimony (Creatinine Corrected) (in μg/g of

Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES)
 
Survey Geometric mean	 Selected percentiles (95% CI) Sample 
years (95% CI) 50th 75th 90th 95th size
Non-Hispanic 	 1999–2000 0.129 (0.109–0.152) 0.125 (0.102–0.152) 0.195 (0.167–0.225) 0.298 (0.239–0.352) 0.400 (0.333–0.444) 768
whites	 2001–2002 0.127 (0.117–0.138) 0.120 (0.113–0.130) 0.176 (0.159–0.198) 0.280 (0.241–0.317) 0.380 (0.318–0.471) 1,132
2003–2004 * 0.081 (<LOD–0.089) 0.139 (0.124–0.147) 0.217 (0.200–0.238) 0.286 (0.253–0.333) 1,074
2005–2006 0.072 (0.068–0.077) 0.070 (0.060–0.070) 0.110 (0.100–0.110) 0.170 (0.150–0.190) 0.230 (0.190–0.280) 1,041
2007–2008 0.064 (0.060–0.069) 0.060 (0.050–0.070) 0.090 (0.080–0.100) 0.140 (0.140–0.160) 0.210 (0.170–0.230) 1,095
2009–2010 0.060 (0.055–0.065) 0.060 (0.050–0.060) 0.090 (0.080–0.100) 0.140 (0.120–0.170) 0.200 (0.170–0.250) 1,225
2011–2012 * 0.060 (<LOD–0.067) 0.097 (0.088–0.108) 0.161 (0.135–0.183) 0.224 (0.181–0.273) 818
All Hispanics	 2011–2012 * 0.058 (<LOD–0.065) 0.085 (0.073–0.097) 0.132 (0.113–0.161) 0.181 (0.153–0.214) 573
Asians	 2011–2012 * <LOD 0.087 (0.072–0.107) 0.153 (0.132–0.177) 0.215 (0.171–0.290) 353
<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
 
*Not calculated: proportion of results below limit of detection was too high to provide a valid result.
 
CI = confidence interval
 
Source:  CDC 2015
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6.  POTENTIAL FOR HUMAN EXPOSURE
washed hair samples from 234 healthy individuals reported a geometric mean concentration and standard 
deviation of 0.078 and 2.5 ppm, respectively.  No significant differences between different sexes or age 
groups were noted (Ohmori et al. 1981).
In another Japanese study, hair and nail samples taken from workers at an antimony refinery, nearby
residents, and a control group were analyzed before and after washing with a nonionic, surface-active 
agent in an ultrasonic cleaner (Katayama and Ishide 1987). The respective concentrations of antimony in
the nails of the three groups were 730, 2.46, and 0.19 ppm before washing and 230, 0.63, and 0.09 ppm 
after washing.  The concentrations of antimony in the hair of workers before and after washing were 
222 and 196 ppm, respectively.  The concentrations of antimony in the hair of control subjects before and 
after washing were 0.21 and 0.15 ppm, respectively.  Nail samples from 71 Americans contained an 
average of 0.41 ppm of antimony.  Averages for residents of four other countries ranged from 0.28 to
0.70 ppm (Takagi et al. 1988).
Elevated urinary antimony levels were reported in workers exposed to airborne antimony (Bailly et al. 
1991; Iavicoli et al. 2002; Kentner et al. 1995; Liao et al. 2004; Ludersdorf et al. 1987).  A National
Occupational Exposure Survey (NOES) conducted by NIOSH from 1981 to 1983 estimated that
373,460 workers were potentially exposed to antimony (molecular formula unknown) in the United States
in 1981–1983 (NIOSH 1989).  An estimated 226,645 workers were exposed to antimony trioxide, 
antimony sulfide, antimony oxide, antimony pentoxide, antimony dialkyldithiocarbamate, and other
antimony compounds.  The total estimated number of workers exposed to antimony and all of its
compounds was 486,347. These estimates are preliminary since all of the data for trade-name products
that may contain antimony were not analyzed.  The NOES was based on field surveys of 4,490 facilities.
It was designed as a nationwide survey based on a statistical sample of virtually all workplace 
environments in the United States where eight or more persons are employed in all standard industrial
codes (SIC) except mining and agriculture.  The NOES database does not contain information on the
frequency, concentration, or duration of exposure of workers to any of the chemicals listed therein.  These
surveys provide only estimates of the number of workers potentially exposed to chemicals in the
workplace.  EPA states that the NOES figures substantially overestimate occupational exposure to
antimony and compounds (EPA 1983a).
Reported levels of antimony were high in occupationally exposed individuals compared to levels in the
urine of control subjects ranging from 0.18–2.16 µg/L.  Levels ranged from 0.08 to 32.6 µg/L in the urine
of refinery workers, from 0.1 to 36.1 µg/L in chemical manufacturers, and from 1.5 to 149.2 µg/L in
***DRAFT FOR PUBLIC COMMENT***
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battery manufacturers. The authors specified that the levels of antimony were 5 times higher from battery
workers than other workers.  Battery manufacturers were likely exposed to stibine (SbH3) during the
charging process of batteries (Smith et al. 1995).
Concentrations of antimony were examined in the urine of workers at the Punchancavi site in Chile.  
Concentrations of total antimony and Sb(V) were 6–6.3 and 2.4–6.2 µg/L, respectively.  Urine sample 
analysis determined that most samples had concentrations of total antimony and Sb(V) that were below
the limit of detection.  No Sb(III) was found in the samples (Quiroz et al. 2011).
6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.8, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume than adults.  A child’s diet often differs from that of
adults.  The developing human’s source of nutrition changes with age: from placental nourishment to 
breast milk or formula to the diet of older children who eat more of certain types of foods than adults.  A
child’s behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their
mouths, sometimes eat inappropriate things (such as dirt or paint chips), and may spend more time
outdoors.  Children also are generally closer to the ground and have not yet developed the adult capacity
to judge and take actions to avoid hazards (NRC 1993).
The NHANES 1999–2012 reported antimony levels in urine (see Tables 6-7 and 6-8) for children in 
different age groups (CDC 2015).  Infant urinary antimony levels reported in the scientific literature are 
similar to those reported for young children in Fourth National Report on Human Exposures to 
Environmental Chemicals (CDC 2009).  Antimony levels >1 µg/L were found in 4% of 126 term infants;
7% had levels <0.02 µg/L and 90.5% had levels <0.5 µg/L (Dezateux et al. 1997). Higher levels of
antimony were found in postmortem liver and serum samples from infants who died as a result of sudden 
infant death syndrome (Cullen et al. 1998; Jenkins et al. 1998).  Mean serum antimony concentrations
ranged from 0.16 to 0.18 µg/L for 100 healthy infants, 2–56 weeks old.  Urinary antimony concentrations
were not detected in 5% of the infants, median urinary antimony concentrations were 0.42 ng/mg
creatinine, and 95% of the infants had antimony concentrations <2.6 ng/mg creatinine.
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6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
In discussing exposure to antimony, it is important to consider what form of antimony a person is exposed 
to and its availability.  High concentrations of antimony may be found in the contaminated soil and 
sediment.  In water, the pentavalent state is predominant, although significant levels of trivalent antimony
and methylated antimony compounds exist.  People who live or work near sources of antimony such as
smelters, coal-fired power plants, and refuse incinerators may be exposed to high levels of antimony in 
airborne dust, soil, and vegetation.  People who live near or work at waste sites that receive slag from
smelters or fly ash from power plants and refuse incinerators may also be exposed to higher than
background levels.  Exposure routes would include either inhalation of contaminated air or ingestion of
contaminated soil or vegetation.  Similarly, people who are exposed to soot and smoke in fires, such as 
firefighters, may be exposed to high levels of antimony.  Occupational exposure to antimony appears to 
be highest for those involved in the production and processing of antimony and antimony oxide.  Workers
in battery-forming areas of lead-storage battery plants may be exposed to high levels of stibine.
6.8  ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of antimony is available.  Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of antimony.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. For inorganic salts, the solubility product coupled with stability
constants for the ionic species in solution are the factors determining how much of the compound goes
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into solution; the solubility in terms of the number of milligrams of the parent compound in solution, as
used for organic compounds, is not meaningful.  All of the solubility products and stability constants for
antimony and its compounds, required for determining the antimony species in natural water and their
concentrations, are not available.  Other physical and chemical properties in Table 4-2 for which there are
no data are generally not well defined for antimony and its compounds or are not useful in determining
their environmental fate.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency Planning
and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit
substance release and off-site transfer information to the EPA.  The TRI, which contains this information 
for 2014, became available in March of 2016.  This database is updated yearly and should provide a list of
industrial production facilities and emissions.
Information on the production, import, and use of antimony and antimony trioxide is readily available
(Carapella 1978; Grund et al. 2012; Llewellyn 1989; Plunkert 1982; USGS 2004, 2015).  However, 
information on the production, import, and use patterns of other antimony compounds is not available, 
and is needed to assess human exposure to these compounds.  Except for the recycling of batteries, little
information is available concerning the disposal of antimony and its compounds. More detailed 
information regarding the form of antimony that is disposed of and the disposal methods is necessary to 
assess the potential exposure to these compounds.
Environmental Fate. In assessing human exposure, the form (valence state, compound, adsorption, 
coprecipitation, particle size) of antimony and its availability must be considered.  This information is site 
specific and is not always available in the literature.
Bioavailability from Environmental Media. Antimony is poorly absorbed following inhalation and 
oral exposure (Felicetti et al. 1979a, 1979b; Gerber et al. 1982; Thomas et al. 1973).  Dermal exposure to 
high levels of antimony trioxide resulted in death in rabbits (Myers et al. 1978).  The application area was
occluded, suggesting that at least some forms of antimony can be absorbed through the skin.  Although 
there is no information on the absorption efficiency of antimony from environmental media in humans, 
there is evidence in animals that it is absorbed. The vegetation and soils at sites near antimony smelters 
are heavily contaminated with antimony.  Elevated levels of antimony in various tissues were observed in
animals living near the smelter (Ainsworth et al. 1990).  An animal study designed to measure the rate of
***DRAFT FOR PUBLIC COMMENT***
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absorption of antimony from environmental media would be useful in assessing the toxicological
significance of levels of antimony in the air and soil near hazardous waste sites.
Food Chain Bioaccumulation. Studies indicate that phytoremediation is possible with accumulation
and uptake of antimony in plants (Anawar et al. 2011; Baceva et al. 2014; Pan et al. 2010; Tschan et al. 
2008, 2009).  Studies on fish and aquatic organisms indicate that the bioconcentration of antimony is low;
however, the studies are older (Callahan et al. 1979; EPA 1980; Maher 1986).  Newer studies on the
bioconcentration of antimony in fish and biomagnification in higher trophic levels of animals are needed.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of antimony in 
contaminated media at hazardous waste sites are needed so that the information obtained on levels of
antimony in the environment can be used in combination with the known body burden of antimony to 
assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste
sites.
Levels of antimony in the water, soil, and sediment are dependent on the site.  Levels of antimony in the
air in Japan were found to be highest from brake abrasion dust (Iijima et al. 2009).  Concentrations of
antimony in water were higher near ore and mining sites.  Levels of antimony in the soil and sediment
were dependent on the distance from the source of contamination; higher levels were found for soil depths
of 0–5 cm (near the surface) and in sediment found upstream (near the site) (Filella et al. 2009b; Migon 
and Mori 1999).
Exposure Levels in Humans. Antimony has been detected in urine, blood, hair, and nails in 
individuals exposed to background levels of antimony (CDC 2015; Miekeley et al. 1998; Takagi et al.
1986, 1988).  Antimony is one of the chemicals measured in urine samples collected from NHANES
participants; the most recent data are from the 2011–2012 survey.  More recent data are needed to assess 
occupational exposure of humans to antimony.  A NOES was conducted; however, the data were from
1981–1983 (NIOSH 1989).
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Antimony levels were measured in urinary samples from NHANES
participants ≥6 years old; however, biomonitoring data are not available for younger children.  
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6.  POTENTIAL FOR HUMAN EXPOSURE
Monitoring studies are needed for infants and young children particularly since there is the potential for
exposure from clothing and household items treated with antimony containing flame retardants.  
Child health data needs relating to susceptibility are discussed in Section 3.13.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. The information amassed in the National Exposure Registry facilitates the 
epidemiological research needed to assess adverse health outcomes that may be related to exposure to this 
substance; however, no exposure registries for antimony were located.  Antimony is not currently one of
the compounds for which a sub-registry has been established in the National Exposure Registry.
Antimony will be considered in the future when chemical selection is made for sub-registries to be 
established.  
6.8.2 Ongoing Studies 
No ongoing environmental fate studies for antimony or antimony compounds were identified using the
NIH RePORTER (2015) database.
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The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring antimony, its metabolites, and other biomarkers of exposure and effect to 
antimony.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the
analytical methods used for environmental samples are the methods approved by federal agencies and
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other
methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
7.1  BIOLOGICAL MATERIALS
Methods for the analytical determination of antimony in biological materials are similar to those used for
environmental samples.  Methodological differences are a function of the level of antimony in the sample,
digestion procedures required to solubilize the sample, and level of potentially interfering substances in
the type of sample.  Antimony occurs at very low levels in biological samples. The accurate
determination of trace levels of antimony in these samples may require special methods (e.g., neutron 
activation) that are both sensitive and selective.
Atomic absorption spectroscopy (AAS) and inductively coupled plasma-atomic emission spectroscopy
(ICP-AES), with or without preconcentration or separation steps, are the most commonly employed 
methods.  Atomic absorption has three variant methods involving direct aspiration into a flame, 
atomization in an electrically heated carbon rod, or generation of stibine that is then passed into a heated 
silica tube.
Instrumental neutron activation analysis (INAA), with or without chemical separation, has very good 
sensitivity and selectivity for antimony, and it has the advantage of being able to measure many elements 
simultaneously.  However, it is slow, costly, and requires special facilities.  INAA is favored for surveys 
where trace levels of many elements are to be determined.  It is often required for measuring antimony in
tissues in which the antimony level is very low. The neutron activation analysis of antimony requires an
exposure to neutron fluxes for 6 hours to 2 days.  After the exposure period, the samples are kept for
several days before counting.  This allows the activity of short half-lived isotopes to decline, and thus
***DRAFT FOR PUBLIC COMMENT***
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improves accuracy of the analysis (Iyengar et al. 1978).  Nondestructive INAA can be used to measure 
concentrations to levels somewhat below 1 ppm.  Nondestructive methods are not only advantageous
because of reduced sample handling, but also because they are independent of the sample matrix and of
the efficiency of the digestion or extraction procedure.  While this is generally adequate for antimony
determinations in hair and lung tissues, the antimony levels in blood serum and kidney tissues are usually
too low to measure without preconcentration (Iyengar et al. 1978).  Detection limits may be limited by
interferences from matrix elements such as sodium, potassium, phosphorus, and bromine.  Lower
detection limits (approximately 0.006 ppm) can be obtained by digestion and solvent extraction to 
eliminate interferences (Mok and Wai 1988).
Determining which form of antimony (usually Sb(III) and Sb(V)) is present in a sample is difficult;
however, methods have been developed to do so in both biological and environmental samples. 
Speciation is possible with the use of anion exchange liquid chromatography (post-column photo-
oxidation) and hydride generation atomic fluorescence spectrometry (high-performance liquid 
chromatography-ultraviolet-hydride generation-atomic fluorescence spectrometry [HPLC-(UV) -HG-
AFS]) as the detection system (De Gregori et al. 2007; Quiroz et al. 2011).
Sector field-high resolution-inductively coupled plasma-mass spectrometry (SF-HR-ICP-MS) was used to
determine the antimony concentration in gunshot residues on hands.  SF-HR-ICP-MS is a selective 
method with high sensitivity.  The SF-HR-ICP-MS method is useful for detecting antimony at very low
concentrations in samples (Sarkis et al. 2007).  Analytical methods and detection limits for antimony in 
biological materials are provided in Table 7-1.  Antimony contained in biological materials such as hair
and nails can be determined by using the same analytical techniques as for blood and tissue, but suitable 
procedures for dissolving the sample matrix must be used (Takagi et al. 1986, 1988).
7.2  ENVIRONMENTAL SAMPLES 
Analytical methods for measuring antimony in environmental samples generally determine the total 
antimony content of the sample. Separate procedures for determining specific antimony compounds have
been developed.  Acid digestion to assure release of antimony from the sample matrix is a crucial step in
the analysis of environmental samples.  Unless the particular type of sample has been well studied, it is
usually important to experiment with different digestion procedures.  For the release of antimony from
***DRAFT FOR PUBLIC COMMENT***
   
 








   
 




































   
 

















    




Table 7-1. Analytical Methods for Determining Antimony in Biological Materials
Analytical Sample Percent
Sample matrix Preparation method method detection limit recovery Reference
Blood, tissue, or Acid digestion Method 8005, No data 106% at NIOSH 1985
haira ICP-AESb 10 µg 
antimony
Gunshot residue Extraction and dilution SF-HR-ICP- No data No data Sarkis et al.
on hand MSb 2007
Pine needles Digestion ICP-AESb 0.41 µg/L 85% Anderson 
(tissue) and Isaacs
1995
Marine biota (algae Extraction, centrifugation, HPLC-(UV)- 0.007 µg /L 96–107% De Gregori
and mollusks) evaporation HG-AFSc et al. 2007
Urine, serum, Acid digestion ICP-MSb 0.0.1 µg//L No data Delves et al.




Urine Microwave digestion HPLC-HG-AFSc 0.01 µg/L No data Quiroz et al.
2011
Feces Digest with concentration Graphite No data 96.9%, Bio/Dynamic











AAS = atomic absorption spectrometry; AES = atomic emission spectroscopy AFS = atomic fluorescence 

spectrometry; HCl = hydrochloric acid; HG = hydride generation; HNO3 = nitric acid; HPLC = High-performance liquid 

chromatography; HR = high resolution; ICP = inductively coupled plasma; MS = mass spectrometry; SF = sector
 
field; UV = ultraviolet
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soil, hydrogen fluoride mixed with perchloric acid or another strong acid is generally required.  In the
determination of trace metals, major concerns include contamination and loss.  Contamination can be 
introduced from impurities in reagents, containers, or laboratory dust.  Losses may also occur due to 
adsorption of the analyte onto container walls.  In the case of antimony, a common source of loss is 
volatilization during acid digestion or ashing in an AAS furnace.  Losses are prevented by application of a 
procedure that utilizes acid digestion in a closed-vessel microwave digestion system.  Microwave 
digestion prevents the escape, and thus the loss, of the volatile antimony compounds.  Insoluble antimony 
silicate is dissociated with the aid of the hydrogen fluoride (Amereih et al. 2005).
The most common methods used for analysis of antimony in environmental samples are AAS with either
flame or graphite furnace and ICP-AES.  Calorimetric methods were used for the determination of
antimony before the widespread use of AAS.  The best known calorimetric method is the rhodamine B
method in which a pink complex is formed when pentavalent antimony reacts with rhodamine B in the
presence of an excess of chloride ions (APHA 1972).  The complex is extracted into an organic solvent
and the absorbance measured at 565 nm.  Trivalent antimony must be oxidized to the pentavalent state
with nitric, sulfuric, and perchloric acids. Water and waste water samples can be analyzed for antimony
by EPA Test Methods 220.1 (atomic absorption, direct aspiration), 220.2 (atomic absorption, furnace
technique), and 200.7 (inductively coupled plasma-atomic emission spectroscopy) (EPA 1983b).  These
methods are suitable for groundwater, surface water, and domestic and industrial effluents.
In open ocean water and in other water samples with a low antimony concentration, pre-concentration 
and/or separation procedure involving co-precipitation, chelation, selective adsorption, or hydride
formation is required before analysis (Andresen and Salbu 1982; Apte and Howard 1986; Maher 1986;
Sturgeon et al. 1985).  The atomic absorption wavelength used for antimony is 217.6 nm.  In the presence
of lead concentrations of the order of 1 g/L, however, a spectral interference may occur at this resonance 
line, and the line at 231.1 nm should be used instead. The spectral absorption of antimony is reduced 
when the concentration of acid increases using direct aspiration.  Therefore, it is important to match the
concentration of acid in standards and samples (EPA 1983b).  Laser-induced fluorescence in graphite 
furnace (LIF-GIF) with intensified charge coupled device (ICCD) detection is also utilized for
environmental samples (water and sediment).  Due to its high sensitivity, this method can detect antimony
at very low concentrations in the sample (Enger et al. 1995).
Similarly, liquid chromatography-HG-AFS is utilized for antimony speciation in environmental samples
(tap water, river water, etc.). The method has low detection limits and is effective in determining which 
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species of antimony is present.  Detection limits were 0.9, 0.5, and 0.7 µg/L for Sb(III), Sb(V), and 
TMSbCl2, respectively (Vinas et al. 2006).  Flow injection-HG-AAS was also utilized in the speciation of
antimony in environmental water samples.  This method has a low detection limit and is low in cost
(Zheng et al. 2006).
Analytical methods and detection limits for antimony in environmental media are provided in Table 7-2.
7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of antimony is available. Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health
effects) of antimony.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.
Exposure.  Methods for determining antimony in biological materials are well developed, and there are
methods available to most laboratories that are satisfactory for testing biological samples that naturally
contain high concentrations of antimony for occupational exposure testing (Delves et al. 1997; NIOSH
1985; Quiroz et al. 2011).  Antimony can occur at very low levels in many biological materials; thus,
methods such as INAA that require special facilities must often be used to achieve adequate sensitivity
(Iyengar et al. 1978).  Standardized methods are available from NIOSH and other sources to measure 
antimony in blood, urine, and tissue (Delves et al. 1997; NIOSH 1985; Quiroz et al. 2011).  Several
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Sample Preparation Analytical Sample Percent
matrix method method detection limit recovery Reference
Soil Dried, microwave HPLC-ID-ICP- No data No data Amereih et al. 2005
digestion MS
Marine Dilution, IF-GF-ICCD 3x10-8 µg No data Enger et al. 1995
sediment acidification with
nitric acid
Soil, Digestion with Method 3050 No data 3% EPA 1986
sediment, 4:1 HNO3 and HCla (modified)a accuracy at
sludge, solid ICP-AES 33 ppm
waste antimony
Soil and Suspension GFAAS 0.03 µg/g No data Lopez-Garcia et al.
sediment 1997
Food Acid digestion and INAA 0.1–0.3 ppb No data Cunningham 1987
resin separation 
following irradiation
aThe digestion procedure in Method 3050 is not suitable for antimony.  A satisfactory digestion procedure has
 
been proposed by Kimbrough and Wakakuwa (1989).
 
AAS = atomic absorption spectrometry; AES = atomic emission spectroscopy; GF = graphite furnace;
 
GFAAS = graphite furnace atomic absorption spectrometry; HCl = hydrochloric acid; HG = hydride generation;
 
HgCl2 = mercuric chloride; HNO3 = nitric acid; HPLC = high-performance liquid chromatography;
 
ICCD = intensified charge coupled device; ICP = inductively coupled plasma; ID = isotopic dilution;
 
INAA = instrumental neutron activation analysis; LC = liquid chromatography; LIF = laser-induced fluorescence;
 
MS = mass spectrometry; NaI = sodium iodide; NIOSH = National Institute for Occupational Safety and Health;
 
Sb(V) = antimony (+5)
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authors have reported that antimony concentrations in hair, nails, blood, or urine are elevated in exposed 
individuals (Katayama and Ishidi 1987); blood and urine levels are considered suitable biomarkers of
exposure for antimony. Available analytical methods are capable of determining the levels of antimony
in these media in both background and occupationally exposed persons.
Effect. No biomarkers of effect were identified for antimony.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. Methods for determining antimony in environmental media are well developed and adequate.  
Standardized methods are available from EPA, NIOSH, and other sources (Amereih et al. 2005; APHA 
1972; Cunningham 1987; De Doncker et al. 1983; de la Calle-Guntinas et al. 1991; Enger et al. 1995;
EPA 1983a, 1986; NIOSH 1987; Vinas et al. 2006; Zheng et al. 2006).  Since most analytical methods
measure total antimony, the methods for analyzing for the parent compound and degradation product are
identical.
7.3.2 Ongoing Studies 
No ongoing studies for examining analytical methods to detect antimony or antimony compounds were
identified using the NIH RePORTER (2015) database.
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8. REGULATIONS, ADVISORIES, AND GUIDELINES
 
MRLs are substance specific estimates that are intended to serve as screening levels. They are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
An acute-duration inhalation MRL of 0.001 mg Sb/m3 was derived for antimony.  The MRL is based on a 
BMCLHEC of 0.035 mg Sb/m3 calculated from the incidence data for squamous metaplasia of the 
epiglottis in mice (NTP 2016) and an uncertainty factor of 30 (3 for extrapolation from animals to humans
using dosimetric adjustments and 10 for human variability).
A chronic-duration inhalation MRL of 0.0003 mg Sb/m3 was derived for antimony.  The MRL is based on 
a BMCLHEC of 0.008 mg Sb/m3 calculated from the incidence data for chronic lung inflammation in
female rats (Newton et al. 1994) and an uncertainty factor of 30 (3 for extrapolation from animals to 
humans using dosimetric adjustments and 10 for human variability).
An acute-duration oral MRL of 1 mg Sb/kg/day was derived based on a NOAEL of 99 mg Sb/kg/day for
focal ulceration of the forestomach in mice (NTP 1992) and an uncertainty factor of 100 (10 for
extrapolation from animals to humans and 10 for human variability).
An intermediate-duration oral MRL of 0.0006 mg Sb/kg/day was derived based on a NOAEL of
0.064 mg Sb/kg/day for decreased serum glucose levels in rats (Poon et al. 1998) and an uncertainty
factor of 100 (10 for extrapolation from animals to humans and 10 for human variability).
The international and national regulations, advisories, and guidelines regarding antimony in air, water,
and other media are summarized in Table 8-1.
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Antimony
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification IARC 2015
Antimony trisulfide Group 3a 
Antimony trioxide Group 2Bb 
WHO Air quality guidelines No data WHO 2010
Drinking water quality guidelines WHO 2011
(antimony and compounds)
Guideline value 0.02 mg/L (20 µg/L)c 




ACGIH TLV (8-hour TWA) ACGIH 2015
Antimony and compounds 0.5 mg/m3 
Antimony trioxide Le 
Stibine 0.1 ppm




DOE PACs DOE 2012a
PAC-1f 
Antimony 0.5 mg/m3 
Antimony pentasulfide 2.5 mg/m3 
Antimony potassium tartrate 1.7 mg/m3 
Antimony trichloride 0.94 mg/m3 
Antimony trioxide 0.6 mg/m3 
Stibine 0.14 ppm
PAC-2f 
Antimony 0.5 mg/m3 
Antimony pentasulfide 22 mg/m3 
Antimony potassium tartrate 1.7 mg/m3 
Antimony trichloride 0.94 mg/m3 
Antimony trioxide 0.6 mg/m3 
Stibine 1.5 ppm
PAC-3f 
Antimony 80 mg/m3 
Antimony pentasulfide 130 mg/m3 
Antimony potassium tartrate 220 mg/m3 
Antimony trichloride 150 mg/m3 
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Antimony




Antimony trioxide 96 mg/m3 
Stibine 9.6 ppm



















Hazardous air pollutant (antimony Yes EPA 2013a
compounds) 42 USC 7412
NIOSH REL (up to 10-hour TWA) NIOSH 2015a,
Antimony and compounds 0.5 mg/m3 2015b
Stibine 0.1 ppm (0.5 mg/m3)
IDLH
Antimony and compounds 50 mg/m3 
Stibine 5 ppm
OSHA PEL (8-hour TWA) for general 0.5 mg/m3 OSHA 2013
industry (antimony and compounds) 29 CFR 1910.1000,
Table Z-1
PEL (8-hour TWA) for shipyards 0.5 mg/m3 OSHA 2014
(antimony and compounds) 29 CFR 1915.1000
Table Z
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Antimony
Agency Description Information Reference
NATIONAL (cont.)
b. Water
EPA Designated as hazardous substances
in accordance with Section
EPA 2013b
40 CFR 116.4





Drinking water standards and health 
advisories (antimony)
EPA 2012
1-day health advisory for a 10-kg 
child
0.01 mg/L




Life-time health advisory 0.006 mg/L
National primary drinking water
standards
EPA 2009
MCL (antimony) 0.006 mg/L
National recommended water quality
criteria: human health for the 
EPA 2015b
consumption of
Water plus organism 5.6 µg/L
Organism only 640 µg/L
Reportable quantities of hazardous
substances designated pursuant to 
Section 311 of the Clean Water Act
No data EPA 2013c
40 CFR 117.3





FDA EAFUS No datai FDA 2013
Allowable level for antimony in bottled 
water
0.006 mg/L FDA 2014
21 CFR 165.110
d. Other
ACGIH Carcinogenicity classification ACGIH 2015
Antimony and compounds No data
Antimony trioxide A2j 
Stibine No data
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Antimony
Agency Description Information Reference
NATIONAL (cont.)
EPA Carcinogenicity classification No data IRIS 1987, 1995
RfC
Antimony trioxide 2 x 10-4 mg/m3 
RfD
Antimony 4 x 10-4 mg/kg/day
Superfund, emergency planning, and 
community right-to-know




TSCA chemical lists and reporting 
periods
No data EPA 2014
40 CFR 712.30
DHHS Carcinogenicity classification No data NTP 2014
aGroup 3: not classifiable as to carcinogenicity to humans.
 
bGroup 2B: possibly carcinogenic to humans.
 
cConcentrations in groundwater <0.001 µg/L; concentrations in surface water <0.2 µg/L; and concentrations in 

drinking water appear to be <5 µg/L.

dBased on a NOAEL of 6.0 mg/kg body weight per day for decreased body weight gain and reduced food and water
 
intake in a 90-day study in which rats were administered potassium antimony tartrate in drinking water, using an 





eEndnote L: Exposure by all routes should be carefully controlled to levels as low as possible.
 




hNR = not recommended due to insufficient data.
 
iThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 

additives or listed or affirmed as GRAS.
 
jA2: Suspected human carcinogen.
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
 
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response,
 
Compensation, and Liability Act; CFR = Code of Federal Regulations; DHHS = Department of Health and Human 

Services; DOE = Department of Energy; DWEL = drinking water equivalent level; EAFUS = Everything Added to 

Food in the United States; EPA = Environmental Protection Agency; ERPG = emergency response planning 

guidelines; EAFUS = Everything Added to Food in the United States; FDA = Food and Drug Administration;
 
GRAS = Generally Recognized As Safe; IARC = International Agency for Research on Cancer; IDLH = immediately
 
dangerous to life or health; IRIS = Integrated Risk Information System; MCL = maximum contaminant level;
 
NAS = National Academy of Sciences; NIOSH = National Institute for Occupational Safety and Health;
 
NOAEL = no-observed-adverse-effect level;NRC = National Research Council; NTP = National Toxicology Program;
 
OSHA = Occupational Safety and Health Administration; PAC = Protective Action Criteria; PEL = permissible
 
exposure limit; RCRA = Resource Conservation and Recovery Act; REL = recommended exposure limit;
 
RfC = inhalation reference concentration; RfD = oral reference dose; TDI = tolerable daily intake; TLV = threshold 
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221ANTIMONY AND COMPOUNDS
10.  GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study— A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-control study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without the outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
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Ceiling Value—A concentration that must not be exceeded. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that, if met, would reduce the uncertainties of
human health risk assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—A condition that poses a threat of life or health, or
conditions that pose an immediate threat of severe exposure to contaminants that are likely to have 
adverse cumulative or delayed effects on health.  
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.
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Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of new cases of individuals in a population who develop a specified condition to 
the total number of individuals in that population who could have developed that condition in a specified 
time period.
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study,
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
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Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
hazardous substance.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
regulatory limit on the amount or concentration of a substance not to be exceeded in workplace air
averaged over any 8-hour work shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests (insects or other organisms harmful to cultivated plants or animals).
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
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10.  GLOSSARY
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as blood:air partition coefficients, and metabolic parameters.  PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a hazardous substance.  The toxicity may be directed to the reproductive organs and/or
the related endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual
behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the
integrity of this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
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Risk—The possibility or chance that some adverse effect will result from a given exposure to a hazardous 
substance.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, existing health 
condition, or an inborn or inherited characteristic that is associated with an increased occurrence of
disease or other health-related event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—A STEL is a 15-minute TWA exposure that should not be
exceeded at any time during a workday.  
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance  to which it is believed that nearly all workers may be repeatedly
exposed, day after day, for a working lifetime without adverse effect. The TLV may be expressed as a 
Time Weighted Average (TLV-TWA), as a Short-Term Exposure Limit (TLV-STEL), or as a ceiling
limit (TLV-C).
Time-Weighted Average (TWA)—An average exposure within a given time period.  
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any substance that is foreign to the biological system.
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A-1ANTIMONY AND COMPOUNDS
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified route and
duration of exposure.  MRLs are based on noncancer health effects only and are not based on a
consideration of cancer effects. These substance-specific estimates, which are intended to serve as
screening levels, are used by ATSDR health assessors to identify contaminants and potential health
effects that may be of concern at hazardous waste sites.  It is important to note that MRLs are not
intended to define clean-up or action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach. They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure.  MRLs are generally based on the most sensitive substance-induced
endpoint considered to be of relevance to humans.  Serious health effects (such as irreparable damage to 
the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that
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are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public.  They 
are subject to change as new information becomes available concomitant with updating the toxicological
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop
F-57, Atlanta, Georgia 30329-4027.
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APPENDIX A




Profile Status: Draft for Public Comment
Route: [X] Inhalation   [ ] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 5
Species: Mice
Minimal Risk Level:  0.001   [ ] mg/kg/day  [X] mg Sb/m3 
Reference: NTP.  2016.  Toxicology and carcinogenicity studies of antimony trioxide (CAS No. 1309-64-
4) in Wistar HAN [Crl:WI (Han)] rats and B6C3F1/N mice (inhalation studies).  National Toxicology
Program, Research Triangle Park, NC.  NTP TR 590. Draft for Peer Review.
Experimental design:  Groups of five male and five female B6C3F1/N mice were exposed to 0, 3.75, 7.5, 
15, 30, or 60 mg/m3 antimony trioxide (0, 3.1, 6.3, 12, 25, and 50 mg Sb/m3) 6 hours/day, 5 days/week for
13 exposures in a 17-day period.  An additional group of five female mice was similarly exposed and held 
for a 28-day recovery period.  The actual concentrations were 3.71, 7.43, 14.7, 30.2, and 59.4 mg
Sb2O3/m3. The MMADs (geometric standard deviations) for the particles were 1.4 (1.9), 1.3 (1.9), 
1.5 (1.9), 1.4 (1.9), and 1.4 (1.9) μm for the 3.1, 6.3, 12, 25, and 50 mg Sb/m3 concentrations, 
respectively.  The following parameters were used to assess toxicity: twice daily observations; body
weights on days 1, 6, 13, and at termination; organ weights (kidney, liver, lung, testis, thymus); and
histopathological examination in the control and 50 mg Sb/m3 group (histopathological examinations of
the larynx, lung, lymph nodes, nose, pharynx, and trachea were conducted to a no-effect level).  In the
animals allowed to recover, antimony levels were measured in blood samples collected at the end of the 
exposure and recovery periods and in the lungs.
Although the mice were exposed to antimony trioxide over a 17-day period, the animals were only
exposed for 13 times and the study was considered to more reflective of effects associated with acute-
duration exposure than intermediate-duration exposure. 
Effect noted in study and corresponding doses: No deaths, clinical findings, or alterations in body weight
gain were observed.  Significant increases in absolute lung weights were observed in males at ≥6.3 mg
Sb/m3 and in females at ≥12 mg Sb/m3; increases in relative lung weights were observed in males at
50 mg Sb/m3 and in females at ≥3.1 mg Sb/m3.  Minimal to mild squamous metaplasia was observed in 
the epiglottis epithelium at ≥25 mg Sb/m3; the incidences were 0/10 in controls and 2/10, 4/9, 10/10, and
10/10 in the 6.3, 12, 25, and 50 mg Sb/m3 groups, respectively.  Increases in the presence of foreign body
(presumably antimony trioxide) were observed in the lungs of mice exposed to ≥3.1 mg Sb/m3. No 
concentration-related alterations in lung clearance were observed. The clearance half-times ranged from
47 to 62 days.
Dose and end point used for MRL derivation: The MRL is based on a BMCL10 of 0.94 mg Sb/m3 for 
squamous metaplasia of the epiglottis in male and female mice.
[ ] NOAEL   [ ] LOAEL  [X] BMCL10 
Several end points were considered for derivation of an acute-duration inhalation MRL for antimony:
altered EKGs and degenerative changes in the heart in rabbits exposed to 19.9 mg Sb/m3 as antimony
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trisulfide (Brieger et al. 1954), lung inflammation in rabbits exposed to 19.9 mg Sb/m3 as antimony
trisulfide (Brieger et al. 1954), squamous metaplasia of the epiglottis in male and female rats exposed to 
≥25 mg Sb/m3 as antimony trioxide (NTP 2016), chronic lung inflammation in rats exposed to ≥25 mg
Sb/m3 as antimony trioxide (NTP 2016), and squamous metaplasia of the epiglottis in male and female
mice exposed to ≥12 mg Sb/m3 as antimony trioxide (NTP 2016).  
For the NTP (2016) study, the incidence data (Table A-1) for squamous metaplasia in rats and mice were 
fit to all available dichotomous models in EPA’s BMDS (version 2.6.0) using the extra risk option.  
Adequate model fit was judged by three criteria:  goodness-of-fit statistics (p-value >0.1), visual
inspection of the dose-response curve, and scaled residual at the data point (except the control) closest to
the predefined benchmark response (BMR).  Among all of the models providing adequate fit to the data, 
the lowest BMCL (95% lower confidence limit on the benchmark concentration) was selected as the POD
when the difference between the BMCLs estimated from these models was >3-fold; otherwise, the BMCL
from the model with the lowest Akaike’s Information Criterion (AIC) was chosen.  For all lesion types, a
BMR of 10% was used.  Since the response level for chronic inflammation was the same for all non-
control concentrations (see Table A-1), BMD modeling was not conducted for this end point and the
NOAEL was used as the POD.  The model predictions for the epiglottal squamous metaplasia for rats and
mice are presented in Tables A-2 and A-3 and the fits of the selected models are presented in Figures A-1 
and A-2.  The Brieger et al. (1954) study only tested one concentration of antimony trisulfide, and was
not considered suitable for BMD modeling; the LOAEL of 19.9 mg Sb/m3 for lung and cardiovascular
effects was considered the POD for this study.  
Table A-1.  Incidence of Respiratory Tract Effects in Male and Female Rats and
 




6.3 12 25 50
Rats















Squamous metaplasia of epiglottis
(male and female)
0/10 –d 2/10 4/9c 10/10c 10/10c 
aMale and female incidences were combined.
 
bIncidence in the female rats was 1/5; males were not examined at these concentrations.
 
cSignificantly different from controls.

dIncidence in the female mice was 2/5; males were not examined at this concentration.
 
***DRAFT FOR PUBLIC COMMENT***



























   
          
          
          
          
          
          
          
          












     




Table A-2.  Model Predictions for the Incidence of Squamous Metaplasia of the




Goodness- Dose Dose BMC10 BMCL10 













Gammac 2 1.04 0.60 0.00 -0.49 0.83 37.76 7.77 4.18
Logistic 2 3.09 0.21 -0.28 1.41 1.41 40.25 16.36 10.83
LogLogisticd,e 2 0.90 0.64 0.00 -0.46 0.75 37.62 8.47 2.95
LogProbitd 3 0.99 0.80 0.00 -0.16 0.78 35.68 10.99 7.27
Multistage (1-degree)f 3 1.03 0.79 0.00 -0.59 0.79 35.78 6.79 4.17
Multistage (2-degree)f 3 1.03 0.79 0.00 -0.59 0.79 35.78 6.79 4.17
Multistage (3-degree)f 3 1.03 0.79 0.00 -0.59 0.79 35.78 6.79 4.17
Probit 2 2.86 0.24 -0.22 1.38 1.38 39.91 15.35 10.31
Weibullc 2 1.04 0.59 0.00 -0.53 0.82 37.77 7.40 4.17
aValues <0.1 fail to meet conventional goodness-of-fit criteria.
 
bScaled residuals at doses immediately below and above the BMC; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSlope restricted to ≥1.
eSelected model.  All models provided adequate fit to the data. BMCLs for models providing adequate fit were not
sufficiently close (differed by >3-fold).  Therefore, the model with lowest BMCL was selected (Log Logistic).
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
ND = not determined, goodness-of-fit criteria, p<0.10; ND (LS) = not determined; largest scaled residual >2
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Figure A-1.  Fit of LogLogistic Model to Data on Incidence of Epiglottal Squamous
 
Metaplasia in Male and Female Rats Exposed to Antimony Trioxide (mg Sb/m3)
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Table A-3.  Model Predictions for the Incidence of Squamous Metaplasia of the 




Goodness- Dose Dose BMC10 BMCL10 













Gammac 3 1.04 0.79 0.00 0.48 -0.71 27.68 5.49 2.39
Logistic 3 0.85 0.84 -0.43 0.62 0.62 27.48 5.83 3.53
LogLogisticd 3 1.77 0.62 0.00 0.66 -0.86 28.64 5.79 3.17
LogProbitd 3 1.55 0.67 0.00 0.56 -0.89 28.31 5.73 3.25
Multistage (1-degree)e,f 4 4.22 0.38 0.00 -1.16 -1.16 30.45 1.40 0.94
Multistage (2-degree)e 4 0.70 0.95 0.00 0.05 0.59 25.41 4.41 1.74
Multistage (3-degree)e 3 0.27 0.97 0.00 0.24 -0.36 26.73 4.34 1.60
Multistage (4-degree)e 3 0.06 1.00 0.00 0.12 0.15 26.46 3.56 1.49
Probit 3 0.59 0.90 -0.34 0.51 0.51 27.12 5.48 3.28
Weibullc 3 0.61 0.89 0.00 0.48 -0.51 27.08 5.33 2.40
aValues <0.1 fail to meet conventional goodness-of-fit criteria.
 
bScaled residuals at doses immediately below and above the BMC; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSlope restricted to ≥1.
eBetas restricted to ≥0.
fSelected model.  All models provided adequate fit to the data. BMCLs for models providing adequate fit were not
sufficiently close (differed by >3-fold).  Therefore, the model with lowest BMCL was selected (Multistage 1 degree).
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
ND = not determined, goodness-of-fit criteria, p<0.10; ND (LS) = not determined; largest scaled residual >2
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Figure A-2.  Fit of 1-Degree Multistage Model to Data on Incidence of Epiglottal
Squamous Metaplasia in Male and Female Mice Exposed to Antimony Trioxide 
(mg Sb/m3)
























A summary of the potential PODs (BMCLs for the selected models, LOAELs, or NOAELs for models
without adequate fit) is presented in Table A-4.  
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Table A-4.  Summary of Potential Points of Departures (PODs) and Human 





PODs RDDR HECsb 
End point (reference) (mg Sb/m3) valuesa (mg Sb/m3)
Squamous metaplasia of the epiglottis in male and female rats 2.95 (BMCL10) 0.162c 0.085
(NTP 2016)
Chronic lung inflammation (NTP 2016) 12 (NOAEL) 0.545c 1.1
Squamous metaplasia of the epiglottis in male and female mice 0.94 (BMCL10) 0.206c 0.035
(NTP 2016)
Lung inflammation in rabbits (Brieger et al. 1954) 19.9 (LOAEL) 0.203d 1.2
Degenerative changes in heart and altered EKG readings in 19.9 (LOAEL) 1.060d 6.2 
rabbits (Brieger et al. 1954)
aRDDR values specific for each region of the respiratory tract (extrathoracic and pulmonary) were calculated using 

EPA’s RDDR calculator with the average of the male and female terminal body weights of 0.189 and 0.0281 kg for
 
rats and mice, respectively, and 4.0 kg for rabbits.

bHEC calculated by multiplying the duration-adjusted POD (POD x 6 hours/24 hours x 5 days/7 days for the NTP
 
[2016] study and POD x 7 hours/24 hours x 5 days/7 days for the Brieger et al. [1954] study) by the RDDR value.
 
cCalculated using a particle size of 1.4 μm (sigma g of 1.9).
 
dCalculated using a particle size of 2 μm (sigma g of 1.9); this is an assumed value; the investigators noted that most
 
of the particles were <2 μm, but did not provide any additional information.
 
BMCL = 95% lower confidence limit on the benchmark concentration; EKG = electrocardiogram;
 
EPA = Environmental Protection Agency; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-
adverse-effect level; NTP = National Toxicology Program; RDDR = regional deposited dose ratio 

Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  3 for extrapolation from animals to humans with dosimetric adjustments
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
HECs were calculated for each potential POD by adjusting for intermittent exposure (6 hours/24 hours, 
5 days/7 days for NTP [2016] and 7 hours/day for Brieger et al. [1954]) and multiplying the PODADJ by 
the RDDR for the appropriate region of the respiratory tract. The RDDRs were calculated using EPA’s 
RDDR calculator with the calculated average male and female terminal body weights of 0.189 and
0.0281 kg for rats and mice, respectively, for the NTP (2016) study and a reference body weight of 4.0 kg
for the rabbits.  The PODHEC values are presented in Table A-4.  
Was a conversion used from intermittent to continuous exposure? Yes, see previous section.
Other additional studies or pertinent information that lend support to this MRL: No human studies have
evaluated the acute inhalation toxicity of antimony.  In laboratory animals, the acute toxicity has been 
evaluated for stibine, antimony trisulfide, and antimony trioxide.  These studies clearly identify the
respiratory tract as one of the most sensitive targets of antimony toxicity (Brieger et al. 1954; NTP 2016;
Price et al. 1979).  A 30-minute exposure to 1.395 mg Sb/m3 as stibine resulted in pulmonary edema and
congestion and death in rats and guinea pigs (Price et al. 1979).  Chronic lung inflammation was observed 
***DRAFT FOR PUBLIC COMMENT***
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in rabbits exposed to 19.9 mg Sb/m3as antimony trisulfide for 5 days (7 hours/day) and in rats exposed to 
25 mg Sb/m3 as antimony trioxide for 12 exposures over a 16-day period (6 hours/day) (NTP 2016).  NTP
(2016) also found squamous metaplasia in the epiglottis of rats and mice exposed to 25 or 12 mg Sb/m3, 
respectively.  The primary extrarespiratory effects also observed following acute exposure were 
degenerative changes in the heart and altered EKG readings in rabbits exposed to 19.9 mg Sb/m3 as 
antimony trisulfide.
There are limited data for comparing the relative toxicity of antimony compounds following acute
inhalation exposure.  The respiratory tract was a sensitive target in animals exposed to stibine, antimony
trioxide, or antimony trisulfide, but differences in the study designs do not allow for a direct comparison.  
Additionally, there are no data to allow for an assessment of the influence of valence state on the 
respiratory toxicity of antimony.
Agency Contact (Chemical Manager): Melanie Buser 
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Profile Status: Draft for Public Comment
Route: [X] Inhalation   [ ] Oral
Duration: [ ] Acute   [ ] Intermediate  [X] Chronic
Graph Key: 18
Species: Rats
Minimal Risk Level:  0.0003   [ ] mg/kg/day  [X] mg Sb/m3 
Reference: Newton PE, Bolte HF, Daly IW, et al.  1994.  Subchronic and chronic inhalation toxicity of
antimony trioxide in the rat.  Fundam Appl Toxicol 22(4):561-576.
Experimental design: Groups of 65 male and 65 female Fischer 344 rats were exposed to 0, 0.06, 0.51, or
4.50 mg/m3 antimony trioxide dust (0, 0.05, 0.43, or 3.8 mg Sb/m3, respectively) 6 hours/day, 
5 days/week for 12 months followed by a 12-month observation period.  Groups of five rats/sex were 
terminated after 6 and 12 months of exposure and at 6 months postexposure; the remaining animals were
terminated 12 months postexposure.  The MMAD was 3.76±0.84 µm with a geometric standard deviation
of 1.79±0.326. The following parameters were used to assess toxicity:  weekly detailed observations,
body weight measurements (weekly for the first 13 weeks and monthly thereafter), ophthalmoscopic
examination, hematological (hemoglobin, hematocrit, erythrocyte count, mean corpuscular hemoglobin, 
hemoglobin concentration, and volume, and total leukocyte counts) and clinical chemistry (aspartate 
aminotransferase, alanine aminotransferase, alkaline phosphatase, blood urea nitrogen, fasting glucose, 
total protein, chloride, sodium, and potassium) indices assessed at 12, 18, and 24 months, and 
histopathological examination of the heart, nasal turbinates, larynx, trachea, lung, and peribronchial
lymph nodes.
Effect noted in study and corresponding doses: No increases in mortality were observed.  Corneal effects 
were observed during the study; however, the investigators noted that the effects were equally distributed 
among exposed and control groups and were similar to spontaneous degenerative conditions observed in 
Fischer 344 rats. The investigators noted a concentration-related increase in the occurrence of
chromodacryorrhea (incidence data not provided); they noted that microscopic periodontal disease was 
also observed in some rats and that the chromodacryorrhea may be secondary to this effect.  At the end of
the recovery period, an increase in the occurrence of cataracts (focal posterior cataract, posterior
subcapsular cataract, complete cataract) was observed (incidences of 6/55, 12/49, 18/64, and 19/60 were
reported in Bio/Dynamics 1990); the incidence was statistically significant at ≥0.43 mg Sb/m3 (Fisher 
Exact Test conducted by SRC).  No treatment-related alterations in body weight gain, hematological 
indices, clinical chemistry indices, or lung weights were observed.  At the end of the exposure period and 
at the end of the recovery period, statistically significant (Fisher Exact Test conducted by SRC) increases 
in the incidence of alveolar/intraalveolar macrophages were observed at ≥0.05 mg Sb/m3.  Histological 
alterations were observed in the lungs of rats killed at the end of the recovery periods: chronic interstitial
inflammation at 0.43 (females only) and 3.8 mg Sb/m3 and interstitial fibrosis at 3.8 mg Sb/m3. Although 
a high incidence of lung inflammation was also observed in controls, the investigators noted that the
inflammation observed in the controls was considered a “spontaneous lesion” and that the incidence and
severity of the inflammation was concentration-related (see Table A-5).  Increases in antimony trioxide 
lung clearance half-times were observed; the half-times (data reported in Bio/Dynamics 1990) in the male
and female rats were 3.0 and 4.2 months, respectively, at 0.43 mg Sb/m3 and 8.7 and 10.2 months, 
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respectively, at 3.8 mg Sb/m3, as compared to 2.5 and 2.2 months, respectively, in the 0.05 mg Sb/m3 
group.  No significant increases in the incidence of neoplastic lesions were observed.
Table A-5.  Incidence and Severity of Chronic Interstitial Lung Inflammation in 
Rats Exposed to Antimony Trioxide for 1 Year with a 1-Year Recovery
(Newton et al. 1994)
Concentration (mg Sb/m3)
Severity 0 0.05 0.43 3.8
Males
Minimal 4/52 (12.5)a 7/52 (18.9) 12/53 (33.3) 0/52 (0)
Slight 19/52 (59.4) 27/52 (73) 24/53 (66.7) 14/52 (29.2)
Moderate 8/52 (25) 3/52 (8.1) 0/53 (0) 32/52 (66.7)
Moderately severe 1/52 (3.1) 0/52 (0) 0/53 (0) 2/52 (3.8)
Females
Minimal 3/49 (9.1) 12/52 (30) 14/54 (29.1) 1/50 (2.1)
Slight 24/49 (72.7) 23/52 (57.5) 23/54 (47.9) 29/50 (60.4)
Moderate 6/49 (18.2) 5/52 (12.5) 11/54 (22.9) 18/50 (37.5)
Moderately severe 0/49 (0) 0/52 (0) 0/54 (0) 0/50 (0)
aPercentage of total lesions with a specific severity score.
Dose and end point used for MRL derivation: BMCL10 of 0.10 mg Sb/m3 (BMCLHEC of 0.008 mg Sb/m3) 
for lung inflammation in female rats.
[ ] NOAEL   [ ] LOAEL [X] BMCL10
Four studies identified LOAEL values of <5 mg Sb/m3 for lung effects in rats (Newton et al. 1994; NTP
2016; Watt 1983) and mice (NTP 2016).  Watt (1983) found increases in the incidence of focal fibrosis, 
adenomatous hyperplasia, cholesterol clefts, and pneumocyte hyperplasia in rats exposed to 1.6 mg Sb/m3 
for 55 weeks.  In rats and mice exposed to 2.5 mg Sb/m3 as antimony trioxide for 2 years, inflammation, 
proteinosis, alveolar/bronchiolar hyperplasia, and fibrosis were observed in the lungs (NTP 2016).  An
increase in lung clearance times was observed in rats exposed to 3.8 mg Sb/m3 as antimony trioxide for
12 months and an increase in the severity and incidence of chronic lung inflammation was observed at
0.43 (females only) and 3.8 mg Sb/m3 was after a 1-year recovery period (Newton et al. 1994).  Some
non-respiratory effects have also been seen at similar concentrations, including lenticular degeneration in
rats exposed to 0.43 mg Sb/m3 (Newton et al. 1994), bone marrow hyperplasia in mice exposed to 2.5 mg
Sb/m3 (NTP 2016), and lymphoid hyperplasia in bronchial and/or mediastinal lymph nodes in rats and
mice exposed to 2.5 mg Sb/m3 (NTP 2016).  Newton et al. (1994) identified the lowest LOAEL value for
chronic interstitial lung inflammation and lenticular degeneration in rats exposed to 0.43 mg Sb/m3 for 
1 year with a 1-year recovery period; these effects were not observed at 0.05 mg Sb/m3. The other
chronic-duration studies identified higher LOAEL values.
BMD modeling was utilized to estimate the potential PODs for the histological alterations observed in
lungs and eyes.  The incidence data from the Newton et al. (1994) (Table A-6) studies were fit to all 
available dichotomous models in EPA’s BMDS (version 2.6.0) using the extra risk option.  Adequate
model fit was judged by three criteria:  goodness-of-fit statistics (p-value >0.1), visual inspection of the
dose-response curve, and scaled residual at the data point (except the control) closest to the predefined 
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BMR.  Among all of the models providing adequate fit to the data, the lowest BMCL was selected as the 
POD when the difference between the BMCLs estimated from these models was >3-fold; otherwise, the
BMCL from the model with the lowest AIC was chosen.  The results of the BMD modeling for lung
inflammation in female rats is presented in Table A-7 and the model fit is presented in Figure A-5.  The
incidence data for lung inflammation in males were not considered suitable for modeling since only the
highest concentration group showed a response; thus, the data provide limited information on the shape of
the concentration-response curve.  For lenticular degeneration, none of the available models provided an 
adequate fit to the data.  
Table A-6. Incidence of Nonneoplastic Lesions in Rats Exposed to Antimony
 
Trioxide for 1 Year with a 1-Year Recovery (Newton et al. 1994)
 
Concentration (mg Sb/m3)
Effect 0 0.05 0.43 3.8
Chronic lung inflammation in males 32/52 37/52 36/53 48/52a 
Chronic lung inflammation in females 33/49 40/52 48/54a 48/50a 
Lenticular degeneration 6/55 12/49 18/64a 19/60a 
aSignificantly different from controls.
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Table A-7.  Model Predictions for Antimony Trioxide, Incidence of Chronic Lung 
Inflammation in Female Rats Exposed to Antimony Trioxide for 1 Year with a
1-Year Recovery Period (Newton et al. 1994)
χ2 Scaled residuals
b 
Goodness Dose Dose BMC10 BMCL10 
of fit below above Overall (mg (mg
Model DF χ2 p-valuea BMC BMC largest AIC Sb/m3) Sb/m3)
Gammac.d 2 4.3 0.12 0.13 1.51 1.51 181.03 0.18 0.10
Logistic 2 4.63 0.10 0.07 1.56 1.56 181.38 0.22 0.13
LogLogistice,f 2 1.15 0.56 -0.43 0.44 -0.81 177.59 0.04 0.01
LogProbitd 2 5.21 0.07 0.26 1.47 1.47 181.64 ND ND
Multistage 2 4.3 0.12 0.13 1.51 1.51 181.03 0.18 0.10
(1-degree)g 
Multistage 2 4.3 0.12 0.13 1.51 1.51 181.03 0.18 0.10
(2-degree)g 
Multistage 2 4.3 0.12 0.13 1.51 1.51 181.03 0.18 0.10
(3-degree)g 
Probit 2 4.9 0.09 0.03 1.62 1.62 181.68 ND ND
Weibullc 2 4.3 0.12 0.13 1.51 1.51 181.03 0.18 0.10
aValues <0.1 fail to meet conventional goodness-of-fit criteria.
 
bScaled residuals at doses immediately below and above the BMC; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSelected model. BMCLs for models providing adequate fit were sufficiently close; therefore the model with the 
lowest AIC was selected
eSlope restricted to ≥1.
fModel considered an outlier because the BMCL was 10 times lower than the other models.
gBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMC = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMCL = 95% lower confidence limit on the BMC (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
ND = not determined, goodness-of-fit criteria,  p<0.10; ND (LS) = not determined; largest scaled residual >2
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Figure A-5.  Fit of Gamma Model to Data on Incidence of Lung Interstitial
 
Inflammation in Female Rats Exposed to Antimony Trioxide (mg Sb/m3)
















 0.5 BMDL BMD 
Gamma Multi-Hit 
0  0.5  1  1.5  2  2.5  3  3.5 
dose 
09:21 03/09 2016 
The PODs for each end point are presented in Table A-8; for lung inflammation in males and lenticular
degeneration, the NOAEL was used as the POD since the incidence data were not considered suitable for
BMD modeling.  The lowest PODHEC was 0.008 mg Sb/m3 for lung inflammation in female rats.
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Table A-8.  Summary of Potential Points of Departure (PODs) for Derivation of
 
Chronic-Duration Inhalation MRL for Antimony
 
POD HECb 
End point (reference) (mg Sb/m3) RDDRa (mg Sb/m3)
Chronic interstitial inflammation in male rats (Newton et al. 0.43 (NOAEL) 0.330 0.025
1994)
Chronic interstitial inflammation in female rats (Newton et al. 0.10 (BMCL10) 0.436 0.008
1994)
Lenticular degeneration in rats (Newton et al. 1994) 0.05 (NOAEL) 2.797 0.025
aRDDR values specific for each region of the respiratory tract (pulmonary and extrarespiratory) were calculated using
EPA’s RDDR calculator with reference body weights of 0.380 and 0.229 kg for male and female rats in the Newton et
al. (1994) study and particle size of 3.76 μm (sigma g of 1.79).
bHEC calculated by multiplying the duration-adjusted POD (POD x 6 hours/24 hours x 5 days/7 days) by the RDDR
value.
BMCL = 95% lower confidence limit on the benchmark concentration; HEC = human equivalent concentration;
MRL = Minimal Risk Level; NOAEL = no-observed-adverse-effect level; POD = point of departure; RDDR = regional
deposited dose ratio
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  3 for extrapolation from animals to humans with dosimetric adjustments
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
HECs were calculated for each potential POD by adjusting for intermittent exposure (6 hours/24 hours, 
5 days/7 days) and multiplying the PODADJ by the RDDR for the appropriate region of the respiratory
tract. The RDDRs were calculated using EPA’s RDDR calculator with reference body weights of
0.380 and 0.229 kg for male and female rats and particle size of 3.76 μm (sigma g of 1.79).  The PODHEC 
values are presented in Table A-8.  
Was a conversion used from intermittent to continuous exposure? Yes, see previous section.
Other additional studies or pertinent information that lend support to this MRL:  The toxicity of airborne
antimony has not been extensively studied in humans.  Several occupational exposure studies have 
reported lung effects (pneumoconiosis, chronic bronchitis) in workers at antimony smelters (Cooper et al.
1968; Potkonjak and Pavlovich 1983; Schnorr et al. 1995).  Signs of upper respiratory tract irritation 
including bleeding of the nose, rhinitis, upper airway inflammation, and laryngitis (Potkonjak and 
Pavlovich 1983; Renes 1953) have also been reported in workers.  Other effects that have been observed
in workers include altered EKGs (Brieger et al. 1954) and dermatitis, which is likely due to direct contact 
with skin (Potkonjak and Pavlovich 1983; Renes 1953). One study also reported reproductive
disturbances and developmental effects (decreases in infant growth) in female workers exposed to
metallic antimony, antimony trioxide, and antimony pentasulfide (Belyaeva 1967).  Although some
studies provided exposure levels, these studies were not considered suitable for derivation of chronic
MRLs because many studies did not include control groups, wide ranges of antimony levels were
reported, and many involved co-exposure to other compounds including arsenic.
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A number of studies have evaluated the chronic toxicity of antimony compounds in rats and mice. These 
studies provide strong evidence that the respiratory tract is the primary target of antimony toxicity, which 
is supported by the systematic review of the toxicity data that concluded that respiratory tract toxicity is a
presumed health effect in humans.  The lowest LOAEL values were identified in three studies involving
antimony trioxide exposure for 1–2 years (Newton et al. 1994; NTP 2016; Watt 1983).  Higher LOAELs
for lung effects were identified for other antimony compounds: 17.5 mg Sb/m3 as antimony ore for
interstitial fibrosis (Groth et al. 1986) and 84 mg Sb/m3 as antimony trisulfide for lipoid pneumonia
(Gross et al. 1952).  Although these LOAELs are higher than those identified for antimony trioxide, the
available data do not allow a comparison between compounds since adverse effects were often observed
at the lowest concentration tested.  A summary of the NOAEL and LOAEL values for the respiratory
effects is presented in Table A-9.  In addition to the pulmonary effects, effects have also been observed in 
the lymph nodes (lymphoid hyperplasia in bronchial and mediastinal lymph nodes), eyes (lenticular
degeneration), and bone marrow (hyperplasia); the LOAELs for these effects (see Table A-9) are similar 
to those identified for respiratory effects.
There are limited data to compare the relative toxicity of antimony compounds.  Chronic studies have
tested antimony trioxide, antimony trisulfide, and antimony ore; the respiratory tract was the most
sensitive target in all of these studies.  It is difficult to compare the potency of the different compounds
because in most cases, the lowest concentration tested was a LOAEL.  No data were available to compare 
the toxicity of trivalent and pentavalent antimony compounds.
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Effect NOAEL LOAEL Reference
(mg Sb/m3) (mg Sb/m3)
Chronic interstitial inflammation in female rats exposed to 0.05 4.3 Newton et al.
antimony trioxide for 1 year 1994
Chronic interstitial inflammation in male rats exposed to 0.43 3.8 Newton et al.
antimony trioxide for 1 year 1994
Lenticular degeneration in rats exposed to antimony trioxide 0.05 0.43 Newton et al.
for 1 year 1994
Lipoid pneumonia in rats exposed to antimony trisulfide for 84 Gross et al. 1952
14.5 months
Interstitial fibrosis and alveolar wall hypertrophy and 36 Groth et al. 1986
hyperplasia in rats exposed to antimony trioxide for 1 year
Interstitial fibrosis and alveolar wall hypertrophy and 17.5 Groth et al. 1986
hyperplasia in rats exposed to antimony ore for 1 year
Focal fibrosis, pneumocyte hyperplasia in rats exposed to 1.6 Watt 1983
antimony trioxide for 55 weeks
Lung inflammation, proteinosis, alveolar epithelial 2.5 NTP 2016
hyperplasia, bronchiole epithelial hyperplasia, lung fibrosis in 
rats exposed to antimony trioxide for 2 years
Nasal respiratory epithelial hyperplasia in rats exposed to 2.5 NTP 2016
antimony trioxide for 2 years
Lymphoid hyperplasia in bronchial and mediastinal lymph 2.5 NTP 2016
nodes in rats exposed to antimony trioxide for 2 years
Lung inflammation, alveolar fibrosis, pleural fibrosis and 2.5 NTP 2016
inflammation, alveolar and bronchiolar epithelial hyperplasia 
in mice exposed to antimony trioxide for 2 years
Nasal respiratory epithelial inflammation in mice exposed to 2.5 NTP 2016
antimony trioxide for 2 years
Bone marrow hyperplasia in mice exposed to antimony 2.5 NTP 2016
trioxide for 2 years
Lymphoid hyperplasia of bronchial lymph nodes in mice 2.5 NTP 2016
exposed to antimony trioxide for 2 years
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level
Agency Contact (Chemical Manager): Melanie Buser
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Profile Status: Draft for Public Comment
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 2
Species: Mice
Minimal Risk Level:  1 [X] mg Sb/kg/day  [ ] ppm
Reference:  NTP.  1992.  Toxicology studies of antimony potassium tartrate in F344/N rats and 
B6C3F1/N mice (drinking water and intraperitoneal injection studies).  National Toxicology Program, 
Research Triangle Park, NC.  NTP TOX 11.    
This study is also reported in:  Dieter MP, Jameson CW, Elwell MR.  1991.  Comparative toxicity and 
tissue distribution of antimony potassium tartrate in rats and mice dosed by drinking water or
intraperitoneal injection.  J Toxicol Environ Health 34:51-82.
Experimental design:  Groups of 10 male and 10 female B6C3F1 mice were exposed to 0, 0.30, 0.65, 
1.25, 2.5, or 5.0 mg/mL antimony potassium tartrate (99–100% purity) in drinking water for 14 days. The
investigators used water consumption data and body weight averages to calculate doses of 0, 59, 98, 174, 
273, and 407 mg/kg/day antimony potassium tartrate (0, 21, 36, 63, 99, and 150 mg Sb/kg/day).  The
following parameters were evaluated to assess toxicity:  twice daily observations, body weight
measurements (days 1 and 8 and at termination), water consumption (days 7 or 8 and day 15), organ 
weights, histopathology of major tissues and organs in control and high-dose groups
(five mice/sex/group) and all early deaths, and histopathological examination of the liver and forestomach
of mice in all groups (five mice/sex/group).
Effect noted in study and corresponding doses: One female mouse in the 150 mg Sb/kg/day group died 
prior to the end of the study.  On day 8, decreases in body weight gain were observed in males exposed to 
99 mg Sb/kg/day and in males and females exposed to 150 mg Sb/kg/day.  However, by the end of the
study, the final weights of all antimony groups were within 93% of the controls.  Decreases in water
consumption were observed at all antimony levels.  The investigators noted that overt signs of toxicity
(rough haircoat, emaciation, abnormal posture, hypoactivity, and decreased fecal material, consistent with 
avoidance of the antimony potassium tartrate containing water) were observed, but did not specify if this
was observed in all groups.  Histological alterations were observed in the forestomach and liver of mice in
the 150 mg/kg/day group.  In the forestomach, focal areas of ulceration with necrosis and inflammation of
the squamous mucosa were observed; the incidence was not reported, although the investigators noted 
that gross forestomach lesions were observed in one male and three females.  In the liver, minimal to
moderate cytoplasmic vacuolization was observed in all mice in the 150 mg Sb/kg/day group; the
vacuolization had a centrilobular distribution with some extension into portal areas.
Dose and end point used for MRL derivation: The NOAEL of 99 mg Sb/kg/day for liver lesions was
selected as the POD for the MRL.  
[X] NOAEL   [ ] LOAEL
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A-20ANTIMONY AND COMPOUNDS
APPENDIX A
BMD modeling was not conducted since lesions were only observed in the high-dose group.  The
transient decrease in body weight observed at 99 and 150 mg Sb/kg/day was not selected as the POD
because this decrease may have been the result of decreased water consumption likely due to taste 
aversion.
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  The investigators 
calculated antimony potassium tartrate doses based on water consumption and body weight data.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL:  Studies conducted in the
1920s and 1940s demonstrate that antimony potassium tartrate is a gastrointestinal irritant in humans
(Dunn 1928) and animals (as reviewed by Elinder and Friberg 1986), resulting in vomiting and diarrhea
shortly after exposure.  Houpt et al. (1984) demonstrated that the mean latency to vomit was 30 minutes
after dogs drank 4.8 mg Sb/kg as antimony potassium tartrate. These gastrointestinal effects are likely
due to the antimony concentration rather than the dose.  NTP (1992) evaluated the acute toxicity of
antimony potassium tartrate in 14-day drinking water studies in rats and mice.  In rats, the highest
concentration (61 mg Sb/kg/day) did not result in significant alterations in body weight or
histopathological alterations in major tissues and organs.  In mice, exposure to 150 mg Sb/kg/day resulted 
in focal ulceration in the forestomach and minimal to moderate hepatocellular cytoplasmic vacuolization.
Exposure to 99 and 150 mg Sb/kg/day resulted in a transient decrease in body weight gain; at termination, 
body weights were within 93% of controls. The decreases in body weight may have been secondary to 
the dramatic decrease in water intake, which was also observed in the exposed mice.
Support for identifying the liver as the critical effect for antimony is supported by intermediate-duration 
studies in which histological alterations were observed in rats exposed to antimony metal or antimony
trioxide (Sunagawa 1981) and increases in alanine aminotransferase and aspartate aminotransferase in
humans receiving injections of pentavalent antimony (Andersen et al. 2005).  Insufficient evidence is
available to allow for a comparison of the hepatotoxicity of different antimony compounds or valence 
states. The absorption rate of antimony potassium tartrate is greater than that of other antimony
compounds (ICRP [1981] recommends rates of 10 and 1%, respectively), which likely results in a higher
toxicity.  More side effects (all effects) were observed in patients treated with antimony potassium tartrate 
than with pentavalent antimony compounds, although studies directly comparing the valency states on
antimony hepatotoxicity were not identified.  Alverez et al. (2005) reported greater cardiotoxicity and 
lethality in guinea pigs receiving intramuscular injections of 10 mg Sb/kg/day as antimony potassium
tartrate, as compared to guinea pigs administered 16 mg Sb/kg/day as meglumine antimoniate.
Agency Contact (Chemical Manager): Melanie Buser
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Profile Status: Draft for Public Comment
Route: [ ] Inhalation [X] Oral
Duration: [ ] Acute [X] Intermediate   [ ] Chronic
Graph Key: 10
Species: Rats
Minimal Risk Level:  0.0006  [X] mg Sb/kg/day  [ ] ppm
Reference:  Poon R, Chu I, Lecavalier P, et al. 1998. Effects of antimony on rats following 90-day 
exposure via drinking water.  Food Chem Toxicol 36:21-35.
Experimental design:  Groups of 15 male and 15 female Sprague-Dawley rats were exposed to 0, 0.5, 5, 
50, or 500 ppm antimony as potassium antimony tartrate (99.95% pure) in drinking water for 13 weeks.  
Based on average water consumption and body weight data, the investigators calculated antimony doses 
of 0, 0.06, 0.56, 5.58, and 42.17 mg Sb/kg/day in males and 0, 0.06, 0.64, 6.13, and 45.69 mg Sb/kg/day
in females.  An additional group of 10 male and 10 female rats was exposed to 0 or 500 ppm for 13 weeks
followed by a 4-week recovery period. The following parameters were used to assess toxicity:  weekly
body weight, food consumption, and water intake measurements; hematological indices (erythrocyte
counts hemoglobin, hematocrit, mean corpuscular volume, and total and differential leukocyte counts);
clinical chemistry indices (albumin, alkaline phosphatase, aspartate aminotransferase, creatine kinase,
sorbitol dehydrogenase, bilirubin, calcium, cholesterol, creatinine, glucose, inorganic phosphate, lactic
dehydrogenase, total protein, urea nitrogen, and uric acid); serum thyroxin and thyroid hormone binding
ratio; organ weights (brain, thymus, heart, kidney, spleen, liver); and histopathological examination 
(brain, pituitary, thyroid and trachea, salivary glands, thymus, lung, heart, liver, kidneys, adrenals, spleen, 
pancreas, esophagus, stomach, small and large intestine, urinary bladder, skin, bone marrow, and gonadal
tissues).
Effect noted in study and corresponding doses:  No alterations in survival or overt signs of toxicity were 
observed.  Decreases in water consumption (35% lower than controls) and food consumption (12%) were
observed in the 42.17/45.69 mg Sb/kg/day group during the exposure period but not during the recovery 
period.  
•	 Body weight:  A decrease in body weight gain, significant in males starting at week 6 and females
at week 12, was observed at 42.17/45.69 mg Sb/kg/day; the body weights appeared to be within 
10% of the controls.  A significant increase in relative kidney weights was observed in the 
42.17/45.69 mg Sb/kg/day group.  
•	 Metabolic:  A dose-related decrease (15–17%) in serum glucose levels was observed in females
exposed to ≥0.64 mg Sb/kg/day; lower values were also observed in the males, but were not
statistically different from controls.  No differences in serum glucose levels were observed at the 
end of the recovery period. ATSDR notes that serum glucose levels in all groups (including
controls) were higher than the range of normal values reported by the animal supplier (Charles 
River Laboratories 2006).
•	 Clinical chemistry:  Decreases in serum creatinine levels and alkaline phosphatase levels were 
observed in males and females exposed to 42.17/45.69 mg Sb/kg/day at the end of the exposure
period, but not at the end of the observation period.  A decrease (24%) in serum cholesterol level
***DRAFT FOR PUBLIC COMMENT***










     
 









   
    
    
     
 
   
     
  
   
   
 
     
 
  
   
   
   
 
     
 
 








   
   
  
    
    
   
   
 




was observed in females exposed to 45.69 mg Sb/kg/day; the toxicological significance of this
alteration is not known.  
•	 Hematological:  Decreases in red blood cells and platelet counts and increases in mean
corpuscular volume were observed in males exposed to 42.17 mg Sb/kg/day; in females, the only
hematological alteration was an increase in monocytes at 45.69 mg Sb/kg/day. Significant 
increases in hepatic ethoxyresorufin-O-deethylase and glutathione-S-transferase activities were 
observed in males at 42.17 mg Sb/kg/day; glutathione-S-transferase activity was also increased in
females at 45.69 mg Sb/kg/day.  
•	 Hepatic:  Histological alterations included anisokaryosis in the liver in all antimony exposed 
groups; dose-related increases in the severity were also observed.  Anisokaryosis was also
observed at the end of the recovery period.  Other hepatic effects included an increase in 
hepatocellular portal density in all antimony groups and minimal nuclear hyperchromicity at
≥0.56/0.64 mg Sb/kg/day, but there was not consistent dose-response relationship for this end
point.  The severity scores for the anisokaryosis were 0.1, 0.6, 1.0, 1.9, and 2.8 in the 0, 0.06, 
0.56, 5.58, and 42.17 mg Sb/kg/day males; a severity score of 1 is considered minimal, 2 is mild, 
and 3 is moderate.  In the females, the respective severity scores were 0.9, 1.5, 2.3, 2.3, and 2.6.  
Similarly, the increase in portal density in the hepatocellular cytoplasm was graded as minimal at
the two lowest doses in the males and females and mild at the two highest doses.  The
anisokaryosis, hepatocellular density, and hyperchromicity are considered adaptive changes and
were not considered adverse.
•	 Skeletal:  In the bone marrow, an increase in myeloid hyperplasia was observed at ≥5.58 mg
Sb/kg/day in males and ≥0.64 mg Sb/kg/day in females.  
•	 Spleen: The following alterations were observed in the spleen: sinus congestion at ≥0.56 mg
Sb/kg/day in males, sinus hyperplasia at 42.17 mg Sb/kg/day in males and ≥0.64 mg Sb/kg/day in 
females, and arterial cuff atrophy at 42.17 mg Sb/kg/day in males.  In the recovery period, 
increases in incidence of sinus congestion (males only), arterial cuff atrophy, periarteriolar
lymphocyte sheath cell density, and sinus hematopoiesis were observed.
•	 Endocrine:  Statistically significant increases in thyroid hormone binding ratio were observed in 
females at 6.13 and 45.69 mg Sb/kg/day.  Thyroid histological alterations included an increase in 
epithelial height, reduced follicle size, and nuclear vesiculation in antimony rats; an increased
occurrence of collapsed follicles was observed in the antimony recovery group.  These thyroid
effects did not show a strong dose-response relationship and did not appear to affect thyroid 
function; the investigators did not consider them adverse.
Dose and end point used for MRL derivation:  NOAEL of 0.06 mg Sb/kg/day for decreased serum
glucose in female rats.
[X] NOAEL   [ ] LOAEL
Three studies identified LOAEL values of 0.1–0.64 mg Sb/kg/day in rats exposed to antimony trichloride
or antimony potassium tartrate. The effects observed at these concentrations included altered vasomotor
response in rat pups exposed to antimony trichloride during gestation and/or lactation and on PNDs 22–60 
(Angrisani et al. 1988; Rossi et al. 1987), decreases in pup growth on PNDs 10–60 (Rossi et al. 1987), 
and decreases in serum glucose levels in rats exposed to antimony potassium tartrate for 13 weeks (Poon
et al. 1998).  These three end points were considered for the basis of the intermediate-duration MRL.  
Developmental toxicity and decreases in serum glucose levels were both considered suspected health
effects in humans based on the systematic review of the available data on antimony; of the two
developmental effects, only the decrease in growth was considered due to the uncertainty associated with
estimating the dose for the vasopressor studies.  In these studies, rats were exposed during gestation 
and/or lactation and then exposed on PNDs 22–60; the 0.1 mg Sb/kg/day dose is an estimate of the 
***DRAFT FOR PUBLIC COMMENT***











      
     
    
     
   
    
 
    
      
     
   
    
    
      
   























    
   
   
     
 






postnatal exposure, but does not include an estimate of prenatal exposure or exposure via breastmilk.  
BMD modeling was considered for the decreases in serum glucose levels and decreases in pup body
weight on PNDs 10 and 22. The serum glucose levels (Table A-10) and pup body weights (Table A-11)
were fit to all available continuous models in EPA’s BMDS (version 2.6.0).  The following procedure for
fitting continuous data was used. The simplest model (linear) was first applied to the data while assuming
constant variance.  If the data were consistent with the assumption of constant variance (p≥0.1), then the
fit of the linear model to the means was evaluated and the polynomial, power, and Hill models were fit to
the data while assuming constant variance.  Adequate model fit was judged by three criteria: goodness-of-
fit p-value (p>0.1), visual inspection of the dose-response curve, and scaled residual at the data point
(except the control) closest to the predefined BMR.  Among all of the models providing adequate fit to
the data, the lowest BMCL was selected as the POD when the difference between the BMCLs estimated
from these models was >3-fold; otherwise, the BMCL from the model with the lowest AIC was chosen.  
If the test for constant variance was negative, the linear model was run again while applying the power
model integrated into the BMDS to account for nonhomogenous variance.  If the nonhomogenous
variance model provided an adequate fit (p≥0.1) to the variance data, then the fit of the linear model to the
means was evaluated and the polynomial, power, and Hill models were fit to the data and evaluated while
the variance model was applied.  Model fit and POD selection proceeded as described earlier.  If the test
for constant variance was negative and the nonhomogenous variance model did not provide an adequate
fit to the variance data, then the data set was considered unsuitable for modeling.  For all models, a BMR
of 1 standard deviation change from the control was used.  
Table A-10.  Serum Glucose Concentrations in Female Rats Exposed to Antimony
Potassium Tartrate for 13 Weeks (Poon et al. 1998)






aSignificantly different from controls
Table A-11. Alterations in Pup Body Weight on Postnatal Days (PNDs) 10 and 22 
in Pups Exposed to Antimony Trichloride During Gestation and Lactation (Rossi
et al. 1987)
Pup body weight (mean ± standard error)
Dose (mg Sb/kg/day) PND 10 PND 22
0 23±1.8 (73)a 58±5.1 (66)
0.07 20±2.6 (80) 52±4.0 (72)
0.7 17±0.4b (63) 31±2.8b (56)
aNumber in parentheses is the number of pups examined; data were not presented in a way that would allow
analysis on a per-litter basis
bSignificantly different from controls
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None of the models provided adequate fit to the serum glucose data or the PND 10 body weight data.  
Although adequate statistical fit was found for the PND 22 body weight data (model results are presented
in Table A-12), the BMDL for the model with the lowest AIC (Exponential, model 3) was 0.72 mg
Sb/kg/day, which is the same value as the empirical LOAEL identified in the study and was not
considered a suitable basis for an MRL. Thus, a NOAEL/LOAEL approach was utilized to identify the
POD for the intermediate-duration oral MRL. The NOAEL and LOAEL values for the decreased serum
glucose level and the decreased pup body weight were similar and the end point with the lowest LOAEL
(decreased serum glucose level) was selected as the basis of the MRL.
Table A-12.  Model Predictions for Antimony, Alterations in Pup Body Weight on 

Postnatal Day (PND) 22 in Pups Exposed to Antimony Trichloride During 

Gestation and Lactation (Rossi et al. 1987)
 
Scaled residualscTest for
significant Dose Dose BMD1SD BMDL1SD 
difference Variance Means below above Overall (mg/kg/ (mg/kg/ 
Model p-valuea p-valueb p-valueb BMD BMD largest AIC day) day)
Constant variance
Lineare <0.0001 <0.0001 0.54 0.05 NA -0.44 1,562.44 NA NA
Nonconstant variance
Exponential
(model 2)d <0.0001 0.61 0.27 0.03 NA -0.31 1,540.28 1.32 0.86
Exponential






Linearf <0.0001 0.61 0.20 0.00 NA 0.39 1,540.70 1.07 0.81
Polynomial
(2-degree)f <0.0001 0.61 0.20 0.00 NA 0.39 1,540.70 1.07 0.80
Powerd <0.0001 0.61 0.20 0.00 NA 0.39 1,540.70 1.07 0.71
aValues >0.05 fail to meet conventional goodness-of-fit criteria.

bValues <0.10 fail to meet conventional goodness-of-fit criteria.
 
cScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose.

dPower restricted to ≥1.
eSelected model.  Constant variance model did not provide adequate fit to the variance data. With nonconstant
variance model applied, all models (except for the Exponential 4, and 5, and Hill models) provided adequate fit to the 
means. BMDLs for models providing adequate fit were sufficiently close (differed by <2–3-fold), so the model with 
the lowest AIC was selected (Exponential 3; the Exponential 2 and 3 had the same AIC, so the model with the more 
conservative BMDL was selected out of these two).
fCoefficients restricted to be negative.
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); NA = not applicable;
ND = not determined (BMDL computation failed); SD = standard deviation
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Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Investigators 
calculated antimony potassium tartrate doses based on water consumption and body weight data.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL:  Several studies have 
evaluated the intermediate-duration toxicity of antimony compounds.  Observed effects include
reductions in body weight gain, hematological effects (alterations in red blood cell and platelet levels),
decreases in serum glucose levels, thyroid (epithelial alterations), and developmental effects (decreased
pup body weight and altered vasomotor response in pups).  The results of several 12–24-week studies 
provide evidence for compound-specific differences in toxicity that are likely reflective of differences in
the relative absorption of the compounds.  More soluble compounds such as antimony potassium tartrate
and antimony trichloride appear to be more toxic than antimony trioxide; see Table A-13 for a list of
LOAELs for different antimony compounds.  
Based on the limited available data, the toxicity of antimony potassium tartrate appears to be higher than 
antimony metal and antimony trioxide, which is likely due to the differences in absorption. ICRP (1981)
recommends an absorption rate of 10% for antimony potassium tartrate and 1% for all other antimony
compounds. A study (Alkhawajah et al. 1996) comparing the developmental toxicity of antimony
trichloride (trivalent), sodium stibogluconate (pentavalent), and meglumine antimonate (pentavalent) in 
rats following intramuscular injections reported similar effects for the three compounds; although no 
direct comparisons were made, the magnitude of the alterations (decreases in fetal viability and body
weight) appears to be similar for the three compounds.
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APPENDIX A
Table A-13.  List of NOAEL and LOAEL Values in Rats Exposed to Antimony or
 
Antimony Compounds for Intermediate Durations
 
NOAEL LOAEL
Effect, duration (reference) Compound (mg Sb/kg/day) (mg Sb/kg/day)
Altered vasomotor response in pups Antimony trichloride in 0.1
exposed during lactation (maternal dose drinking water (post-weaning
was 0.8 mg Sb/kg/day) and post-lactation dose)
on PNDs 22–60 (Angrisani et al. 1988) 
Altered vasomotor response in pups Antimony trichloride in 0.1
exposed during gestation and lactation drinking water (post-weaning
(maternal dose was 0.7 mg Sb/kg/day) and dose)
post-lactation on PNDs 22–60 (Rossi et al.
1987)
Decreased pup growth on PNDs 10–60 in Antimony trichloride in 0.07 0.7
pups exposed during gestation, lactation, drinking water
and postnatally (Rossi et al. 1987)
Decreases in serum glucose in female rats Antimony potassium 0.06 0.64
exposed for 13 weeks (Poon et al. 1998) tartrate in drinking 
water
Decreased red blood cell count in male rats Antimony metal in diet 620
exposed for 24 weeks (Sunagawa 1981)
Cloudy swelling in hepatic cords in male Antimony metal in diet 620
rats exposed for 24 weeks (Sunagawa 
1981)
Increased disorder of hepatic cords in male Antimony trioxide in 370 740
rats exposed for 24 weeks (Sunagawa diet
1981)
No alterations in hematological, serum Antimony trioxide in 1,408
clinical chemistry, or histopathology of diet
major tissues and organs in rats exposed 
for 13 weeks (Hext et al. 1999)
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level
Agency Contact (Chemical Manager): Melanie Buser
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ANTIMONY B-1
APPENDIX B.  FRAMEWORK FOR ATSDR’S SYSTEMATIC REVIEW OF 

HEALTH EFFECTS DATA FOR ANTIMONY
 
To increase the transparency of ATSDR’s process of identifying, evaluating, synthesizing, and 
interpreting the scientific evidence on the health effects associated with exposure to antimony, ATSDR
utilized a slight modification of NTP’s Office of Health Assessment and Translation (OHAT) systematic 
review methodology (NTP 2013, 2015; Rooney et al. 2014).  ATSDR’s framework is an eight-step
process for systematic review with the goal of identifying the potential health hazards of exposure to 
antimony:
• Step 1.  Problem Formulation
• Step 2.  Literature Search and Screen for Health Effects Studies
• Step 3.  Extract Data from Health Effects Studies
• Step 4.  Identify Potential Health Effect Outcomes of Concern
• Step 5.  Assess the Risk of Bias for Individual Studies
• Step 6.  Rate the Confidence in the Body of Evidence for Each Relevant Outcome
• Step 7. Translate Confidence Rating into Level of Evidence of Health Effects
• Step 8.  Integrate Evidence to Develop Hazard Identification Conclusions
B.1  PROBLEM FORMULATION
The objective of the toxicological profile and this systematic review was to identify the potential health
hazards associated with inhalation, oral, or dermal/ocular exposure to antimony.  The inclusion criteria 
used to identify relevant studies examining the health effects of antimony are presented in Table B-1. 
Data from human and laboratory animal studies were considered relevant for addressing this objective.
Human studies were divided into two broad categories:  observational epidemiology studies and 
controlled exposure studies.  The observational epidemiology studies were further divided:  cohort studies
(retrospective and prospective studies), population studies (with individual data or aggregate data), and 
case-control studies.
B.2  LITERATURE SEARCH AND SCREEN FOR HEALTH EFFECTS STUDIES
A literature search and screen was conducted to identify studies examining the health effects of antimony.  
Studies for other sections of the toxicological profile were also identified in the literature search and
screen step.  Although these studies were not included in the systematic review process, the results of
some studies (e.g., parenteral administration, mechanistic studies, toxicokinetic studies) were considered 
in the final steps of the systematic review. ATSDR primarily focused on peer-reviewed articles without
publication date or language restrictions.  Non-peer-reviewed studies that were considered relevant to the 
assessment of the health effects of antimony have undergone peer review by at least three ATSDR-
selected experts who have been screened for conflict of interest.
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ANTIMONY B-3
APPENDIX B
B.2.1  Literature Search
The following databases were searched in February 2015; the literature search was intended to update the
existing toxicological profile for antimony (ATSDR 1992), and thus, the literature search was restricted to
studies published between January 1990 to February 2015:
• PubMed 
• National Library of Medicine’s TOXLINE
• Scientist and Technical Information Network’s TOXCENTER
• National Pesticide Information Retrieval System (NPIRS)
• Toxic Substances Control Act Test Submissions (TSCATS) and TSCATS2 
Review articles were identified and used for the purpose of providing background information and 
identifying additional references.  ATSDR also identified reports from the grey literature, which included 
unpublished research reports, technical reports from government agencies, conference proceedings and 
abstracts, and theses and dissertations.
The search strategy used the chemical name, CAS numbers (i.e., 7440-36-0, 1315-04-4, 1314-60-9, 
28300-74-5, 10025-91-9, 1309-64-4, 1345-04-6, 7803-52-3) synonyms, and Medical Subject
Headings (MeSH) terms for antimony.  A total of 5,489 records were identified and imported into 
EndNote (version 5).  After the identification and removal of 546 duplicates by EndNote, the
remaining 4,943 records were moved to the literature screening step.  
B.2.2  Literature Screening 
A two-step process was used to screen the literature search results to identify relevant studies examining
the health effects of antimony:
• Title and Abstract Screen
• Full Text Screen
Title and Abstract Screen. Within the Endnote library, titles and abstracts were screened manually for
relevance.  Studies that were considered relevant were moved to the second step of the literature
screening process.  Studies were excluded when the title and abstract clearly indicated that the study did
not meet the inclusion criteria (Table B-1).  In the Title and Abstract Screen step, 4,946 records were
reviewed; 71 studies were considered relevant to Section 3.2 of the toxicological profile and were moved 
to the next step in the process.  
Full Text Screen. The second step in the literature screening process was a full text review of individual
studies considered relevant in the Title and Abstract Screen step.  Each study was reviewed to determine 
whether it met the inclusion criteria; however, the quality of the studies was not evaluated at this step of
the process.  In addition to these 71 studies identified in the update literature search, 68 studies cited in 
the supplemental document for the existing profile were included in the full study screen, bringing the
total number of studies for the qualitative review to 139.  Of the 139 studies undergoing Full Text Screen, 
98 studies did not meet the inclusion criteria; some of the excluded studies were used as background 
information on toxicokinetics or mechanisms of action or were relevant to other sections of the
toxicological profile. 
A summary of the results of the literature search and screening is presented in Figure B-1.
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Total Number of Records: 5,489 
Duplicates Found and Removed: 546 
Number of Records Screened: 4,943 
Number of Records Excluded as Not Relevant: 4,872 
Number of Articles Screened: 71 
Number of Articles Excluded for Criteria: 98 
Number of Studies for Qualitative Review: 41 
Number of Previous Cited Studies Added: 68 
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B.3  EXTRACT DATA FROM HEALTH EFFECTS STUDIES
Relevant data extracted from the individual studies selected for inclusion in the systematic review were 
collected in customized data forms in Distiller.  A summary of the type of data extracted from each study
is presented in Table B-2.  For references that included more than one experiment or species, data
extraction records were created for each experiment or species.
A summary of the extracted data for each study is presented in the Supplemental Document for Antimony
and overviews of the results of the inhalation, oral, dermal exposure studies are presented in Section 3.2
of the profile and in the Levels Significant Exposures tables in Section 3.2 of the profile (Tables 3-1, 3-3, 
and 3-5, respectively).
B.4  IDENTIFY POTENTIAL HEALTH EFFECT OUTCOMES OF CONCERN 
Overviews of the potential health effect outcomes for antimony identified in human and animal studies
are presented in Tables B-3 and B-4, respectively. The available human studies examined a limited
number of end points and reported respiratory, cardiovascular, gastrointestinal, musculoskeletal, 
immunological, reproductive, and developmental effects.  Animal studies examined a number of end 
points following inhalation, oral, or dermal exposure.  These studies examined most systemic end points
and reported respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal,
endocrine, dermal, ocular, body weight, and metabolic effects.  Additionally, animal studies have reported 
immunological, reproductive, and developmental effects.  
Respiratory, cardiovascular (damage to the myocardium and/or EKG alterations), gastrointestinal, 
metabolic (alterations in blood glucose levels), and developmental effects were considered sensitive 
outcomes, i.e., effects were observed at low concentrations or doses.  Studies examining these potential
outcomes were carried through to Step 4 of the systematic review.
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Table B-2.  Data Extracted From Individual Studies
Citation
Chemical form
Route of exposure (e.g., inhalation, oral, dermal)
Specific route (e.g., gavage in oil, drinking water)
Species
Strain
Exposure duration category (e.g., acute, intermediate, chronic)
Exposure duration
Frequency of exposure (e.g., 6 hours/day, 5 days/week)
Exposure length
Number of animals or subjects per sex per group 
Dose/exposure levels
Parameters monitored
Description of the study design and method
Summary of calculations used to estimate doses (if applicable)
Summary of the study results
Reviewer’s comments on the study
Outcome summary (one entry for each examined outcome)
No-observed-adverse-effect level (NOAEL) value
 
Lowest-observed-adverse-effect level (LOAEL) value
 
Effect observed at the LOAEL value
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Observational 2(1) 3 1 2 1 1 2
2 3 1 1 1 1 1
Experimental
Oral studies
Observational 1 3(0) 1 1 1 1 1 2a 2






Number of studies examining end point 0 1 2 3






Numbers in parentheses represent those studies looking at the specific cardiovascular end points of interest to this systematic review (damage 
to the myocardium and/or EKG alterations).
aOne study (Zheng et al. 2014) was excluded because it measured risk of “adverse pregnancy outcome” but did not provide information on the 
end points examined and was not considered suitable for the systematic review.
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6 6 6 7 4 7
2(1) 2 3 1 3




Intermediate-duration 4 2 2 1 5 1 1
4 3 0 1 1 1 0 1 1
Chronic-duration 1 3 2 3 6 7
50 2 0 1 0 2 2 0 4 0 1
Oral studies
Acute-duration 2 2 3 2 2 2 2 3
0 0 2 0 1 0 0 1
Intermediate-duration 2 4(2) 7 4 11
5
42 1 3 2 1 1
0 1 0 4 0 2 0 0 0 0
1 1 1 3
1 1 1 0 3
Chronic-duration 1(0) 1 2 1 2










Intermediate-duration 1 1 1 1 1 1 1
0 0 0 0 1 0 0
Chronic-duration
Number of studies examining end point 0 1 2 3
 
Number of studies reporting outcome 0 1 2 3
 
Numbers in parentheses represent those studies looking at the specific cardiovascular end points of interest to this systematic review (damage 
to the myocardium and/or EKG alterations).
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B.5 ASSESS THE RISK OF BIAS FOR INDIVIDUAL STUDIES
B.5.1  Risk of Bias Assessment
The risk of bias of individual studies was assessed using OHAT’s Risk of Bias Tool (NTP 2015). The 
risk of bias questions for observational epidemiology studies, human-controlled exposure studies, and 
animal experimental studies are presented in Tables B-5, B-6, and B-7, respectively.  Each risk of bias 
question was answered on a four-point scale:
• Definitely low risk of bias (++)
• Probably low risk of bias (+)
• Probably high risk of bias (-)
• Definitely high risk of bias (– –)
In general, “definitely low risk of bias” or “definitely high risk of bias” were used if the question could be
answered with information explicitly stated in the study report.  If the response to the question could be
inferred, then “probably low risk of bias” or “probably high risk of bias” responses were typically used.  
Table B-5.  Risk of Bias Questionnaire for Observational Epidemiology Studies
Selection bias
Were the comparison groups appropriate?
Confounding bias
Did the study design or analysis account for important confounding and modifying variables?
Attrition/exclusion bias
Were outcome data complete without attrition or exclusion from analysis?
Detection bias
Is there confidence in the exposure characterization?
Is there confidence in outcome assessment?
Selective reporting bias
Were all measured outcomes reported?
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Table B-6.  Risk of Bias Questionnaire for Human-Controlled Exposure Studies
Selection bias
Was administered dose or exposure level adequately randomized?
Was the allocation to study groups adequately concealed?
Performance bias
Were the research personnel and human subjects blinded to the study group during the study?
Attrition/exclusion bias
Were outcome data complete without attrition or exclusion from analysis?
Detection bias
Is there confidence in the exposure characterization?
Is there confidence in outcome assessment?
Selective reporting bias
Were all measured outcomes reported?
Table B-7.  Risk of Bias Questionnaire for Experimental Animal Studies
Selection bias
Was administered dose or exposure level adequately randomized?
 
Was the allocation to study groups adequately concealed?
 
Performance bias
Were experimental conditions identical across study groups?
 
Were the research personnel blinded to the study group during the study?
 
Attrition/exclusion bias
Were outcome data complete without attrition or exclusion from analysis?
Detection bias
Is there confidence in the exposure characterization?
 
Is there confidence in outcome assessment?
 
Selective reporting bias
Were all measured outcomes reported? 
Other bias
Did the study design or analysis account for important confounding and modifying variables? 
After the risk of bias questionnaires were completed for the health effects studies, the studies were 
assigned to one of three risk of bias tiers based on the responses to the key questions listed below and the 
responses to the remaining questions.
•	 Is there confidence in the exposure characterization? (only relevant for observational studies)
•	 Is there confidence in the outcome assessment? 
•	 Does the study design or analysis account for important confounding and modifying variables?
(only relevant for observational studies)
First Tier. Studies placed in the first tier received ratings of “definitely low” or “probably low” risk of
bias on the key questions AND received a rating of “definitely low” or “probably low” risk of bias on the
responses to at least 50% of the other applicable questions.
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Second Tier. A study was placed in the second tier if it did not meet the criteria for the first or third tiers.
Third Tier. Studies placed in the third tier received ratings of “definitely high” or “probably high” risk of
bias for the key questions AND received a rating of “definitely high” or “probably high” risk of bias on 
the response to at least 50% of the other applicable questions.
The results of the risk of bias assessment for the different types of antimony health effects studies 
(observational epidemiology and animal experimental studies) are presented in Tables B-8 and B-9, 
respectively.
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ANTIMONY B-12
APPENDIX B
Table B-8.  Summary of Risk of Bias Assessment for Antimony—Observational Epidemiology Studies
Risk of bias criteria and ratings
Confounding Attrition / Selective 
















































































































































































Outcome:  Respiratory effects
Cohort studies
Jones 1994 (antimony metal and – – + NA – + Second
antimony trioxide)
Renes 1953 (antimony oxides) NA – + + + + Second
Schnorr et al. 1995 (antimony oxides) + – + – + + Second
Cooper et al. 1968 (antimony trioxide) NA – + NA + + Second
Taylor 1966 (antimony trichloride) NA – + – – + Third
Cross-sectional studies
Brieger et al. 1954 (antimony trisulfide) NA – + + + + Second
Case series
Potkonjak and Pavlovich 1983 (antimony NA – + NA + + Second
oxides)
Outcome:  Cardiovascular effects (myocardium damage and/or EKG alterations)
Cross Sectional studies
Brieger et al. 1954 (antimony trisulfide) NA - + + + + Second
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Table B-8.  Summary of Risk of Bias Assessment for Antimony—Observational Epidemiology Studies
Risk of bias criteria and ratings
Confounding Attrition / Selective 
















































































































































































Outcome:  Gastrointestinal Effects
Cohort studies
Renes 1953 (antimony oxides) NA – + + + + Second
Cross-sectional studies
Brieger et al. 1954 (antimony trisulfide) NA – + + + + Second
Case series
Taylor 1966 (antimony trichloride) NA – + – – + Third
Outcome:  Developmental Effects
Cohort studies
Belyaeva 1967 (antimony metal, antimony – – + + – + Second
trioxide, antimony pentasulfide)
Case-control studies
Longerich et al. 1991 (not reported) + – + – + + Second
++ = definitely low risk of bias; + = probably low risk of bias; – = probably high risk of bias; – – = definitely high risk of bias; NA = not applicable
*Key question used to assign risk of bias tier
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ANTIMONY B-14
APPENDIX B
Table B-9.  Summary of Risk of Bias Assessment for Antimony—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 





















































































































































































































































































Outcome:  Respiratory effects (inhalation only)
Inhalation acute exposure
Brieger et al. 1954 (rabbit) NA NA NA NA + - + + NA Second
(antimony trisulfide)
NTP 2016 (rat, antimony trioxide) ++ + ++ + ++ ++ ++ ++ NA
++ + ++ + ++ ++ ++ ++ NA
– + + + + + – – NA
– + + + + + – – NA
trisulfide)
Brieger et al. 1954 (rat, antimony
trisulfide)
NA NA NA NA + – + + NA Second
First
NTP 2016 (mouse, antimony First
trioxide)
 
Price et al. 1979 (rat, stibine)
 Second
Price et al. 1979 (guinea pig, Second
stibine)
Inhalation intermediate exposure
Belyaeva 1967 (rat, antimony + + + – + – – + NA Second
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Table B-9.  Summary of Risk of Bias Assessment for Antimony—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 





















































































































































































































































































Dernehl et al. 1945 (guinea pig, – – – – + – – + NA
antimony trioxide) Third
Newton et al. 1994 (rat, antimony
trioxide)
– + + – ++ ++ + + NA First
+ + + + + ++ + – NA
+ + + + + ++ + – NA
– + + – ++ ++ + + NA
++ + ++ + ++ ++ ++ ++ NA
++ + ++ + ++ ++ ++ ++ NA
– + ++ + ++ + + ++ NA
– + ++ + ++ + + ++ NA
Inhalation chronic exposure
Gross et al. 1952 (rat, antimony
trisulfide)
– + + – + – + + NA First





Groth et al. 1986 (rat, antimony ore) First
Newton et al. 1994 (rat, antimony
trioxide)
First
NTP 2016 (rat, antimony trioxide) First
NTP 2016 (mouse, antimony
trioxide)
First
Watt 1983 (rat, antimony trioxide) First
Watt 1983 (pig, antimony trioxide) First
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ANTIMONY B-16
APPENDIX B
Table B-9.  Summary of Risk of Bias Assessment for Antimony—Experimental Animal Studies
Risk of bias criteria and ratings
Reference
Outcome:  Cardiovascular effects(myocardium damage and/or EKG alterations)
Inhalation acute exposure
Brieger et al. 1954 (rabbit, antimony Second
trisulfide) NA NA NA NA + – + + NA
Inhalation intermediate exposure






















































































































































































































































































Selection bias Performance bias bias Detection bias bias Other bias
trisulfide) NA NA NA NA + + +
Brieger et al. 1954 (rabbit, antimony




Brieger et al. 1954 (dog, 7 weeks,
antimony trisulfide)
NA NA NA NA + – + + NA Second
Brieger et al. 1954 (dog, 10 weeks,
antimony trisulfide)
NA NA NA NA + – + + NA Second
Dernehl et al. 1945 (guinea pig, 
antimony trioxide)
– – – – + – – + NA
Third
Newton et al. 1994 (rat, antimony
trioxide)
– + + – ++ ++ + + NA First
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Table B-9.  Summary of Risk of Bias Assessment for Antimony—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 






















































































































































































































































































Groth et al. 1986 (rat, antimony
trioxide)
+ + + + + + – NA
First
Groth et al. 1986 (rat, antimony ore) First
Newton et al. 1994 (rat, antimony
trioxide)
First
NTP 2016 (rat, antimony trioxide) First
NTP 2016 (mouse, antimony
trioxide)
First
Watt 1983 (rat, antimony trioxide) – + ++ + ++ + + ++ First
Watt 1983 (pigs, antimony trioxide) – + ++ + ++ + + ++ First
Oral acute exposure
++
+ + + + + ++ + – NA
– + + – ++ ++ + + NA
++ + ++ + ++ ++ ++ ++ NA
++ + ++ + ++ ++ ++ ++ NA
NA
NA
NTP 1992 (rat, antimony potassium
tartrate) + + ++ + ++ ++ ++ ++ NA
First
NTP 1992 (mouse, antimony
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Table B-9.  Summary of Risk of Bias Assessment for Antimony—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 






















































































































































































































































































Hext et al. 1999 (rat, antimony + + + + + ++ + + NA First
trioxide)
Poon et al. 1998 (rat, antimony
potassium tartrate)
+ + ++ + + ++ + + NA First
++
+ + + + + ++ + – NA
++ + ++ + ++ ++ ++ ++ NA




Outcome:  Gastrointestinal effects
Inhalation chronic exposure




Groth et al. 1986 (rat, antimony ore) First
NTP 2016 (rat, antimony trioxide) First
NTP 2016 (mouse, antimony First
trioxide)
Watt 1983 (rat, antimony trioxide) – + ++ + ++ + + ++ First
Watt 1983 (pig, antimony trioxide) – + ++ + ++ + + ++ First
Oral acute exposure
Houpt et al. 1984 (dog, antimony – NA First
potassium tartrate) + + + + – + +
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APPENDIX B
Table B-9.  Summary of Risk of Bias Assessment for Antimony—Experimental Animal Studies
Risk of bias criteria and ratings
Attrition/ Selective 
exclusion reporting 





















































































































































































































































































NTP 1992 (rat, antimony potassium
tartrate) + + ++ + ++ ++ ++ ++
NTP 1992 (mouse, antimony










Poon et al. 1998 (rat, antimony
potassium tartrate) + + + + + + + – First
Outcome:  Metabolic effects (altered blood glucose levels)
Oral intermediate exposure
Poon et al.  1998 (rat, antimony
potassium tartrate) + + + + + + + – NA First
Oral chronic exposure
Schroeder et al. 1970 (rat, antimony
potassium tartrate) + + + + + – + – NA First
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Table B-9.  Summary of Risk of Bias Assessment for Antimony—Experimental Animal Studies
Risk of bias criteria and ratings



























































































































































































































































































Outcome:  Developmental effects
Inhalation intermediate exposure
Belyaeva 1967 (rat, antimony
trisulfide) + + + – + – – + NA Second
Oral intermediate exposure
Angrisani et al. 1988 (rat pup CV, 
antimony trichloride) + + + + + – + + NA First
Rossi et al. 1987 (rat, antimony
trichloride) + + + + + – + + NA First
Rossi et al. 1987 (rat pup CV, 
antimony trichloride) + + + + + – + + NA First
++ = definitely low risk of bias; + = probably low risk of bias; – = probably high risk of bias; – – = definitely high risk of bias; NA = not applicable
*Key question used to assign risk of bias tier
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B.6  RATE THE CONFIDENCE IN THE BODY OF EVIDENCE FOR EACH RELEVANT
OUTCOME
Confidences in the bodies of human and animal evidence were evaluated independently for each potential
outcome.  ATSDR did not evaluate the confidence in the body of evidence for carcinogenicity; rather, the
Agency defaulted to the cancer weight-of-evidence assessment of other agencies including DHHS, EPA,
and IARC.  The confidence in the body of evidence for an association or no association between exposure 
to antimony and a particular outcome was based on the strengths and weaknesses of individual studies.
Four descriptors were used to describe the confidence in the body of evidence for effects or when no 
effect was found:
•	 High confidence: the true effect is highly likely to be reflected in the apparent relationship
•	 Moderate confidence: the true effect may be reflected in the apparent relationship
•	 Low confidence: the true effect may be different from the apparent relationship




Confidence in the body of evidence for a particular outcome was rated for each type of study: case-
control, case series, cohort, population, human-controlled exposure, and experimental animal.  In the
absence of data to the contrary, data for a particular outcome were collapsed across animal species, routes 
of exposure, and exposure durations.  If species (or strain), route, or exposure duration differences were 
noted, then the data were treated as separate outcomes.
B.6.1  Initial Confidence Rating
In ATSDR’s modification to the OHAT approach, the body of evidence for an association (or no 
association) between exposure to antimony and a particular outcome was given an initial confidence 
rating based on the key features of the individual studies examining that outcome. The presence of these 
key features of study design was determined for individual studies using four “yes or no” questions in 
Distiller, which were customized for observational epidemiology, human-controlled exposure, or 
experimental animal study designs.  Separate questionnaires were completed for each outcome assessed in
a study.  The key features for observational epidemiology (cohort, population, and case-control) studies, 
human-controlled exposure studies, and experimental animal studies are presented in Tables B-10, B-11, 
and B-12, respectively.  The initial confidence in the study was determined based on the number of key
features present in the study design: 
•	 High Initial Confidence: Studies in which the responses to the four questions were “yes”.
•	 Moderate Initial Confidence: Studies in which the responses to only three of the questions
were “yes”.
•	 Low Initial Confidence: Studies in which the responses to only two of the questions were “yes”.
•	 Very Low Initial Confidence: Studies in which the response to one or none of the questions
was “yes”.
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Exposure was experimentally controlled 
Exposure occurred prior to the outcome
Outcome was assessed on individual level rather than at the population level
A comparison group was used




A comparison group was used or the subjects served as their own control
A sufficient number of subjects were tested
Appropriate methods were used to measure outcomes (i.e., clinically-confirmed outcome versus self-
reported)
Appropriate statistical analyses were performed and reported or the data were reported in such a way to 
allow independent statistical analysis
Table B-12.  Key Features of Study Design for Experimental Animal Studies
A concurrent control group was used
A sufficient number of animals per group were tested
Appropriate parameters used to assess a potential adverse effect
Appropriate statistical analyses were performed and reported or the data were reported in such a way to 
allow independent statistical analysis
The presence or absence of the key features and the initial confidence levels for studies examining
respiratory, cardiovascular, gastrointestinal, metabolic, and developmental effects observed in the 
observational epidemiology and animal experimental studies are presented in Tables B-13 and B-14, 
respectively.
A summary of the initial confidence ratings for each outcome is presented in Table B-15.  If individual
studies for a particular outcome and study type had different study quality ratings, then the highest 
confidence rating for the group of studies was used to determine the initial confidence rating for the body
of evidence; any exceptions were noted in Table B-15.
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Outcome:  Respiratory effects (inhalation only)
Cohort studies
Jones 1994 (antimony metal and 
antimony trioxide)
Renes 1953 (antimony oxides)
Schnorr et al. 1995 (antimony oxides)
No Yes Yes Yes
Moderate
No Yes Yes No Low
No Yes Yes Yes Moderate
Cross-sectional studies
Brieger et al. 1954 (antimony trisulfide) No Yes Yes No Low
Cooper et al. 1968 (antimony trioxide) No Yes Yes No Low
Case series
Potkonjak and Pavlovich 1983 Low
(antimony oxides)
No Yes Yes No Low
No Yes Yes No
Taylor 1966 (antimony trichloride)
Outcome:  Cardiovascular effects
Cross-sectional studies
Brieger et al. 1954 (antimony trisulfide) No Yes Yes No Low
Outcome:  Gastrointestinal effects
Cohort studies
Renes 1953 (antimony oxides) No Yes Yes No Low
Cross-sectional studies
Brieger et al. 1954 (antimony trisulfide) No Yes Yes No Low
Case series
Taylor 1966 (antimony trichloride) No Yes Yes No Low
Outcome:  Developmental effects
Cohort studies
Belyaeva 1967 (antimony metal, Low
antimony trioxide, antimony 
pentasulfide) No No Yes Yes
Case-control studies
Longerich et al. 1991 (not reported) No No Yes Yes Low
***DRAFT FOR PUBLIC COMMENT***

























       
       
    
       
         
        
        
        
       
        
         
    
      
         
       
        
         
         
           
         
        
        
         
   
       
    
    
 
 
       
         
    
    
 
 
     


















































































Outcome:  Respiratory effects (inhalation only)
Inhalation acute exposure
Brieger et al. 1954 (rabbit, antimony
trisulfide)
NTP 2016 (rat, antimony trioxide)
NTP 2016 (mouse, antimony trioxide)
Price et al. 1979 (rat, stibine)
Price et al. 1979 (guinea pig, stibine)
Yes No Yes No Moderate
Yes No Yes Yes Moderate
Yes No Yes Yes Moderate
Yes No Yes No Low
Yes No Yes No Low
Yes Yes Yes No Moderate
Yes Yes Yes No Moderate
Yes No Yes No Low
Yes Yes Yes Yes High
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes Yes Yes Yes
Yes No Yes Yes








Belyaeva 1967 (rat, antimony trisulfide)
Brieger et al. 1954 (rat, antimony trisulfide)
Dernehl et al. 1945 (guinea pig, antimony
trioxide)
Newton et al. 1994 (rat, antimony trioxide)
Inhalation chronic exposure
Gross et al. 1952 (rat, antimony trisulfide) Yes Yes Yes Yes High
Groth et al. 1986 (rat, antimony trioxide)
Groth et al. 1986 (rat, antimony ore)
Newton et al. 1994 (rat, antimony trioxide)
NTP 2016 (rat, antimony trioxide)
NTP 2016 (mouse, antimony trioxide)
Watt 1983 (rat, antimony trioxide)








Outcome:  Cardiovascular effects (myocardium damage or altered EKG)
Inhalation acute exposure
Brieger et al. 1954 (rabbit, antimony No
trisulfide) Yes No Yes Low
Inhalation intermediate exposure
Brieger et al. 1954 (rat, antimony trisulfide)
Brieger et al. 1954 (rabbit, antimony
trisulfide)
Brieger et al. 1954 (dog, 7 weeks, antimony
trisulfide)
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Brieger et al. 1954 (dog, 10 weeks, 
antimony trisulfide)
Dernehl et al. 1945 (guinea pig, antimony
trioxide)




Yes No Yes No Low
Yes Yes No Yes Moderate
Yes Yes No Yes Moderate
Yes Yes No Yes Moderate
Yes Yes No Yes Moderate
Yes Yes No Yes Moderate
Yes Yes No Yes Moderate
Yes Yes No Yes Moderate
Yes No Yes No Low
Yes No No Yes Low
Yes No No Yes Low
Yes Yes No Yes Moderate
Yes Yes No Yes Moderate
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Yes No Yes Yes Moderate
Yes Yes Yes Yes High
Yes No Yes Yes Moderate
Yes No Yes Yes Moderate
Inhalation chronic exposure
Groth et al. 1986 (rat, antimony trioxide)
Groth et al. 1986 (rat, antimony ore)
Newton et al. 1994 (rat, antimony trioxide)
NTP 2016 (rat, antimony trioxide)
NTP 2016 (mouse, antimony trioxide)
Watt 1983 (rat, antimony trioxide)
Watt 1983 (pigs, antimony trioxide)
Oral acute exposure
NTP 1992 (rat, antimony potassium tartrate)
NTP 1992 (mouse, antimony potassium
tartrate)
Oral intermediate exposure
Hext et al. 1999 (rat, antimony trioxide)
Poon et al. 1998 (rat, antimony potassium
tartrate)
Outcome:  Gastrointestinal effects
Inhalation chronic exposure
Groth et al. 1986 (rat, antimony trioxide) Yes Yes Yes Yes High
Groth et al. 1986 (rat, antimony ore)
NTP 2016 (rat, antimony trioxide)
NTP 2016 (mouse, antimony trioxide)
Watt 1983 (rat, antimony trioxide)
Watt 1983 (pig, antimony trioxide)
Oral acute exposure
Houpt et al. 1984 (dog, antimony potassium
tartrate)
NTP 1992 (rat, antimony potassium tartrate)
NTP 1992 (mouse, antimony potassium 
tartrate)
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Hext et al. 1999 (rat, antimony trioxide)
Poon et al. 1998 (rat, antimony potassium
tartrate)
Yes Yes Yes Yes High
Yes Yes Yes Yes High
Outcome:  Metabolic effects (altered blood glucose levels)
Oral intermediate exposure
Poon et al.  1998 (rat, antimony potassium
tartrate) Yes Yes Yes Yes High
Oral Chronic exposure
Schroeder et al. 1970 (rat, antimony
potassium tartrate) Yes Yes Yes Yes High
Outcome:  Developmental effects
Inhalation intermediate exposure
Belyaeva 1967 (rat, antimony trisulfide) Yes Yes Yes No Moderate
Oral intermediate exposure
Angrisani et al. 1988 (rat pup CV, antimony
trichloride) Yes Yes Yes Yes High
Rossi et al. 1987 (rat, antimony trichloride) Yes Yes Yes Yes High
Rossi et al. 1987 (rat pup CV, antimony
trichloride) Yes Yes Yes Yes High
***DRAFT FOR PUBLIC COMMENT***


















    
     
      
        
 
      
        
      
      
     
      
      
 
       
      
         
     
      
       
 
       
       
       
      
      
       
 
      
      
         
      
       
       
       
    
     
      
       





Table B-15.  Initial Confidence Rating for Antimony Health Effects Studies
Initial study Initial confidence
confidence rating




Brieger et al. 1954 (rabbit, antimony trisulfide) Moderate
NTP 2016 (rat, antimony trioxide) Moderate
NTP 2016 (mouse, antimony trioxide) Moderate Moderate
Price et al. 1979 (rat, stibine) Low
Price et al. 1979 (guinea pig, stibine) Low
Inhalation intermediate exposure
Animal studies
Belyaeva 1967 (rat, antimony trisulfide) Moderate
Brieger et al. 1954 (rat, antimony trisulfide)




Newton et al. 1994 (rat, antimony trioxide) High
Inhalation chronic exposure
Human studies
Renes 1953 (antimony oxides) Low
Schnorr et al. 1995 (antimony oxides) Moderate
Cooper et al. 1968 (antimony trioxide) Low Moderate
Potkonjak and Pavlovich 1983 (antimony oxides) Low
Taylor 1966 (antimony trichloride) Low
Animal studies
Gross et al. 1952 (rat, antimony trisulfide) High
Groth et al. 1986 (rat, antimony trioxide) High
Groth et al. 1986 (rat, antimony ore) High
Newton et al. 1994 (rat, antimony trioxide)




NTP 2016 (mouse, antimony trioxide) High
Watt 1983 (rat, antimony trioxide) High
Watt 1983 (pig, antimony trioxide) Moderate
Studies finding no effects
Inhalation chronic exposure
Human studies
Brieger et al. 1954 (antimony trisulfide) Low
ModerateJones 1994 (antimony metal and antimony
trioxide)
Moderate
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Outcome:  Cardiovascular effects
Studies finding effects on myocardium and/or EKGs
Inhalation acute exposure
Animal studies
Brieger et al. 1954 (rabbit, antimony trisulfide) Low Low
Inhalation intermediate exposure
Animal studies
Brieger et al. 1954 (rat, antimony trisulfide) Moderate
Brieger et al. 1954 (rabbit, antimony trisulfide) Low Moderate




Brieger et al. 1954 (antimony trisulfide) Low Low
Studies finding no effects on myocardium and/or EKGs
Inhalation intermediate exposure
Animal studies
Brieger et al. 1954 (dog, 7 weeks, antimony
trisulfide)
Low
ModerateDernehl et al. 1945 (guinea pig, antimony trioxide) Low
Newton et al. 1994 (rat, antimony trioxide) Moderate
Inhalation chronic exposure
Animal studies
Groth et al. 1986 (rat, antimony trioxide) Moderate
Moderate
Groth et al. 1986 (rat, antimony ore) Moderate
Newton et al. 1994 (rat, antimony trioxide) Moderate
NTP 2016 (rat, antimony trioxide) Moderate
NTP 2016 (mouse, antimony trioxide) Moderate
Watt 1983 (rat, antimony trioxide) Moderate
Watt 1983 (pigs, antimony trioxide) Low
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NTP 1992 (rat, antimony potassium tartrate) Low Low
NTP 1992 (mouse, antimony potassium tartrate) Low
Oral intermediate exposure
Animal studies
Hext et al. 1999 (rat, antimony trioxide) Moderate
Moderate
Poon et al. 1998 (rat, antimony potassium tartrate) Moderate
Studies finding no effects
Inhalation chronic exposure
Animal studies
Groth et al. 1986 (rat, antimony trioxide) High
High
Groth et al. 1986 (rat, antimony ore) High
NTP 2016 (rat, antimony trioxide) High
Watt 1983 (rat, antimony trioxide) High
Watt 1983 (pig, antimony trioxide) Moderate




Brieger et al. 1954 Low
Renes 1953 Low Low
Taylor 1966 Low
Animal studies
NTP 2016 (mouse, antimony trioxide) High High
Oral acute exposure
Animal studies
Houpt et al. 1984 (dog, antimony potassium High
tartrate) High
NTP 1992 (mouse, antimony potassium tartrate) Moderate
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NTP 1992 (rat, antimony potassium tartrate) Moderate Moderate
Oral intermediate exposure
Animal studies
Hext et al. 1999 (rat, antimony trioxide) High
High
Poon et al. 1998 (rat, antimony potassium tartrate) High
Outcome:  Metabolic effects 
Studies finding effects on serum glucose levels
Oral intermediate exposure
Animal studies
Poon et al.  1998 (rat, antimony potassium tartrate) High High
Oral chronic exposure
Animal studies
Schroeder et al. 1970 (rat, antimony potassium
tartrate)
High High




Belyaeva 1967 (rat, antimony trisulfide) Moderate Moderate
Inhalation chronic exposure
Human studies





Angrisani et al. 1988 (rat, pup CV, antimony
trichloride)
High
Rossi et al. 1987 (rat, pup CV, antimony
trichloride)
High High
Rossi et al. 1987 (rat, antimony trichloride) High
***DRAFT FOR PUBLIC COMMENT***























    
     
      
       
 
   
 
  
   
       
    
  
 
   
  
 
     
   
 
     
   
    
  
 
   
      
      
 
     
   
    
 
    
 

















































































Studies finding no effects
Inhalation chronic exposure
Human studies
Longerich et al. 1991 (not reported) Low Low
B.6.2 Adjustment of the Confidence Rating 
The initial confidence rating was then downgraded or upgraded depending on whether there were
substantial issues that would decrease or increase confidence in the body of evidence. The nine properties 
of the body of evidence that were considered are listed below. The summaries of the assessment of the 
confidence in the body of evidence for respiratory, cardiovascular, gastrointestinal, metabolic, and
developmental effects are presented in Table B-16.  If the confidence ratings for a particular outcome 
were based on more than one type of human study, then the highest confidence rating was used for
subsequent analyses.  An overview of the confidence in the body of evidence for all health effects 
associated with antimony exposure is presented in Table B-17.
Five properties of the body of evidence were considered to determine whether the confidence rating
should be downgraded:
•	 Risk of bias. Evaluation of whether there is substantial risk of bias across most of the studies 
examining the outcome.  This evaluation used the risk of bias tier groupings for individual studies
examining a particular outcome (Tables B-8 and B-9).  Below are the criteria used to determine
whether the initial confidence in the body of evidence for each outcome should be downgraded 
for risk of bias:
o	 No downgrade if most studies are in the risk of bias first tier
o	 Downgrade one confidence level if most studies are in the risk of bias second tier
o	 Downgrade two confidence levels if most studies are in the risk of bias third tier
•	 Unexplained inconsistency. Evaluation of whether there is inconsistency or large variability in
the magnitude or direction of estimates of effect across studies that cannot be explained.  Below
are the criteria used to determine whether the initial confidence in the body of evidence for each 
outcome should be downgraded for unexplained inconsistency:
o	 No downgrade if there is little inconsistency across studies or if only one study evaluated 
the outcome
o	 Downgrade one confidence level if there is variability across studies in the magnitude or
direction of the effect
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o	 Downgrade two confidence levels if there is substantial variability across studies in the 
magnitude or direct of the effect
•	 Indirectness. Evaluation of four factors that can affect the applicability, generalizability, and 
relevance of the studies:
o	 Relevance of the animal model to human health—unless otherwise indicated, studies in
rats, mice, and other mammalian species are considered relevant to humans 
o	 Directness of the end points to the primary health outcome—examples of secondary
outcomes or nonspecific outcomes include organ weight in the absence of histopathology
or clinical chemistry findings in the absence of target tissue effects
o	 Nature of the exposure in human studies and route of administration in animal studies— 
inhalation, oral, and dermal exposure routes are considered relevant unless there are
compelling data to the contrary
o	 Duration of treatment in animal studies and length of time between exposure and
outcome assessment in animal and prospective human studies—this should be considered
on an outcome-specific basis
Below are the criteria used to determine whether the initial confidence in the body of evidence for
each outcome should be downgraded for indirectness:
o	 No downgrade if none of the factors are considered indirect
o	 Downgrade one confidence level if one of the factors is considered indirect
o	 Downgrade two confidence levels if two or more of the factors are considered indirect
•	 Imprecision. Evaluation of the narrowness of the effect size estimates and whether the studies 
have adequate statistical power.  Data are considered imprecise when the ratio of the upper to 
lower 95% CIs for most studies is ≥10 for tests of ratio measures (e.g., odds ratios) and ≥100 for
absolute measures (e.g., percent control response).  Adequate statistical power is determined if
the study can detect a potentially biologically meaningful difference between groups (20%
change from control response for categorical data or risk ratio of 1.5 for continuous data).  Below
are the criteria used to determine whether the initial confidence in the body of evidence for each
outcome should be downgraded for imprecision:
o	 No downgrade if there are no serious imprecisions
o	 Downgrade one confidence level for serious imprecisions
o	 Downgrade two confidence levels for very serious imprecisions 
•	 Publication bias. Evaluation of the concern that studies with statistically significant results are
more likely to be published than studies without statistically significant results.
o	 Downgrade one level of confidence for cases where there is serious concern with
publication bias
Four properties of the body of evidence were considered to determine whether the confidence rating
should be upgraded:
• Large magnitude of effect. Evaluation of whether the magnitude of effect is sufficiently large
so that it is unlikely to have occurred as a result of bias from potential confounding factors.  
o	 Upgrade one confidence level if there is evidence of a large magnitude of effect in a few
studies, provided that the studies have an overall low risk of bias and there is no serious
unexplained inconsistency among the studies of similar dose or exposure levels;
confidence can also be upgraded if there is one study examining the outcome, provided 
that the study has an overall low risk of bias
***DRAFT FOR PUBLIC COMMENT***
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•	 Dose response. Evaluation of the dose-response relationships measured within a study and 
across studies.  Below are the criteria used to determine whether the initial confidence in the body
of evidence for each outcome should be upgraded:
o	 Upgrade one confidence level for evidence of a monotonic dose-response gradient
o	 Upgrade one confidence level for evidence of a non-monotonic dose-response gradient
where there is prior knowledge that supports a non-monotonic dose-response and a non-
monotonic dose-response gradient is observed across studies
•	 Plausible confounding or other residual biases. This factor primarily applies to human studies 
and is an evaluation of unmeasured determinants of an outcome such as residual bias towards the 
null (e.g., “healthy worker” effect) or residual bias suggesting a spurious effect (e.g., recall bias).
Below is the criterion used to determine whether the initial confidence in the body of evidence for
each outcome should be upgraded:
o	 Upgrade one confidence level for evidence that residual confounding or bias would 
underestimate an apparent association or treatment effect (i.e., bias toward the null) or
suggest a spurious effect when results suggest no effect
•	 Consistency in the body of evidence. Evaluation of consistency across animal models and 
species, consistency across independent studies of different human populations and exposure
scenarios, and consistency across human study types. Below is the criterion used to determine 
whether the initial confidence in the body of evidence for each outcome should be upgraded:
o Upgrade one confidence level if there is a high degree of consistency in the database
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Table B-16. Adjustments to the Initial Confidence in the Body of Evidence
Adjustments to the initial
Initial confidence confidence rating Final confidence
Outcome:  Respiratory effects
Studies finding effects
Human studies Moderate -1 risk of bias Low
Animal studies High +1 magnitude, +1 consistency High
Outcome:  Cardiovascular effects
Studies finding effects on myocardium and/or EKGs
Human studies Low -1 risk of bias, Very low
Animal studies Moderate -1 risk of bias Low
Outcome:  Gastrointestinal effects
Studies finding effects
Human studies Low -1 risk of bias Very low
Animal studies High None High
Outcome:  Metabolic effects
Studies finding effects on serum glucose levels
Animal studies High None High
Outcome:  Developmental effects
Studies finding effects
Human studies Low -1 risk of bias Very low
Animal studies High None High
Studies finding no effects
Human studies Moderate -1 risk of bias, Low
Studies finding no effects on myocardium and/or EKGs
Animal studies Moderate None Moderate
Studies finding no effects
Animal studies High None High
Studies finding no effects
Human studies Low -1 risk of bias Very low
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B-35ANTIMONY AND COMPOUNDS
Table B-17.  Confidence in the Body of Evidence for Antimony
Confidence in body of evidence
Outcome
Human studies Animal studies
Respiratory effects
Effect Low High
No effect Low No data
Cardiovascular effects
Effects on myocardium/EKG Very low Low
No effect on myocardium/EKG No data Moderate
Gastrointestinal effects
Effect Very low High
No effect No data High
Metabolic effects
Effect No data High
No effect No data No data
Developmental effects
Effect Very low High
No effect Very low No data
B.7  TRANSLATE CONFIDENCE RATING INTO LEVEL OF EVIDENCE OF HEALTH 
EFFECTS
In the seventh step of the systematic review of the health effects data for antimony, the confidence in the 
body of evidence for specific outcomes was translated to a level of evidence rating.  The level of evidence 
rating reflected the confidence in the body of evidence and the direction of the effect (i.e., toxicity or no 
toxicity); route-specific differences were noted. The level of evidence for health effects was rated on a 
five-point scale:  
•	 High level of evidence: High confidence in the body of evidence for an association between 
exposure to the substance and the health outcome
•	 Moderate level of evidence: Moderate confidence in the body of evidence for an association 
between exposure to the substance and the health outcome
•	 Low level of evidence: Low confidence in the body of evidence for an association between 
exposure to the substance and the health outcome
•	 Evidence of no health effect: High confidence in the body of evidence that exposure to the
substance is not associated with the health outcome
•	 Inadequate evidence: Low or moderate confidence in the body of evidence that exposure to the
substance is not associated with the health outcome or very low confidence in the body of
evidence for an association between exposure to the substance and the health outcome
A summary of the level of evidence of health effects for antimony is presented in Table B-18.
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Table B-18.  Level of Evidence of Health Effects for Antimony
Confidence in body Direction of health Level of evidence for
Outcome of evidence effect health effect
Human studies
Respiratory effects (inhalation only)
Low Health effect Low
Low No effect Inadequate
Cardiovascular—myocardial and EKG alterations
Very Low Health effect Inadequate
Gastrointestinal effect
Very Low Health effect Inadequate
Metabolic—serum glucose alterations
No data – No data
Developmental effects
Very Low Health effect Inadequate
Animal studies
Respiratory effects (inhalation only)
High Health effect High
Cardiovascular—myocardial and EKG alterations
Low Health effect Low
Moderate No effect Inadequate
Gastrointestinal effects
High Health effect High
High No effect Evidence of no health effect
Metabolic—serum glucose alterations
High Health effect High
Developmental effects
High Health effect High
No data - No data
B.8 INTEGRATE EVIDENCE TO DEVELOP HAZARD IDENTIFICATION CONCLUSIONS
The final step involved the integration of the evidence streams for the human studies and animal studies 
to allow for a determination of hazard identification conclusions.  For health effects, there were four
hazard identification conclusion categories:
• Known to be a hazard to humans
• Presumed to be a hazard to humans
• Suspected to be a hazard to humans
• Not classifiable as to the hazard to humans
The initial hazard identification was based on the highest level of evidence in the human studies and the 
level of evidence in the animal studies; if there were no data for one evidence stream (human or animal),
then the hazard identification was based on the one data stream (equivalent to treating the missing
***DRAFT FOR PUBLIC COMMENT***










    
 
 
      
     
  
     
    
 
   
     
    
 
   
 
       

















     
 






evidence stream as having low level of evidence). The hazard identification scheme is presented in
Figure B-2 and described below:
•	 Known: A health effect in this category would have:
o	 High level of evidence for health effects in human studies AND a high, moderate, or low
level of evidence in animal studies.
•	 Presumed: A health effect in this category would have:
o	 Moderate level of evidence in human studies AND high or moderate level of evidence in
animal studies OR
o	 Low level of evidence in human studies AND high level of evidence in animal studies
•	 Suspected: A health effect in this category would have:
o	 Moderate level of evidence in human studies AND low level of evidence in animal
studies OR
o	 Low level of evidence in human studies AND moderate level of evidence in animal
studies
•	 Not classifiable: A health effect in this category would have:
o	 Low level of evidence in human studies AND low level of evidence in animal studies



























Not Classifiable Suspected PresumedLow
Low Moderate High
Level of evidence for health effects in animal studies
Other relevant data such as mechanistic or mode-of-action data were considered to raise or lower the level
of the hazard identification conclusion by providing information that supported or opposed biological
plausibility.
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Two hazard identification conclusion categories were used when the data indicated that there may be no 
health effect in humans:
•	 Not identified to be a hazard in humans
•	 Inadequate to determine hazard to humans
If the human level of evidence conclusion of no health effect was supported by the animal evidence of no 
health effect, then the hazard identification conclusion category of “not identified” was used.  If the
human or animal level of evidence was considered inadequate, then a hazard identification conclusion 
category of “inadequate” was used.  As with the hazard identification for health effects, the impact of
other relevant data was also considered for no health effect data.  
The hazard identification conclusions for antimony are listed below and summarized in Table B-19.  
Presumed Health Effects
•	 Respiratory effects following inhalation exposure 
o	 Low evidence from studies of antimony workers (Cooper et al. 1968; Potkonjak and
Pavlovich 1983; Renes 1953; Schnorr et al. 1995; Taylor 1966).
o	 High level of evidence in rats, mice, rabbits, guinea pigs, and pigs from acute exposure to 
antimony trisulfide, antimony trioxide, and stibine (Brieger et al. 1954; NTP 2016; Price
et al. 1979), intermediate exposure to antimony trisulfide and antimony trioxide
(Belyaeva 1967; Brieger et al. 1954; Dernehl et al. 1945; Newton et al. 1994), and
chronic exposure to antimony trisulfide, antimony trioxide, and antimony ore (Gross et
al. 1952; Groth et al. 1986; Newton et al. 1994; NTP 2016; Watt 1983).  
•	 Gastrointestinal effects
o	 Inadequate evidence from studies of antimony workers (Brieger et al. 1954; Renes 1953;
Taylor et al. 1966).
o	 High level of evidence for gastrointestinal irritation in dogs (Houpt et al. 1984) and mice
(NTP 1992, 2016).  Inhalation and oral studies in rats with initial confidences of high or
moderate did not find histological alterations in the gastrointestinal tract following
inhalation exposure to antimony trioxide (Groth et al. 1986; NTP 2016; Watt 1983) or
antimony ore (Groth et al. 1986) or oral exposure to antimony trioxide (Hext et al. 1999)
or antimony potassium tartrate (NTP 1992; Poon et al. 1998).
Suspected Health Effects
•	 Cardiovascular-myocardial and EKG alterations
o	 Inadequate evidence in humans exposed to antimony trisulfide (Brieger et al. 1954)
o	 Low evidence in rats, rabbits, and dogs exposed via inhalation to antimony trisulfide
(Brieger et al. 1954) and in rats exposed to antimony potassium tartrate (Schroeder et al. 
1970).  No myocardial alterations were observed in rat, mouse, pig, or guinea pig
antimony ore or antimony trioxide inhalation studies with initial moderate confidence 
levels (Dernehl et al. 1945; Groth et al. 1986; Newton et al. 1994; Watt 1983) or in
antimony trioxide and antimony potassium tartrate oral studies with initial moderate
confidence level (Hext et al. 1999; NTP 1992; Poon et al. 1998).
o	 Although the hazard identification for myocardial and EKG alterations should be not
classifiable based on inadequate evidence in humans and low evidence in animals, the
level of the hazard identification was raised to suspected health effect based on consistent
evidence of EKG alterations in patients treated with injected trivalent or pentavalent 
antimony compounds (Dancaster et al. 1966; Honey 1960; Lawn et al. 2006; Neves et al. 
2009; Sundar et al. 1998; Thakur 1998) and in animal studies involving parenteral
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administration (Alvarez et al. 2005; Bromberger-Barnea and Stephens 1965; Cotten and 
Logan 1966).  
•	 Metabolic effect (decreases in blood glucose levels)
o	 No data are available on whether inhalation, oral, or dermal exposure to antimony alters
blood glucose levels in humans.
o	 High evidence in animal studies based on two studies that found decreases in blood 
glucose levels following intermediate (Poon et al. 1998) or chronic (Schroeder et al. 
1970) oral exposure.  Decreases in blood glucose levels were also found in rats following
repeated intramuscular injection of two organic pentavalent compounds (Alkhawajah et
al. 1992b).
o	 Based on the high evidence found in the two animal studies, decreases in blood glucose
levels should be classified as a presumed health effect.  However, because blood glucose 
levels have only been assessed in two studies administering antimony via 
environmentally relevant routes of exposure, the hazard identification was downgraded to 
suspected health effect.
•	 Developmental effects
o	 Inadequate evidence of developmental effects (decreases in infant growth) from an
occupational exposure study (Belyaeva 1976).  
o	 High evidence of developmental toxicity from animal studies.  An inhalation study found 
decreases in the number of offspring in rats exposed to antimony trioxide during
gestation (Belyaeva 1967).  An antimony trichloride oral exposure study found decreases
in postnatal growth resulting from gestation and lactation exposure, but no effect on the
number of offspring or abnormalities (Rossi et al. 1987).  
o	 Decreases in birth weight and decreases in the number of viable offspring were observed
in rat studies involving gestation and/or lactation exposure to subcutaneously
administered meglumine antimoniate (Coelho et al. 2014a; Miranda et al. 2006) or
intramuscularly administered sodium stibogluconate, meglumine antimoniate, or
antimony trichloride (Alkhawajah et al. 1992a).
o	 Although the hazard identification for developmental effects, particularly for decreased 
growth, should be presumed health effect based on inadequate evidence in humans and
high evidence in humans, the hazard identification was lowered to suspected health effect
based on the small number of studies evaluating the developmental toxicity of antimony
by environmentally relevant routes of exposure.
Table B-19.  Hazard Identification Conclusions for Antimony
Outcome	 Hazard identification 
Respiratory effects Presumed health effect following inhalation exposure
Cardiovascular-myocardial and EKG alterations Suspected health effect following exposure to soluble 
antimony compounds
Gastrointestinal effects Presumed health effect
Metabolic effects (decreased serum glucose Suspected health effect
levels)
 
Developmental effects Suspected health effect
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C-1ANTIMONY AND COMPOUNDS
APPENDIX C.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions:
1.	 What effects are known to occur in humans?
2.	 What effects observed in animals are likely to be of concern to humans?
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
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MRLs should help physicians and public health officials determine the safety of a community living near
a hazardous substance emission, given the concentration of a contaminant in air or the estimated daily
dose in water.  MRLs are based largely on toxicological studies in animals and on reports of human 
occupational exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement,
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in
conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.
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See Sample LSE Table 3-1 (page C-6)
(1)	 Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2)	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable
exposure period within the LSE table and figure.
(3)	 Health Effect. The major categories of health effects included in LSE tables and figures include 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4)	 Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5)	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6)	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen,
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7)	 System.  This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8)	 NOAEL.  A NOAEL is the highest exposure level at which no adverse effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
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(9)	 LOAEL.  A LOAEL is the lowest dose used in the study that caused an adverse health effect.
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile.
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in
experimental or epidemiologic studies.  CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12)	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page C-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health
effects observed within the acute and intermediate exposure periods are illustrated.
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15)	 Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.
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(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).
(19)	 Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
























    
      









































































































































































→	 Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)Exposure 
Less serious Serious (ppm)Key to 	 frequency/ NOAEL
(ppm)figurea Species duration System (ppm)	 Reference
→	 INTERMEDIATE EXPOSURE
5 6 7 8 9 10



























10	 (CEL, lung tumors,
nasal tumors)
10	 (CEL, lung tumors,
hemangiosarcomas)
↓
Nitschke et al. 1981
Wong et al. 1982
NTP 1982
NTP 1982
→	 a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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D-1ANTIMONY AND COMPOUNDS
APPENDIX D. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software 
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
DOT Department of Transportation
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D-2ANTIMONY AND COMPOUNDS
APPENDIX D
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg kilokilogram; 1 kilokilogram is equivalent to 1,000 kilograms and 1 metric ton
Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
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D-3ANTIMONY AND COMPOUNDS
APPENDIX D
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
mt metric ton
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
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OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
PEL-C permissible exposure limit-ceiling value
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
REL-C recommended exposure level-ceiling value
RfC reference concentration (inhalation)
RfD reference dose (oral)
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase (same as aspartate aminotransferase or AST)
SGPT serum glutamic pyruvic transaminase (same as alanine aminotransferase or ALT)
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TLV-C threshold limit value-ceiling value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
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WHO World Health Organization
> greater than
≥ greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
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